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A B S T R A C T
Background
Dental plaque associated gingivitis is a reversible inflammatory condition caused by accumulation and persistence of microbial biofilms
(dental plaque) on the teeth. It is characterised by redness and swelling of the gingivae (gums) and a tendency for the gingivae to bleed
easily. In susceptible individuals, gingivitis may lead to periodontitis and loss of the soft tissue and bony support for the tooth. It is
thought that chlorhexidine mouthrinse may reduce the build-up of plaque thereby reducing gingivitis.
Objectives
To assess the effectiveness of chlorhexidine mouthrinse used as an adjunct to mechanical oral hygiene procedures for the control of
gingivitis and plaque compared tomechanical oral hygiene procedures alone ormechanical oral hygiene procedures plus placebo/control
mouthrinse. Mechanical oral hygiene procedures were toothbrushing with/without the use of dental floss or interdental cleaning aids
and could include professional tooth cleaning/periodontal treatment.
To determine whether the effect of chlorhexidine mouthrinse is influenced by chlorhexidine concentration, or frequency of rinsing
(once/day versus twice/day).
To report and describe any adverse effects associated with chlorhexidine mouthrinse use from included trials.
Search methods
Cochrane Oral Health’s Information Specialist searched the following databases: Cochrane Oral Health’s Trials Register (to 28 Septem-
ber 2016); the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library (searched 28
September 2016); MEDLINE Ovid (1946 to 28 September 2016); Embase Ovid (1980 to 28 September 2016); and CINAHL EB-
SCO (Cumulative Index to Nursing and Allied Health Literature; 1937 to 28 September 2016). We searched ClinicalTrials.gov and
the World Health Organization International Clinical Trials Registry Platform for ongoing trials. No restrictions were placed on the
language or date of publication when searching the electronic databases.
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Selection criteria
We included randomised controlled trials assessing the effects of chlorhexidine mouthrinse used as an adjunct to mechanical oral
hygiene procedures for at least 4 weeks on gingivitis in children and adults. Mechanical oral hygiene procedures were toothbrushing
with/without use of dental floss or interdental cleaning aids and could include professional tooth cleaning/periodontal treatment. We
included trials where participants had gingivitis or periodontitis, where participants were healthy and where some or all participants
had medical conditions or special care needs.
Data collection and analysis
Two review authors independently screened the search results extracted data and assessed the risk of bias of the included studies. We
attempted to contact study authors for missing data or clarification where feasible. For continuous outcomes, we used means and
standard deviations to obtain the mean difference (MD) and 95% confidence interval (CI). We combined MDs where studies used
the same scale and standardised mean differences (SMDs) where studies used different scales. For dichotomous outcomes, we reported
risk ratios (RR) and 95% CIs. Due to anticipated heterogeneity we used random-effects models for all meta-analyses.
Main results
We included 51 studies that analysed a total of 5345 participants. One study was assessed as being at unclear risk of bias, with the
remaining 50 being at high risk of bias, however, this did not affect the quality assessments for gingivitis and plaque as we believe that
further research is very unlikely to change our confidence in the estimate of effect.
Gingivitis
After 4 to 6 weeks of use, chlorhexidine mouthrinse reduced gingivitis (Gingival Index (GI) 0 to 3 scale) by 0.21 (95% CI 0.11 to 0.31)
compared to placebo, control or no mouthrinse (10 trials, 805 participants with mild gingival inflammation (mean score 1 on the GI
scale) analysed, high-quality evidence). A similar effect size was found for reducing gingivitis at 6 months. There were insufficient data
to determine the reduction in gingivitis associated with chlorhexidine mouthrinse use in individuals with mean GI scores of 1.1 to 3
(moderate or severe levels of gingival inflammation).
Plaque
Plaque was measured by different indices and the SMD at 4 to 6 weeks was 1.45 (95% CI 1.00 to 1.90) standard deviations lower in
the chlorhexidine group (12 trials, 950 participants analysed, high-quality evidence), indicating a large reduction in plaque. A similar
large reduction was found for chlorhexidine mouthrinse use at 6 months.
Extrinsic tooth staining
There was a large increase in extrinsic tooth staining in participants using chlorhexidine mouthrinse at 4 to 6 weeks. The SMD
was 1.07 (95% CI 0.80 to 1.34) standard deviations higher (eight trials, 415 participants analysed, moderate-quality evidence) in
the chlorhexidine mouthrinse group. There was also a large increase in extrinsic tooth staining in participants using chlorhexidine
mouthrinse at 7 to 12 weeks and 6 months.
Calculus
Results for the effect of chlorhexidine mouthrinse on calculus formation were inconclusive.
Effect of concentration and frequency of rinsing
There were insufficient data to determine whether there was a difference in effect for either chlorhexidine concentration or frequency
of rinsing.
Other adverse effects
The adverse effects most commonly reported in the included studies were taste disturbance/alteration (reported in 11 studies), effects
on the oral mucosa including soreness, irritation, mild desquamation and mucosal ulceration/erosions (reported in 13 studies) and a
general burning sensation or a burning tongue or both (reported in nine studies).
Authors’ conclusions
There is high-quality evidence from studies that reported the Löe and Silness Gingival Index of a reduction in gingivitis in individuals
with mild gingival inflammation on average (mean score of 1 on the 0 to 3 GI scale) that was not considered to be clinically relevant.
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There is high-quality evidence of a large reduction in dental plaque with chlorhexidine mouthrinse used as an adjunct to mechanical oral
hygiene procedures for 4 to 6 weeks and 6 months. There is no evidence that one concentration of chlorhexidine rinse is more effective
than another. There is insufficient evidence to determine the reduction in gingivitis associated with chlorhexidine mouthrinse use in
individuals with mean GI scores of 1.1 to 3 indicating moderate or severe levels of gingival inflammation. Rinsing with chlorhexidine
mouthrinse for 4 weeks or longer causes extrinsic tooth staining. In addition, other adverse effects such as calculus build up, transient
taste disturbance and effects on the oral mucosa were reported in the included studies.
P L A I N L A N G U A G E S U M M A R Y
Chlorhexidine mouthrinse to reduce gingivitis and plaque build-up
Review question
Does the use of chlorhexidine mouthrinse (a broad spectrum antiseptic) in addition to other conventional tooth cleaning help to control
and improve gingivitis (inflammation of the gums)? Does the frequency of rinsing or the concentration of the solution affect the result
and are there any undesirable side effects?
Background
Gingivitis is a reversible condition when gums become red, swollen and can bleed easily. Gingivitis is also very common - studies suggest
that as many as 50% to 90% of adults in the UK and USA suffer from it. In susceptible people gingivitis may lead to periodontitis,
which is not reversible. In periodontitis inflammation is accompanied by loss of ligaments and bone supporting the teeth. If untreated
it may eventually lead to tooth loss. Severe periodontitis is the sixth most widespread disease globally.
It is recognised that maintaining a high standard of oral hygiene is important for the prevention and treatment of gingivitis. Toothbrush-
ing is the main method for maintaining good oral hygiene. Other cleaning methods commonly used include dental floss, interdental
brushes and scaling and polishing carried out by a dental professional. Some people have difficulty controlling plaque build-up and
preventing gingivitis using only conventional tooth cleaning. Therefore people sometimes use mouthrinses containing chlorhexidine
in addition to conventional tooth cleaning. These mouthrinses are readily available over the counter; prescriptions generally not being
required outside the USA.
Study characteristics
We included 51 studies that analysed a total of 5345 participants. The evidence in this review is up to date as of 28 September
2016. Generally study participants were children and adults who had gingivitis or periodontitis, were able to use usual tooth cleaning
methods and were healthy. We did not exclude studies where some or all participants had medical conditions or special care needs as
we considered the use of mouthrinses with chlorhexidine to be particularly relevant to them. The included studies assessed the effects
of chlorhexidine mouthrinse used for at least 4 weeks in addition to conventional tooth cleaning on gingivitis in children and adults.
Key results
There is high-quality evidence that the use of mouthrinses containing chlorhexidine in addition to usual toothbrushing and cleaning
for 4 to 6 weeks or 6 months leads to a large reduction in the build-up of plaque. There is also high-quality evidence of a moderate
reduction in gingivitis in people with a mild level of it, although because the level of disease was already low this is not considered
clinically important. The nature of the available evidence does not allow us to determine the level of reduction of gingivitis in people
with moderate to severe levels of it.
There was no evidence that one concentration or strength of chlorhexidine rinse was more effective than another.
Rinsing for 4 weeks or longer causes tooth staining, which requires scaling and polishing carried out by a dental professional. Other
side effects have been reported, including build-up of calculus (tartar), temporary taste disturbance and temporary shedding of/damage
to the lining of the mouth.
Quality of the evidence
One study was assessed as being at unclear risk of bias, with the remaining 50 being at high risk of bias, however this did not affect the
quality assessments for gingivitis and plaque as we believe that further research is very unlikely to change our confidence in the estimate
of effect.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Chlorhexidine mouthrinse compared with placebo/control mouthrinse/no mouthrinse for gingival health
Patient or population: adults and children with gingivit is
Settings: any
Intervention: chlorhexidine mouthrinse
Comparison: placebo/ control mouthrinse or no mouthrinse
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Chlorhexidine
Gingival Index 4 to 6
weeks (Löe and Silness
Gingival Index) (0 to 3
on an increasing scale)
The mean gingivit is
scores ranged across
control groups f rom 0.
17 to 1.401
The mean gingivit is
score in the chlorhex-
idine group was 0.21
lower (0.11 to 0.31
lower)
805
(10 trials)
⊕⊕⊕⊕2,3
high
The ef fect size at 6
months was sim ilar
Insuf f icient evidence
for dif f erences in ef -
fect size for dif f erent
chlorhexidine concen-
trat ion or f requency of
use
Insuf f icient evidence to
determ ine the ef fect
size in individuals with
moderate or severe
levels of gingival in-
f lammation on average
(mean GI scores 1.1 to
3)
Plaque 4 to 6 weeks
(various increasing
scales including Plaque
Index (0 to 3 scale) and
Turesky Modif icat ion of
Plaque Index ranged
f rom 0.75 to 1.06
Turesky Modif icat ion of
the Quigley and Hein In-
dex ranged f rom 1.2 to
The SMD was 1.45
lower in the chlorhex-
idine group indicat ing
a large reduct ion in
plaque f rom 1.00 to 1.
950
(12 trials)
⊕⊕⊕⊕2,3
high
The ef fect for the
Plaque Index (4 trials;
223 part icipants) was
0.58 (95% CI 0.39 to 0.
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the Quigley and Hein In-
dex (0 to 5 scale))
3.3 90 standard deviat ions 78) lower
The ef fect for the
Turesky Modif icat ion of
the Quigley and Hein In-
dex (5 trials; 546 part ic-
ipants) was 0.78 (95%
CI 0.70 to 0.85) lower
There were also large
ef fects for the plaque
at 6 months
Tooth staining 4 to 6
weeks
(various increasing
scales)
The mean tooth stain-
ing score was mea-
sured on dif ferent
scales
The SMD for tooth
staining in the chlorhex-
idine group was
1.07 (0.80 to 1.34) stan-
dard deviat ions higher
415
(8 trials)
⊕⊕⊕©4
moderate
Data have not been
converted to original
scale as many dif ferent
scales are used. The
SMD ef fect size is con-
sidered large
There were also 2 tri-
als present ing dichoto-
mous data showing
large signif icant ef fect
RR 5.41 (95%CI 2.03 to
14.47)
There was also a large
ef fect for tooth staining
for chlorhexidine at 7 to
12 weeks and 6 months
Other adverse effects 22 trials reported at least 1 adverse ef fect apart f rom extrinsic tooth staining and calculus formation in the chlorhexidine rinse arms. The adverse
ef fects most commonly reported were taste disturbance/ alterat ion (reported in 11 trials), ef fects on the oral mucosa including mucosal irritat ion,
soreness, m ild desquamation, mucosal ulcerat ion/ erosions, oral mucosal lesions (reported in 13 trials) and a general burning sensat ion and/ or a
burning tongue (reported in 9 trials)
* The basis for the assumed risk (e.g. the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervent ion (and its 95%CI)
CI: conf idence interval; GI: Gingival Index; RR: risk rat io; SMD: standardised mean dif ference
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GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: we are very uncertain about the est imate
1The mean gingivit is score for the control group was 0.93 (median is 1.0).
2Although most trials included in the meta-analyses were assessed as at high risk of bias we did not downgrade the GRADE
assessments for this reason because we believe that further research is very unlikely to change our conf idence in the est imate
of ef fect.
3Not downgraded for high heterogeneity as results consistent.
4Downgraded as 8 trials at high risk of bias.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
6
C
h
lo
rh
e
x
id
in
e
m
o
u
th
rin
se
a
s
a
n
a
d
ju
n
c
tiv
e
tre
a
tm
e
n
t
fo
r
g
in
g
iv
a
l
h
e
a
lth
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Plaque-associated periodontal disease involves the inflammation
of the gingivae (gums) and the supporting structures of the teeth.
The first stage of the disease is plaque-associated gingivitis (inflam-
mation of the gingivae), which is a reversible inflammatory con-
dition characterised by redness and swelling of the gingivae and
a tendency for the gingivae to bleed easily. It is caused by the ac-
cumulation and persistence of microbial biofilms (dental plaque)
on the teeth (Löe 1965). Gingivitis is very common with studies
suggesting that as many as 50% to 90% of adults in the UK and
USA suffer from gingivitis (NICE 2012). In susceptible individu-
als, gingivitis may lead to the second stage of periodontal disease,
periodontitis. Periodontitis is an irreversible condition, where in-
flammation of the gingivae is accompanied by connective tissue
destruction and loss of the periodontal ligament and alveolar bone
supporting the tooth. If untreated, periodontitis may ultimately
lead to tooth loss. Severe periodontitis is the sixth most prevalent
disease of man with a global age-standardised prevalence of 11.2%
(Kassebaum 2014). It has a negative impact on oral-health-related
quality of life (Al-Harthi 2013;Marcenes 2013; Needleman 2004;
Tonetti 2015), affecting both physical function and social inter-
action (Cunha-Cruz 2007; Ng 2006). The response of the indi-
vidual to gingival irritation by the microbial biofilm is modulated
by local, systemic and genetic factors, and it is recognised that
gingivitis will only progress to periodontitis in some individuals
and at some sites. However as the microbial biofilm is a prerequi-
site for both conditions, gingival inflammation is considered a key
risk factor in the initiation of periodontitis (Chapple 2015; Lang
2009). Indeed, consistent inflammation of the gingivae and gin-
gival bleeding are predictive of future attachment loss and tooth
loss (Schatzle 2004).
Although it is not possible to identify those individuals whowill go
on to develop severe periodontitis, the importance of maintaining
a high standard of oral hygiene in the prevention and treatment
of periodontal diseases is well recognised (Axelsson 2004; Ohrn
2009; van der Weijden 2011). Furthermore, the most important
predictor of periodontal diseases, regardless of age is poor oral hy-
giene (Abdellatif 1987). Thus, the population approach to pre-
vention of periodontal diseases should promote adequate plaque
control and removal of the microbial biofilm for all individuals.
Description of the intervention
Mechanical disruption and removal of the microbial biofilm is
commonly achieved by toothbrushing and interdental cleaning
(Berchier 2008). However, adequate removal of the microbial
biofilm with mechanical methods alone can be difficult for some,
with many individuals finding it difficult to maintain an effec-
tive level of plaque control (Marsh 1992; Salzer 2015; Slot 2012;
van der Weijden 2005; van der Weijden 2011; van der Weijden
2015). For these individuals, the level of plaque control that is
achieved by regular mechanical cleaning alone may not be suffi-
cient to prevent the onset or recurrence of periodontal diseases
(Serrano 2015).Therefore chemical methods of removing the mi-
crobial biofilm such as antimicrobial mouthrinses have been rec-
ommended for use as either an adjunct to, or in some limited
situations, a replacement for mechanical removal of the microbial
biofilm.
Chlorhexidine is a broad spectrum bisbiguanide antiseptic which
was first introduced into clinical medicine in 1953 in the form of
an antiseptic cream (Eley 1999; Foulkes 1973). It is a strong base
and is practically insoluble in water (Karpinski 2015). In clinical
medicine its water soluble salts, in particular chlorhexidine diglu-
conate, are most commonly used (Foulkes 1973; Karpinski 2015).
In dentistry, chlorhexidine is used in a variety of formulations and
vehicles, such as mouthrinses, gels, sprays and varnishes. Problems
can be encountered when delivering chlorhexidine as a gel or a
toothpaste as the chlorhexidine may bind to ingredients in the
products reducing its activity (Eley 1999). Although considerable
advances have beenmade in recent years in the formulationof these
and other chlorhexidine vehicles, mouthrinses have the advantage
of having a long history of use for oral health. They are already
accepted as part of a normal oral hygiene regimen, used follow-
ing normal mechanical tooth cleaning (van der Weijden 2015).
Chlorhexidine-containing mouthrinses are marketed worldwide
under a number of trade names and are in widespread use for
chemical plaque control. This family of rinses are mainly indi-
cated for use as adjuncts to mechanical cleaning, in specific clin-
ical situations where mechanical oral hygiene is difficult, such as
postsurgery, in individuals with intermaxillary fixation, in fixed
appliance orthodontic therapy and in individuals with intellectual
and physical disabilities (Addy 1986). Chlorhexidine mouthrinse
is mainly available in concentrations of 0.1%, 0.12% or 0.2%
chlorhexidine digluconate as well as in low concentration (≤
0.06%) rinse. The effect of chlorhexidine on themicrobial biofilm
is dose-dependant (Keijser 2003). The optimum dose of chlorhex-
idine in a mouthrinse is considered to be 20 mg twice daily (Löe
1970) equivalent to 10 mL of 0.2% chlorhexidine mouthrinse (20
mg) or 15 mL of 0.12% chlorhexidine mouthrinse (18 mg) (Eley
1999; Keijser 2003). A rinse time of 30 seconds appears to be
effective and acceptable although 60-second rinse times are also
advocated (Bonesvoll 1974; Keijser 2003).
How the intervention might work
The action of chlorhexidine mouthrinse as a treatment adjunct
in managing inflammation of the gingivae involves its antimi-
crobial properties, which reduce the bacterial load of the micro-
bial biofilm and should therefore reduce levels of inflammation
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and help prevent primary and secondary plaque-associated peri-
odontal disease. Chlorhexidine digluconate has the ability to kill
a wide variety of micro-organisms including gram-positive and
gram-negative bacteria (aerobes and anaerobes) (Emilson 1977) as
well as fungi including yeasts (Greenstein 1986; Puig Silla 2008).
When chlorhexidine mouthrinse is used, the positively charged
(cationic) chlorhexidine molecule binds to the negatively charged
microbial cell wall and interferes with the osmotic equilibrium of
the micro-organism. Depending on the dose, chlorhexidine can
have a bacteriostatic or bacteriocidal effect. At low concentrations,
chlorhexidine is bacteriostatic causing leakage of low molecular
weight substances from the microbial cell and inhibiting repro-
duction. At higher concentrations chlorhexidine is bacteriocidal
and causes cell death by precipitating the cytoplasmic contents of
the microbial cell (Greenstein 1986; Puig Silla 2008). This abil-
ity of chlorhexidine to adsorb and adhere to negatively charged
surfaces is central to its success as an antimicrobial agent. The
chlorhexidine molecule has the ability to adsorb to anionic (neg-
atively charged) substrates such as hydroxyapatite, pellicle, sali-
vary glycoproteins and mucous membranes exerting an immedi-
ate bacteriocidal effect. When slowly released over time from the
pellicle-coated enamel surface, it provides a prolonged bacterio-
static effect in vivo (Bonesvoll 1974; Bonesvoll 1974a; Bonesvoll
1978; Jenkins 1988; Rolla 1971). This property of chlorhexidine
is known as its substantivity and is what sets chlorhexidine apart
from many other antimicrobial agents.
Chlorhexidine mouthrinse use is associated with a number of local
adverse effects the most common being the formation of brown
staining on the teeth and oral tissues, particularly the tongue
(Addy 1986). Several theories have been put forward to explain
the cause of this characteristic staining, however most evidence
points to the staining being a result of precipitation of anionic di-
etary chromogens (e.g. from tea, coffee, tannins from wine) onto
adsorbed chlorhexidine cations (Addy 1985; Addy 1985a; Watts
2001). Other less common local adverse effects have also been re-
ported including supragingival calculus accumulation (Eley 1999;
Mandel 1994; Van Strydonck 2012), oral mucosal lesions (Addy
1986; Flotra 1971; Van Strydonck 2012), and altered taste per-
ception (Addy 1986; Eley 1999; Marinone 2000; Van Strydonck
2012). The occurrence of side effects tends to be reduced with
lower chlorhexidine concentrations (Addy 1986; Cumming and
Löe 1973; Flotra 1971; Keijser 2003). With the exception of ex-
trinsic staining of the teeth and calculus accumulation which re-
quire removal by professional tooth cleaning, the adverse effects
are transient and resolve once chlorhexidine mouthrinse use has
ceased (Flotra 1971; Greenstein 1986). These local adverse effects
limit the use of chlorhexidine to short or moderate term use in
specific clinical circumstances (van derWeijden 2015). Chlorhex-
idine is poorly absorbed by the oral tissues and the gastrointestinal
tract and is considered to have very low toxicity (Foulkes 1973;
Greenstein 1986). Parotid gland swelling has been reported fol-
lowing chlorhexidine mouthrinse use (Addy 1986; Eley 1999; van
der Weijden 2010). There have been rare reports of type 1 hyper-
sensitivity reactions to chlorhexidine used in the mouth or on the
lips (Pemberton 2012) but severe reactions such as anaphylaxis
do not appear to have occurred as a result of using chlorhexidine
mouthrinse to maintain periodontal health.
Why it is important to do this review
Chlorhexidine mouthrinse is readily available and a prescription
is generally not required outside the USA (Moran 2008). Its effi-
cacy in controlling plaque and gingivitis in humans in the absence
of active oral hygiene was first demonstrated over 40 years ago
by Harald Löe and colleagues (Löe 1970). Nowadays chlorhexi-
dine mouthrinse is mostly used as an adjunct to regular mechan-
ical oral hygiene and is commonly regarded as the gold standard
against which other antiplaque agents are measured (Jones 1997;
Marsh 1992). The last decade has seen the publication of two
meta-analyses (Gunsolley 2006;Gunsolley 2010) and a number of
systematic reviews (including one metareview) of the effectiveness
of chlorhexidine mouthrinse (Boyle 2014; Serrano 2015; van der
Weijden 2015; Van Strydonck 2012). In most of these publica-
tions chlorhexidinemouthrinse was one of a number of antiplaque
chemical agents under review. The one dedicated review of the
effectiveness of chlorhexidine mouthrinse compared to placebo,
control or regular oral hygiene employed slightly different inclu-
sion criteria to this review but included tooth staining as an out-
come in addition to gingivitis and plaque (Van Strydonck 2012).
However, the search for this review was conducted in April 2011
and adverse effects other than extrinsic tooth staining were not
prespecified outcomes in the review.
Given the numerous clinical indications for the use of chlorhexi-
dine mouthrinse for gingivitis and plaque control, and the ready
availability of chlorhexidinemouthrinse over-the-counter inmany
parts of the world, it is important to conduct a Cochrane system-
atic review of chlorhexidine mouthrinse as an adjunctive treat-
ment for gingival health in order to provide, rigorous, up-to-date
evidence for patients, oral health practitioners and policy makers.
This should take into account the risk of bias of the studies that
have been conducted, as well as assessing the possible adverse ef-
fects of the chlorhexidine mouthrinse.
O B J E C T I V E S
To assess the effectiveness of chlorhexidine mouthrinse used as
an adjunct to mechanical oral hygiene procedures for the con-
trol of gingivitis and plaque compared to mechanical oral hy-
giene procedures alone ormechanical oral hygiene procedures plus
placebo/control mouthrinse. Mechanical oral hygiene procedures
were toothbrushing with/without the use of dental floss or inter-
dental cleaning aids and could include professional tooth clean-
ing/periodontal treatment.
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To determine whether the effect of chlorhexidine mouthrinse is
influenced by chlorhexidine concentration, or frequency of rinsing
(once/day versus twice/day).
To report anddescribe any adverse effects associatedwith chlorhex-
idine mouthrinse use (reporting of adverse effects is limited to
those detailed in the included trials).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel-group randomised controlled trials (RCTs)
irrespective of language or publication status where the duration
of mouthrinsing was at least 4 weeks.The minimum duration of
rinsing was selected to reflect the ’real life’ use of chlorhexidine
as a short-term adjunct to mechanical oral hygiene procedures.
Studies where the duration of mouthrinsing was less than 4 weeks
were excluded. Cross-over studies were excluded due to concerns
that chlorhexidine could exert an effect beyond the washout pe-
riod. It would not be possible to conduct a split-mouth study of
mouthrinse use, however split-mouth studies comparing different
scaling and root planing regimens and different periodontal sur-
gical techniques often incorporate a chlorhexidine and placebo/
control comparison. Such study designs were considered inappro-
priate to answer the question posed by this review and were ex-
cluded. We would have included properly designed cluster-RCTs
if any such studies had met the inclusion criteria.
Types of participants
We included RCTs involving children or adults with gingivitis
or periodontitis provided they were capable of performing nor-
mal mechanical oral hygiene procedures (in accordance with other
Cochrane reviews, we classified all participants aged 16 years or
less as children and those older than 16 years as adults). We in-
cluded trials where some or all of the participants had medical
conditions or special care needs as we considered the intervention
to be particularly relevant to these individuals/groups.
Types of interventions
Experimental intervention: chlorhexidinemouthrinse (used at any
concentration, volume, frequency or duration of rinsing) used
in conjunction with mechanical oral hygiene procedures (tooth-
brushing with/without the use of dental floss or interdental clean-
ing aids and could include professional tooth cleaning/periodontal
treatment).
Comparator interventions: mechanical oral hygiene alone (tooth-
brushing with/without the use of dental floss or interdental clean-
ing aids and could include professional tooth cleaning/periodontal
treatment), or mechanical oral hygiene used in conjunction with
placebo/control mouthrinse.
We included studies:
• where the chlorhexidine mouthrinse also contained
fluoride;
• where gum care or antigingivitis dentifrices (that did not
contain chlorhexidine) were used for mechanical oral hygiene
provided that they were used in both experimental and
comparator arms;
• with and without baseline prophylaxis (scale and polish)
but all study arms had to have the same treatment.
We excluded studies:
• where chlorhexidine mouthrinse was used as a monotherapy
in the absence of mechanical oral hygiene procedures;
• where the chlorhexidine mouthrinse formed part of a
combined intervention with other agents (such as other
chlorhexidine vehicles, e.g. dentifrice-containing chlorhexidine,
or other antimicrobial agents (e.g. cetylpyridinium chloride
(CPC)) that the comparator arm/s did not receive because we
would have been unable to separate the effect of the
chlorhexidine from the effect of the other active agents;
• where the mechanical oral hygiene procedures were not the
same in both the chlorhexidine mouthrinse and the comparator
arms e.g. studies or study arms where experimental or
comparator arms received more intensive or more frequent
professional mechanical cleaning or used additional mechanical
cleaning aids e.g. dental floss as part of the intervention that was
different from the other study arms;
• where chlorhexidine mouthrinse was applied locally e.g.
with a brush or via subgingival irrigation.
Types of outcome measures
Primary outcomes
Gingivitis measured using any appropriate index/scale.
Only trials that reported gingivitis as an outcome were considered
for inclusion in the review. The clinical features of gingivitis can
be assessed non-invasively by visual assessment of colour, contour
and gingival bleeding or invasively using an instrument to pro-
voke bleeding or both (Lorenz 2009). The Gingival Index of Löe
and Silness (GI) utilises both visual assessment and assessment of
bleeding on provocation. It can be measured at specific sites using
six index teeth (Löe and Silness 1963) or all teeth (Löe 1967).
Each site is scored on a 0 to 3 increasing scale and an average score
can be calculated for each tooth assessed. The mean score for an
individual represents an average score for the areas examined. The
Modified Gingival Index (MGI) (Lobene 1986) can be used as a
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full-mouth index or applied to selected teeth and is measured non-
invasively on a 0 to 4 increasing scale i.e. there is no attempt to use
pressure to elicit bleeding. Many indices measure gingivitis solely
by assessing bleeding on provocation but the techniques used to
elicit bleeding can vary between indices. The Gingival Bleeding
Index (Ainamo and Bay 1975) uses a blunt pocket probe to gently
probe the orifice of the gingival crevice. If bleeding occurs within
about 10 seconds after testing, a positive finding is recorded. The
percentage of sites with gingival bleeding are calculated for the
individual.
It is not uncommon for multiple measures of gingivitis to be pre-
sented within one study. Therefore the following hierarchy was
developed to simplify data extraction.
• Where gingival inflammation and gingival bleeding were
reported within the same study we extracted data on both
outcomes.
• Where gingival inflammation was reported using more than
one index within a study, the GI (Löe and Silness 1963; Löe
1967) was chosen over other indices and the MGI (Lobene
1986) was chosen next if the gingival index was not reported.
• Where gingival bleeding was reported within a study as
bleeding on probing (BOP) (Ainamo and Bay 1975) and the
proportion of sites with BOP using the GI (i.e. GI scores 2 or 3)
(Löe and Silness 1963; Löe 1967), BOP was chosen over the
proportion of sites with BOP (GI scores 2 or 3).
Within the gingival index, the severity (the average extent of the
disease) was considered a measure of gingival inflammation and
occurrence (the proportion of sites with BOP i.e. GI scores 2 or
3) was considered a measure of gingival bleeding.
Outcome data at 4 to 6weeks, 7 to 12weeks, 13weeks to 6months
and greater than 6 months were collected and reported but the
primary analysis of the gingivitis data was concerned with short-
term use (4 to 6 weeks), along with a longer term measure at 6
months.
Secondary outcomes
Data on the following secondary outcomes were extracted from
eligible trials that also reported gingivitis as an outcome.
• Dental plaque measured using any appropriate index/scale.
Although dental plaque can be measured using a variety of
different indices, the Plaque Index (Silness and Löe 1964) and
the Turesky modification of the Quigley and Hein index (TQH)
(Turesky 1970) are commonly used to measure dental plaque.
Both use an increasing scale to quantify the amount of plaque
present. The Plaque Index uses a 0 to 3 increasing scale to
quantify the amount of plaque on each surface (buccal, lingual,
mesial and distal) of six index teeth. An average score for each
tooth and for the individual can then be calculated. The TQH
uses a 0 to 5 increasing scale to quantify the amount of plaque on
the buccal and lingual surfaces of the teeth. An average score for
the individual can then be calculated. Where dental plaque was
measured using more than one index within a study; the Plaque
Index (Silness and Löe 1964) was chosen over other indices and
the TQH (Turesky 1970) was chosen next if the Plaque Index
was not reported.
• Calculus measured using any appropriate index/scale.
• Tooth staining measured using any appropriate index/scale.
• Adverse effects (e.g. mucosal desquamation, taste
disturbances, allergic reactions).
Search methods for identification of studies
Electronic searches
Cochrane Oral Health’s Information Specialist conducted system-
atic searches in the following databases for randomised controlled
trials and controlled clinical trials without language or publication
status restrictions:
• Cochrane Oral Health’s Trials Register (searched 28
September 2016) (Appendix 1);
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 8) in the Cochrane Library (searched
28 September 2016) (Appendix 2);
• MEDLINE Ovid (1946 to 28 September 2016) (Appendix
3);
• Embase Ovid (1980 to 28 September 2016) (Appendix 4);
• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature; 1937 to 28 September 2016)
(Appendix 5).
Subject strategiesweremodelled on the search strategy designed for
MEDLINE Ovid. Where appropriate, they were combined with
subject strategy adaptations of the highly sensitive search strategy
designed by Cochrane for identifying randomised controlled trials
and controlled clinical trials as described in theCochraneHandbook
for Systematic Reviews of Interventions Chapter 6 (Lefebvre 2011).
Searching other resources
We searched the following trial registries for ongoing studies:
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (clinicaltrials.gov; searched 28 September
2016) (Appendix 6);
• World Health Organization International Clinical Trials
Registry Platform (apps.who.int/trialsearch; searched 28
September 2016) (Appendix 7).
We searched the reference lists of included studies and relevant sys-
tematic reviews for further studies. We attempted to contact com-
panies that manufacture chlorhexidine mouthrinse (Colgate Pal-
molive (Periogard), 3M (Peridex), GlaxoSmithKline (Corsodyl))
and companies that manufacture other types of mouthrinse (John-
son & Johnson (Listerine), P&G (Oral B brand)) to identify un-
published and ongoing studies.
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We did not perform a separate search for adverse effects of inter-
ventions. Only the adverse effects that were described in the in-
cluded studies were considered.
Data collection and analysis
Selection of studies
Two review authors independently and in duplicate screened the
titles and abstracts of the list of studies identified by the search-
ing process against the inclusion criteria for the review to iden-
tify eligible and potentially eligible studies. We obtained full-text
copies of all the potentially eligible studies, and also of studies with
insufficient information in the title/abstract to make a decision
on eligibility. The review authors were not blinded to the journal
name, authors, institution, results or sources of funding when as-
sessing eligibility of the identified studies. Two review authors in-
dependently and in duplicate assessed the full-text copies to iden-
tify those that met the inclusion criteria. We contacted study au-
thors for clarification or missing information relating to eligibility
where necessary and feasible. We linked multiple reports of the
same study together under one single study title. We resolved any
disagreements on eligibility through discussion but, if this was not
possible, an experienced member of the Cochrane Oral Health
editorial team (HWorthington) was consulted to achieve consen-
sus. We recorded any studies failing to meet the inclusion criteria,
along with reasons for exclusion.
The eligibility of the non-English language reportswere assessed by
two review authors independently and in duplicate. Relevant sec-
tions of the reports were translated with the assistance of Cochrane
Oral Health. Non-English language reports that met the inclusion
criteria for the review were translated in full.
This process is summarised in the ’Study flow diagram’ (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
Two review authors independently and in duplicate extracted data
from the included studies using a customised Excel spreadsheet
that was piloted on a small sample of studies. We contacted study
authors for clarification or missing information where necessary
and feasible. We resolved any disagreements through discussion
and where agreement could not be reached, an experienced mem-
ber of the Cochrane Oral Health editorial team (HWorthington)
was consulted to achieve consensus.
We recorded the following data for each included study, which
were then tabulated in the ’Characteristics of included studies’
tables.
• Trial design, location/setting, number of centres, study
duration.
• Details of the participants including demographic
characteristics, criteria for inclusion and exclusion, and relevant
information on gingivitis levels at baseline, numbers randomised
to each study arm, and numbers analysed in each arm.
• Details of the type of experimental/comparator
intervention, concentration and volume of mouthrinse,
frequency and duration of rinsing, baseline prophylaxis (scale
and polish), details of oral hygiene instruction (OHI),
supervision of mouthrinsing, timing of mouthrinsing in relation
to toothbrushing and postrinsing instructions.
• Details of the outcomes reported, including method and
timing of assessment.
• Sample size calculations, source of study funding,
information about adverse effects, proportion of smokers in the
studies/study arms and declarations/conflicts of interest.
• Outcome data: For gingivitis and plaque we extracted
outcome data from the end point of each study with the
exception of studies where the duration of rinsing was longer
than 6 months. In this situation interim data for gingivitis and
plaque at 6 months were extracted in addition to data at the end
point of the study. We considered interim data on extrinsic tooth
staining and calculus formation important in determining the
time of onset of these adverse effects. Therefore, where they were
reported, data on extrinsic tooth staining and calculus formation
were extracted at interim time points as well as at the end point
of each study. Outcome data were grouped according the
following time intervals: 4 to 6 weeks, 7 to 12 weeks, 13 weeks
to 6 months and greater than 6 months. Where data on extrinsic
tooth staining or calculus were reported twice within one time
interval, the later results were data extracted. Where an outcome
was measured after rinsing has ceased, we considered the time
point that rinsing ceased as the primary end point. Studies that
measured gingivitis and plaque outcomes only after cessation of
rinsing were included in a separate analysis of the long-term
effects of rinsing with chlorhexidine mouthrinse on gingivitis
and plaque. We did not extract extrinsic tooth staining and
calculus data reported after rinsing had ceased.
• Where studies reported mean scores for the Gingival Index
at 4 to 6 weeks or 6 months but did not report a measure of
variance and a measure of variance could not be obtained from
the authors of the studies, the variance was estimated from the
standard deviations reported in similar trials that used the same
index at the same time point as described in Chapter 16 of the
Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Where mean scores and measures of variance
were reported only in graphs and the data could not be obtained
from the authors of the studies, data were estimated by reading
the data off the graphs in the published report for inclusion in
meta-analyses. The graphs were enlarged and the data were
estimated independently and in duplicate. Any disagreements
were resolved by discussion. A sensitivity analysis was conducted
to gauge the effects of estimating these outcome data on the
overall results.
Assessment of risk of bias in included studies
Two review authors assessed the risk of bias of all included studies,
independently and in duplicate, using Cochrane’s domain-based,
two-part tool as described in Chapter 8 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We con-
tacted study authors for clarification ormissing information where
necessary and feasible. We tried to resolve any disagreements on
risk of bias through discussion but, if this was not possible, an ex-
periencedmember of the Cochrane Oral Health editorial team (H
Worthington) was consulted to achieve consensus. A ’Risk of bias’
table was completed for each included study. For each domain of
risk of bias, we first described what was reported to have happened
in the study in order to provide a rationale for the second part,
which involved assigning a judgement of ’low risk’ of bias, ’high
risk’ of bias, or ’unclear risk’ of bias.
For each included study, we assessed the following seven domains
of risk of bias.
• Random sequence generation (selection bias): use of simple
randomisation (e.g. random number table, computer-generated
randomisation, central randomisation by a specialised unit),
restricted randomisation (e.g. random permuted blocks),
stratified randomisation and minimisation were assessed as at
low risk of bias. Other forms of simple randomisation, such as
repeated coin tossing, throwing dice or dealing cards, were also
considered as at low risk of bias. If a study report used the phrase
’randomised’ or ’random allocation’ but with no further
information, and if randomisation could not be confirmed, we
assessed it as unclear for this domain.
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• Allocation concealment (selection bias): use of centralised/
remote allocation, pharmacy-controlled randomisation (i.e.
allocation of sequentially numbered mouthrinse containers of
identical appearance) and sequentially numbered, sealed, opaque
envelopes were assessed as at low risk of bias. If a study report did
not mention allocation concealment, we assessed it as unclear for
this domain.
• Blinding of participants and personnel (performance bias):
if blinding was not mentioned, we assessed this domain as at
unclear risk of bias. We only considered personnel blinding for
studies with supervised mouthrinsing. If a study was described as
double blind, we assumed that the intention was for participants
and outcome assessors to be blinded to group allocation, however
due to the propensity for chlorhexidine to stain the teeth and
oral tissues and the association of its use with visible adverse
effects such as mucosal desquamation and mucosal lesions, we
considered the potential effect of these on blinding as follows.
◦ Where tooth staining/adverse effects were reported
narratively or measured using a scale (where relevant) and were
higher in the chlorhexidine rinse arm/s, we considered that
participants could have worked out which study arm they were
in and this could have affected their oral health behaviours and
hence the outcome and assessed this domain as at high risk of
bias irrespective of whether participant blinding was indicated.
◦ Where tooth staining/adverse effects were reported
narratively or measured using a scale (where relevant) but were
not higher in the chlorhexidine rinse arm/s and participant
blinding was also indicated, we assessed this domain as at low
risk of bias.
◦ Where tooth staining/adverse effects were not
reported, although we considered it likely in this situation that
tooth staining or other visible adverse effects could have occurred
and been noticeable in the chlorhexidine rinse arm/s after 4
weeks or more of rinsing, we assessed this domain as unclear as
there was not enough information upon which to base a
judgement.
◦ Where it was not possible to blind participants and
personnel due to differences in the experimental and comparator
interventions this domain was assessed as at high risk of bias.
• Blinding of outcome assessment (detection bias): if blinding
was not mentioned, we assessed this domain as at unclear risk of
bias. If a study was described as double blind, we assumed that
the intention was for participants and outcome assessors to be
blinded to group allocation, however due to the propensity for
chlorhexidine to stain the teeth and oral tissues and the
association of its use with visible adverse effects such as mucosal
desquamation and mucosal lesions, we considered the potential
effect of these on blinding as follows.
◦ Where tooth staining/adverse effects such as mucosal
desquamation and mucosal lesions that could be visible to the
outcome assessor were reported narratively or measured using a
scale (where relevant) and were higher in the chlorhexidine arm/
s, we considered that outcome assessors could have worked out
which study arm participants were in and therefore could not be
adequately blinded. In this situation we assessed this domain as
at high risk of bias irrespective of whether blinding of outcome
assessment was indicated.
◦ Where tooth staining/adverse effects such as mucosal
desquamation and mucosal lesions that could be visible to the
outcome assessor were reported narratively or measured using a
scale (where relevant) but were not higher in the chlorhexidine
arm/s and blinding of outcome assessment was also indicated, we
assessed this domain as at low risk of bias.
◦ Where tooth staining/adverse effects such as mucosal
desquamation and mucosal lesions that could be visible to the
outcome assessor were not reported, although we considered it
likely that tooth staining or other visible adverse effects could
have occurred and been noticeable in the chlorhexidine arm/s
after 4 weeks of more of rinsing, we assessed this domain as
unclear as there was not enough information upon which to base
a judgement.
• Incomplete outcome data (attrition bias): if 10% or less of
randomised participants were excluded from the analysis, we
assessed this as at low risk of bias. However, when attrition was
greater than 10%, assuming the missing participants in one
group had a higher mean (e.g. gingivitis score) than those in the
other group, as the attrition rate increased, so would the mean
difference (MD) between groups, as described in Chapter 8 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). This situation led to a judgement of high risk of
bias if we believed that the attrition was high enough to have
resulted in a distortion of the true intervention effect, or if there
was considerably greater attrition in one group than another. If
attrition was greater than 10%, but with the additional factors of
not being reported by group and insufficient reporting of reasons
for attrition, this led to a judgement of unclear risk of bias. If it
was not clear from the study report how many participants were
randomised into each group, we assessed it as at unclear risk of
bias for this domain.
• Selective reporting (reporting bias): if the study either
reported outcomes not stated a priori in the methods section or
the study protocol (if available) or did not report outcomes
stated in the methods section, we assessed this as at high risk of
bias. If gingivitis and plaque outcomes were reported with
insufficient information to allow us to use the outcome data in a
meta-analysis (e.g. no information on variance), we assessed it as
at high risk of bias. We considered the reporting of adverse
effects associated with the use of chlorhexidine mouthrinse to be
important outcomes. For an assessment of low risk of bias we
required either a statement that there were no adverse effects
associated with the chlorhexidine rinse or if present, that adverse
effects be reported by group. Where tooth staining was not
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reported or was measured using an index but insufficient data
were reported to allow us to use the data in a meta-analysis we
assessed it as at high risk of bias. Where tooth staining was not
measured using an index but its presence/absence was reported
we assessed this as at low risk of bias, provided that the
information was reported for all participants by group.
• Other bias: any other potential source of bias that may
feasibly alter the magnitude of the effect estimate (e.g. baseline
imbalances in potentially important prognostic factors between
intervention groups and differential diagnostic activity by
outcome assessors).
We summarised the risk of bias as follows.
Risk of bias Interpretation In outcome In included studies
Low risk of bias Plausible bias unlikely to seriously
alter the results
Low risk of bias for all key domains Most information is from studies at
low risk of bias
Unclear risk of bias Plausible bias that raises some
doubt about the results
Unclear risk of bias for one or more
key domains
Most information is from studies at
low or unclear risk of bias
High risk of bias Plausible bias that seriously weak-
ens confidence in the results
High risk of bias for one or more
key domains
The proportion of information
from studies at high risk of bias is
sufficient to affect the interpreta-
tion of results
Unit of analysis issues
The participant was the unit of analysis. We were unable to use
data from studies that reported number of sites rather than number
of individuals in the meta-analyses, as failure to take the clustering
into account could lead to an overestimate of effect, with narrower
confidence intervals and smaller P values. Had we included clus-
ter-RCTs we would have analysed the results taking account of the
clustering present in the data, otherwise we would have used the
methods outlined in Section 16.3.4 of the Cochrane Handbook for
Systematic Reviews of Interventions in order to perform an approx-
imately correct analysis (Higgins 2011).
Dealing with missing data
We attempted, where feasible, to contact the authors of studies
to obtain missing data or for clarification. Where appropriate, we
used the methods outlined in Chapter 16 of the Cochrane Hand-
book for Systematic Reviews of Interventions in order to estimate
missing standard deviations for themain outcome only (gingivitis)
(Higgins 2011). We did not use any further statistical methods
or carry out any further imputation to account for missing data.
Where mean scores and measures of variance were only reported
in graphs and could not be obtained from the authors of the stud-
ies, data were estimated by reading the data off the graphs in the
published report for inclusion in meta-analyses. The graphs were
enlarged and the data were estimated independently and in dupli-
cate. Any disagreements were resolved by discussion.
Assessment of heterogeneity
If meta-analyses were performed, we assessed the possible presence
of heterogeneity visually by inspecting the point estimates and
confidence intervals on the forest plots; if the confidence intervals
had poor overlap then heterogeneity was considered to be present.
We also assessed heterogeneity statistically using a Chi2 test, where
a P value < 0.1 indicated statistically significant heterogeneity.
Furthermore, we quantified heterogeneity using the I2 statistic. A
guide to interpretation of the I2 statistic given in Section 9.5.2 of
the Cochrane Handbook for Systematic Reviews of Interventions is as
follows (Higgins 2011):
• 0% to 40%: might not be important;
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• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
Assessment of reporting bias within studies has already been de-
scribed in the sectionAssessment of risk of bias in included studies.
Reporting biases can occur when reporting (or not reporting) re-
search findings is related to the results of the research (e.g. a study
that did not find a statistically significant difference/resultmay not
be published). Reporting bias can also occur if ongoing studies
are missed (but that may be published by the time the systematic
review is published), or if multiple reports of the same study are
published, or if studies are not included in a systematic review due
to not being reported in the language of the review authors. We
attempted to limit reporting bias in the first instance by conduct-
ing a detailed, sensitive search, including searching for ongoing
studies, and any studies not reported in English were translated.
If there were more than 10 studies included in a meta-analysis for
the primary outcome (gingivitis), we assessed the possible pres-
ence of reporting bias by testing for asymmetry in a funnel plot.
We carried out statistical analysis using the methods described by
Egger 1997 for continuous outcomes.
Data synthesis
We carried out a meta-analysis only where studies of similar com-
parisons reported the same outcomes at the same time interval.We
combined mean differences (MDs) where studies used the same
scale and standardised mean differences (SMDs) where studies
used different scales for continuous outcomes. For dichotomous
outcomes, we reported risk ratios (RR) and 95% confidence in-
tervals. Due to anticipated heterogeneity we used random-effects
models for all meta-analyses.
We reported the results from studies not suitable for inclusion in
a meta-analysis both in the results and in additional tables.
Subgroup analysis and investigation of heterogeneity
Where there were sufficient studies, we carried out the following
subgroup analyses.
• Baseline prophylaxis (scale and polish) versus none.
• Children versus adults.
• Different chlorhexidine concentrations.
• Initial levels of gingivitis.
• Gingivitis only versus gingivitis + periodontitis.
Sensitivity analysis
In order to ensure our conclusions were robust, we carried out sen-
sitivity analyses (where there were sufficient studies for each out-
come) by excluding studies where outcome data were read from
graphs, studies where standard deviationswere estimated and stud-
ies where periodontal treatment was conducted during the study.
Wewould have carried out sensitivity analyses by excluding studies
at high and unclear risk of bias, however this was not possible as
apart from one study at unclear risk of bias, all of the included
studies were at high risk of bias.
Presentation of main results
We produced a ’Summary of findings’ table for chlorhexi-
dine mouthrinse compared to placebo/control mouthrinse or no
mouthrinse for the following outcomes: gingivitis measured us-
ing the Gingival Index at 4 to 6 weeks, plaque at 4 to 6 weeks,
tooth staining at 4 to 6 weeks and other adverse effects. We
used GRADE methods (GRADE 2004), and the GRADEpro
GDT online tool for developing ’Summary of findings’ tables (
www.guidelinedevelopment.org). We assessed the quality of the
body of evidence for each outcome by considering the overall risk
of bias of the included studies, the directness of the evidence, the
inconsistency of the results, the precision of the estimates, and the
risk of publication bias. We categorised the quality of each body
of evidence as high, moderate, low, or very low.
R E S U L T S
Description of studies
Results of the search
The searches resulted in 1520 references after de-duplication. Two
review authors screened the titles against the inclusion criteria for
this review, independently and in duplicate, discarding 1424 ref-
erences in the process. We obtained full-text copies of the remain-
ing 96 references (94 studies) and examined them independently
and in duplicate, excluding 38 studies at this stage. A further four
studies are awaiting assessment of their eligibility to be included in
the review and one study is ongoing. Therefore, fifty-one studies
(53 records) met the inclusion criteria for this review. This process
is presented diagrammatically in Figure 1.
Included studies
Characteristics of the trial designs and settings
Fifty-one studiesmet the inclusion criteria for this review. All stud-
ies were of parallel-group design. Sixteen studies had two study
arms and compared chlorhexidine rinse with placebo rinse. How-
ever, thirty-five studies had multiple study arms and not all study
arms were relevant to this review. Twenty-two studies had three
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arms; 10 had four arms and two had five arms. One of the studies
with four study arms (Flotra 1972) had three chlorhexidine rinse
groups and one placebo rinse group but presented data only for
two groups: the three chlorhexidine study arms combined and the
placebo group. One additional study (Feres 2012) had three main
therapeutic arms which were each divided into chlorhexidine rinse
and placebo rinse groups using a 2 x 3 factorial design.
Sixteen studies were conducted in the USA, six in Brazil, five in the
UK, four in Germany, three in India, three in Sweden, two in each
of the following countries: Canada, Mexico and Spain, and one
in each of the following countries: Argentina, China, Iran, Italy,
Norway, Switzerland, the Netherlands and Turkey. The settings of
the studies were diverse and often poorly reported. Twenty-seven
studies were conducted in a dental school/university setting and an
additional three studies were assumed, based on the information
provided, to have been conducted in a dental school/university set-
ting (Emling 1992; Pereira 2011; Van Strydonck 2008). Two stud-
ies were conducted under “dental office conditions” (Grossman
1986; Grossman 1989), two in general dental practices (Eaton
1997; Fine 1985) and one in a private practice limited to peri-
odontics (Sanz 1989). Three studies were conducted in a school
setting (de la Rosa 1988; de la Rosa 1988b; Jayaprakash 2007).
The remaining studieswere conducted inmilitary garrisons (Flotra
1972;Hase 1998); pensioners/nursinghomes (Lopez-Jornet 2012;
Weitz 1992); a bone marrow transplant unit (Ferretti 1987) and
a knitting factory (Corbet 1997). Three studies were conducted
at what we assumed were clinical research facilities (Charles 2004;
Jose 2015; Stookey 2005) and in four studies the setting of the
study was not clear (Flemmig 1990; Hase 1995; Sanz 1994; Taller
1993). The numbers of centres involved in the studies was often
unclear but it appeared that all but two of the studies were con-
ducted at a single centre. One study (Eaton 1997) was conducted
at five suburban dental practices in Southern England and another
study (Jose 2015) was conducted at two sites (Manchester and
Wirral) in the UK.
In 19 studies direct support from industry was explicitly stated.
Nine studies received support from P&G; three from GSK; two
from Teledyne and one from each of the following companies:
GABA, J&J, Oral B, Smithkline Beecham and Warner Lambert.
Three studies that did not appear to be funded directly by industry
explicitly stated that oral care products used in the study had been
provided by industry (Anderson 1997; Sanz 1994; Stookey 2005).
Three studies (Hase 1995;Hase 1998; Lang 1998) were associated
with Biosurface PharmaAB through authorship and another study
was associated with ’Dental Products Testing’ and Pfizer through
authorship (Charles 2004).Of the remaining studies that reported
a source of support, two appeared to be funded by universities (
Rahmani 2006; Taller 1993); six appeared to be funded by research
grants (Anauate-Netto 2014; Bajaj 2011; Corbet 1997; Faveri
2006; Feres 2009; Feres 2012); and in 17 studies there was no
statement regarding funding or support. Only one study (Zimmer
2015) stated that the conduct of the research and final decisions
regarding the study report were independent of the funder (GSK).
Only 13of the studies described a sample size calculation. For six of
these studies (Faveri 2006; Feres 2009; Feres 2012; Graziani 2015;
Turkoglu 2009; Van Strydonck 2008) the sample size required was
reported and achieved but for three of these studies the sample
size was based on pocket probing depth (PPD) (Faveri 2006; Feres
2012) and clinical attachment loss (CAL) (Feres 2009) rather than
gingivitis. Two studies reported the sample size calculation and
number of participants required in each group but the minimum
sample size was not achieved at the end of the studies (Hase 1998;
Lang 1998). Five of the studies (Axelsson 1987; Brightman 1991;
Charles 2004; Eaton 1997; Zimmer 2015) described the sample
size calculation but not the required sample size so we were unable
to determine if the required sample size was achieved. In one study
the sample size calculation was not described but the required
sample size was reported and achieved (Bhat 2014).
Characteristics of the participants
A total of 6995 participants provided data for the included studies.
The total number of participants providing data for the study arms
relevant to this review (excluding the irrelevant study arms) was
5345 with the numbers analysed in each study ranging from 20
to 852.
Six studies involved children and adolescents (Anderson 1997;
Bajaj 2011; Brightman 1991; de la Rosa 1988; de la Rosa 1988b;
Jayaprakash 2007). The age range of the children was 8 to 16 and
three of these studies also included some young adults aged 17 and
18 (Brightman 1991; de la Rosa 1988; de la Rosa 1988b). Four
studies while predominantly focused on adults, included children
and adolescents among the participants: in Axelsson 1987 partic-
ipants were aged 16 to 50 years old; in Fine 1985 no participants
under the age of 12 were included; and in Navarro 1998 the age
range of participants was 14 to 35 years old. In Ferretti 1987, a
study involving individuals undergoing bone marrow transplanta-
tion and chemoradiotherapy, the age range was 5 to 51 years old.
The remaining forty-one studies involved adults. The age range of
adult participants was 17 to 94 years with the mean age ranging
from 20 to 83.
Twenty-two studies had a greater proportion of females thanmales
and in four studies, the proportion of males was greater (Lang
1998; Southern 2006; Stookey 2005; Taller 1993). In five stud-
ies there was an equal balance of males to females (Bhat 2014;
Graziani 2015; Pereira 2011; Turkoglu 2009; Zimmer 2006). Five
studies involved male participants only (de la Rosa 1988; de la
Rosa 1988b; Hase 1995; Hase 1998; Navarro 1998) and in the
remaining 15 studies, the proportion of males to females was not
reported. Eight studies included smokers among the participants
(Charles 2004; Eaton1997; Ernst 2005; Jose 2015; Joyston-Bechal
1993; Overholser 1990; Zimmer 2006; Zimmer 2015) with the
proportion of smokers in each study ranging from 11% to 41%.
10 studies excluded smokers and in the remaining 33 studies, the
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smoking status of the participants was not reported.
Twenty-four studies reported gingivitis at baseline using the Gin-
gival Index of Löe and Silness (Löe and Silness 1963; Löe 1967).
In one study involving dental students (Lucas 1999) where normal
gingiva were obtained in a pre-experimental phase by scaling and
polishing and twice daily brushing, the mean baseline gingivitis
score was zero. In two other studies (Navarro 1998; Jayaprakash
2007) gingivitis at baseline was particularly low, mean gingival
index scores were 0.049 and 0.057 respectively. In the remaining
21 studies the mean gingival index ranged from 0.53 to 1.87 with
an overall mean of 1.09.
In many of the included studies, the periodontal status of the par-
ticipants was not explicitly described. In 15 studies, the partici-
pants appeared to have gingivitis but no periodontitis whereas in
nine studies, the participants had periodontitis of varying severity
in addition to gingivitis (Chaves 1994; Corbet 1997; Ernst 2005;
Faveri 2006; Feres 2009; Feres 2012; Graziani 2015; Rahmani
2006; Sanz 1989). In three of these studies the periodontitis was
untreated at baseline (Faveri 2006; Feres 2009; Feres 2012) and
in one study the participants required osseous periodontal surgery
(Sanz 1989). In 16 studies it was unclear whether the participants
had periodontitis in addition to gingivitis but it was deemed likely
that at least some of the participants in these studies had periodon-
titis; two studies involved older adults (Lopez-Jornet 2012 (aged >
65 years) and Weitz 1992 (mean age 83)) and in the remaining 14
studies, the inclusion criteria allowed for the participants to have
deep pockets and clinical attachment loss but the periodontal sta-
tus of the people actually included in the study was not described.
In 11 studies the participants clearly had gingivitis at baseline, but
it was unclear whether the participants also had periodontitis.
Characteristics of the interventions
Nine studies compared chlorhexidine rinse and mechanical oral
hygiene with mechanical oral hygiene alone.Two of these stud-
ies had additional chlorhexidine mouthrinse arms that were also
included in the analysis (Jose 2015; Zimmer 2015). All of these
studies except Jose 2015 also had additional arms that were not
relevant to this review. Forty-two studies compared chlorhexidine
rinse with placebo or control rinse. Six of these studies had addi-
tional chlorhexidine mouthrinse arms. Data from five of these six
studies were included in the analysis (Flotra 1972; Graziani 2015;
Hoffmann 2001; Jayaprakash 2007; Overholser 1990; Segreto
1986).We couldnot include data from the three separate chlorhex-
idine arms for Flotra 1972 because the authors combined the three
arms into one experimental group. Twenty of these 42 studies
comparing chlorhexidine rinse with placebo or control rinse also
had additional arms that were not relevant to this review.
Of the studies with one concentration of chlorhexidine
mouthrinse, 10 evaluated 0.2% chlorhexidine mouthrinse; 29
evaluated 0.12% chlorhexidine mouthrinse; two evaluated 0.1%
chlorhexidine mouthrinse (Bajaj 2011; Ernst 2005) and four eval-
uated 0.05% or 0.06% chlorhexidine mouthrinse (Jayaprakash
2007; Joyston-Bechal 1993; Zimmer 2006; Zimmer 2015). Four
studies had additional arms evaluatingdifferent chlorhexidine con-
centrations (Axelsson 1987; Flotra 1972;Hoffmann 2001; Segreto
1986) and in two studies, the concentration of the chlorhexidine
rinse was not reported (Fine 1985; Turkoglu 2009).
Most of the studies evaluating 0.2% chlorhexidine mouthrinse
used a volume of 10 mL twice daily for one minute whereas most
of the studies evaluating 0.1%or 0.12%chlorhexidinemouthrinse
used a volume of 15 mL twice daily. Duration of rinsing for the
studies of 0.1% and 0.12% chlorhexidine mouthrinse varied from
30 seconds to 1 minute but most of the studies employed a 30-
second rinse. The studies of 0.05% and 0.06% chlorhexidine
mouthrinse predominantly used a volume of 10 mL once or twice
a day for 30 seconds. In some studies with multiple arms differ-
ent volumes of rinse were used in different arms: in three studies
the placebo/control arms and other non-chlorhexidine active rinse
groups rinsed with 20 mL while the chlorhexidine arms rinsed
with 10 mL (Axelsson 1987) or 15 mL (Charles 2004; Overholser
1990); in another study the 0.1% chlorhexidine arm rinsed with
15 mL while the two 0.06% chlorhexidine arms used 10 mL of
rinse (Hoffmann 2001).
In six studies the volume of rinse used by participants was not
reported. In three of these studies participants rinsed twice daily
but rinse volume and duration were not reported (Chaves 1994;
Rahmani 2006; Sanz 1994). In two of the studies, participants
rinsed once a day for 30 seconds with an unknown volume of
rinse (Fine 1985; Zimmer 2006). In another study rinse volume,
frequency and duration were not reported (Emling 1992).
Of the nine studies that compared chlorhexidine rinse and me-
chanical oral hygiene with mechanical oral hygiene alone, six in-
volved regular mechanical cleaning using a toothbrush and tooth-
paste (Chaves 1994; Flemmig 1990; Jose 2015; Taller 1993;
Zimmer 2006; Zimmer 2015). In one study floss and wood points
were also used by participants (Fine 1985). In another study partic-
ipants underwent conventional ultrasonic debridement (Rahmani
2006) and were given interdental cleaning aids, and participants
in a further study used a toothbrush and no toothpaste (Van
Strydonck 2008).
Thirty-five of the 51 studies compared chlorhexidine mouthrinse
with placebo and seven studies compared chlorhexidine
mouthrinse with control. The control rinses were 5% hydroal-
cohol solution (Charles 2004); coloured and flavoured 5% hy-
droalcohol solution (Overholser 1990); 0.5% benzene alcohol
(Flotra 1972); saline (Bhat 2014; Graziani 2015) and water (Bajaj
2011; Hoffmann 2001). In one of these studies comparing 0.2%
chlorhexidinemouthrinse with placebo rinse, participants were in-
structed to brush without toothpaste before using the mouthrinse
(Hase 1995). In another study comparing 0.12% chlorhexidine
mouthrinse with placebo rinse, all participants used a gum care
dentifrice (Blend-a-med) (Sanz 1994).
Thirty-six studies reported a baseline prophylaxis to remove plaque
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and thus assess the potential for chlorhexidine mouthrinse to in-
hibit plaque accumulation and its ability to reduce gingivitis. In
two of the studies that reported a baseline prophylaxis, an addi-
tional prophylaxis was also provided 2weeks before baseline (Brecx
1993; Hoffmann 2001). In another study the baseline prophylaxis
was conducted during the first week of the study (Stookey 2005).
Participants in eight of the nine studies in which some or all of
the participants had periodontitis at baseline either had profes-
sional prophylaxis at baseline (Chaves 1994; Ernst 2005; Graziani
2015), or adjunctive professional non-surgical (Faveri 2006; Feres
2009; Feres 2012; Rahmani 2006) or surgical periodontal treat-
ment (Sanz 1989) during the study. In the three studies where the
participants with periodontitis had a professional prophylaxis at
baseline only, scaling and polishing was supragingival (Graziani
2015) or the extent of the professional cleaning was not clear
(Chaves 1994; Ernst 2005).
Participants in six studies did not have a baseline prophylaxis.
These studies were thus designed to assess the potential for
chlorhexidine mouthrinse to reduce plaque and gingivitis in indi-
viduals who do not obtain professional tooth cleaning or scaling
prior to commencing mouthrinse use (Corbet 1997; Jayaprakash
2007; Jenkins 1993; Lopez-Jornet 2012; Southern 2006; Weitz
1992). One of these studies included participants with untreated
periodontitis (Corbet 1997). Participants in this study received
no professional prophylaxis and no oral hygiene instructions. In
seven studies it was not clear whether a baseline prophylaxis had
been carried out (Anauate-Netto 2014; Bajaj 2011; Bhat 2014;
Emling 1992; Taller 1993; Turkoglu 2009; Zimmer 2015). In one
study (Zimmer 2006), the screening examination was followed by
calculus removal in the lower front teeth only. In another study,
where it was not clear whether the participants had periodontitis
in addition to gingivitis, there was no prophylaxis at baseline but
supragingival scaling was performed at week 9 and subgingival
scaling was performed after 13 weeks (Flotra 1972).
Twenty-two studies reported that participants received some form
of oral hygiene instruction. Where details were reported about
the oral hygiene instruction, it usually involved instruction about
toothbrushing technique. In two studies, oral hygiene instruction
included instruction in the use of interdental cleaning aids (i.e. in-
terdental brushes or dental floss or both) (Chaves 1994; Graziani
2015) and in another three studies participants were given inter-
dental cleaning aids; presumably instruction in their use was in-
cluded in the oral hygiene instruction but this not clear from the
text (Fine 1985; Rahmani 2006; Taller 1993). In two studies par-
ticipants were advised on duration and frequency of brushing but
not technique (Pereira 2011; Van Strydonck 2008) and in another
study, participants were given brief instruction about using the
toothbrush they were given but were not given any instructions
about duration or technique of toothbrushing (Zimmer 2006).
The participants in 27 studies did not receive any oral hygiene in-
struction. In 18 of these studies participants were advised to con-
tinue their usual oral hygiene practices throughout the duration
of the studies. The participants in one of these 18 studies (Ferretti
1987) were undergoing bone marrow transplant and chemoradio-
therapy and their usual oral hygiene regimen involved oral clean-
ing with a foam rubber toothbrush substitute and saline solution
irrigations. In another of these studies where continuation of usual
oral hygiene practices was advised, it was explicitly stated that use
of interproximal cleaning devices was permitted if they were part
of participants’ usual oral hygiene routine (Zimmer 2015). In two
studies it was not clear whether participants received oral hygiene
instruction (Bajaj 2011; Stookey 2005). In one of these studies
toothbrushing was supervised Monday to Friday in the mornings
but it is not clear if oral hygiene instructions were provided to
participants (Stookey 2005).
In 38 studies mouthrinsing was unsupervised. Mouthrinsing was
fully supervised in only three studies, all conducted in a school
setting (de la Rosa 1988; de la Rosa 1988b; Jayaprakash 2007).
In 10 studies mouthrinsing was partially supervised for practical
reasons. In five of the studies mouthrinsing was fully supervised
on weekdays only (Axelsson 1987; Bajaj 2011; Bhat 2014; Lang
1998;Overholser 1990); in another two studies,mouthrinsingwas
supervised once a day on weekdays only (Charles 2004; Stookey
2005). In another three studies the mouthrinsing was supervised
except for two weeks during the Chinese New Year (Corbet 1997);
after participants were discharged from hospital (Ferretti 1987)
and when participants were at military training (Hase 1998).
Thirty studies reported instructing participants to use the
mouthrinse after toothbrushing. Three of these studies speci-
fied waiting 30 minutes after toothbrushing before using the
mouthrinse (Feres 2012; Turkoglu 2009; Zimmer 2015). One
of these studies specified waiting five timed minutes before
mouthrinsing (Jose 2015). One study reported instructing par-
ticipants to use mouthrinse at a separate time to toothbrush-
ing (Charles 2004). In the remaining 20 studies the timing of
mouthrinsing in relation to toothbrushing was not reported.
Inmost of the studies the duration of the intervention (mouthrins-
ing with chlorhexidine) was 6 months or less broken down as fol-
lows: 4 to 6 weeks (15 studies); 2 months (9 studies); 10 weeks (1
study); 3 months (9 studies); 4 months (2 studies) or 6 months
(13 studies). In two studies the duration of the intervention was
longer than 6 months; one study of 9 months’ duration (Bajaj
2011) and another of 24 months’ duration (Banting 1989).
Inmost studies the final follow-up assessment was at the end of the
intervention phase. However in four studies participants ceased
mouthrinsing before the final outcome assessment. In these studies
the final assessment of the outcomes was carried out 4 weeks (
Faveri 2006; Ferretti 1987), 4months (Feres 2009) and 10months
(Feres 2012) after mouthrinsing had ceased. For this review, we
considered the time that mouthrinsing ceased to be the primary
end point for data extraction.
Characteristics of the outcomes
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Gingivitis
Gingival inflammation
Thirty-eight studies included gingival inflammation as an out-
come. The most commonly used index for measuring gingival
inflammation was the Gingival Index of Löe and Silness (GI)
(Löe and Silness 1963; Löe 1967). The following indices were
also used to measure gingival inflammation: the Modified Gin-
gival Index (MGI) (Lobene 1986), the Papillary Bleeding Score
(PBS) (Loesche 1979), and the Papillary Marginal Gingival Index
(PMGI) (de la Rosa and Sturzenberger 1976). Thirty-one studies
measured gingival inflammation using the GI; two studies used
theMGI (Eaton 1997; Overholser 1990); one study used the PBS
(Anauate-Netto 2014); and four studies used the PMGI (de la
Rosa 1988; de la Rosa 1988b; Ferretti 1987; Segreto 1986). In
one of these studies (Segreto 1986), the PMGI was measured with
visual inspection only (no probing) in addition to the GI. One
study reported a total mean score for a non-specific gingival in-
flammation index (Fine 1985).
Gingival bleeding
Thirty-four studies included gingival bleeding as an outcome. The
following indices were used to measure gingival bleeding: the GI
(Löe and Silness 1963; Löe 1967) scores 2 and 3, the Gingival
Bleeding Index of Ainamo and Bay (Ainamo and Bay 1975), the
Eastman Interdental Bleeding Index (Caton and Polson 1985),
the Bleeding Index/Bleeding on Marginal Probing (Saxton and
van der Ouderaa 1989; van der Weijden 1994), a modification
of the method described by Cowell et al (Cowell 1975), Papillary
Bleeding Score (PBS) (proportionof siteswith aPBS≥ 2) (Loesche
1979) and the Papillary Bleeding Index (Muhlemann 1977; Saxer
1975).
Thirteen studies reported gingival bleeding using scores 2 and 3
from the GI. One of these studies (Southern 2006) also reported
bleeding on probing after 15 seconds. Another two studies (Hase
1998; Lang 1998) measured bleeding on probing and the method
used suggests that it was based on scores 2 and 3 of the GI. Three
studies (Graziani 2015; Pereira 2011; Rahmani 2006) measured
gingival bleeding using the Gingival Bleeding Index of Ainamo
and Bay. Two studies (Brightman 1991; Overholser 1990) used
the Eastman Interdental Bleeding Index. Two studies (Ernst 2005;
Van Strydonck 2008) reported the Bleeding Index/Bleeding on
Marginal Probing. One study (Joyston-Bechal 1993) used a mod-
ification of the method described by Cowell et al. One study
(Anauate-Netto 2014) reported the proportion of sites with a PBS
≥ 2 and three studies (Turkoglu 2009; Zimmer 2006; Zimmer
2015) used the Papillary Bleeding Index. A further seven studies
measured the proportion of sites with bleeding on probing but
were not specific about the index used (Chaves 1994; Faveri 2006;
Feres 2009; Feres 2012; Flemmig 1990; Hase 1995; Taller 1993);
three of these studies also reported the mean proportion of sites
with gingival bleeding but were not specific about the index used
(Faveri 2006; Feres 2009; Feres 2012).
Plaque
Forty-eight studies included plaque as an outcome. The major-
ity of the studies measured dental plaque accumulation using
the Plaque Index of Silness and L e (Silness and Löe 1964) or
the Turesky modification of the Quigley and Hein Index (TQH)
(Turesky 1970). The following indices were also used to mea-
sure plaque: Soparker’s modification of the TQH (Lobene 1982),
the Modified Proximal Plaque Index (MPPI) (Zimmer 2005), the
Quigley and Hein Plaque Index (Quigley 1962), the Approxi-
mal Plaque Index (API) (Lange 1977), a full-mouth plaque score
(FMPS) (O’Leary 1972), and the method described by Greene
and Vermilion (Greene and Vermillion 1964).
Twenty-one studies reported using the Plaque Index of Silness and
L e. Nineteen studies reported using TQH. One of these studies
(Jose 2015) used Soparker’s modification of the TQH, and one of
these studies (Zimmer 2015) reported the MPPI in addition to
TQH. Two studies in the same report that used the TQH (de la
Rosa 1988; de la Rosa 1988b) did not report any outcome data for
plaque. One study (Zimmer 2006) reported both the MPPI and
the Quigley and Hein Plaque Index. The following indices were
reported in one study each: the Quigley and Hein Plaque Index
(Turkoglu 2009), the API (Ernst 2005), FMPS (Graziani 2015),
and themethod described by Greene and Vermilion (Lucas 1999).
Three studies (Faveri 2006; Feres 2009; Feres 2012) measured the
presence or absence of plaque accumulation but were not specific
about the index used.
Adverse effects
Calculus
Twelve studies reported calculus as an outcome. Seven studies
(Banting 1989; Charles 2004; Emling 1992; Flemmig 1990; Hase
1998; Overholser 1990; Sanz 1994) reported using the Volpe-
ManholdCalculus Index (Manhold 1965; Volpe 1965). Two stud-
ies (Corbet 1997; Lang 1998) reported using the Calculus Sur-
face Index (CSI) (Ennever 1961). One study (Anderson 1997)
reported using the Retention Index (Björby and Löe 1966; Löe
1967).One study (Turkoglu 2009) used a calculus index described
in the National Institutes of Health (NIH) report ’Oral health
of United States adults’ (report not available online) and in one
study the index used was not specified (Grossman 1986). In two
additional studies accumulation of calculus in the chlorhexidine
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rinse groups was noted but not measured using an index or scale
(de la Rosa 1988; de la Rosa 1988b).
Extrinsic tooth staining
Twenty-one studies included extrinsic tooth staining as an out-
come but this was measured and reported in a variety of different
ways. In 16 studies, the following indices were used to measure
extrinsic tooth staining: the Discolouration Index (Lobene 1968),
the Discolouration Index of Lang and Räber (Lang and Räber
1981), the Shaw and Murray Index (Shaw 1977), the Gingival
Modification of the Lobene Stain Index (GMSI) (Grundemann
2000; Lobene 1968), and Meckels stain grading method (Lang
1982). Seven studies (Axelsson 1987; Charles 2004; Emling 1992;
Ernst 2005; Joyston-Bechal 1993; Navarro 1998; Overholser
1990) reported the Lobene Discolouration Index. Five studies
(Anderson 1997; Brecx 1993; Corbet 1997; Hoffmann 2001;
Lang 1998) reported the Discolouration Index of Lang and Räber.
One study (Hase 1998) reported the Shaw and Murray Index and
another (Jenkins 1993) a modification of the Shaw and Murray
Index. One study (Van Strydonck 2008) reported the GMSI and
one study (Ferretti 1987) used Meckels stain grading method.
One study (Brightman 1991) reported using theMeanStain Sever-
ity Index that was created at the Case Western Reserve University
school of dentistry, to record intensity and area of stain. Another
study (Graziani 2015) reported dividing the buccal surfaces of
the eight central incisors into three areas: incisal, approximal and
gingival according to Lobene 1968 and Grundemann 2000 and
using a Staining Index (SI) to record the dichotomous presence
or absence of staining in each area and to calculate the percentage
of the total area showing staining. Three studies (Flemmig 1990;
Grossman 1989; Sanz 1994) described their method of measuring
tooth staining but did not specify a particular index.
Sixteen of the other included studies described information re-
garding tooth staining/discolouration/pigmentation reported by
study participants (Anauate-Netto 2014; Bhat 2014; Feres 2009;
Hase 1995; Pereira 2011); noted by the clinicians during the
clinical examination but not measured using an index or scale
(de la Rosa 1988; de la Rosa 1988b; Flotra 1972; Grossman
1986; Lopez-Jornet 2012; Turkoglu 2009; Zimmer 2006; Zimmer
2015); or listed as a reason for participant withdrawal from the
studies (Banting 1989; Eaton 1997). In one study (Sanz 1989) the
presence or absence of tooth staining was assessed from clinical
photographs of the mandibular facial anterior teeth. We included
information regarding tooth staining from these studies in meta-
analyses where possible but were unable to include participant-re-
ported data, data where staining of teeth were reported combined
with tongue staining or denture staining or where tooth staining
was reported grouped with other adverse effects.
Other adverse effects
Fourteen studies did not report any adverse effects apart from ex-
trinsic staining of teeth or oral tissues alone or both (Brecx 1993;
Brightman 1991; Ferretti 1987;Grossman 1989;Hoffmann 2001;
Joyston-Bechal 1993; Lopez-Jornet 2012; Overholser 1990; Van
Strydonck 2008; Zimmer 2015) or with calculus (Corbet 1997;
Flemmig 1990; Grossman 1986; Sanz 1994). Twenty-two stud-
ies reported at least one adverse effect relating to the chlorhex-
idine mouthrinse use apart from extrinsic tooth staining/stain-
ing of the oral tissues and calculus. Three studies (Chaves 1994;
Feres 2009; Segreto 1986)mentioned a bitter or unacceptable taste
associated with the chlorhexidine mouthrinse and no other ad-
verse effects, except for one of the studies (Feres 2009) which also
mentioned tooth staining. Adverse effects were not mentioned in
six studies (Bajaj 2011; Fine 1985; Jayaprakash 2007; Rahmani
2006; Southern 2006; Weitz 1992). The remaining six studies
that did not report any adverse effects or issues with acceptabil-
ity of the chlorhexidine rinse indicated that there were no oral
mucosal lesions (Charles 2004); no severe/serious adverse effects/
events (Faveri 2006; Stookey 2005); or adverse reaction/effect
(Feres 2012); no irreversible pathology (Lucas 1999); or pathology
related to the chlorhexidine mouthrinse use (Taller 1993).
Excluded studies
We excluded 38 studies from the review (see ’Characteristics of
excluded studies’ table). Below is a summary of the reasons for
excluding these studies.
• In seven studies it was not clear whether the studies were
randomised and attempts to contact the authors for clarification
were unsuccessful (Bay 1975; Goutham 2013; Lang 1982;
Ousehal 2011; Paknejad 2006; Todkar 2012; Vechis-Bon 1989).
• In four studies the mechanical oral hygiene procedures were
not the same in the chlorhexidine rinse and comparator arms
(Bouwsma 1992; Brown 2002; Madden 2008; Subhash 1985).
• In 11 studies the comparison was with another active rinse
and there was no placebo/control or mechanical oral hygiene
only group (Biswas 2014; CTRI 2014; Ernst 1998; Eshwar
2016; Haffajee 2009; McKenzie 1992; NCT01750801;
NCT02546804; Persson 1991; Priya 2015; Radafshar 2017).
• Four studies were excluded because the chlorhexidine arm
included another active agent that the comparator arms did not
have. We would have been unable to separate the effect of the
chlorhexidine rinse from the effect of the other active agent
(Cortelli 2015; Luoma 1978; Quirynen 2005; Quirynen 2006).
• In one study the chlorhexidine arm received a more
intensive intervention including cognitive behavioural education
(2 hours) compared to the control arm who received standard
care (Persson 1998). In another study (Caton 1993) the
chlorhexidine arm received oral hygiene instructions but the
control arm did not. The mechanical oral hygiene procedures
were potentially not the same in both arms in these two studies.
• One study was unpublished and we were unable to obtain a
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copy of the study despite following up several lines of enquiry
(Segreto 1993).
• In one study, it was not clear from the published report
whether the study was a randomised trial. Additional
information obtained from the contact author indicated quasi-
randomisation (participants were assigned to groups according to
the order that they came to the University) (Leyes Borrajo 2002).
• One study was reported in an abstract. The authors were
contacted but they did not have access to the data (Saltini 1988).
• One study compared chlorhexidine, zinc and placebo
mouthrinses but each rinse arm was further split into those who
received a professional prophylaxis prior to the start of the study
and those that did not. The study outcomes were not reported in
a format that could be used in the review and the authors of the
study were unable to provide any additional data (Fischman
1975).
• In one study (Nadkerny 2015) the duration of rinsing was
only 15 days and this was not apparent until the full text of the
paper was reviewed.
• In three studies we had concerns about the duplication of
outcome data in different studies from the same research group
(Gupta 2014; Gupta 2015; Karim 2014) and contact with the
authors failed to provide an adequate explanation or reassurance.
Another study from this research group was excluded due to
these concerns (Gupta 2015a).
• One study was excluded because the chlorhexidine
mouthrinse was not used as an adjunct to regular mechanical
oral hygiene (Yates 2002).
Risk of bias in included studies
Allocation
Random sequence generation
Nineteen studies reported sufficient details of the method of ran-
dom sequence generation to allow us to assign a judgement of low
risk of bias. The remaining 32 studies either stated that partici-
pants were randomised to groups, with no further details, or gave
an inadequate description of the method. For these studies, we
assigned a judgement of unclear risk of bias.
Allocation concealment
Eleven studies described various methods of allocation conceal-
ment which implied that the random sequence was adequately
protected and administered as it was generated, thus we assigned
a judgement of low risk of bias. Two studies were rated as being at
high risk of bias because personnel involved in the studies used a
random number table to assign participants to groups, and could
have foreseen upcoming assignments (Faveri 2006; Fine 1985).
The remaining 38 studies did not report sufficient information
on the randomisation process to allow a judgement of either low
or high risk of bias, so we assigned a judgement of unclear risk of
bias to them.
Overall, seven studies had a rating of low risk of bias for the two
above domains, and therefore were at low risk of selection bias.
The two studies that had a rating of high risk of bias for allocation
concealment were therefore at high risk of selection bias. The
remaining 42 studies were at unclear risk of bias.
Blinding
The majority of studies contained a placebo arm with the inten-
tion of blinding participants and personnel. However, we consid-
ered blinding unlikely to be successful due to the propensity for
chlorhexidine to stain the teeth and oral tissues and the association
of its use with clinically apparent adverse effects such as mucosal
desquamation and mucosal lesions.
Blinding of participants and personnel (performance bias)
Forty-one studies were assigned a judgement of high risk of bias
either because staining or adverse events were reported at a higher
rate in the chlorhexidine arms, or because a placebo comparison
was not used and therefore no blinding was attempted. In these
studies, participants could be aware of their allocated interven-
tion and this could have affected their motivation and oral health
behaviour. Two studies were assigned a judgement of low risk of
bias as there was no difference in staining between the groups,
so the blinding appeared to have been maintained (Ferretti 1987;
Lopez-Jornet 2012). In the remaining eight studies, blinding was
intended through the use of placebo but staining was not reported,
so there was insufficient information on which to base a judge-
ment. We rated these studies as being at unclear risk of bias.
Blinding of outcome assessment (detection bias)
Thirty-three studies were assigned a judgement of high risk of bias
because the outcomes assessors could have noticed the higher rates
of staining or adverse events or both in the chlorhexidine arms.
Five studies were rated as having low risk of bias. Two of these
studies showed no difference in staining between groups (Axelsson
1987; Lopez-Jornet 2012). Two studies used masking strategies
(whereby a subset of participants were assessed with and without
plastic tooth covers and painting of the tongue with food dyes)
which revealed that measurements of gingivitis were no different
when an examiner thought the participant had received chlorhex-
idine or not (Grossman 1986; Grossman 1989). One study per-
formed a sensitivity analysis on participants with no visible side
effects, which showed no difference to the analysis including all
participants, and we judged that bias had not affected the results
(Zimmer 2006). We rated the remaining 13 studies at unclear risk
22Chlorhexidine mouthrinse as an adjunctive treatment for gingival health (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of bias because extrinsic tooth staining was not reported. These
studies either implied that the outcome assessors were blinded,
or did not discuss it, but in any case it was not possible to judge
whether or not any blinding could have been successful.
Incomplete outcome data
We did not have any concerns regarding attrition bias in 23 stud-
ies, so we rated them as at low risk of bias. Nineteen studies were
assigned a judgement of high risk of bias due to either a high overall
proportion of attrition, differences in the proportion of attrition
between groups, or because the reasons for attrition differed be-
tween groups and were linked to the intervention. The remaining
nine studies were rated as unclear because the numbers per group
at either baseline or evaluation were not reported, thus preventing
us from calculating the attrition.
Selective reporting
Fourteen studies adequately reported all expected and planned
outcomes, so we rated them as having low risk of bias. The re-
maining 37 studies were rated at high risk of bias, mainly due to
lack of reporting of measures of variance along with the means for
each group, and no reporting of tooth staining and other adverse
effects.
Other potential sources of bias
Eleven studies were assigned a judgement of low risk of bias. Three
studies were assigned a judgement of high risk of bias due to base-
line imbalances between groups in important prognostic factors
or outcomes of the review or both (Bajaj 2011; Graziani 2015;
Sanz 1989). The remaining 37 studies were rated as unclear due
to a lack of reporting of details of either calibration of outcome as-
sessment or baseline measurements, meaning that we were unable
to assess the potential for differential measurement of outcomes
or baseline imbalances respectively.
Overall risk of bias
Fifty studies were at high risk of bias overall as they had at least
one domain rated at high risk of bias. One study was rated at
unclear risk of bias overall as it had at least one domain rated at
unclear risk of bias, but with no domains rated at high risk of bias
(Lopez-Jornet 2012). A summary of the risk of bias of the included
studies is presented in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison
Chlorhexidine rinse versus placebo/control rinse or
no intervention
Gingivitis
Gingival Index of Löe and Silness
At 4 to 6 weeks, eight studies analysing 466 participants (seven
at high and one at unclear risk of bias) comparing chlorhexidine
rinse with placebo or control rinse and two studies analysing 339
participants (both at high risk of bias) comparing chlorhexidine
with no rinse, presented data using the Gingival Index (GI) of Löe
and Silness (Löe 1967; Löe and Silness 1963) (Analysis 1.1). The
mean GI score across the control groups ranged from 0.17 to 1.4
with a mean of 0.93 and a median of 1. There was no clear differ-
ence between the placebo/control and no rinse control subgroups
(P = 0.33). The pooled effect estimate of the comparison for all
trials showed a reduction in gingivitis in favour of chlorhexidine
rinse (mean difference (MD) -0.21, 95% confidence interval (CI)
-0.31 to -0.11, P < 0.0001) demonstrating a moderate effect (GI
on 0 to 3 increasing scale). There was substantial heterogeneity
between the studies (P = 0.001; I2 = 67%).
There was no clear difference between the different control group
subgroups at 6 months (P = 0.11). The overall effect estimate
showed a reduction in gingivitis in favour of the chlorhexidine
rinse (MD -0.20, 95% CI -0.30 to -0.11, P < 0.0001, 13 high
risk of bias studies, 2616 participants) (Analysis 1.2). The mean
GI score across the control groups ranged from 0.1 to 1.25 with a
mean of 0.8 and a median of 0.7. There was considerable hetero-
geneity (P < 0.00001; I2 = 96%).
There were insufficient data to determine the reduction in gin-
givitis associated with chlorhexidinemouthrinse use in individuals
with higher mean GI scores of 1.1 to 3 (moderate or severe levels
of gingival inflammation).
Investigation of heterogeneity
We undertook an investigation of the reasons for heterogeneity for
the GI scores, at both 4 to 6 weeks and 6months, for the following
subgroups: adults compared to children; baseline gingivitis alone
compared to gingivitis and periodontitis at baseline; prophylaxis/
scale and polish at baseline compared to none; baseline mean gin-
givitis score < 1 versus scores ≥ 1, by undertaking metaregression
in Stata version 14 (Stata 2015) (Additional Table 1; Table 2). The
only subgroup analysis that was significant (P = 0.045) was for
prophylaxis or not at 6 months, where the trials including a pro-
phylaxis had a lesser effect for the chlorhexidine rinse than those
without. This may explain some of the heterogeneity at 6 months.
Chlorhexidine concentration and frequency of rinsing
At 4 to 6 weeks there was no difference between the studies with
concentrations of 0.2% and 0.1%/0.12%chlorhexidine, and there
was an insufficient number of studies in the concentration sub-
groups at 6 months to undertake the analysis (Additional Table
3). Participants in one study included in the meta-analysis for 4
to 6 weeks for the GI rinsed once a day, participants in the other
studies rinsing twice per day so we were unable to undertake an
analysis. Participants in two studies at 6 months rinsed once per
day compared with 11 rinsing twice but there was no difference
between these subgroups (P = 0.56, Additional Table 4).
Other data
Meta-analyses of studies comparing chlorhexidine rinse with
placebo or control rinse after 7 to 12 weeks and > 6 months of
rinsing (all at high risk of bias), using the GI of Löe and Silness
(Löe 1967; Löe and Silness 1963), showed an effect size similar
to the 4 to 6 weeks and 6 month studies (MD -0.47, 95% CI -
0.76 to -0.18 and MD -0.50, 95% CI -1.11 to 0.11 respectively).
The uncertainty around the effect estimate at > 6 months (two
studies of 9 and 24 months duration) is reflected in the 95% CI.
Furthermore, there was considerable heterogeneity in both meta-
analyses (P < 0.0001, I2 = 86%; P < 0.0001, I2 = 99% respectively)
(Additional Table 5).
One 4-week study (Anauate-Netto 2014) at high risk of bias that
was not included in the meta-analysis found no statistically signif-
icant differences in Papillary Bleeding Score (Loesche 1979) be-
tween the chlorhexidine (0.12%) and placebo group. Three stud-
ies (Fine 1985; Hoffmann 2001; Overholser 1990) at high risk of
bias, reporting gingival inflammation at 4 to 6 months were not
included in the meta-analysis. Two of the three studies found a
reduction in the GI (P = 0.043) (Hoffmann 2001) and the mod-
ified GI (P < 0.001) (Overholser 1990) for the 0.1% and 0.12%
chlorhexidine groups respectively compared to the control rinse
(Additional Table 6). Results for 7 to 12 weeks studies not in-
cluded in meta-analyses are supportive of a reduction in gingival
inflammation associated with chlorhexidine mouthrinse use (Ad-
ditional Table 6).
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Gingival bleeding
A variety of different indices were used to measure gingival bleed-
ing, therefore standardised mean differences (SMD) are presented.
There was no clear difference between the placebo/control and the
no rinse subgroups at either 4 to 6weeks or 6months (Analysis 1.3;
Analysis 1.4). At 4 to 6 weeks, eight studies analysing 649 partici-
pants (all at high risk of bias) comparing chlorhexidine rinse with
placebo/control or with no rinse that reported gingival bleeding
were combined in a meta-analysis. The overall effect estimate for
all studies, both placebo/control and no rinse controls, was moder-
ate at 4 to 6 weeks (SMD -0.56, 95%CI -0.79 to -0.33) showing a
reduction in gingival bleeding in favour of the chlorhexidine rinse
(P < 0.00001). There was evidence of moderate heterogeneity (P
= 0.16; I2 = 34%).
At 6 months, eight studies analysing 1132 participants (all at high
risk of bias) reported gingival bleeding and were combined in a
meta-analysis. The overall effect estimate for all studies was also
moderate at 6months (SMD-0.72, 95%CI -1.02 to -0.42), show-
ing a reduction in gingival bleeding in favour of the chlorhexidine
rinse (P < 0.00001). There was evidence of considerable hetero-
geneity between the studies at 6 months (P < 0.00001; I2 = 81%).
Chlorhexidine concentration and frequency of rinsing
No statistically significant differences were found between the sub-
groupswith different chlorhexidine concentrations, at 4 to 6weeks
and 6 months (Additional Table 3). At both 4 to 6 weeks and 6
months all participants in the included studies for gingival bleed-
ing were instructed to rinse twice per day, so no analysis for the ef-
fect of frequency of rinsing could be undertaken (Additional Table
4).
Other data
Ameta-analysis of two studies (both at high risk of bias) analysing
196 participants comparing chlorhexidine rinse with no rinse con-
trols using the Papillary Bleeding Index (Muhlemann 1977; Saxer
1975) after 8 weeks of rinsing showed no evidence of a difference
in gingival bleeding (MD -0.07, 95% CI -0.16 to 0.02) (Addi-
tional Table 5).
Another meta-analysis of five studies (all at high risk of bias)
analysing 182 participants comparing chlorhexidine rinse with
placebo rinse using a variety of different gingival bleeding indices
after 7 to 12 weeks of rinsing showed a strong effect in favour of
the chlorhexidine rinse (SMD -1.29, 95% CI -1.85 to -0.72, P
< 0.00001). There was evidence of substantial heterogeneity (P =
0.02; I2 = 64%) (Additional Table 5).
Three studies analysing 99 participants (all at high risk of bias)
comparing chlorhexidine rinse with placebo rinse, using bleeding
on probing, presented longer-term data 1, 4 and 10 months after
chlorhexidine mouthrinsing had ceased and were combined in
a meta-analysis that showed a small retained effect in favour of
chlorhexidine (MD -0.12, 95% CI -0.20 to -0.04) (Additional
Table 5).
Three studies (Axelsson 1987; Graziani 2015; Sanz 1989) at high
risk of bias reporting gingival bleeding at 4 to 6 weeks were not
included in the meta-analysis (Additional Table 7). All three stud-
ies reported a reduction in gingival bleeding for 0.1%, 0.12% and
0.2% chlorhexidine rinses compared to placebo or control rinse.
Four studies (Banting 1989; Charles 2004; Lucas 1999; Sanz
1994) at high risk of bias reporting gingival bleeding at 6 months
were not included in themeta-analysis (Additional Table 7). Three
of these studies reported a reduction in gingival bleeding for 0.12%
chlorhexidine rinse compared to placebo or control rinse. Banting
1989 demonstrated a reduction in gingival bleeding at 2 years for
0.12% chlorhexidine compared to placebo (P < 0.0001). Results
for 7 to 12weeks studies not included inmeta-analyses are support-
ive of a reduction in gingival bleeding associated with chlorhexi-
dine mouthrinse use (Additional Table 7).
Plaque
A variety of different indices were used to measure plaque, there-
fore SMDs are presented. There was no difference between the
placebo/control or no rinse control subgroups for plaque at 4 to
6 weeks (P = 0.93) (Analysis 1.5). The overall effect was based on
12 trials analysing 950 participants, 11 at high and one at unclear
risk of bias, and showed a large effect in favour of chlorhexidine
rinse (SMD -1.45, 95% CI -1.90 to -1.00). Four of these trials
analysing 223 participants reported the Plaque Index (0 to 3 in-
creasing scale) (Silness and Löe 1964) and showed a reduction
in plaque in favour of chlorhexidine rinse (MD -0.58, 95% CI -
0.78 to -0.39) (Analysis 1.6); five of these trials analysing 546 par-
ticipants reported the Turesky modification of the Quigley Hein
Index (0 to 5 increasing scale) (Turesky 1970) and also showed a
reduction in plaque in favour of chlorhexidine rinse (MD -0.78,
95% CI -0.85 to -0.70) (Analysis 1.7).
At 6 months, although both subgroups showed a reduction in
plaque favouring the chlorhexidine rinse (Analysis 1.8), there was
a difference between the size of the effect estimates for the placebo/
control and no rinse subgroups (P = 0.02). The higher estimate for
the chlorhexidine rinse compared to placebo/control rinse based
on nine trials analysing 1933 participants (all at high risk of bias)
with a large effect (SMD -1.59, 95% CI -1.89 to -1.29) is com-
pared with a moderate effect for the chlorhexidine rinse compared
to no rinse control groups based on 2 trials analysing 142 partic-
ipants (both at high risk of bias) (SMD -0.68, 95% CI -1.35 to
-0.01). There was substantial heterogeneity among the studies in
each subgroup (P < 0.00001; I2 = 84%; P = 0.06; I2 = 72% for
placebo/control and no rinse subgroups respectively). Five studies
analysing 1108 participants reported data for the Plaque Index
at 6 months. There was no clear difference between the placebo/
control and no rinse subgroups, and the overall effect was -0.62
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(95%CI -1.12 to -0.12) (Analysis 1.9). Six trials, all with placebo/
no treatment controls, analysing 967 participants reported the
Turesky modification of the Quigley Hein Index at 6 months and
also showed a reduction in plaque in favour of chlorhexidine rinse
(MD -0.73, 95% CI -0.88 to -0.57) (Analysis 1.10).
Chlorhexidine concentration and frequency of rinsing
No differences were found between the subgroups with different
chlorhexidine concentrations (Additional Table 3). At 4 to 6weeks
the participants in one trial were instructed to rinse once per day
compared with twice a day in the other 11 trials so no analysis for
the effect of frequency of rinsing could be undertaken. Similarly
at 6 months the participants in one trial were instructed to rinse
once per day compared with twice a day in the other 10 trials so no
analysis for the effect of frequency of rinsing could be undertaken
(Additional Table 4).
Other data
Meta-analyses of studies that compared chlorhexidine mouthrinse
with placebo (10 studies all at high risk of bias analysing 423 par-
ticipants) or no rinse control (two studies both at high risk of bias
analysing 196 participants) at 7 to 12 weeks showed a reduction
in plaque (using various indices) in favour of chlorhexidine rinse
(SMD -1.74, 95% CI -2.51 to -0.98 and SMD -0.77, 95% CI -
1.07 to -0.47 respectively, Additional Table 5) both indicating a
strong effect. There was considerable heterogeneity among the 10
placebo-controlled studies P < 0.00001; I2 = 91%.
One large 9-month study (at high risk of bias) (Bajaj 2011)
analysing 852 participants comparing 0.1% chlorhexidine rinse
with distilled water found a large reduction in plaque (0 to 3 in-
creasing scale) in the chlorhexidine rinse group (MD -1.55, 95%
CI -1.79 to -1.31, Additional Table 5).
Four studies analysing 132 participants (all at high risk of bias)
comparing chlorhexidine rinse with placebo rinse presented data
1, 4 and 10 months after rinsing had ceased, using a variety of
indices, and were combined in a meta-analysis that showed a large
retained effect in favour of chlorhexidine (SMD -1.10, 95% CI -
1.18 to -0.40, Additional Table 5). However, there was substantial
heterogeneity between the studies (P = 0.02; I2 = 71%).
One study (Sanz 1989) at high risk of bias reporting a plaque out-
come at 6 weeks that was not included in themeta-analysis showed
a reduction in plaque for 0.12% chlorhexidine rinse compared to
placebo rinse (Additional Table 8).
Five studies at high risk of bias reporting a plaque outcome at 6
months that were not included in the meta-analysis also showed a
reduction inplaque for 0.12%, 0.1%, 0.05%and 0.06%chlorhex-
idine rinse compared to placebo or control rinse (Banting 1989;
Hoffmann 2001; Jayaprakash 2007; Lucas 1999; Sanz 1994) (Ad-
ditional Table 8).
Banting 1989, which was not included in the meta-analysis
demonstrated a reduction in plaque at 2 years for 0.12% chlorhex-
idine compared to placebo. Results for 7 to 12 weeks studies not
included in meta-analyses were generally supportive of a reduc-
tion in plaque associated with chlorhexidine mouthrinse use (Ad-
ditional Table 8).
Adverse effects
Calculus
Two studies analysing 102 participants, both at high risk of bias,
and with placebo/control rinses, presented data on calculus at 4
to 6 weeks. There was insufficient evidence to determine whether
using chlorhexidine rinse for 4 to 6 weeks was associated with
increased calculus formation (SMD 0.02, 95% CI -0.09 to 0.14)
(Analysis 1.11).
At 7 to 12 weeks, five studies (all high risk of bias) analysing 330
participants, with a placebo/control rinse presented calculus data,
along with one study analysing 95 participants with a no rinse
control also at high risk of bias (Analysis 1.12). There was a differ-
ence between the subgroups for control type, with there being in-
sufficient evidence to determine an effect on calculus for chlorhex-
idine rinse compared to placebo/control rinse (SMD 0.14, 95%
CI -0.08 to 0.36). The single study in the no rinse control group,
however, showed more calculus in the chlorhexidine rinse group
compared to the no rinse control group (SMD 1.02, 95%CI 0.59
to 1.45) demonstrating a large effect. There was evidence of sub-
stantial heterogeneity (P =0.004; I2 = 71%).
At 6 months there was a difference between the subgroups for
control type. There was only one study (at high risk of bias),
analysing 91 participants, with a no rinse control group which
showed an increase in calculus in the chlorhexidine rinse group
(SMD 1.39, 95% CI 0.93 to 1.85) demonstrating a large effect
(Analysis 1.13). The pooled result for the three studies (at high
risk of bias) analysing 232 participants with placebo/control rinses
showed an increase in calculus associated with chlorhexidine rinse
(SMD 0.60, 95% CI 0.24 to 0.96) demonstrating a moderate
effect. There was evidence of moderate heterogeneity (P = 0.16; I
2 = 46%).
Chlorhexidine concentration and frequency of rinsing
No statistically significant difference was found between the sub-
groups with different chlorhexidine concentrations at 7 to 12
weeks, however the data at 6 months indicated a larger effect (in-
creased calculus formation in the chlorhexidine rinse group) for the
lower concentration chlorhexidine mouthrinse (Additional Table
3). Participants in all the included trials with calculus data at 4 to
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6, 7 to 12 weeks and 6 months were asked to use the mouthrinse
twice a day, so no analysis of frequency could be undertaken (Ad-
ditional Table 4).
Other data
Five studies at high risk of bias reporting interim and end scores for
calculus at various time points from 4 weeks to 2 years (Anderson
1997; Banting 1989; Charles 2004; Grossman 1986; Sanz 1994)
that were not included in the meta-analysis all found increased
supragingival calculus in the 0.12% chlorhexidine rinse groups
compared to the placebo and control rinse groups (Additional
Table 9). Increased calculus was noted in two other studies but
not measured using an index or scale (de la Rosa 1988; de la Rosa
1988b).
Extrinsic tooth staining
Different dichotomous and continuous indices were used to mea-
sure tooth staining. At 4 to 6 weeks both the dichotomous data
(two studies at high risk of bias, 156 participants) and the con-
tinuous data (eight studies at high risk of bias, 415 participants)
showed more tooth staining in the chlorhexidine rinse group. A
large effect estimate was found for both the dichotomous data (risk
ratio (RR) 5.41, 95% CI 2.03 to 14.47, Analysis 1.14) and con-
tinuous data (SMD 1.07, 95% CI 0.80 to 1.34, Analysis 1.16).
There was no strong evidence of heterogeneity between the trials
reporting continuous data (P = 0.14, I2 = 36%).
Only one study, analysing 118 participants, reported dichotomous
data for tooth staining at 7 to 12 weeks, with more tooth staining
in the chlorhexidine group (RR 2.50, 95% CI 1.29 to 4.83) (
Analysis 1.15). Eleven studies, analysing 581 participants (at high
risk of bias) reported data on different continuous scales showing
an increase in tooth staining associated with chlorhexidine rinse at
7 to 12 weeks (SMD 1.19, 95% CI 0.98 to 1.40), demonstrating
a large effect (Analysis 1.17).
Four studies analysing 323 participants, at high risk of bias, re-
ported continuous data at 6 months using different tooth stain-
ing indices. The pooled effect estimate indicated a large effect for
tooth staining due to the chlorhexidine rinse (SMD 1.54, 95%
CI 1.22 to 1.86) (Analysis 1.18). There was no strong evidence of
heterogeneity (P = 0.19; I2 = 36%).
Chlorhexidine concentration and frequency of rinsing
Subgroup comparisons for chlorhexidine concentration were not
significant (Additional Table 3). In one study providing tooth
staining data at both 4 to 6 weeks and 7 to 12 weeks, participants
rinsed three times a day, and in one of the studies at 4 to 6 weeks
participants rinsed only once per day, whereas in all the other stud-
ies participants rinsed twice per day (Additional Table 4). There
were insufficient studies in the subgroups to make a meaningful
comparison on frequency at any time point.
Other data
Thirteen studies reported information about tooth staining that
could not be included inmeta-analyses. Eight studies that reported
data on extrinsic tooth staining could not be included in meta-
analyses because no measure of variance was reported (Charles
2004; Flotra 1972; Grossman 1989;Hoffmann 2001; Sanz 1994),
no outcome data were reported (Grossman 1986) or because
the mean value in the control groups was zero (Axelsson 1987;
Graziani 2015). All of these studies reported higher levels of extrin-
sic tooth staining in the chlorhexidine compared to control arms at
4 to 6 weeks (Axelsson 1987; Flotra 1972; Graziani 2015); 7 to 12
weeks (Charles 2004; Grossman 1989); and at 6 months (Charles
2004; Grossman 1986; Grossman 1989; Hoffmann 2001; Sanz
1994). In five other studies tooth staining was reported combined
with either denture staining (Lopez-Jornet 2012), discolouration
of oral tissues (Hase 1995; Turkoglu 2009; Zimmer 2006) or was
reported as ’discolouration’ and it was not clear whether this related
to teeth, oral tissues or both (Bhat 2014). In four of these five stud-
ies staining/discolouration was higher in the chlorhexidine rinse
groups at 4 to 6 weeks (Bhat 2014; Hase 1995; Turkoglu 2009;
Zimmer 2006) and 7 to 12 weeks (Zimmer 2006) (Additional
Table 10).
In five additional studies, increased tooth staining (de la Rosa
1988; de la Rosa 1988b; Feres 2009), ’pigmentation’ (Pereira
2011) and ’yellow teeth’ (Anauate-Netto 2014) were reported in
relation to the chlorhexidine rinse arms. In two studies staining
of teeth in the chlorhexidine rinse arm was listed as a reason for
participant withdrawal from the studies (Banting 1989; Eaton
1997).
Other adverse effects
Twenty-two studies reported at least one adverse effect apart from
extrinsic tooth staining and calculus formation in the chlorhexi-
dine rinse arms. Apart from extrinsic tooth staining, the adverse
effects most commonly reported in the chlorhexidine rinse arms
of the included studies were taste disturbance/alteration (reported
in 11 studies), effects on the oral mucosa (reported in 13 studies)
and a general burning sensation or a burning tongue or both (re-
ported in nine studies).
Taste disturbance/alteration was reported in 11 studies (Anauate-
Netto 2014; Bhat 2014; Ernst 2005; Graziani 2015; Hase 1998;
Jenkins 1993; Jose 2015; Lang 1998; Pereira 2011;Turkoglu 2009;
Zimmer 2006). The proportion of participants experiencing taste
disturbance/alteration was reported in eight of these studies and
was consistently higher in the chlorhexidine rinse arms (3% to
30%) than in the placebo/control/oral hygiene (OH) only arms
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(0% to 7%) with one exception (Bhat 2014) where a higher pro-
portion of participants in the saline control arm experienced taste
disturbances (45.4% versus 63.6%).
A general burning sensation (Anderson 1997; Bhat 2014; Emling
1992; Hase 1995; Sanz 1989; Zimmer 2006) and/or a burning
tongue (Anauate-Netto 2014; Jose 2015; Lang 1998) was reported
in the chlorhexidine rinse arms in nine studies. The proportion
of participants affected was reported in four of the nine studies
(Anderson 1997; Bhat 2014; Jose 2015;Zimmer2006) and ranged
from 4.6% to 50% in the chlorhexidine arms compared to 0% in
the placebo/control/OH only arms. Hase 1995 reported ’burning
sensation’ rated by participants on a visual analogue scale from
none (0) to 100 (verymuch). Themean visual analogue scale score
for the chlorhexidine rinse arm was approximately 18 compared
to 8 for the placebo arm.
Effects on the oral mucosa of participants in the chlorhexidine
rinse arms were reported in 13 studies. Specific effects were de-
scribed asmucosal irritation (Anauate-Netto 2014; Emling 1992),
sensitivities of the oral mucosa (Ernst 2005), mucosal soreness
(Jenkins 1993), mild desquamation (de la Rosa 1988; de la Rosa
1988b; Navarro 1998), mucosal ulceration (Hase 1995; Turkoglu
2009), mucosal erosions (Jenkins 1993), soft tissue conditions
(Banting 1989), oral mucosal lesions (Axelsson 1987; Flotra 1972)
and adversemucosal reaction (Eaton 1997).Where itwas reported,
the proportion of participants experiencing effects on the oral mu-
cosa was generally low. For example, clinically apparent mucosal
ulceration was reported in 12% (n = 3) of participants in the
chlorhexidine rinse armof one study (Turkoglu 2009) andmucosal
erosions affected 4% (n = 2) of participants in the chlorhexidine
rinse arm of another study (Jenkins 1993). However one study re-
ported a high proportion of oral mucosal lesions in participants in
the chlorhexidine (0.2%) rinse arm (25%, n = 6) (Axelsson 1987).
Discolouration/pigmentation of the oral soft tissues was reported
in seven studies and was consistently higher in the chlorhexidine
rinse arms ranging from 9% to 88% compared to 0% to 7% in
the placebo/control/OH only arms (Graziani 2015; Pereira 2011;
Hase 1995; Hase 1998; Lang 1998; Turkoglu 2009; Zimmer
2006). Coated tongue was reported as an adverse effect in one
study (Jose 2015).
Less commonly reported adverse effects included transient anaes-
thetic sensation, hypoaesthesia and paraesthesia; affecting 5% to
18% of participants in the chlorhexidine rinse arms (Hase 1995;
Hase 1998; Jenkins 1993; Jose 2015; Lang 1998; Zimmer 2006).
Lastly, in relation to acceptability, an unacceptable or unpleasant
taste was reported by participants in the chlorhexidine rinse arms
of eight studies (Anauate-Netto 2014; Chaves 1994; Eaton 1997;
Feres 2009; Hase 1995; Jenkins 1993; Sanz 1989; Segreto 1986).
Sensitivity analysis
We undertook a sensitivity analysis for the GI at both 4 to 6
weeks and 6 months, excluding trials where we had to estimate
the standard deviation from similar studies, or had to read the
data from graphs. The pooled estimate for 4 to 6 weeks (excluding
Jenkins 1993 and Sanz 1989) was: MD -0.23 (95% CI -0.36 to
-0.10), and at 6 months (excluding Banting 1989; Chaves 1994;
Jayaprakash 2007; Lucas 1999; Sanz 1994) MD -0.25 (95% CI -
0.39 to -0.10). These estimates are similar to those for the overall
pooling of the studies.
We undertook a sensitivity analysis for the GI at both 4 to 6
weeks and 6 months excluding trials where professional periodon-
tal treatment was carried out during the study (i.e. Faveri 2006;
Feres 2009; Feres 2012; Flotra 1972; Rahmani 2006; Sanz 1989).
The pooled estimate for 4 to 6 weeks (excluding Rahmani 2006
and Sanz 1989 ) was: MD -0.21 (95% CI -0.32 to -0.10), and at
6 months (excluding Flotra 1972) MD -0.19 (95% CI -0.29 to -
0.10). These estimates are similar to those for the overall pooling
of the studies.
Assessment of reporting biases
Themeta-analysis for GI at 4 to 6weeks included 10 trials. Testing
for asymmetry in a funnel plot using the methods described by
Egger 1997, using “metabias” command in Stata (P = 0.019),
although significant, the estimate of bias was negative indicating
that the bias was lack of large studies (not small studies). The
meta-analysis for GI at 6 months included 13 trials, and there
was no evidence of publication bias from the funnel plot and this
was confirmed by testing for asymmetry in a funnel plot using the
same methods (P = 0.95). Two of the plaque meta-analyses at 4 to
6 weeks and 6 months had more than 10 studies but funnel plots
cannot be investigated when SMD models are used. All the other
meta-analyses had less than 10 trials, so we were unable to assess
reporting bias for these.
D I S C U S S I O N
Summary of main results
There was high-quality evidence that using chlorhexidine
mouthrinse as an adjunct to regular mechanical oral hygiene pro-
cedures for 4 to 6 weeks and 6 months results in a moderate re-
duction in gingivitis compared to placebo, control or mechani-
cal oral hygiene alone. This reduction in gingivitis, in individu-
als with mild gingival inflammation on average (mean score of 1
on the 0 to 3 Gingival Index (GI) scale) is not considered to be
clinically important. Heterogeneity was considerable in the meta-
analyses at 4 to 6 weeks and 6 months and subgroup analysis was
only able to explain some of the heterogeneity at 6 months, due to
whether or not a prophylaxis or scale and polish was conducted at
the start of the study. The standardised mean differences (SMDs)
for gingival bleeding at 4 to 6 weeks and 6 months also indicate
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that chlorhexidine mouthrinse has a moderate effect on gingival
bleeding compared to placebo, control or mechanical oral hygiene
alone. There was insufficient evidence to determine the reduction
in gingivitis associated with chlorhexidine mouthrinse use in in-
dividuals with mean GI scores of 1.1 to 3 indicating moderate or
severe levels of gingival inflammation.
There was also high-quality evidence that chlorhexidine
mouthrinse reduces plaque at 4 to 6 weeks and 6 months. SMDs
for plaque for both control subgroups at 4 to 6 weeks and at
6 months indicate a large effect. The four studies that used the
Plaque Index (0 to 3 increasing scale) and the four studies that
used the Turesky Modification of the Quigley and Hein Index (0
to 5 increasing scale) at 4 to 6 weeks indicate a reduction in plaque
in favour of the chlorhexidine mouthrinse.
There was no evidence that one concentration of chlorhexidine
rinse was more effective than another in reducing gingivitis and
plaque. Participants in most of the studies included in the meta-
analyses used a rinse frequency of twice daily, limiting our ability to
analyse the effect of rinse frequency on gingivitis and plaque. We
were only able to evaluate the effect of rinse frequency for gingivitis
measured at 6 months using the GI, however, no difference in
effect was observed.
There was moderate-quality evidence that chlorhexidine rinse
causes a large amount of extrinsic tooth staining when used for pe-
riods of 4 weeks or longer. Comparison of subgroups with differ-
ent chlorhexidine concentrations was not statistically significant.
There was insufficient evidence to determine whether using
chlorhexidine rinse for 1 to 3monthswas associatedwith increased
calculus formation. There was some evidence of increased calculus
formation related to rinsing with chlorhexidine mouthrinse for a
period of 6 months. However, overall evidence for the effect of
chlorhexidinemouthrinse on calculus formationwas inconclusive.
Twenty-two of the 51 studies included in this review reported at
least one adverse effect apart from extrinsic tooth staining and
calculus formation in the chlorhexidine rinse arms. The adverse
effects most commonly reported in the chlorhexidine rinse arms
of the included studies were taste disturbance/alteration (reported
in 11 studies), effects on the oral mucosa including mucosal irri-
tation, soreness, mild desquamation, mucosal ulceration/erosions
and oral mucosal lesions (reported in 13 studies) and a general
burning sensation or a burning tongue or both (reported in nine
studies).
Overall completeness and applicability of
evidence
Chlorhexidine mouthrinse is effective in reducing gingivitis and
plaque when used as an adjunct to regular mechanical oral hygiene
procedures for 4 weeks or longer. The consistency of effect for
chlorhexidine mouthrinse on gingivitis and plaque across studies
included in this review was remarkable though not surprising con-
sidering that chlorhexidine mouthrinse has long been regarded as
the gold standard of antimicrobial mouthrinses.The primary out-
come of this review was gingivitis which can be measured using a
variety of different indices. The clinical features of gingivitis can
be assessed non-invasively by visual assessment of colour, contour
and gingival bleeding or invasively using an instrument to provoke
bleeding or both (Lorenz 2009). Our review clearly demonstrates
the many different indices that can be used to measure gingivitis.
While these many indices were developed to provide a standard-
ised reproducible method of quantifying gingivitis for descriptive
or comparative purposes in epidemiology and clinical trials respec-
tively, the subjectivity involved in their use remains problematic.
The presence/absence of bleeding on provocation would appear
to be the more objective approach (Ciancio 1986; Lorenz 2009;
Polson and Caton 1985). However, the probing technique, the
depth to which the instrument is inserted, the force with which it
is applied, the time allowed to elapse between applying the stim-
ulus and recording the outcome and even the angulation of the
instrument can have an effect on the bleeding response (Lorenz
2009; Polson and Caton 1985; van derWeijden 1994). Moreover,
calibration of examiners and demonstrating inter- and intraexam-
iner reliability are hampered by the inability to obtain the same
response upon repeated application of the stimulus to provoke
gingival bleeding at the same site (Lorenz 2009; Polson and Caton
1985). In synthesising the evidence from primary research studies
evaluating chlorhexidine mouthrinse as an adjunctive treatment
for gingival health, the many different approaches to measuring
gingivitis, particularly gingival bleeding, presented difficulties in
combining the study results to produce a summary of the effect of
the mouthrinse.
To facilitate the analysis, we grouped the indices into those that
measured principally gingival inflammation visually and invasively
(e.g. the Gingival Index (Löe 1967; Löe and Silness 1963)) or vi-
sually only (e.g. the Modified Gingival Index (Lobene 1986)) and
those that measured gingival bleeding (e.g. bleeding on probing
(BOP) (Ainamo and Bay 1975) or the Eastman Interdental Bleed-
ing Index (Caton and Polson 1985)). We endeavoured to include
both types of index formeasuring gingivitis in the review, therefore
where both were reported within a study, both were data extracted.
Our main analysis was based on the studies that reported gingival
inflammation using theGingival Index (Löe 1967; Löe and Silness
1963) at 4 to 6 weeks and 6 months to reflect both the short- and
long-term effect of chlorhexidine mouthrinse. Our results showed
that after 4 to 6 weeks of use, chlorhexidine mouthrinse reduced
gingivitis by a mean of 0.21 of a unit on the Gingival Index (GI)
scale when compared to a placebo/control mouthrinse or mechan-
ical oral hygiene alone. Based on these studies, a reduction in gin-
givitis of 0.11 to 0.31 of a unit on the GI scale could be expected
with use of chlorhexidine mouthrinse for a period of 4 to 6 weeks
in individuals with mild gingival inflammation on average (mean
score of 1 on the 0 to 3 GI scale). A similar mean effect size of
0.20 of a unit reduction on the GI scale was found for gingivitis
at 6 months also in individuals with mild gingival inflammation
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on average.
The GI is measured on a 0 to 3 increasing scale with 0 indicat-
ing normal gingivae. However, each one unit increase on the scale
does not indicate the same proportionate deterioration in gingival
condition and a low mean GI score could mask the presence of
a small number of sites with moderate or severe levels of gingival
inflammation. With this in mind, depending on the average gin-
givitis level in an individual, a one unit reduction could indicate
a shift from severe inflammation and a tendency for spontaneous
bleeding to moderate inflammation and BOP or from moderate
inflammation and BOP to mild inflammation but no BOP. As
previously mentioned, the participants who contributed data to
the meta-analyses of the GI at 4 to 6 weeks had a low mean gin-
gival index score at baseline. The clinical relevance of a mean re-
duction of one fifth of a unit on the GI scale is therefore not clear.
Our results for gingival bleeding indicate that using chlorhexi-
dine mouthrinse for 4 to 6 weeks or 6 months has a moderate ef-
fect on gingival bleeding. Although these meta-analyses included
some studies where participants appeared to have a high propor-
tion of sites with BOP at baseline, the variety of different gingival
bleeding indices employed meant that we were unable to deter-
mine the mean reduction in gingivitis associated with chlorhexi-
dine mouthrinse use in individuals with moderate or severe levels
of gingival inflammation. When the SMDs for gingival bleeding
were expressed in the units of the bleeding aspect of the GI (GI≥
2) the effect size was equivalent to a 7% reduction in the percent-
age of sites with BOP at 4 to 6 weeks and a 4% reduction in the
percentage of sites with BOP at 6 months. Use of chlorhexidine
mouthrinse was associated with a large reduction in plaque at 4 to
6 weeks and 6 months. The mean reduction in plaque associated
with chlorhexidine mouthrinse use at 4 to 6 weeks was equiva-
lent to approximately half a unit on the 0 to 3 Plaque Index scale
(Silness and Löe 1964) or three quarters of a unit on the 0 to 5
Turesky modification of the Quigley and Hein Index (TQH) scale
(Turesky 1970).
Statistical heterogeneity was evident in many of our meta-analyses
and was likely due to variation in the characteristics of the individ-
ual included studies. Investigation of the observed heterogeneity
was conducted for our main outcome, measured using the GI at 4
to 6 weeks and 6 months using prespecified characteristics. There
was a decrease in the effect estimate for the GI at 6 months when
a prophylaxis or scale and polish was conducted at the start of the
study compared to studies where no prophylaxis or scale and polish
was undertaken. This is not consistent with our knowledge of the
mechanism of action of chlorhexidine mouthrinse which would
appear to be more effective in preventing plaque accumulation
when applied to a clean tooth surface than reducing pre-existing
plaque (Eley 1999). Nonetheless, the results indicate that some of
the heterogeneity for theGI at 6months was due to whether or not
a prophylaxis or scale and polish was conducted at the beginning
of the study. We have presented all of the meta-analyses despite
the high heterogeneity due to the remarkable consistency of the
direction of effect across the different analyses.
We included studies that evaluated chlorhexidine mouthrinse use
in individuals with gingivitis only or gingivitis and periodonti-
tis. Where it was reported, the level of gingivitis in the included
studies at baseline was generally low. The majority of the studies
that evaluated chlorhexidine mouthrinse use in individuals with
periodontitis evaluated its effect as an adjunct to surgical or non-
surgical periodontal treatment. In a small number of the studies
that evaluated chlorhexidine mouthrinse use in individuals with
periodontitis, it was difficult to ascertain whether the professional
tooth cleaning provided was appropriate for the level of disease
present. For example, in two of these studies it was reported that
professional cleaning was undertaken at baseline but no further
details were provided (Chaves 1994; Ernst 2005). In another study
where 17% to 50% of participants in the study groups were diag-
nosed with periodontitis, supragingival scaling and polishing only
was provided at baseline (Graziani 2015). In one study a propor-
tion of the participants clearly had periodontitis and abundant cal-
culus, however no professional treatment or oral hygiene instruc-
tions were provided to the participants (Corbet 1997). The in-
clusion of these studies could be criticised because antimicrobials
such as chlorhexidine have limited capacity to penetrate subgingi-
vally and are therefore suggested for use as an adjunct to mechan-
ical debridement rather than as an alternative therapy (Greenstein
1986;Ohrn 2009). Furthermore, self-medicationwith an effective
antimicrobial agent such as chlorhexidine mouthrinse “may mask
more serious underlying periodontal disease” (Tonetti 2015). It
is well recognised that control of supragingival plaque alone will
not be sufficient to treat periodontitis (Eley 1999; Hull 1980),
disruption of the subgingival plaque by mechanical debridement
will also be required (Kornman 1986; Ohrn 2009).
We would have liked to investigate how the effect of chlorhexidine
mouthrinse on gingival health varies depending on the level of
underlying periodontal disease. However, the periodontal status
of the participants in the included studies often was not clearly
reported at baseline. In many cases, the inclusion criteria allowed
for individuals to have pocket probing depths and clinical attach-
ment loss consistent with periodontitis but the periodontal status
of the people actually enrolled in the study was not described. Fur-
thermore, where participants were advised to continue their regu-
lar oral hygiene practices during the study, no information about
their frequency of toothbrushing or their use of interdental clean-
ing aids was reported. Therefore, our ability to explore the effect
of the adjunctive use of chlorhexidine mouthrinse on gingivitis in
individuals with different levels of periodontal disease at baseline
and in individuals with treated and untreated periodontitis was
hampered both by the small number of studies available at each
time point and by poor reporting of the relevant information in
the included studies.
We were able to conduct a metaregression analysis of 4 to 6 week
and 6-month studies where participants had gingivitis only com-
pared to studies where participants had gingivitis and periodonti-
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tis (both treated and untreated during the study). The results did
not disclose any statistically significant difference in the effect of
the chlorhexidine mouthrinse on the gingival index at either time
point, however only eight studies were included in the metaregres-
sion at 4 to 6 weeks and only nine studies were included in the
metaregression at 6 months. We cannot specifically comment on
the effect of chlorhexidine used adjunctively during periodontal
treatment on periodontal outcomes such as pocket probing depth
and clinical attachment loss because the focus of this review was
gingivitis and therefore periodontal outcomes were outside the
scope of the review.
Retention of chlorhexidine in the oral cavity is key to its effective-
ness as an antimicrobial agent (Bonesvoll 1974; Bonesvoll 1974a;
Bonesvoll 1978; Jenkins 1988; Rolla 1971) and is dependant on
a number of different factors including concentration and dura-
tion of application (Tomás 2010). In relation to concentration,
the effect of chlorhexidine on plaque is dose-dependant and a sim-
ilar effect can be achieved with larger volumes of lower concen-
tration solutions providing the optimal dose of approximately 20
mg twice a day is delivered (Bonesvoll 1978). All but four of the
included studies evaluated either 0.2%, 0.12% or 0.1% chlorhex-
idine mouthrinse and only two of these studies provided data
for 0.2% compared to 0.1% (Axelsson 1987) or 0.12% (Segreto
1986) chlorhexidine mouthrinse within the same study. Most of
the studies that evaluated 0.2% chlorhexidine mouthrinse em-
ployed a rinse volume of 10 mL twice a day while most of the
studies that evaluated 0.12% or 0.1% chlorhexidine mouthrinse
employed a rinse volume of 15 mL twice a day. Therefore regard-
less of the concentration of chlorhexidine mouthrinse used, the
dose of chlorhexidine was effectively the same in the majority of
the studies and corresponded to the optimal dose of 18 mg to 20
mg twice a day. It has been demonstrated that increasing the du-
ration of rinsing with 0.12% or 0.2% chlorhexidine mouthrinse
from 30 to 60 seconds results in greater substantivity of the rinse
(Tomás 2010). The longer duration of rinsing employed by most
of the studies in this review that evaluated 0.2% chlorhexidine
mouthrinse could be expected to translate into greater retention of
chlorhexidine in these studies and hence a greater effect on gingivi-
tis and plaque. However, 75% of the chlorhexidine that is retained
after rinsing for 60 seconds with 0.2% chlorhexidine rinse is re-
tained after the first 30 seconds of rinsing (Bonesvoll 1974) and a
rinse duration of 30 seconds for 0.12% chlorhexidine mouthrinse
has been shown to be both effective and acceptable (Keijser 2003).
Therefore, most of the studies included in this review used the
optimal dose of chlorhexidine for at least 30 seconds which may
partly explain why we did not find any difference in effect between
the different concentration rinses. The two included studies that
provided data for a direct comparison between 0.2% and 0.1%/
0.12% chlorhexidine rinse found no difference in effect between
the different concentration rinses used with the same volume and
duration of rinsing (Axelsson 1987; Segreto 1986).
Studies that evaluated the effectiveness of chlorhexidine
mouthrinse on gingivitis using a cross-over study design were ex-
cluded from this review. This was due to concerns that the du-
ration of the washout phase between the trial periods might not
be sufficient to rule out a carry-over effect due to chlorhexidine
mouthrinse. Carry-over can threaten the internal validity of a
cross-over study and is of particular concern in studies involv-
ing chlorhexidine mouthrinse due to the established substantivity
or prolonged effect of chlorhexidine mouthrinse. Evidence-based
guidance on the appropriate duration of washout phase is absent
from the literature and the washout periods commonly used ap-
pear to range from 2 days to 3 weeks (Berchier 2010; Newcombe
1995). The very limited data we have in this review regarding gin-
givitis and plaque outcomes recorded after cessation of chlorhex-
idine mouthrinsing suggest a residual effect on these outcomes
weeks or months after rinsing with chlorhexidine has ceased. Al-
though no firm conclusions can be drawn regarding the appro-
priateness of using a cross-over study design when the study in-
cludes a chlorhexidine mouthrinse arm, the uncertainty surround-
ing carry-over in relation to chlorhexidine mouthrinse warrants
further investigation.
Low concentration (0.05%/0.06%) chlorhexidine mouthrinses
are currently marketed for long-term daily use. Side-effects associ-
ated with chlorhexidine mouthrinse use are dose-dependant and
tend to decrease when the concentration is lowered (Cumming
and Löe 1973; Flotra 1971). Therefore in lowering the concentra-
tion of chlorhexidine, it is hoped that side effects will be reduced
while maintaining the effect on gingivitis and plaque (Keijser
2003). Only five studies that evaluated chlorhexidine concentra-
tions less than 0.1%met the inclusion criteria for this review. Two
studies evaluated 0.05% (Jayaprakash 2007; Joyston-Bechal 1993)
and three studies evaluated 0.06% chlorhexidine mouthrinse
(Hoffmann 2001; Zimmer 2006; Zimmer 2015). Although all of
these studies demonstrated a reduction in plaque, the effect on
gingivitis was not clear. This might be explained by the lower con-
centration rinses having a mainly bacteriostatic action that may
produce an effect below the threshold required to produce a cor-
responding reduction in gingivitis. Despite the reduced concen-
tration of chlorhexidine, extrinsic tooth staining occurred in all
four studies of low concentration chlorhexidine mouthrinse that
reported a staining outcome (Hoffmann 2001; Joyston-Bechal
1993; Zimmer 2006; Zimmer 2015). There has been some debate
about the mechanism by which chlorhexidine mouthrinse pro-
duces extrinsic tooth staining. However, it is currently understood
to be a result of precipitation of anionic dietary chromogens onto
adsorbed chlorhexidine cations (Watts 2001) and thus the mecha-
nism by which chlorhexidine mouthrinse produces extrinsic tooth
staining appears to be closely linked to its mechanism of action.
Therefore lack of staining is likely to indicate lack of effectiveness
(Addy 2005; Eley 1999). Some degree of tooth staining can there-
fore be expected to feature evenwith low chlorhexidine concentra-
tion rinses. However, with the exception of Zimmer 2006, there
were no reports of other adverse effects relating to the low concen-
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tration chlorhexidine mouthrinse apart from staining of the teeth
and oral tissues.
Use of chlorhexidine mouthrinse is associated with a number of
adverse effects, the most common being extrinsic staining of the
teeth and oral soft tissues (Addy 1986). In many of the studies
included in this review, adverse effects were inadequately reported
or not reported at all. It is important that adverse effects due to
chlorhexidine mouthrinse use are reported alongside evidence for
effectiveness with enough detail to allow health professionals and
the public to make an informed decision about recommending,
prescribing or using the mouthrinse.
From our included studies it was clear that rinsing with any con-
centration of chlorhexidine mouthrinse for 4 weeks or longer was
associated with an increase in extrinsic tooth staining. A number
of the included studies reported higher levels of calculus in the
chlorhexidine rinse arms but the meta-analyses were inconclusive.
Other adverse effects such as taste disturbance/alteration, burning
sensation and pigmentation of the oral soft tissues were also re-
ported in a number of included studies. Effects on the oral mu-
cosa such as mucosal ulceration, lesions or erosions and a transient
anaesthetic sensation, hypoaesthesia and paraesthesia were also re-
ported in a number of included studies and can be considered
more severe but the proportion of participants experiencing these
adverse effects in any study tended to be low.While extrinsic tooth
staining and calculus build-up due to chlorhexidine mouthrinse
use must be removed by professional tooth cleaning incurring the
costs associated with a visit to a dental professional, the other as-
sociated adverse effects are known to be transient in nature and to
resolve once mouthrinsing ceases (Flotra 1971; Greenstein 1986).
However, these adverse effects, although transient, can be severe
and development of extrinsic tooth staining with short-term use
of the mouthrinse is an obvious deterrent to using chlorhexidine
mouthrinse.
Quality of the evidence
Although all the included studies were randomised controlled tri-
als (RCTs), 50 of the 51 included studies were assessed as at high
risk of bias overall, as they had at least one domain rated at high
risk of bias. The reason many of the studies were assessed as at high
risk of bias was due to problems with the blinding of participants,
personnel, and outcome assessors. The majority of studies con-
tained a placebo arm with the intention of blinding participants
and personnel. However, we considered blinding unlikely to be
successful due to the propensity for chlorhexidine to stain the teeth
and oral tissues and the association of its use with clinically visible
adverse effects such asmucosal desquamation andmucosal lesions.
This also applied to the blinding of outcome assessors, in trials
with either a placebo, control, or mechanical oral hygiene alone.
This was not the fault of the investigators who in many studies
went to great lengths to try to ensure blinding. Consequently we
assessed 42 (82%) studies as at high risk of bias for either sort of
blinding bias (performance bias or detection bias).
Thirty-seven studies were rated at high risk of selective reporting
bias, mainly due to lack of reporting of measures of variance along
with the means for each group, and no reporting of tooth staining
and other adverse effects.
It is worth mentioning that 22 of the included studies were pub-
lished prior to the first publication of the first iteration of the
CONSORTStatement in 1996 (Begg 1996) and their quality was
therefore partly judged according to reporting standards that did
not exist at the time of their publication. An additional nine studies
were published prior to the publication of the revised CONSORT
Statement in 2001 (Moher 2001). However, disappointingly, in-
stances of poor reporting were not confined to the studies that
predated widespread awareness of the CONSORT Statement.
Despite most studies included in the meta-analyses being assessed
as at high risk of bias we did not downgrade the GRADE assess-
ments for gingivitis and plaque for this reason. This is because we
believe that further research is very unlikely to change our confi-
dence in the estimate of effect for these outcomes. The grade as-
sessments for the body of evidence for chlorhexidine mouthrinse
compared with placebo, control or mechanical oral hygiene alone
for gingivitis measured using the Löe and Silness Gingival Index
and for plaque measured using various indices were therefore rated
as high quality. Although there was high heterogeneity for some
of these meta-analyses we did not downgrade for this due to con-
sistency of the direction of effect.
Over half of the included studies were either funded directly, re-
ceived support for the study or were affiliated in some way with
industry. Although a high level of industry funding is far from
ideal, the reality is that without industry funding few trials eval-
uating the effectiveness of chlorhexidine mouthrinse would have
been conducted. However, it is noteworthy that of the 19 included
studies funded directly by industry, only one study (Zimmer 2015)
stated that the conduct of the research and final decisions regard-
ing the study report were independent of the company funding
the research.
Potential biases in the review process
In order to prevent judgements about the eligibility criteria for
studies being influenced by prior knowledge of the study results,
the methods to be used in the review should be established and
documented in advance of the review being undertaken (Higgins
2011). We made a number of changes to the protocol in relation
to the types of studies and types of participants to be included in
the review. We also clarified additional criteria for the inclusion of
studies based on type of intervention that were implicit but not
explicitly stated in the protocol. We amended the assessment of
the blinding domains in the ’Risk of bias’ tool to allow studies
to obtain a judgement of ’low’ or ’unclear’ risk of bias in certain
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circumstances compared to the blanket judgement of high risk of
bias that was stated in the published protocol.
A hierarchy to guide data extraction for gingivitis and plaque data
was developed to facilitate data extraction and analysis. The main
analysis however, was based on the main prespecified gingivitis
index: the Gingival Index of Löe and Silness (Löe 1967; Löe
and Silness 1963). Full details of the changes to the protocol are
described in the Differences between protocol and review section.
It is acknowledged that it may not always be appropriate to adhere
to the published protocol (Higgins 2011). Therefore, while these
changes to the protocol could introduce a risk of bias, the changes
were made in the early stages of the review before any analyses of
the results were undertaken and are therefore considered unlikely
to have been influenced by knowledge of the study results or the
results of the review. Furthermore, each decision was appropriately
justified andwasmade to improve the scientific quality and clinical
applicably of the review.
We estimated the standard deviations for four studies that mea-
sured the Gingival Index at 6 months (Banting 1989; Jayaprakash
2007; Lucas 1999; Sanz 1994) and one study that measured the
Gingival Index at 4 to 6 weeks (Sanz 1989) using data from the
same outcomes measured at the same time point in other simi-
lar studies so that we could include these data in meta-analyses.
Where mean scores or measures of variance of the mean scores or
both were not reported in the text or in tabular form, and could
not be obtained from the authors of the studies, data were esti-
mated by reading them off the graphs in the published report for
inclusion in meta-analyses for six studies (Brecx 1993; Brightman
1991; Chaves 1994; Ferretti 1987; Jenkins 1993; Joyston-Bechal
1993). The graphswere enlarged and the datawere estimated inde-
pendently and in duplicate. A sensitivity analysis for the Gingival
Index at both 4 to 6 weeks and 6 months, excluding trials where
we had to estimate the standard deviation from similar studies, or
had to read the data from graphs, showed that the effect estimates
were similar to those for the overall pooling of the studies.
Agreements and disagreements with other
studies or reviews
Van Strydonck 2012 conducted a comprehensive review of the
effect of chlorhexidine mouthrinse on plaque, gingival inflamma-
tion and tooth staining in studies of 4 weeks or longer. This review
was very similar to our review but slight differences in the inclu-
sion criteria and the dates of the literature searches meant that
a slightly different group of studies were reviewed by Van Stry-
donck et al. The review focused on healthy adults only, considered
chlorhexidinemouthrinse used as amonotherapy or as an adjunct,
and excluded patients with periodontitis or dentures as well as
orthodontic and implant patients. In addition, apart from tooth
staining, adverse effects although reported in the review, were not
prespecified outcomes. Of the 30 studies included in this review,
27 are common to our review. The results of the meta-analysis
of studies reporting the GI at all time points included data from
seven studies, six of which were included in our meta-analyses at
either 4 to 6 weeks, 7 to 12 weeks or 6 months. The weighted
mean difference for the GI in this review was -0.32 which is sim-
ilar to the mean difference for the GI reported in our review. Ex-
trinsic tooth staining, increased calculus formation and change of
taste sensation were also noted to have frequently occurred in the
included studies. Considerable heterogeneity in the design, study
duration and rinse regimen were also noted to be present.
Boyle 2014 systematically reviewed the evidence relating to the
efficacy of the most frequently used mouthrinses for the control
of supragingival plaque and gingivitis. Both the scope of the liter-
ature search and the inclusion criteria were narrower than in our
review. Of the 17 trials involving chlorhexidine mouthrinse in-
cluded in this review 16 are common to our review. The reported
’summary relative differences’ facilitated comparison between the
different mouthrinse preparations being reviewed. Results for the
chlorhexidine mouthrinse studies are supportive of the effective-
ness of chlorhexidine mouthrinse primarily for the control of both
gingivitis and plaque relative to control but also relative to other
active mouthrinse preparations.
A systematic review by Serrano 2015 evaluated the effectiveness
of adjunctive antiplaque chemical agents including chlorhexidine
mouthrinse in RCTs of at least 6 months duration. The review
included 14 studies evaluating chlorhexidine mouthrinse. Due to
differences in inclusion criteria, 12 of these studies are common to
our review. The authors reported a significant benefit for rinsing
with 0.1% to 0.2% chlorhexidine mouthrinse based on a meta-
analysis of four studies (weighted mean difference on the GI -
0.185) but a non-significant effect for chlorhexidine mouthrinse
at concentrations of ≤ 0.06%. In common with our review was
the presence of high heterogeneity which made it difficult to pool
the data and was an acknowledged limitation of the review.
Gunsolley 2006 conducted a meta-analysis of 6-month
mouthrinse studies for the control of gingivitis and plaque. Six
of the included studies evaluated the effect of 0.12% chlorhexi-
dine mouthrinse using the GI and all six were common to our
review. The analysis indicated a moderate effect for gingivitis and
a large effect for plaque. A subsequent metareview also conducted
by Gunsolley drew on the data from the earlier meta-analysis and
found a weighted mean percentage reduction of 28.7% for the GI
and 40.4% for the Plaque Index (Gunsolley 2010) based on the
same six studies.
The efficacy of 0.12% chlorhexidine mouthrinse compared to
0.2% on plaque and periodontal parameters was systematically re-
viewed by Berchier 2010. The review included eight studies with
rinse duration from 3 days to 3 months that directly compared
0.12% with 0.2% chlorhexidine mouthrinse. The review found
no difference in the effect on gingivitis between the two concentra-
tions of chlorhexidine. The small significant difference in plaque
inhibition in favour of 0.2% chlorhexidine was thought to be of
negligible clinical relevance. Our review included two studies that
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provided data for a direct comparison between 0.2% and 0.1%/
0.12% chlorhexidine rinse (Axelsson 1987; Segreto 1986), one of
which was also included in the Berchier review (Segreto 1986).
There was no difference in effect between the different concen-
tration rinses used with the same volume and duration of rinsing
in these two studies. Similarly our subgroup analysis found no
evidence that one concentration of chlorhexidine rinse was more
effective than another in reducing gingivitis and plaque.
van der Weijden 2015 conducted a metareview of the evidence
regarding the efficacy and safety of chemical agents in mouthrinses
to manage gingivitis and plaque. The evidence for chlorhexi-
dine mouthrinse was drawn from the systematic reviews (Serrano
2015; Van Strydonck 2012) and meta-analyses (Gunsolley 2006;
Gunsolley 2010) described above. Berchier 2010 contributed data
for the comparison of active ingredients. This review reaffirmed
the effectiveness of chlorhexidine mouthrinse for reducing plaque
and gingivitis. The body of evidence resulting from these three
reviews was rated as ’strong’. Due to the heterogeneity in themeta-
analyses, the authors advised caution in interpreting the difference
of means as it “may not provide an exact measure of the results”
(van der Weijden 2015). Although the authors concluded that
chlorhexidine is the “first choice”, they also acknowledged that
the development of taste disturbance, tooth staining and calculus
formation prohibit long-term adjunctive use of the mouthrinse.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review found high-quality evidence of a large reduction in
dental plaque with chlorhexidine mouthrinse used as an adjunct
to mechanical oral hygiene procedures for 4 to 6 weeks and 6
months. We also found high-quality evidence from studies that
reported the Löe and Silness Gingival Index of a reduction in
gingivitis in individuals with mild gingival inflammation on av-
erage (mean score of 1 on the 0 to 3 Gingival Index (GI) scale),
that was not considered to be clinically relevant. There was no
evidence that one concentration of chlorhexidine mouthrinse was
more effective than another. There was insufficient evidence to de-
termine the reduction in gingivitis associated with chlorhexidine
mouthrinse use in individuals with mean GI scores of 1.1 to 3 in-
dicating moderate or severe levels of gingival inflammation. Rins-
ing with chlorhexidine mouthrinse for 4 weeks or longer causes
extrinsic tooth staining. In addition, other adverse effects such as
calculus build-up, transient taste disturbance and effects on the
oral mucosa were reported in the included studies.Chlorhexidine
mouthrinse is indicated in particular clinical situations for short
periods of time. Using chlorhexidine mouthrinse for longer pe-
riods of time in individuals with special care needs who cannot
maintain an adequate level of plaque control using mechanical
cleaning methods alone must be carefully weighed against the ad-
verse effects associated with its use.
Implications for research
The majority of the studies included in the main analysis of the
Gingival Index at 4 to 6 weeks and 6 months involved healthy
participants with low levels of gingivitis.There was insufficient ev-
idence to determine the reduction in gingivitis associated with
chlorhexidine mouthrinse use in individuals with mean GI scores
of 1.1 to 3 indicating moderate or severe levels of gingival inflam-
mation. Some of the studies included in the meta-analyses of gin-
gival bleeding at 4 to 6 weeks and 6 months included participants
with a high proportion of sites with bleeding on probing.However,
due to the variety of different gingival bleeding indices employed,
we were unable to determine the mean reduction in gingivitis as-
sociated with chlorhexidine mouthrinse use in individuals with
moderate or severe levels of gingival inflammation. Further well-
conducted randomised controlled trials are needed to investigate
the effect size for adjunctive chlorhexidine mouthrinse use in in-
dividuals with moderate or severe levels of gingival inflammation.
Agreement among the experts about which indices are most ap-
propriate for measuring gingivitis in studies evaluating antimicro-
bial mouthrinses would facilitate future evidence syntheses. Ev-
idence-based guidance regarding patient selection for chlorhexi-
dine mouthrinse use would help to provide clarity regarding the
’particular clinical situations’ in which short-term use of chlorhex-
idine mouthrinse is recommended.
Only five studies evaluating 0.05% or 0.06% chlorhexidine
mouthrinse met the inclusion criteria for this review. These stud-
ies demonstrated a reduction in plaque but the effect of these
low-concentration mouthrinses on gingivitis was not clear or con-
sistent. As low-concentration chlorhexidine mouthrinse is cur-
rently marketed for long-term daily use, well-conducted ran-
domised controlled trials are needed to investigate the effect of
these mouthrinses on gingivitis and to record any adverse effects
associated with their use.
Due to the unavoidable influence of extrinsic tooth staining asso-
ciated with use of chlorhexidine mouthrinse on blinding of par-
ticipants, personnel and outcome assessors, particular attention
must be given to robust study design and rigorous reporting of the
other domains in the Cochrane ’Risk of bias’ tool. In particular,
estimates of effect should be fully reported with a measure of vari-
ance so that data can be included inmeta-analyses. Evidence of ad-
verse effects should also be fully reported for each study arm. The
CONSORT Statement (Schulz 2010) should be used to optimise
reporting in future studies. The appropriateness of using studies
with cross-over design that include chlorhexidinemouthrinse war-
rants further investigation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anauate-Netto 2014
Methods Trial design: parallel (3 arms - 2 arms relevant to this review)
Location: dental clinics at University Bandeirante of Sao Paulo, Sao Paulo, Brazil
Number of centres: 1
Study duration: the recruitment period is not stated. Study duration and duration of
rinsing was 4 weeks
Participants Participants: healthy adults
Inclusion criteria: at least 20 teeth, no clinical signs of periodontal disease, aged between
18 and 55 years, normal saliva secretion rate
Exclusion criteria: smokers, pregnancy, taking oral topical or systemic medication
Baseline gingivitis: (Papillary Bleeding Score) overall (3 groups) mean 1. Gp A: mean 1.
1 (SD 0.5); Gp B: mean 1.0 (SD 0.5); Gp C: mean 0.9 (SD 0.4)
Age at baseline (years): overall: 40. Gp A: mean 41.6 (SD 13.4); Gp B: mean 39.4 (SD
9.8); Gp C: mean 39 (SD 11.7)
Gender: overall: male 24 (40%), female 36 (60%). Gp A: male 7 (35%), female 13
(65%); Gp B: male 8 (40%), female 12 (60%); Gp C: male 9 (45%), female 11 (55%)
Number randomised: 60 (Gp A: 20; Gp B: 20; Gp C: 20)
Number evaluated: 60 (Gp A: 20; Gp B: 20; Gp C: 20)
Interventions Comparison: CHX rinse versus propolis rinse* versus placebo rinse
Gp A (n = 20): CHX 0.12%, 15 mL, twice daily, duration not specified, 4 weeks
*Gp B (n = 20): alcohol-free, 2% typified propolis (plus mint flavour, polioxyethelers,
sorbitol, blue colour and water), 15 mL, twice daily, duration not specified, 4 weeks. We
excluded this arm from the risk of bias and analysis
Gp C (n = 20): placebo (same ingredients as Gp B without the propolis), 15 mL, twice
daily, duration not specified, 4 weeks
Prophylaxis at baseline: not reported
OHI: none given. Subjects followed their usual oral hygiene procedures
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: quote: “Rinsing was performed
in the morning and before bedtime after ordinary oral hygiene procedures”
Outcomes Gingivitis (gingivial inflammation: Papillary Bleeding Score, gingival bleeding: PBS ≥
2); adverse reactions; assessed at 4 weeks
Funding Quote: “This study was supported by a grant from FAPESP (Fundacao de amparo a
pesquisado estado de Sao Paulo) protocol no. 2007/53047-3”
Notes Sample size calculation: quote: “It was not possible to conduct a sample size and power
analysis... because of lack of randomized clinical trials of propolis on gingivitis”
Adverse effects: Gp A (CHX): 23 reports (burning sensation, taste alteration, yellow
teeth, breath alteration, tongue burning, mucosal irritation, bitter taste); Gp B (propolis)
: 7 reports (breath alteration, burning sensation, taste alteration, yellow teeth, bitter taste)
; Gp C (placebo): 9 reports (taste alteration)
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Anauate-Netto 2014 (Continued)
Non-smokers
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a computer-generated list of ran-
dom numbers was used”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quote: “Rinses were prepared in dark-bot-
tles, which were consecutively numbered
according to the randomization schedule.
.. Study coordinator, examiners, and par-
ticipants were unaware of group allocation.
The group identity was generated and kept
in Florianopolis, SC, Brazil while the study
was conducted in Sao Paulo, SP, Brazil”
Comment: remote/central randomisation
should have ensured that the random se-
quence was implemented as it was gener-
ated, without any manipulation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “double-blind placebo-controlled”
and “rinses
were prepared in dark-bottles.” The
placebo mouthrinse matched the propolis
mouthrinse without the active ingredient
Comment: the level of adverse reactions in
theCHX group (n = 23) was higher than in
the propolis (n = 7) and placebo groups (n =
9) may have meant that participants could
have worked out which group they were
in and this could have affected their oral
health behaviours and hence the outcome.
The direction of this potential bias is not
clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “double-blind”. The incidence of
adverse reactions in the CHX group (n =
23) was higher than in the propolis (n = 7)
and placebo groups (n = 9)
Comment: the authors do not report pre-
cisely who was blinded, but even if this
includes the outcome assessors the higher
level of adverse effects including tooth
staining in the CHX group could have al-
47Chlorhexidine mouthrinse as an adjunctive treatment for gingival health (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Anauate-Netto 2014 (Continued)
lowed the outcome assessors to work out
which individuals were in the CHX group
and could have affected the outcome assess-
ment. The direction of this potential bias
is not clear
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) High risk All outcomes stated in the methods section
are reported in the results section. Adverse
effects including ’yellow teeth’ are reported
aggregated as the total number of partici-
pants affected by group. Insufficient infor-
mation on tooth staining is reported for us
to use the data in a meta-analysis
Other bias Low risk Quote: “PBS measurements were per-
formed by an experienced examiner (AAA).
Intra-examiner reliability exercises revealed
a Kappa test score of 0.85, indicating ad-
equate reproducibility of PBS measure-
ments”
Comment: the potential for differential di-
agnostic activity was minimised
Groups were balanced at baseline (NS dif-
ferences) for age, gender and race. The
groups appear balanced for PBS at baseline
Anderson 1997
Methods Trial design: parallel (2 arms)
Location: Postgraduate Clinic of Orthodontics, University of Texas-Houston, USA
Number of centres: 1
Study duration: recruitment period is not reported. Study duration and duration of
rinsing was 3 months
Participants Participants: adolescents undergoing orthodontic treatment
Inclusion criteria: quote: “The participants did not suffer from any systemic compli-
cations nor were they taking any medications that may have had an effect on the oral
tissues. All the participants had banding of at least one molar per quadrant”
Exclusion criteria: not reported
Baseline gingivitis: (GI) overall 0.925. Gp A: mean 1.04 (no SD); Gp B: mean 0.81 (no
SD)
Age at baseline (years): range 11-15
Gender: not reported
Number randomised: 32 (Gp A: 16; Gp B: 16)
Number evaluated: 28 (Gp A: 13; Gp B: 15)
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Anderson 1997 (Continued)
Interventions Comparison: CHX rinse versus placebo rinse
Gp A (n = 16): CHX (Peridex) 0.12%,15 mL, twice daily, 30 seconds, 3 months
GpB (n=16): placebo (identical to the experimental rinse except for the active ingredient)
, 15 mL, twice daily, 30 seconds, 3 months
Prophylaxis at baseline: quote: “they received a dental prophylaxis which included the
removal of plaque, calculus and stains from the teeth by scaling and polishing” (8-10
days before baseline measurements)
OHI: they received oral and written toothbrushing instructions with the same toothpaste
(Crest regular flavour) to be performed twice daily. The method used was the Modified
Bass technique. Soft rounded toothbrushes were supplied to all patients
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinse instructions: not reported
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1963); plaque (PI Silness & Löe
1964); calculus (Retention Index, Löe 1967); assessed at 1, 2 and 3 months follow-up
Probing depths (CP-12 Hu Friedy periodontal probe) - not relevant to this review and
tooth staining (Discolouration Index, Lang 1981); assessed at 3 months only
Funding Quote: “Partially supported by Procter & Gamble, by providing the chlorhexidine and
placebo for the patients in this study”
Notes Sample size calculation: not reported
Adverse effects: quote: “...no side effects were reported as a result of the use of either
the experimental or the control solutions except for one patient in CHX group who
acknowledged a burning sensation on the mucosa after the use of the experimental so-
lution.” No significant differences were found between the groups for discolouration or
calculus accumulation, although tooth discolouration “was more evident in the experi-
mental group” and for calculus accumulation “the higher mean values were always found
in the experimental group”
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “They were randomised to two
groups”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The control group received ex-
actly the same instructions with a flavoured
placebo solution which was identical to the
experimental solution except for the active
ingredient…” and “..the discoloration was
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Anderson 1997 (Continued)
more evident in the experimental groupbut
it was not statistically significant”
Comment: the study is not described as
blind by the authors but the methods de-
scribed indicate that it was intended for the
participants to be unaware of the allocated
intervention. However, the higher level of
staining in the active group (although not
statistically significant) meant that partici-
pants could have worked out which group
they were in and this could have affected
their oral health behaviours and hence the
outcome. The direction of this potential
bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No information is provided
Comment: the study is not described as
blind by the authors. The higher level
of staining in the CHX group (although
not statistically significant) meant that the
outcome assessor could not be adequately
blinded and this could have affected the
outcome assessment. The direction of this
potential bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk 12.5% (4/32) of randomised participants
were not included in the analysis. Attrition
by group: CHX 3/16 (18.8%), placebo 1/
16 (6.3%)
2 individuals left the study after they
received the baseline prophylaxis (CHX
group), 1 before the 30 day evaluation
(CHX group) and 1 was unable to return
for the 60 and 90 day evaluations (control
group)
Comment: attrition was quite high in the
CHXgroup as proportionof the total num-
ber in the group. Although the attrition
is unlikely to be due to the intervention
(CHX) (2 of the 3 participants who left
the CHX group left the study before they
started rinsing), if the missing participants
hadhighermean gingivitis scores in 1 group
than the other, as the attrition rate in-
creased, so would over/understatement of
the mean difference
Selective reporting (reporting bias) High risk Mean scores and standard deviations for all
outcomes were reported by tooth surface
only which meant that with the exception
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Anderson 1997 (Continued)
of the tooth staining data (where we were
able to combine data for buccal and lingual
surfaces), we could not use the data inmeta-
analyses
Other bias Unclear risk No information is provided on intra-
or inter-examiner reproducibility. There
were no significant differences between the
means of the plaque indices and gingival
indices recorded on all surfaces for both ex-
perimental and control groups. The Reten-
tion Index,Discolouration Index andmean
probing depthmeasurements were also bal-
anced
Mean age and gender are not reported
Axelsson 1987
Methods Trial design: parallel (4 arms - 3 arms are relevant to this review)
Location: dental school, Sweden
Number of centres: 1
Study duration: recruitment period is not reported. Study duration and duration of
rinsing was 6 weeks
Participants Participants: volunteers aged 16-50 years with gingivitis
Inclusion criteria: not reported.
Exclusion criteria: periodontal attachment loss or bone loss
Baseline gingivitis (mean (SE): (GI Löe & Silness 1963) overall 1.21. Gp A: mean 1.18
(0.08); Gp B: mean 1.26 (0.07); Gp C: mean 1.19 (0.07); Gp D: mean 1.21 (0.08))
Age at baseline (years): mean age not reported, range 16-50
Gender: not reported
Number randomised: 96, (Gp A: 24; Gp B: 24, Gp C: 24, Gp D: 24)
Number evaluated: 88, (Gp A: 18; Gp B: 24, Gp C: 24; Gp D: 22)
Interventions Comparison: CHX (Hibitane 0.2%) versus CHX (Hibitane 0.1%) versus Listerine*
versus control
Gp A (n = 24): CHX (Hibitane) 0.2%, 10 mL, twice daily, 60 seconds, 6 weeks
Gp B (n = 24): CHX (Hibitane) 0.1%, 10 mL, twice daily, 60 seconds, 6 weeks
*Gp C (n = 24): Listerine, 20 mL, twice daily, 30 seconds, 6 weeks. We excluded this
arm from the risk of bias and analysis
GpD (n = 24): control rinse (composition not described), 20mL, twice daily, 30 seconds,
6 weeks
Prophylaxis at baseline: scaling and professional tooth cleaning after the baseline exam-
ination
OHI: they were supplied with a soft nylon toothbrush and Colgate MFP toothpaste,
were instructed to refrain from using commercial mouthrinses and continued to exercise
their regular non-supervised self-performed plaque control programs
Rinsing was supervised Mon-Fri and unsupervised at weekends
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Axelsson 1987 (Continued)
Timing of mouthrinsing in relation to toothbrushing is not reported
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1963, gingival bleeding:%GI scores
0, 1, 2 or 3) assessed at 6 weeks
Plaque (TQH Turesky 1970); extrinsic tooth stain (Lobene 1968); assessed at 3 and 6
weeks
A complete intraoral soft tissues examination was performed after 3 and 6 weeks
Funding No information provided
Notes Sample size calculation: quote: “The study was designed to provide a minimal power of
0.70 for detecting a clinically important difference to be statistically significant at the
0.05 probability level. The final sample size was based on the maximum determined
among the separate requirements of the plaque and gingival index scores.” The sample
size required is not reported
Adverse effects: mucosal lesions occurred in 6 subjects in the Hibitane group (0.2%), 1
subject in the control group complained of oral irritation which worsened during the
study
The order of examinations were a) soft tissue condition, b) stain index, c) gingival index,
d) plaque index
Declarations/conflicts of interest: none stated
Groups A and B were combined for the main analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Volunteers were assigned either to
1 of 3 different treatment groups or to a
control group according to a randomised
code by which double-blinding was main-
tained”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk Quote: “Volunteers were assigned either to
1 of 3 different treatment groups or to a
control group according to a randomised
code by which double-blinding was main-
tained”
Comment: it is not clear who assigned the
participants to the groups or whether par-
ticipants or investigators could foresee as-
signment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study is described as double-blind.The
authors do not report precisely who was
blinded. The composition of the control is
not described. There were negligible differ-
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Axelsson 1987 (Continued)
ences in extrinsic tooth staining between
the groups at 3 and 6 weeks
Comment: neither participants nor person-
nel could be truly blind as different vol-
umes and rinse times were used in dif-
ferent groups and rinsing was supervised
on weekdays. Knowledge of which product
waswhich could have influenced behaviour
of participants andhence the outcome.The
direction of this potential bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The authors state that the study is “dou-
ble-blind” but do not report precisely who
was blinded. There were negligible differ-
ences in extrinsic tooth staining between
the groups at 3 and 6 weeks. All intrao-
ral examinations (including tooth staining)
were performed by a single examiner
Incomplete outcome data (attrition bias)
All outcomes
High risk 11% (8/72) of randomised participants
were not included in the analysis
Attrition by group: Hibitane 0.2% 6/24
(25%); Hibitane 0.1% (0%); control 2/24
(8.3%). Reasons for attrition: Hibitane 0.
2%: mucosal lesions; control: oral irrita-
tion, personal reasons
Comment: there were differential group
losses with proportionately more losses
from the Hibitane 0.2% group (due to the
occurrence ofmucosal lesions) which could
have influenced the outcome
Selective reporting (reporting bias) High risk All outcomes stated in the methods sec-
tion are reported in the results section. We
calculated standard deviations for gingivi-
tis and plaque from the standard errors re-
ported in the tables. We also calculated the
% of gingival units with a GI score of 2 or
3 however, no measure of variance was re-
ported so we could not include the data in
meta-analyses. Extrinsic tooth staining and
adverse effects were adequately reported.
We combined groups A and B for the main
analysis
Other bias Unclear risk All intraoral examinations (including tooth
staining) were performed by a single ex-
aminer. No information is provided on in-
traexaminer reproducibility. Mean gingivi-
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Axelsson 1987 (Continued)
tis, plaque and stain scores at baseline ap-
pear to be reasonably balanced
The age range is quite wide (16-50) but
baseline data on age and gender balance are
not reported
Bajaj 2011
Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: Department of Pedodontics and Preventative Dentistry, Manipal College of
Dental Sciences, Manipal, India
Number of centres: 1
Study duration: recruitment periodnot reported.Durationof study is 9months; duration
of rinsing is not explicitly stated, assumed to be 9 months
Participants Participants: quote: “Children with similar socioeconomic status, dietary habits, oral
hygiene status, and KAP (knowledge, attitude and practice) status were included. Fur-
ther, only children who had a minimum of one to two established carious lesions were
considered. The subjects were selected from residential schools”
Exclusion criteria: not reported
Baseline gingivitis: GI Löe & Silness 1967, Gp A (0.54 SD 0.22); Gp B (0.59 SD 0.73)
; Gp C (1.16 SD 0.21)
Age at baseline (years): 8 to 12 years, not reported by group
Gender: not reported
Number randomised: 1431 (not reported by group)
Number evaluated: 1309 (Gp A: 440; Gp B: 457; Gp C: 412)
Interventions Comparison: CHX rinse versus Triphala rinse* versus control rinse
Gp A (440 analysed): CHX (Clohex 0.1% (diluted from 0.2%)) 10 mL, 1 min, once
daily
*Gp B (457 analysed): Triphala (0.6%) 10 mL, not reported, once daily. We excluded
this arm from the risk of bias and analysis
Gp C (412 analysed): control (distilled water) 10 mL, not reported, once daily
[Conflicting reports for duration of rinsing - 2 min rinse reported in methods for CHX
rinse (duration of rinsing for Triphala and control not reported) and 1min rinse reported
in discussion for all 3 rinses. Rinse duration stated in the discussion is reported here]
Prophylaxis at baseline: not reported
OHI: not reported
Rinsing supervised during the week, non-supervised at weekends and during vacations
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: quote: “The children were advised not to eat or rinse for the
next 30 min”
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1967) and plaque (PI Silness & Löe
1964) recorded at 3, 6 and 9 months follow-up. Microbiological analysis (Streptococcus
and Lactobacillus counts) at baseline 6 and 9 months follow-up (not relevant to this
review)
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Bajaj 2011 (Continued)
Funding Quote: “This research project was funded by the Indian Council of Medical Research”
Notes Sample size calculation: quote: “Large sample size was selected anticipating the possible
attrition of the sample due to varying cultural background and migration of few students
to other schools” (actual calculation not mentioned)
Adverse effects: not reported
Declarations/conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the subjects were allocated to the
specific treatment by block randomization”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “it was a double-blind clinical
trial.... Both solutions (chlorhexidine and
Triphala) were made of identical colors.
The bottles were then coded and then at
the end of the study, the decoding was
done” and “The schools were distributed in
such a manner so that there was no inter-
mingling within the students of different
groups.” The control solution was distilled
water. Rinsing was supervised by teachers
on school days
Comments: the authors do not report pre-
cisely who was blinded. Blinding of the
teachers is not explicitly stated. Higher lev-
els of tooth staining are likely to have been
noticeable in the CHX group, however,
tooth staining is not reported and therefore
not enough information is provided upon
which to base a judgement on the likely ef-
fect of staining. The control group rinsed
with distilled water and could have worked
out which group they were in which could
have affected their oral health behaviours
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “it was a double-blind clinical trial.
..” No other information relating to blind-
ing of outcome assessment is reported
Comment: the authors do not report pre-
cisely who was blinded. Higher levels of
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Bajaj 2011 (Continued)
tooth staining are likely to have been
noticeable in the CHX groups, however,
tooth staining is not reported and therefore
not enough information is provided upon
which to base a judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition after 9months (all arms included)
122/1431 (8.53%). Numbers lost in each
group are not reported. Authors report %
lost by group as follows: CHX 7.36%, con-
trol 10.62%.Reasons for losses: quote: “the
majority of times attrition occurred due to
family reasons where the parents changed
the school of their child”
Comments: attrition is reasonably low
(highest in the control group), reasonably
balanced across groups and reasons for
losses are unlikely to be related to the in-
terventions
Selective reporting (reporting bias) High risk There are marked inconsistencies between
data reported in text and data reported in
figure 1 in relation to mean plaque scores.
Tooth staining and adverse effects are not
reported
Other bias High risk The number of examiners is not reported
and there is no reference to training or
calibration. Children are reported to have
had similar SES, dietary habits, oral hy-
giene methods and KAP (knowledge, atti-
tudes and practice) status. Children had a
minimum of 1 to 2 established carious le-
sions. The control group (distilled water)
hadmuch higher mean plaque and gingivi-
tis scores than the CHX group at baseline:
plaque: CHX 0.76, control 1.76; gingivi-
tis: CHX 0.54, control 1.16. (Data taken
from the text rather than figures: see com-
ment above about inconsistencies between
the text and the figures)
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Banting 1989
Methods Trial design: parallel, 2 arms
Location: not specified, but assumed to be the University of Western Ontario Dental
School, Ontario, Canada
Number of centres: assumed 1
Study duration: recruitment period not stated. Duration of study and duration of rinsing
was 24 months
Participants Participants: employees from 3 hospitals, from the University of Western Ontario, and
from the general public of London, Ontario
Inclusion criteria: quote: “subjects had to be at least 18 years of age and with at least 16
natural teeth (including four molars) and some gingivitis”
Exclusion criteria: quote: “Persons with advanced periodontal disease and/or gross dental
neglect, those taking antibiotics regularly or within oneweek of the baseline examination,
and those with a history of hepatitis, tuberculosis, heart disease, or other severe or
debilitating medical conditions were excluded”
Baseline gingivitis: not reported
Age at baseline: not reported but minimum age of 18 years
Gender: not reported
Number randomised: 456 (CHX 231, control 225)
Number evaluated at 6 months: 383 (CHX 190, control 193)
Number evaluated at 24 months: 272 (CHX 112, control 160)
Interventions Comparison: CHX versus placebo rinse
CHX 0.12% (n = 231): 15 mL, twice daily, 30 seconds, 24 months
Control (placebo - composition not described) (n = 225): 15mL, twice daily, 30 seconds,
24 months
Prophylaxis at baseline: quote: “All subjects were then (after baseline assessment) given
a professional scaling and prophylaxis by a dental hygienist.” Professional prophylaxis
and scaling was repeated for all individuals every 6 months
OHI: none. Quote: “Toothbrushes and Crest dentifrice were also made available, but
no additional oral care instruction was provided”
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing and postrinse instructions are not
reported
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1967, gingival bleeding: GI scores
2 or 3), at 6, 12, and 24 months
Plaque (TQH Turesky 1970), at 6, 12, and 24 months
Calculus (supragingival calculus deposits (Volpe-Manhold Calculus Index, Volpe 1965)
and subgingival calculus deposits) at 24 months only
Funding Quote: “The support of this study by The Procter & Gamble Company, Cincinnati,
Ohio, is gratefully acknowledged”
Notes Sample size calculation: not reported
Adverse effects: quote: “Staining of the teeth was cited as the most common reason for
subjects not continuing in the study.” At the 24-month examination, subjects in the
treatment group had higher mean supragingival calculus scores, however at the same
time, more subjects in the CHX group were free of subgingival calculus. Soft tissue
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conditions were observed in 33% of the subjects at baseline, in 13% of the subjects at
1 year and in 12% of subjects at 2 years. The proportion and type of oral soft tissue
conditions were similar for the treatment and control groups
Declarations/conflicts of interest: none stated. However, the second and third authors
on the paper are affiliated to the Procter & Gamble Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “..subjects were stratified by gen-
der, age, and periodontal status and then
randomly assigned to a control or treat-
ment. Subjects residing in the same house-
hold were assigned to the same treatment
group”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Tooth staining was noted in the CHX
group
Comment: participant blinding is not
mentionedbut the use of a control ’placebo’
(compositionnot described) indicate that it
was intended for the participants to be un-
aware of the allocated intervention. How-
ever, the higher level of staining in theCHX
group meant that participants could have
worked out which group they were in and
this could have affected their oral health be-
haviours and hence the outcome. The di-
rection of this potential bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Toothcover devices and tongue-
masking were used at the one-year gingivi-
tis examination to eliminate potential ex-
aminer bias related to extrinsic staining.
” Tooth staining was noted in the CHX
group
Comment: gingivitis and gingival bleeding
results at 6 and 24 months and plaque and
PPD results at 6, 12 and 24 months are
at high risk of bias due to the higher level
of tooth staining in the CHX group. The
outcome assessors could not be adequately
blinded and this could have affected the
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outcome assessment. The direction of this
potential bias is unclear. The impact of us-
ing tooth cover devices and tongue-mask-
ing at 12 months on blinding is not clear
Incomplete outcome data (attrition bias)
All outcomes
High risk 6 months:
16% (73/456) of randomised participants
were not included in the analysis at 6
months. Attrition by group CHX 41/231
(18%), control 32/225 (14%)
24 months:
40% (184/456) of randomised participants
were not included in the analysis at 24
months. Attrition by group CHX 119/231
(51.5%), control 65/225 (28.9%)
Reasons for attrition: tooth stainingwas the
most common reason. Other reasons were
not reported
Comment: attrition was high in both
groups. There were proportionately more
losses from the CHX group (due to tooth
staining)
Selective reporting (reporting bias) High risk No baseline measure of gingival health was
provided. Nomeasures of variance were re-
ported. Mean plaque scores were reported
only in graphs. The mean supra- and sub-
gingival calculus scores were not reported.
We estimated the standard deviation for
gingivitis (measured using the GI) as the
median of the SDs in the placebo/control
groups from similar studies that also used
theGI at 6months so that we could include
the gingivitis data in the meta-analyses
Other bias Unclear risk Quotes: “One examiner was used for each
of the soft-tissue, gingivitis and plaque
measurements.” “...two examiners were
used for the pocket depth assessments.” No
information is provided on intraexaminer
reproducibility
Subjects residing in the same household
were assigned to the same treatment group.
The number of participants who resided in
the same household is not reported. The
potential effect of clustering was not con-
sidered in the analysis and is not clear
Participant characteristics are not described
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Methods Trial design: parallel (3 arms - 2 arms relevant to this review)
Location:Department of PublicHealthDentistry,DarshanDentalCollege andHospital,
Udaipur, Rajasthan, India
Number of centres: 1
Study duration: recruitment period not reported. Study duration and duration of rinsing
was 4 weeks
Participants Participants: undergraduate dental students
Inclusion criteria: quote: “The dental students with age group of 18-24 years, students
willing to participate and with dentition of ≥20 teeth and a minimum of 5 teeth per
quadrant, no relevantmedical history andnoperiodontal treatment during past 3months
were included”
Exclusion criteria: quote: “Students with orthodontic appliances or severe misaligned
teeth, receiving antibiotic therapy or medication within past 6 months, presence of any
systemic illness, subjects availing oral prophylaxis since past 6 months and students
unable to comply with study appointment schedule were excluded”
Baseline gingivitis: GI Löe & Silness 1963, Gp A: mean 0.77 (SD 0.43); Gp B: mean 0.
62 (SD 0.52); Gp C: mean 0.91 (SD 0.84)
Age at baseline (years): Gp A: mean 20.95 (SD 0.1); Gp B: mean 20.2 (SD 0.7); Gp C:
20.79 (SD 1.2). Range 18-24
Gender: male 37 (51%), female 35 (49%), not broken down by group
Number randomised: total 72 (Gp A: 24; Gp B: 24; Gp C: 24)
Number evaluated: total 66 (Gp A: 22; Gp B: 22; Gp C: 22)
Interventions Comparison: CHX (ClohexPlus) rinse versus herbal (Hiora) rinse* versus control
(Nirlife) rinse
Gp A (n = 24): CHX (0.20%) 10 mL, twice daily, 60 seconds, 4 weeks
*Gp B (n = 24): herbal (Hiora) rinse 10 mL, twice daily, 60 seconds, 4 weeks. We
excluded this arm from the risk of bias and analysis
Gp C (n = 24): control (0.05% saline) 10 mL, twice daily, 60 seconds, 4 weeks
Prophylaxis at baseline: not reported
OHI: quote: “All the participants were instructed to follow their routine oral hygiene
practices along with the assigned regimen and to maintain a reminder sheet on daily
product use”
Supervised and non-supervised rinsing: quote: “Each one of the daily rinses was super-
vised on each weekday and also supervised by a daily recall message for reminding them
to use the assigned mouthwash”
Timing of mouthrinsing in relation to toothbrushing: after toothbrushing
Postrinsing instructions: not reported
Outcomes Gingivitis: (gingival inflammation:GI Löe&Silness 1963); plaque (TQHTuresky 1970)
; adverse effects (burning sensation, dryness, taste disturbance, discolouration) assessed
at 4 weeks
Funding Quote: “Research funding: None declared”
Notes Sample size calculation: quote: “From the pilot study, it was found that the overall
prevalence of plaque and gingivitis was 80%. Considering for the drop outs logistic and
technical problems the sample size was inflated by 20%, hence the sample size was 72
with 24 participants in each group”
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Adverse effects: a majority of the adverse effects resulted in Gp A (CHX group). It was
observed that most of the study participants in Gp A complained of mild discolouration
18 (81.8%), moderate discolouration 2 (9.1%) and dry mouth 18 (81.8%), whereas
taste disturbance was higher in Gp C 14 (63.6%) as compared to Gp A 10 (45.4%). The
least taste disturbance was seen in Gp B 2 (9.1%). The burning sensation was highest in
Gp A 11 (50%) as compared to Gp B 9 (40.9%) and absent in Gp C
Declarations/conflicts of interest: quote: “Authors’ conflict of interest disclosure: The
authors stated that there are no conflicts of interest regarding the publication of this
article”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “... All the subjects were provided
with their assigned mouthrinses and were
divided into Group A, Group B and Group
C randomly using simple lottery method
with 24 participants in each group”
Comment: if “simple lottery method” cor-
responds to drawing lots then we can con-
sider risk of bias to be low
Allocation concealment (selection bias) Unclear risk Quote: “The assignment of the participants
to the groups and the codes to the product
was done by a person not involved in the
examination”
Comment: insufficient information is pro-
vided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “All the mouthrinses were dis-
pensed in the identical bottles and thereby
ensuring a total subject masking. The
examiner and the participants were also
blinded with regard to the mouthrinse al-
located to them thereby ensuring a dou-
ble-blinded study” and “Normal saline was
coloured to resemble the mouthwashes.”
A burning sensation was reported by al-
most half of the participants in the 2 active
mouthrinse groups. 81.8% of study partic-
ipants in the CHX group complained of
mild discolouration and 9.1% of moderate
discolouration
Comment: higher levels of tooth staining
were reported by most of the study partici-
pants in the CHX group. The higher level
of staining in the CHX group meant that
participants could have worked out which
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group they were in and this could have af-
fected their oral health behaviours
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The examiner and the partici-
pants were also blinded with regard to the
mouthrinse allocated to them thereby en-
suring a double-blinded study.” A burning
sensation was reported by almost half of
the participants in the 2 active mouthrinse
groups. 81.8% of study participants in
the CHX group complained of mild dis-
colouration and 9.1% of moderate dis-
colouration
Comment: the higher level of staining in
the CHX group meant that the outcome
assessor could not be adequately blinded
and this could have affected the outcome
assessment. The direction of this potential
bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition after 4 weeks: 4/48 (8.3%). By
group: CHX 2/24 (8.3%), control 2/24 (8.
3%). Reasons for losses not broken down
by group: quote: “Two students did not re-
port after 1 month in spite of several re-
calls, three students were irregular in using
mouthwash found during surprise visit and
one of the students became ill and had to
quit the study due to antibiotic coverage”
Comments: losses are reasonably low and
are balanced across groups
Selective reporting (reporting bias) High risk Standard deviations of mean scores for gin-
givitis (CHX group only) are not reported
at 4 weeks. We used the SD for the CHX
group at baseline so that we could include
the gingivitis data (measured using the GI)
in the meta-analyses. Adverse effects in-
cluding ’discolouration’ are reported (pro-
portions with each adverse effect by group)
Other bias Low risk Quote: “The kappa statistical analysis for
inter examiner variability for Turesky et al.
Plaque index and Loe and Silness gingival
index was 0.89 and 0.97, whereas the in-
tra examiner was 0.90 and 0.94 respectively
showing high degree of conformity in ob-
servational judgment. All recordings were
made by a single examiner”
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No statistically significant difference in
mean age, mean baseline plaque scores and
mean baseline gingival index scores
Brecx 1993
Methods Trial design: parallel (3 arms - 2 arms relevant to this review)
Location: assumed to be at the Health Science Campus, University ofManitoba, Canada
Number of centres: 1
Study duration: recruitment period is not stated. Study duration and duration of rinsing
was 3 months
Participants Participants: quote: “Either medical or physiotherapy students, as well as non-dental
laboratory staff, from the Health Science Campus, University of Manitoba”
Inclusion criteria: healthy adults
Exclusion criteria: not reported
Baseline gingivitis: (GI) Gp A: mean 0.6 (no SD); Gp B: mean 0.6 (no SD); Gp C: mean
0.6 (no SD)
Age at baseline (years): range 21-33
Gender:male 15 (42%), female 21 (58%), breakdown by group group data not reported,
but gender distribution stated to be ’very similar’ across treatment groups
Number randomised: 36 (assumed Gp A: 12; assumed Gp B: 12; assumed Gp C: 12)
Number evaluated: 31 (Gp A: 10; Gp B: 9; Gp C: 12)
Interventions Comparison: CHX gluconate solution versus Meridol rinse* versus placebo rinse
Gp A (n = 12): CHX 0.2%,10 mL, twice daily, 1 min, 3 months
*Gp B (n = 12): Meridol, 10 mL, twice daily, 1 min, 3 months. We excluded this arm
from the risk of bias and analysis
Gp C (n = 12): placebo (quinine-hydrochloride solution), 10 mL, twice daily, 1 min, 3
months
Prophylaxis at baseline: quote: “In the pretreatment phase, the individuals were subjected
to a thorough prophylaxis, but not instructed in any form of mechanical plaque control.
” Subjects had teeth professionally cleaned and continued their usual oral hygiene for
a period of 2 weeks until “month 0” at which time their teeth were polished again.
They received a new toothbrush (Butler 411) for the 2 weeks preceding the beginning
of month 0
OHI: none given. Quote: “ ..but not instructed in any form of mechanical plaque
control”
Non-supervised rinsing
Timing of mouthrisning in relation to toothbrushing: quote: “The participants were
instructed to make sure to rinse twice daily regardless of their brushing habits. However,
if they did brush, they were asked to use the mouthrinse after their toothbrushing”
.
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1967); plaque (PI Silness & Löe
1964), assessed at day 14, month 0, and after 1, 2, and 3 months of rinsing in addition
to usual tooth cleaning
Tooth stain (Modification of the Discolouration Index, Lang & Räber 1981). Time
period not explicitly stated
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Dental plaque for vital fluorescence (VF) examination was collected at months 0, 1, 2,
and 3 (not relevant to this review)
Funding Quote: “This investigation was supported by a grant from GABA International Ltd,
Therwil, Switzerland”
Notes Sample size calculation: not reported
Adverse effects: tooth staining i.e. higher DI scores in Meridol and CHX groups than
placebo at end of study. At all time points the Meridol group showed less staining than
the CHX group
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The subjects were randomly as-
signed to three groups..”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “double-blind”, “..all solutions
had the same color and were kept in the
same kind of bottle (PET white, opaque).
” A placebo containing 0.02% quinine-hy-
drochloride solution was used
Quote: “The DI increased with time in all
groups... At the end of the study, the Meri-
dol and chlorhexidine groups exhibited
higher scores (p<0.001) than the placebo
group”
Comment: the higher level of tooth stain-
ing in the CHX group meant that partici-
pants could have worked out which group
they were in and this could have affected
their oral health behaviours and hence the
outcome. The direction of this potential
bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotes: “double-blind”, “All readings were
noted by the same investigator..” and “The
DI increased with time in all groups..
. At the end of the study, the Meridol
and chlorhexidine groups exhibited higher
scores (p<0.001) than the placebo group”
Comment: the higher level of staining in
the CHX group meant that the outcome
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assessor could not be adequately blinded
and this could have affected the outcome
assessment. The direction of this potential
bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk Assuming equal numbers in groups at the
start (as this was not reported) attrition
after 3 months was 2/24 (13.9%). Attri-
tion by group was 2/12 (16.7%) CHX;
no losses from placebo group. Reasons not
broken down by group. Reasons for losses
(all study arms): quote: “One subject de-
cided to stop participation, and four oth-
ers were dismissed for multiple evidence of
non-compliance (no-show without several
calls, no rinse during 1 min, too much so-
lution left in the bottle, etc)”
Comment: there were differential group
losses with losses from the CHX group and
none from the placebo group. The num-
ber of participants lost over the 3months is
small but because the groups were small at
baseline the proportionate losses are high
Selective reporting (reporting bias) High risk Mean scores for tooth staining at 4 weeks
were not reported in the text and were read
off graphs. Information on variance was
only reported graphically as standard error
bars on the graphs. Therefore, we estimated
the standard error for gingivitis, plaque and
tooth staining, from the graphs and used
this information to calculate the standard
deviations of the mean scores so that we
could include the data in the meta-analy-
ses. Apart from tooth staining, adverse ef-
fects were not mentioned
Other bias Unclear risk Quote: “All readings were noted by the
same investigator, with an intra-individual
variation below 5%”
Comment: the examiner reproducibility is
good
Quote: “The periodontal status at time of
selection (day-14) as well as age range and
gender distribution were very similar...”
Comment: no supporting data are pro-
vided
The mean GI scores for the 3 groups at
baseline appear similar. ThemeanDI scores
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for the 3 groups at baseline also appear
similar (on the graph). The mean plaque
scores in the placebo group at baseline (on
the graph) appear higher than in the CHX
group. It is difficult to assess the baseline
balance as the data are not reported or com-
mented on in the text
Brightman 1991
Methods Trial design: parallel (2 arms)
Location: assumed to be at Case Western Reserve University School of Dentistry, Cleve-
land, Ohio, USA
Number of centres: 1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 3 months
Participants Participants: quote: “Subjects for this study were selected from the Department of Or-
thodontics at Case Western Reserve University School of Dentistry, Cleveland, Ohio”
Inclusion criteria: quote: “Forty-four subjects qualified on the basis of the following
criteria: (1) They were under-going full-banded edgewise extraction treatment with
brackets on their anterior teeth and bands on their molars; (2) four premolars had been
extracted; (3) they were at least 11 years of age and no more than 17 years of age; (4)
evidence of gingivitis was present, but there was no evidence of periodontitis; (5) there
was no evidence of decalcification on their teeth; (6) there was no known hypersensitivity
to chlorhexidine; (7) there were no known medical problems or evidence of current
antibiotic therapy; and (8) no anterior composites were present”
Exclusion criteria: not specifically stated but are implicit in the inclusion criteria
Baseline gingivitis: not reported
Age at baseline (years): Gp A: mean 14.88 (SD 1.78); Gp B: mean 14.78 (SD1.52);
range 11-17
Gender: overall: male (42%), female (58%). Group data not specified
Number randomised: 36 (Gp A: 18, Gp B: 18)
Number evaluated: 34 (Gp A: 16, Gp B: 18)
Interventions Comparison: CHX mouthrinse versus placebo mouthrinse
Gp A (n = 18): CHX (Peridex) 0.12%, 1/2 ounce, twice daily, 30 seconds, 3 months
Gp B (n = 18): placebo (identical to test mouthrinse but without the CHX), 1/2 ounce,
twice daily, 30 seconds, 3 months
Prophylaxis at baseline: quote: “Each of the subjects was given a thorough prophylaxis
and instructed in oral hygiene procedures”
OHI: quotes: “Participants were provided with 3 toothbrushes (one for each month
of the study) and 3 tubes of toothpaste.” “All subjects were instructed to use the Bass
technique of toothbrushing and to brush with the Crest toothpaste that was provided.
” “The patients were all instructed to use one toothbrush every month. They were to
brush only with Crest toothpaste with fluoride, once in the morning after breakfast and
once in the evening before bedtime. They were all instructed to brush a minimum of 3
minutes to ensure thorough brushing”
Non-supervised rinsing
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Timing of mouthrinsing in relation to toothbrushing: after brushing
Postrinsing instructions: no liquid or food to be taken after using mouthrinse for at least
30 minutes
Outcomes Gingivitis (gingival inflammation: GI Silness & Löe 1964 and 1967; gingival bleeding:
Eastman Interdental Bleeding Index, Caton and Polson 1985); plaque (PI Löe & Silness
1964 and 1967); staining intensity and area (method created at Case Western Reserve
University School of Dentistry, Department of Periodontics); assessed at 6 weeks, and 3
months follow-up
Funding Funding: not reported
Notes Sample size calculation: quote: “This study was designed to provide a minimal power of
87% for detecting a clinically important difference to be statistically significant at the 0.
05 probability level”
Adverse effects: quote: “Both the chlorhexidine group and the placebo group showed
significant increases in the degree of stain, but the chlorhexidine group had a more
significant amount of stain”
Declarations/conflict of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Two tables of random numbers,
one for the male population and one for
the female population, were used, and the
subjects were thus assigned to one of two
treatment groups”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “These measures (use of random
number tables) ensured that neither the in-
vestigators nor the patients knew whether
participantswere in the experimental group
or the placebo group”
Comment: the authors indicated that the
participants were blind to group allocation
(although the use of a random number ta-
ble would not have ensured blinding)
Quotes: “The placebo mouthrinse was
identical to the experimental mouthrinse
except that the placebo mouthrinse did not
contain chlorhexidine. The appearance and
the taste of both mouthrinses were sim-
ilar. They were both colored blue, mint
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flavored, and contained in amber-colored
bottles” and “Themean stain severity index
for the chlorhexidine group showed signif-
icantly more stain at 12 weeks (p<0.001)
for all of the sites measured”
Comment: despite the efforts undertaken
by the investigators the increased staining
in the CHX group is likely to have compro-
mised the attempted participant blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “These measures (use of random
number tables) ensured that neither the in-
vestigators nor the patients knew whether
participantswere in the experimental group
or the placebo group”
Comment: the authors indicated that the
investigators were blind to group allocation
(although the use of a random number ta-
ble would not have ensured blinding)
Quote: “The GI and the PI were scored
by the primary investigator, and the stain
index and the bleeding index were scored
by a second investigator, who was a senior
dental student. This was done to minimise
bias, so that the investigator who was scor-
ing theGI and PI was not influenced by the
degree of extrinsic stain, which is a com-
mon side effect of chlorhexidine”
Comment: despite the efforts undertaken
by the investigators to blind outcome
assessment, the primary investigator, al-
though not scoring the stain, would likely
still be aware of increased staining in some
individuals and this meant that the out-
come assessors could not be adequately
blinded and this could have affected the
outcome assessment. The direction of this
potential bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition after 3 months was 2/36 (5.6%)
. Attrition by group: 2/18 (11.1%) CHX;
no losses from placebo group. Reasons for
losses fromCHX group: “inability to coop-
erate” 2 lost from CHX mouthrinse group
after less than 1 week
Comment: it is not known whether the
“inability to cooperate” of the 2 partici-
pants lost from the CHX group were re-
lated to use of the CHXmouthrinse. How-
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ever, the number of participants lost over
the 3 months is small and unlikely to have
affected the results
Selective reporting (reporting bias) High risk Mean scores for all outcomes are reported
graphically with 95%CI bars in the graphs.
We estimated the mean scores and 95%
CIs for all outcomes. We used the infor-
mation on the 95% CIs to calculate the
SDs of the mean scores so that we could
include the data in meta-analyses. Apart
from tooth staining, adverse effects were
not mentioned
Other bias Unclear risk The outcomes were measured by 2 inves-
tigators one of which was a senior dental
student. No information is provided on in-
traexaminer reproducibility (Interexaminer
not relevant as the 2 examiners recorded
different variables)
Comment: not enough information is pro-
vided
Mean scores for gingivitis, plaque and tooth
stain as represented on graphs appear quite
balanced. However, the statistical signifi-
cance of the differences is not reported
Charles 2004
Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: assumed research facility, USA
Number of centres: assumed to be 1
Study duration: recruitment period is not stated. Duration of study and duration of
rinsing was 6 months
Participants Participants: adults aged 20-57
Inclusion criteria: quote: ”a minimum of 20 sound, natural teeth; a mean plaque index
(PI) (Turesky et al 1970) of at least 1.95; a mean GI (Loe & Silness 1963) of at least 0.
95“
Exclusion criteria: quote: ”Teeth that were grossly carious, fully crowned or extensively
restored, orthodontically banded, abutments, or third molars were not included in the
tooth count. Subjects with gross oral pathology or who were taking antibiotic or antiin-
flammatory drugs were excluded“
Baseline gingivitis: (GI), Gp A: mean 1.35 (SE 0.04); Gp B: mean 1.31 (SE 0.04); Gp
C: mean 1.27 (SE 0.03)
Age at baseline (years): Gp A: mean 31.4 (SD 9.4); Gp B: mean 32.0 (SD 6.6); Gp C:
mean 32.2 (SD 6.3). Range 20-57 (all arms of study)
Gender (reported for completers): overall; male 39 (36%); female 68 (64%). Gp A: male
13 (36%), female 23 (64%); Gp B: male 12 (35%), female 22 (65%); Gp C: male 14
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(38%), female 23 (62%)
Number randomised: 108 (Gp A: 36, Gp B: 34, Gp C: 38)
Number evaluated: 107 (Gp A: 36, Gp B: 34, Gp C: 37)
Interventions Comparison: CHX 0.12% (Peridex) versus EO (essential oil mouthrinse, Listerine
antiseptic)* versus control (5% hydroalcohol negative control)
Gp A (n = 36): CHX (Peridex) 0.12%,15 mL, twice daily, 30 seconds, 6 months
*Gp B (n = 34): Listerine, 20 mL, twice daily, 30 seconds, 6 months. We excluded this
arm from the risk of bias and analysis
Gp C (n = 38): control (5% hydroalcohol), 20 mL, twice daily, 30 seconds, 6 months
Prophylaxis at baseline: quote: ”Following the baseline examination, each subject received
a complete dental prophylaxis to remove all plaque, calculus, and extrinsic stain“
OHI: none given. Quote: ”....subjects followed their usual oral hygiene and dietary
habits..“ Soft nylon toothbrushes and fluoridated toothpaste were provided to all subjects
and replenished periodically as need for the duration of the study
Quote: ”One of the daily rinses was supervised on each weekday“
Postrinsing instructions: not reported
Timing of mouthrinsing in relation to toothbrushing: quote: ”Rinsings were not done
at time of toothbrushing but at separate times“
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1963; gingival bleeding: % bleeding
sites (GI scores 2 or 3 indicating bleeding)); plaque (TQH, Turesky 1970); extrinsic
tooth stain (Lobene Discolouration Index, Lobene 1968); supragingival calculus (Volpe-
Manhold Calculus Index, Manhold 1965, Volpe 1965, 1967, Barnett 1989), assessed at
3 and 6 months follow-up
Funding Funding: the authors are affiliated to Dental Products Testing and Pfizer
Notes Sample size calculation: quote: ”This study was designed to provide a minimal power of
0.80 for detecting a statistically significant difference in plaque and gingivitis scores at
the 0.05 probability level“
Adverse effects: during the course of the study no oral mucosal lesions that could be
attributed to any of the test mouthrinses were observed”
Smokers: by groupGpA: 8/36 (22%);GpB: 8/34 (24%);GpC: 6/38 (16%) (differences
are not statistically significant)
Declarations/conflicts of interest: the authors are affiliated with Dental Products Testing
and Pfizer. No explicit conflicts of interest were declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotes: “Subjects were randomised into
three groups”, “...assigned to either one of
two test groups or a negative control group
according to a computer generated random
code”
Comment: adequatemethod of random se-
quence generation
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Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “One of the daily rinses was su-
pervised on each weekday.” No mention of
blinding of study participants
Comment: the study compared CHX with
essential oil and control (5% hydroalco-
hol) and different volumes of the rinses
were used making participant and person-
nel blinding difficult to achieve. Lack of
blinding could have affected participants’
oral health behaviours and hence the out-
come but direction of this potential bias is
unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotes: “observer blind” and “At 3 and
6 months, there was significantly more
gingival region stain in the essential oil
group (p<0.05) and the chlorhexidine
group (p<0.001) compared with the con-
trol group..”
Comment: the higher level of staining in
the CHX group meant that the outcome
assessor could not be adequately blinded
and this could have affected the outcome
assessment. The direction of this potential
bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 participant was lost over the 6
months. Attrition by group 1/38 (2.63%)
placebo group.No losses fromCHXgroup.
Reasons for losses: personal reasons. Lost
after the 3-month exam and results for this
individual were included in the 3-month
exam
Comment: the reason the individual was
lost was not related to the intervention
Selective reporting (reporting bias) High risk We calculated standard deviations for gin-
givitis and plaque from the standard errors
reported in the tables.We couldnot include
data on % bleeding sites in meta-analyses
as the data were reported for total number
of sites rather than individuals. Informa-
tion on the variance of the mean calculus
and stain scores was not reported and those
outcomes could not be included in meta-
analyses
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Other bias Low risk Quotes: “All examinations were conducted
by a single, experienced dental examiner.
Reliability was established for the gingival
index (GI) with a statistic of 0.75, which
indicates satisfactory calibration.”
“There were no statistically significant dif-
ferences among the treatment groups with
respect to age, gender, smoking..” There
were no statistically significant differences
among the treatment groups in relation
to the gingival and calculus indices. The
plaque index was significantly lower in the
control group than in the CHX group at
baseline
Comment: all participants had a baseline
prophylaxis to remove all plaque, calculus
and extrinsic stain. It can be assumed that
theywere similar with respect to plaque and
stain at the start of the study
Chaves 1994
Methods Trial design: parallel (4 arms - 2 arms are relevant to this review)
Location:USA, exact location not reported. Setting appears to be a university department
of periodontics
Number of centres: 1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 6 months
Participants Participants: adults with chronic generalised gingivitis
Inclusion criteria: quote: “...presence of more than 20 teeth, not more than 4 sites with
probing depth (PD) deeper than 6 mm, bleeding on probing (BOP) frequency of higher
than 30% at screening visit with no systemic diseases or medications influencing gingival
inflammation”
Exclusion criteria: opposite of the inclusion criteria
Baseline gingivitis: (GI) not reported
Age at baseline (years): mean overall 35.1; range 19-62. No breakdown by group is
reported
Gender: male 32%; female 68%. No breakdown by group is reported
Number randomised: 125 (not reported by group)
Number evaluated: 104 (Gp A: 24; Gp B: 21; Gp C: 32; Gp D: 27)
Interventions Comparison: brush+CHX (CHX) versus brush+CHX irrigation (Irr+CHX)a versus
brush+water irrigation (Irr+H2O)
b versus brush
GpA (n = 24): CHX (Peridex) 0.12%, 1:3 dilution (with water), twice daily, no duration
reported, 6 months
aGp B (n = 21): CHX 0.04% Irr, 400 mL, once daily, no duration reported, 6 months.
We excluded this arm from our risk of bias and analysis
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bGp C (n = 32): Irr+H2O, 400 mL, once daily, no duration reported, 6 months. We
excluded this arm from our risk of bias and analysis
Gp D (n = 27): brush, N/A
Note: Numbers stated above relate to completers. No figures were reported by group for
those who were randomised
Prophylaxis at baseline: yes, but no details reported
OHI: quote: “After baseline data collection, all patients received instructions on the use of
a toothbrush and dental floss by watching a standardized video tape.” “[after prophylaxis]
further oral hygiene instructions specific to the treatment group [were provided]”
Postrinsing instructions: not reported
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Outcomes Gingivitis (gingival inflammation: GI Löe 1963); gingival bleeding: BOP (automated
probe (Floride probe) using 20 grams of force, Gibbs et al 1988); plaque (PI Silness
& Löe 1964); assessed at 3 and 6 months follow-up. Probing depth and subgingival
microbial samples were taken from sites presenting probing depths > 4 mm and BOP at
baseline visit (not relevant to this review)
Funding Funding: quote: “This study was supported by TeledyneWater Pik, Denver, CO” (USA)
Notes Sample size calculation: not reported
Adverse effects: quote: “Several of the patients who did not return to the scheduled
examination visits reported an unacceptable taste associated with the chlorhexidine. No
patient reported adverse reaction or side effects to the mouthrinse ....”
Declarations/conflicts of interest: not reported
Additional information was obtained from Chaves 1993
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned
to one of four groups based on a random
number table that was computer gener-
ated”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The clinical examiners were
blinded to the treatment groups, however
dental assistants and hygienists were re-
sponsible for providing information and
support to their respective plaque control
group”
Comment: blinding of participants was not
possible due to the differences in the inter-
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vention groups being compared. The den-
tal assistants and hygienists were aware of
the group allocations of participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The clinical examiners were
blinded to the treatment groups....The
clinical examiners did not have access to
any of the clinical or compliance records
during the study”
Comment: tooth staining is likely to have
been noticeable in the CHX group after 6
months, and in this situation the outcome
assessor could have worked out which in-
dividuals used CHX and not be adequately
blinded. However, tooth staining is not re-
ported and there is not enough information
upon which to base a judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition after 6 months (all study arms)
was 21/125 (16.8%). Attrition by group is
not reported. Reasons for loss to follow-up:
several of the patients who did not return
to the scheduled exam visits reported an
unacceptable taste associated with CHX
Comment: several participants were lost
from the 2 CHX groups because they did
not like the taste of the rinse. Exact num-
bers lost from each group are not reported
but the number of participants in the 2
CHX groups completing the trial seemed
to be appreciably lower than in the 2 groups
not using CHX. Assuming themissing par-
ticipants in 1 group had a higher mean (e.
g. gingivitis score) than those in the other
groups, as the attrition rate increased, so
would the mean difference between groups
Selective reporting (reporting bias) High risk Mean scores for all outcomes are reported
graphically with SD bars in the graphs. We
estimated the mean scores and SDs for all
outcomes so that we could include the data
in meta-analyses. Information on adverse
effects is reported but no specific informa-
tion relating to tooth staining is reported
Other bias Unclear risk Quote Chaves 1993: “The clinical exami-
nations were carried out by 6 different ex-
aminers with each patient being evaluated
by the same examiner at all time periods..
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.prior to the initiation of the study, all ex-
aminers participated in group seminars and
clinical sessions on the assessment of clin-
ical parameters and the use of the Florida
Probe and were compared to a single stan-
dard examiner. Although no attempt was
made to evaluate inter or intra-examiner
reproducibility, no statistically significant
differences were found between the exam-
iners when PD, BOP and GI were evalu-
ated..”
The groups appear reasonably balanced (on
graph) with respect to GI, BOP and PI at
baseline. The actual data at baseline are not
reported
Comment: not enough information is pro-
vided
Corbet 1997
Methods Trial design: parallel (2 arms)
Location: knitting factory assumed to be in Ho Tung, Guangdong, China
Number of centres: assumed to be 1
Study duration: recruitment period not stated. Duration of study 6 months, but data
only reported for 3 months
Participants Participants: quotes: “All were employed in a knitting factory in the area of Ho Tung,
Province of Guangdong, People’s Republic of China. However, most of the participants
were migrant workers and originated from other Provinces such as Henan, Hebei and
Sichuan” and “..a population with established gingivitis and abundant supra- and sub-
gingival plaque and calculus”
Inclusion criteria: quote: “The subjects were admitted to the study if they were in good
general health and had not been exposed to antibiotic therapy for at least 6 months.
Furthermore, at least 20 teeth had to be present. No probing depth of pockets exceeded
6 mm and no loss of attachment of more than 2 mm was encountered”
Exclusion criteria: quote: “Subjects with known allergies, haematological disorders or
diabetes mellitus were not allowed to participate. Also, pregnant women were excluded”
Gingivitis (at baseline for the completers): GI: overall mean 1.43 (SE 0.01); Gp A: mean
1.40 (SE 0.02); Gp B: mean 1.46 (SE 0.01)
Age at baseline (years): range 17-39. Overall mean 22.5 (4.95). Gp A: mean 23.0 (4.34)
; Gp B: mean 22.3 (5.26)
Gender: overall: male 13 (21.7%), female 47 (78.3%). Gp A: male 5 (25%), female 15
(75%); Gp B: male 8 (20%), female 32 (80%)
Number randomised: 60 (Gp A: 20; Gp B: 40)
Number evaluated: At 3-month measurement: 36 (Gp A: 13; Gp B: 23)
Interventions Comparison: CHX versus placebo control
Gp A (n = 20): CHX (Peridex) 0.12%, 15 mL, twice daily, 45 seconds, 6 days per week
for 6 months
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Gp B (n = 40): placebo (identical in composition to the test rinse only without the active
ingredient), 15 mL, twice daily, 45 seconds, 6 days per week for 6 months
Prophylaxis at baseline: quote: “A unique feature of the present study was that no pre-
experimental prophylaxis was performed prior to the commencement of the supervised
rinsing”
OHI: none given. Quote: “No attempts were made to influence the sparsely performed
oral hygiene practices of the participants”
Postrinsing instructions: not reported
Supervision of rinsing: quote: “The supervision of the daily rinses by factory staff assured
an almost 100% compliance and hence, it may be assumed that optimal conditions
for a test of the therapeutical principle of chlorhexidine mouthrinses were provided...
All rinsings were supervised by one of the supervisors in the factory. The rinsings were
performed at 8.00 am and at 7.00 pm, and were timed for 45s.” Note: there was a 2-
week period during the study when participants were not supervised as they returned
home during the Chinese New Year holiday. Quote: “During the 2 weeks of the Chinese
New Year holiday (January 1995), mouthrinses were provided for the subjects to take to
their homes and instructions on their usage was given by the supervisor”
Timing of mouthrinsing in relation to toothbrushing: not reported
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1963, Löe 1967; gingival bleeding:
sites with scores 2 or 3 indicating bleeding); plaque (PI Silness & Löe 1964); stain
(Discolouration Index Lang & Räber 1981); calculus (Calculus Surface Severity Index
system (CSSI), Ennever et al 1961); assessed at 3 and 6months follow-up. *Note: Quote:
“this report is limited to the 3-month data”
Funding Quote: “This study was supported by a grant for collaborative research of the Clinical
Research Foundation (CRF) for the Promotion of Oral Health, University of Berne,
Switzerland”
Notes Sample size calculation: not reported
Adverse effects: not reported except for tooth staining and calculus
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “Randomised controlled clinical
trial”, “...subjects were divided into two
groupsmatched according to themean gin-
gival index”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “..double-masked.” The placebo
rinse was identical in composition to the
test rinse only without the active ingredi-
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ent (CHX). Rinsings were supervised and
blinding of the factory supervisors is not ex-
plicitly stated but it is considered unlikely
that they were aware of the content of the
rinses
Quotes: “The overall increase in mean dis-
coloration index was significantly higher
in the Test than the Control group” and
“There were significantly (p < 0.05) more
surfaces scoring DI = 1, 2 or 3 in the Test
group (39%) than in the control group
(28%)”
Comment: the participants in the CHX
groupmayhave noticed the increased stain-
ing and worked out which group they were
in and this may have affected their oral
health behaviours
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotes: “..double-masked”, “The same ex-
aminers calibrated for one particular index
system scored the same clinical index in all
subjects at baseline and after 3 months”,
“The overall increase inmean discoloration
index was significantly higher in the Test
than the Control group” and “There were
significantly (p < 0.05) more surfaces scor-
ing DI = 1, 2 or 3 in the Test group (39%)
than in the control group (28%)”
Comment: it is not clear if the “double-
masked” included the examiners. Even if
the masking refers to the examiners, it is
likely that the examiners were aware of
which participants were using CHX due to
the increased tooth staining associated with
CHX rinse
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition at 3 months was 24/60 (40%).
Attrition by group: 7/20 (35%) CHX, 17/
40 (42.5%) placebo. Reasons for losses (not
broken down by group): the participants
were mostly migrant workers from other
provinces within China. 19 subjects failed
to return from their homes after the Chi-
nese New Year holiday and 5 were excluded
due to pregnancy
Quote: “Themean baseline scores for those
subjects completing the study were not sig-
nificantly different for the test and con-
trol group, respectively, although they were
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slightly different when compared with the
baseline data of the original study popula-
tion”
Comment: losses were very high and al-
though the reasons for losses are not related
to the intervention the proportion of those
lost is so high that a distortion of the true
intervention effect cannot be ruled out
Selective reporting (reporting bias) High risk We calculated standard deviations for gin-
givitis (GI), plaque, calculus and staining
from the standard errors reported in the
text. No information was reported on the
variance for gingival bleeding (% sites scor-
ing 0, 1, 2, or 3). No information regard-
ing adverse effects apart from tooth stain-
ing and calculus were reported. This is a
6-month study but only 3-month data are
reported
Other bias Unclear risk No information is provided on intra- and
interexaminer reproducibility
Baseline characteristics of the participants
were balanced forGI, PI, CSSI,DI, age and
gender
de la Rosa 1988
Methods Trial design: parallel (2 arms)
Location: a boarding school in Monterrey, Mexico
Number of centres: 1
Study duration: recruitment period not stated. Duration of study and duration of rinsing
was 12 weeks
Participants Participants: boarding school boys
Inclusion criteria: quote: “For acceptance into the study, they had to have some degree
of plaque-induced gingivitis”
Exclusion criteria: quote: “Those with gross oral neglect or pathoses that needed prompt
care were not accepted”
Baseline gingivitis: (Papillary Marginal Gingivitis Index; mean baseline score of all sites
graded for individuals examined at 6 weeks) Gp A: mean 0.6933; Gp B: mean 0.6513
Age at baseline (years): range 8-18
Gender: 100% male
Number randomised: not reported
Number evaluated: 92 (Gp A: 46; Gp B: 46)
Interventions Comparison: CHX versus placebo
Gp A (completers n = 46): CHX 0.12%, 15 mL, twice daily, 30 seconds, 12 weeks
Gp B (completers n = 46): placebo (composition not described), 15 mL, twice daily, 30
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seconds, 12 weeks
Prophylaxis at baseline: quote: “...all subjects received a dental prophylaxis to remove
any dental accretions”
OHI: quote: “At the beginning of the studies, the subjects received soft toothbrushes
and brushing instructions”
Postrinsing instructions: not reported
Supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: quote: “The evening rinsing was
preceded by a one-minute toothbrushing with a sodium fluoride dentifrice, Crest”
Outcomes Gingivitis (gingival inflammation: Papillary Marginal Gingivitis Index, de la Rosa and
Sturzenberger 1976, severity (mean score all sites) and occurrence (proportion of sites
with a PMGI score ≥1)); plaque (TQH, Turesky 1970); assessed at 6 and 12 weeks
follow-up
Funding Funding: quote: “Theworkwas supported by a grant of the Procter&GambleCompany,
Cincinnati, OH”
Notes Sample size calculation: not reported
Adverse effects: quotes: “Some mild epithelial desquamations were observed in some
chlorhexidine subjects… There was no discomfort reported in association with these
transient incidences in our study. Neither was there a consequence on oral health… there
was an increase in extrinsic tooth stain and supragingival calculus in the chlorhexidine
groups..” and “There was no lasting side effect on the oral soft tissue or the health of the
users”
Declarations/conflicts of interest: potential conflict of interest: the second author is a
Senior Dentist at the Procter and Gamble Company and the third author is an Associate
Director, Peridex Research, Procter and Gamble Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “..subjects were stratified by age
intervals (<12 and >/= 12) and stratified
by seven intervals of gingivitis scores rang-
ing from <0.25 to >1.50. Within these
strata, the subjects were distributed into the
chlorhexidine or the placebo groups at ran-
dom”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors report that the study is “dou-
ble-blind”. The comparison group rinsed
with placebo rinse, no details are given re-
garding the formulation or presentation of
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the placebo
Comment: it is not clear whether the ’su-
pervisory personnel’ who dispensed the
toothpaste and mouthrinse and supervised
the rinsing were blind.The authors report
an increase in extrinsic tooth stain and
supragingival calculus in the CHX group.
The higher level of tooth staining and cal-
culus in the CHX group meant that partic-
ipants could have worked out which group
they were in (or that they were in the ac-
tive mouthrinse group) and this could have
affected their oral health behaviours and
hence the outcome. The direction of this
potential bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The authors report that the study is “dou-
ble-blind”. Quote: “Previous records were
not available at subsequent examinations
nor did examiners have any knowledge as
to which treatment group a given subject
belonged”
Comment: the authors report an increase in
extrinsic tooth stain and supragingival cal-
culus in the CHX group. The higher level
of staining and calculus in the CHX group
meant that the outcome assessor could not
be adequately blinded and this could have
affected the outcome assessment. The di-
rection of this potential bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers at baseline not reported, so at-
trition from baseline cannot be calculated.
Between 6weeks and 3months 4 (8%) par-
ticipants were lost from the CHX group
and 6 (11.5%) participants were lost from
the placebo group
Selective reporting (reporting bias) High risk The SDs for the main outcome (mean gin-
givitis occurrence and severity) are not re-
ported. The ancillary outcome (plaque) is
mentioned but not fully reported possibly
because the result was not statistically sig-
nificant
Other bias Unclear risk No information is provided on intra- and
interexaminer reproducibility
The groups appear balanced for gingivi-
tis at baseline. The authors state that the
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baseline scores demonstrate comparability
of the test and control groups. However,
the statistical significance of the differences
is not reported
de la Rosa 1988b
Methods Trial design: parallel (2 arms)
Location: a boarding school in Monterrey, Mexico
Number of centres: 1
Study duration: recruitment period is not stated. Study duration and duration of rinsing
was 10 weeks
Participants Participants: boarding school boys
Inclusion criteria: quote: “For acceptance into the study, they had to have some degree
of plaque-induced gingivitis”
Exclusion criteria: quote: “Those with gross oral neglect or pathoses that needed prompt
care were not accepted”
Baseline gingivitis: (Papillary Marginal Gingivitis Index; mean score of all sites graded
at baseline for those examined at 10 weeks) Gp A: mean 0.4544; Gp B: mean 0.4263
Age at baseline (years): range 8-18
Gender: 100% male
Number randomised: not reported
Number evaluated: 99 (Gp A: 49; Gp B: 50)
Interventions Comparison: CHX versus placebo
Gp A (completers n = 49): CHX 0.12% (Peridex), 15 mL, twice daily, 30 seconds, 10
weeks
Gp B (completers n = 50): placebo (composition not described), 15 mL, twice daily, 30
seconds, 10 weeks
Prophylaxis at baseline: quote: “...all subjects received a dental prophylaxis to remove
any dental accretions”
OHI: quote: “At the beginning of the studies, the subjects received soft toothbrushes
and brushing instructions”
Postrinsing instructions: not reported
Supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: quote: “The evening rinsing was
preceded by a one-minute toothbrushing with a sodium fluoride dentifrice, Crest”
Outcomes Gingivitis (gingival inflammation: Papillary Marginal Gingivitis Index, de la Rosa and
Sturzenberger 1976; severity (mean score all sites) and occurrence (proportion of sites
with a PMGI score ≥1); assessed at 10 weeks follow-up
Plaque (TQH, Turesky 1970)
Funding Funding: quote: “Theworkwas supported by a grant of the Procter&GambleCompany,
Cincinnati, OH”
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Notes Sample size calculation: not reported
Adverse effects: quotes: “Some mild epithelial desquamations were observed in some
chlorhexidine subjects… There was no discomfort reported in association with these
transient incidences in our study. Neither was there a consequence on oral health… there
was an increase in extrinsic tooth stain and supragingival calculus in the chlorhexidine
groups..” and “There was no lasting side effect on the oral soft tissue or the health of the
users”
Declarations/conflicts of interest: potential conflict of interest: the second author is a
Senior Dentist at the Procter and Gamble Company and the third author is an Associate
Director, Peridex Research, Procter and Gamble Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “..subjects were stratified by age
intervals (<12 and >/= 12) and stratified
by seven intervals of gingivitis scores rang-
ing from <0.25 to >1.50. Within these
strata, the subjects were distributed into the
chlorhexidine or the placebo groups at ran-
dom”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors report that the study is “dou-
ble-blind”. The comparison group rinsed
with placebo rinse, no details are given re-
garding the formulation or presentation of
the placebo
Comment: it is not clear whether the ’su-
pervisory personnel’ who dispensed the
toothpaste and mouthrinse and supervised
the rinsing were blind. The authors re-
port an increase in extrinsic tooth stain and
supragingival calculus in the CHX group.
The higher level of tooth staining and cal-
culus in the CHX group meant that partic-
ipants could have worked out which group
they were in (or that they were in the ac-
tive mouthrinse group) and this could have
affected their oral health behaviours and
hence the outcome. The direction of this
potential bias is unclear
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk The authors report that the study is “dou-
ble-blind”. Quote: “Previous records were
not available at subsequent examinations
nor did examiners have any knowledge as
to which treatment group a given subject
belonged”
Comment: the authors report an increase in
extrinsic tooth stain and supragingival cal-
culus in the CHX group. The higher level
of staining and calculus in the CHX group
meant that the outcome assessor could not
be adequately blinded and this could have
affected the outcome assessment. The di-
rection of this potential bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers at baseline not reported, so attri-
tion from baseline cannot be calculated
Selective reporting (reporting bias) High risk The SDs for the main outcome (mean gin-
givitis occurrence and severity) are not re-
ported. The ancillary outcome (plaque) is
mentioned but not fully reported possibly
because the result was not statistically sig-
nificant
Other bias Unclear risk No information is provided on intra- and
interexaminer reproducibility
The groups appear balanced for gingivi-
tis at baseline. The authors state that the
baseline scores demonstrate comparability
of the test and control groups. However,
the statistical significance of the differences
is not reported
Eaton 1997
Methods Trial design: parallel (2 arms)
Location: suburban general dental practices in the South of England at Staines, Ripley,
Lydd, Leigh on Sea, and West Malling, UK
Number of centres: 5
Study duration: recruitment period is not stated. Study duration and duration of rinsing
was 3 months
Participants Participants: healthy subjects, existing patients of the 5 general dental practices
Inclusion criteria: quote: “Inclusion criteria were: a willingness to participate in the study,
a minimum of 16 natural teeth, the presence of chronic gingivitis but no pocket probing
depths in excess of 4 mm or radiographic evidence of bone loss, no need for urgent
treatment, between the ages of 18 and 65 years, in good health and a willingness to
83Chlorhexidine mouthrinse as an adjunctive treatment for gingival health (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Eaton 1997 (Continued)
refrain from using any mouthrinses other than those provided in the study”
Exclusion criteria: quote: “Exclusion criteria were: acute gingivitis or other periodontal
conditions, existing lesions of the oral mucosa, the receipt of antibiotics within 14 days of
the baseline examination, history of diabetes, hepatitis B, tuberculosis or other infective
or metabolic diseases, allergy to oral care products, the use of chlorhexidine or other
antibacterial mouthrinses within three months of the start of the study, pregnancy or
childbirth within the previous year, partial dentures, clinically unacceptable restorations,
smoking more than 10 cigarettes per day and the receipt of any medication with a history
of potential to alter gingival response”
Baseline gingivitis: (Modified GI) Gp A: mean CHX 0.56 (SD 0.4); Gp B: mean 0.54
(SD 0.4)
Age at baseline (years): Gp A: mean 34.8 (SD 11.4); Gp B: mean 34.9 (SD 12.7); range
of 18-65
Gender: overall: male 41 (34%), female 80 (66%).
Number randomised: 121 (Gp A: 60; Gp B: 61). 24 subjects were at 4 practices each
and 25 subjects were at the fifth practice
Number evaluated: 98 (Gp A: 48; Gp B: 50)
Interventions Comparison: CHX versus control (placebo in aqueous solution)
Gp A (n = 60): CHX (Peridex) 0.12%, 15 mL, twice daily, 30 seconds, 3 months
Gp B (n = 61): control, 15 mL, twice daily, 30 seconds, 3 months
Prophylaxis at baseline: quote: “All were then (after baseline examination) given a dental
prophylaxis... After initial baseline prophylaxis, patients were given no further prophy-
laxes during the study”
OHI: quote: “Patientswere instructed touse only these oral hygiene items [medium,mul-
titufted toothbrush and sodium fluoride containing toothpaste] throughout the study.
They were asked to brush their teeth as normally”
Postrinsing instructions: not reported
Non-supervised rinsing
Timing ofmouthrinsing in relation to toothbrushing:mouthrinsing after toothbrushing,
after breakfast and last thing at night
Outcomes Gingivitis (Modified Gingival Index, Eaton 1997); plaque (PI Silness & Löe 1964);
assessed at 6 and 12 weeks follow-up
Funding Funding: Procter and Gamble (Health & Beauty Care) Europe Ltd sponsored the study
Notes Sample size calculation: quote: “Sample size calculations were based on detecting a
difference of 20% in gingivitis between placebo and ChD group if it existed at a 2-tailed
significance level of 5% with 95% power”
Participants included smokers (smoking up to and including 10 cigarettes a day)
Adverse effects: participants in the CHX group left the study due to staining of teeth (4)
, taste (1) and adverse mucosal reaction (1)
Declarations/conflicts of interest: potential conflict of interest with author EZak (Procter
and Gamble Health & Beauty Care Europe). No other declarations other than that of
funding (above)
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “mouthrinses....were dispensed on
a randomised double-blind basis, accord-
ing to a random code”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors state that the study is double-
blind. The CHX and placebo mouthrinses
were distributed in coded but otherwise in-
distinguishable containers
Comment: tooth staining from the CHX
was noted as a reason for loss to follow-
up in the study and may have been visible
to the participants in the test group. This
meant that participants could have worked
outwhich group theywere in and this could
have affected their oral health behaviours
and hence the outcome. The direction of
this potential bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The authors state that the study is double-
blind
Comment: although the authors indicate
that the clinical examiners were blinded to
the treatment groups, tooth staining from
the CHX was noted as a reason for loss to
follow-up in the study. This meant that the
outcome assessor could not be adequately
blinded and this could have affected the
outcome assessment. The direction of this
potential bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition at 12 weeks 23/121 (19%). Attri-
tion by group: 12/60 (20%) CHX, 11/61
(18%) placebo. Reasons for loss to follow-
up: CHX: 5 withdrawn because they had
taken antibiotics during the study for non-
oral reasons, a further 6 for factors relat-
ing directly to the mouthrinses (4 tooth-
staining, 1 taste, 1 adverse mucosal reac-
tion), 1 was unwilling/unable to continue
in the study. Placebo: 8 withdrawn be-
cause they had taken antibiotics during the
study for non-oral reasons, 3 for miscella-
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neous reasons including using a different
mouthrinse, heavy smoking and unspeci-
fied unwillingness to continue
Comment: half of those lost from theCHX
group were lost due to reasons directly re-
lated to using the CHX mouthrinse. Most
losses in the placebo group were protocol
violations. Although numerically the drop-
outs are similar, the reasons are different
and may bias in favour of CHX
Selective reporting (reporting bias) High risk Adverse effects including tooth staining
were reported in relation to withdrawals
from the study only but are considered im-
portant outcomes and should have been re-
ported for all participants where relevant
Other bias Low risk Interexaminer scores 0.78-0.85 for PI
and 0.73-0.94 for the Modified Gingival
Index. Examiners maintained scores 0.
51-0.90 for PI and 0.73-1.00 for the Mod-
ified Gingival Index during the 12 months
required to complete the study. No men-
tion of intraexaminer calibration
Groups are balanced for age, sex, gingivitis
and plaque at baseline
Emling 1992
Methods Trial design: parallel (5 arms - 4 arms relevant to this review)
Location: assumed to be at School of Dental Medicine, University of Pennsylvania,
Philadelphia, PA, USA
Number of centres: 1
Study duration: recruitment period is not stated. Study duration and duration of rinsing
was 2 months
Participants Participants: healthy subjects regardless of race or sex
Inclusion criteria: minimum of 20 crowned natural teeth; quote: “All subjects reported
that theywere free from any known reaction or sensitivity to any dentifrices, mouthrinses,
or oral hygiene products. The female subjects entered into the study gave verbal assurance
that they were not pregnant... All subjects agreed to refrain from any routine dental
treatment or prophylaxis other than emergency procedures. They also agreed to use only
the assigned treatments, and to comply with daily use as directed by the instructions
given to them at the time of the product distribution”
Exclusion criteria: quote: “No subjects had orthodontic bands or diseases present of the
hard tissues (osteomyelitis, fractures, cysts, odontomas, etc). There were no neoplastic
growths in the oral cavity, advancedperiodontal diseases, or diseases of the buccalmucosa,
tongue, or floor of the mouth such as abscesses, ulcerations, hyperplasia, hypertrophy, or
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granulomas. None of the subjects entered into the study were currently using antibiotics
or had used any antibiotics at least two weeks prior to the onset of the study”
Baseline gingivitis is reported separately for buccal and lingual surfaces
Baseline gingivitis for buccal surfaces: Gp A: mean 1.04 (0.59); Gp B: mean 0.92 (0.48)
; Gp C: mean 0.95 (0.62); Gp D: mean 1.24 (0.68); Gp E: mean 1.00 (0.48)
Baseline gingivitis for lingual surfaces: Gp A: mean 1.26 (0.56); Gp B: mean 1.18 (0.
61); Gp C: mean 1.18 (0.55); Gp D: mean 1.26 (0.55); Gp E: mean1.07 (0.51)
Age at baseline (range): 18-60
Gender: not stated. Subjects were accepted without reference to race or sex
Number randomised: 65 (assumed to be 13 in each group)
Number evaluated: not reported
Interventions Comparison: (Crest + CHX) versus (Rembrandt + CHX) versus (Crest + CHX until
week 4 then Rembrandt + CHX from week 4 to week 8)* versus (Crest + placebo)
versus (Rembrandt + placebo)
Gp A (n = 13): CHX (Peridex) 0.12% + Crest; amount not reported; frequency not
reported; rinse time not reported, 8 weeks
Gp B (n = 13): CHX (Peridex) 0.12% + Rembrandt; amount not reported; frequency
not reported; rinse time not reported, duration not reported
*Gp C (n = 13): CHX (Peridex) 0.12% + Crest (baseline to week 4); CHX (Peridex)
0.12% + Rembrandt; amount not reported; frequency not reported; rinse time not
reported; duration not reported. We excluded this arm from our data extraction, risk of
bias and analysis
GpD (n = 13): placebo + Crest; amount N/A; frequency not reported; rinse not reported;
rinse time not reported; duration not reported
Gp E (n = 13): placebo + Rembrandt; amount N/A; frequency not reported; rinse not
reported; rinse time not reported; duration not reported
Prophylaxis: not reported
OHI: quote: “At each examination time, subjects reported to the study having not
brushed their teeth for a period of 10-12 hours”
Postrinsing instructions: not reported
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: after toothbrushing
Outcomes Gingivitis (gingival inflammation: GI Löe& Silness 1963); plaque (TQH,Turesky 1970)
; extrinsic tooth stain (area and intensity) (DI, Lobene 1968); supragingival calculus
(Volpe-Manhold Calculus Index, Volpe-Manhold 1965); assessed at 2, 4, 6, and 8 weeks
follow-up
Funding Funding: not reported
Notes Sample size calculation: not reported
Adverse effects: quote: “Eight subjects using Peridex complained of burning and/or
irritation of the gingiva or palatal mucosa. No other changes of the gingiva were observed
during the study.” Increases in stain intensity and area were noted in all CHX rinse
groups during the study. Groups C and D had significant increases in mean calculus
scores
Declarations/conflicts of interest: none stated. First authorworks for InternationalDental
Research Ltd, Moorestown, NJ, USA
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomly assigned
to one of 5 groups..”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “The study was conducted in a
double-blind manner. Neither the subjects
nor the clinical examiners were aware of
the product assignments at any time dur-
ing the study”, and “The dentifrices and
the mouthrinses were all in similar pack-
ages labelled only with a subject’s assigned
number and the investigators emergency
day and night phone numbers”
Increases in stain intensity and area were
noted in all CHX rinse groups during the
study
Comment: The higher level of tooth stain-
ing in the CHX groups meant that partici-
pants could have worked out which group
they were in (or that they were in 1 of the
active mouthrinse groups) and this could
have affected their oral health behaviours
and hence the outcome. The direction of
this potential bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotes: “The study was conducted in a
double-blind manner. Neither the subjects
nor the clinical examiners were aware of
the product assignments at any time dur-
ing the study”, and “The dentifrices and
the mouthrinses were all in similar pack-
ages labelled only with a subject’s assigned
number and the investigators emergency
day and night phone numbers”
Increases in stain intensity and area were
noted in all CHX rinse groups during the
study
Comment: the higher level of tooth stain-
ing in the CHX groups meant that the
outcome assessor could not be adequately
blinded and this could have affected the
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outcome assessment. The direction of this
potential bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information is provided
Selective reporting (reporting bias) Low risk All outcomes stated in the methods sec-
tion are adequately reported in the results
section. For gingivitis, plaque, stain inten-
sity and stain area, means and SDs for buc-
cal and lingual surfaces were combined for
each group. Then, CHX + Crest and CHX
+ Rembrandt groups were combined into
a CHX + toothpaste group and placebo +
Crest and placebo + Rembrandt were com-
bined into a placebo + toothpaste group to
be included in meta-analyses
Other bias Unclear risk No information is provided on number of
examiners or intra- and interexaminer re-
producibility
Baseline GI, plaque, calculus and stain in-
dices were not statistically significantly dif-
ferent between the groups at baseline
Ernst 2005
Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: Department for Operative Dentistry, Johannes Gutenberg University of
Mainz, Germany
Number of centres: 1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 4 weeks
Participants Participants: quotes: “soldiers stationed in Mainz, Germany” and “students from the
dental clinic of Johannes Gutenberg University Mainz, Germany”
Inclusion criteria: quote: “Each volunteer had gingivitis or slight periodontitis”
Exclusion criteria: quote: “General exclusion criteria were systemic diseases and long-
term medications”
Baseline gingivitis (GI, Löe & Silness): Gp A: mean 1.21 (SD 0.68); Gp B: mean 1.11
(SD 0.88); Gp C: mean 1.09 (SD 0.71)
Age of completers (years): Gp A: mean 28.4 (SD 8.5); Gp B: mean 32.2 (SD 12.2); Gp
C: mean 31.3 years (SD 9.5). Overall age range 18-58. Gp A: range 18-50; Gp B: range
22-58; Gp C: range 22-54
Gender: not reported
Number randomised: 101 (not reported by group)
Number evaluated: 90 (Gp A: 33; Gp B: 29; Gp C: 28)
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Interventions Comparison: CHX versus Hexetidine* versus placebo
Gp A (completers n = 33): CHX 0.1%, 15 mL, twice daily, 30 seconds, 4 weeks
*Gp B (completers n = 29): Hexetidine 0.1%, 15 mL, twice daily, 30 seconds, 4 weeks.
We excluded this arm from the risk of bias and analysis
Gp C (completers n = 28): placebo, 15 mL, twice daily, 30 seconds, 4 weeks
Prophylaxis at baseline: quote: “Each subject’s teeth were professionally cleaned after-
wards”
OHI: quote: “The subjects were given detailed instructions on oral hygiene. Each subject
received a new toothbrush (Oral B, P35, Gilette/Oral B) and several trial packages of
a standardized toothpaste (Emex, GABA). The subjects were asked to brush their teeth
with the new toothbrush and toothpaste after breakfast and dinner each day”
Non-supervised rinsing
Timing of mouthrinising in relation to toothbrushing: after toothbrushing
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1967; gingival bleeding: Bleeding
Index, van der Weijen 1994); plaque (Approximal Plaque Index, Lange 1977); extrinsic
tooth stain (Discolouration Index, no reference provided but as described it appears to
be the severity aspect of the Discolouration Index (Lobene 1968)); assessed at 2 weeks
(GI and DI) and at 4 weeks (all indices). Volunteers were questioned about changes to
taste, oral sensitivity, taste of mouthrinse, and about their opinion of the mouthrinse
(the latter only asked after 4 weeks); assessed at 4 weeks follow-up
Funding Not reported
Notes Sample size calculation: not reported
Adverse effects: quote: “A total of 28 of 90 subjects reported obvious changes in their
sense of taste after using the mouthrinse. The number of subjects using mouthrinse B
reported themost incidences of a change in their sense of taste. A total of 18 of 29 subjects
(62.1%) complained about changes in their sense of taste. Only 8 of 33 subjects (24.2%)
usingmouthrinse A reported a change in the sense of taste. In the group usingmouthrinse
C, 2 out of 28 subjects (7.1%) complained about obvious changes in their sense of
taste... A relatively high number of subjects using mouthrinse B complained about oral
mucosa sensitivities. Two subjects out of this groups showed such severe changes in terms
of intensive red, inflamed areas at the intermediate check-up that mouthrinse use was
discontinued immediately... In group 1 (using mouthrinse A), 5 of 33 subjects (15%)
showed sensitivities of the oral mucosa... A total of 24% of the subjects in group 1
suffered from changes in their sense of taste.” Tooth staining was significantly higher in
the CHX group compared to the 2 other groups
Smokers: Gp A 17/33 (51.5%); Gp B 12/29 (41.4%); Gp C 8/28 (28.6%)
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “...divided randomly into two
groups” and “the solutionswere handedout
randomly to each subject”
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Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Low risk Quote: “All mouthrinses were coded and
placed into identical bottles. The bottles
were labelled A, B, or C by the pharmacy at
the Universtiy Clinic Mainz, Mainz, Ger-
many. The solutions were handed out ran-
domly to each subject”
Comment: the details suggest that conceal-
ment of allocation sequence was adequate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “Double-blind..” and
“All mouthrinses were coded and placed
into identical bottles. The bottles were la-
belled A, B or C by the pharmacy at the
University Clinic Mainz, Mainz, Germany.
. each solution contained the same appli-
cation and dosage instructions. The bottles
were not decoded until after all the follow-
up examinations and final statistical analy-
ses had been completed.” The placebo con-
tained propyleneglycol, glycerol, gentian-
tincture, pigment E 124 and purified water
Comment: the CHX group developed
more tooth staining than the placebo group
wwhich meant that participants could have
worked out which group they were in (or
that they were in 1 of the active mouthrinse
groups) and this could have affected their
oral health behaviours and hence the out-
come. The direction of this potential bias
is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotes: “Double-blind..” and “All
mouthrinses were coded and placed into
identical bottles. The bottles were labelled
A, B or C by the pharmacy at the Univer-
sity Clinic Mainz, Germany.. each solution
contained the same application and dosage
instructions. The bottles were not decoded
until after all the follow-up examinations
and final statistical analyses had been com-
pleted... All exams were done by clinicians
at the Department of Operative Dentistry,
Johannes Gutenberg University”
Comment: the CHX group developed
more tooth staining than the placebo group
which meant that the outcome assessor
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could not be adequately blinded and this
could have affected the outcome assess-
ment. The direction of this potential bias
is unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition at 5 weeks 11/101 (10.9%). Not
broken down by group
Reasons for losses: non-compliance
Selective reporting (reporting bias) Low risk All outcomes stated in the methods section
are adequately reported in the results sec-
tion. Adverse effects including tooth stain-
ing are reported in detail
Other bias Unclear risk No information is provided on number of
examiners, intra- and interexaminer repro-
ducibility or training of examiners
The mean scores for GI, Bleeding Index,
Approximal Plaque Index and DI appear
similar at baseline. Mean age of completers
and age range appear similar. There were a
higher proportion of cigarette smokers in
Gp A compared to Gp C. Gender is not
reported
Faveri 2006
Methods Trial design: parallel (2 arms)
Location: Periodontal Clinic of Guarulhos University, Guarulhos, Sao Paulo, Brazil
Number of centres: assumed to be 1
Study duration: the recruitment period is not stated. Study duration is 84 days (-21 days
to +63 days post-therapy. Duration of rinsing was 63 days (-21 days to +42 days post-
therapy)
Participants Participants: adults referred to the periodontal clinic of Guarulhos University, Brazil
Inclusion criteria: quote: “The study included subjects >30 years of age with at least 15
teeth and a minimum of six teeth with at least one site with PD between 5 and 7 mm
and CAL between 5 and 10 mm”
Exclusion criteria: quote: “The exclusion criteria were as follows: previous periodontal
therapy, pregnancy, nursing, smokers, any systemic condition that could affect the pro-
gression of periodontal disease or that required antibiotic coverage for routine dental
therapy, allergy to CHX and antibiotic therapy in the previous 6 months”
Baseline gingivitis: (gingival gleeding yes/no), Gp A: mean 33.02 (+/-11.37); Gp B:
mean 40.17 (+/-19.46)
Age at baseline (years): range not stated. Gp A: mean 48.5 (+/-8.8); Gp B: mean 42.1
(+/-6.5)
Gender: overall: male 13 (45%); female 16 (55%). Gp A: male 5 (36%), female 9 (64%)
; Gp B: male 8 (53%), female 7 (47%)
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Number randomised: 30 (Gp A: 15; Gp B: 15)
Number evaluated: 29 (Gp A: 14; Gp B: 15)
Interventions Comparison: (CHX + SRP) versus (placebo control + SRP)
Gp A (n = 14): CHX 0.12% + SRP, 15 mL, twice daily, 1 min, 63 days
Gp B (n = 15): placebo control (composition not described) + SRP, 15 mL, twice daily,
1 min, 63 days
Prophylaxis at baseline: quote: “During the initial phase, subjects received... full-mouth
supragingival scaling”
OHI: quote: “During the initial phase, subjects received... instruction in proper home-
care techniques.” All participants received scaling and root planing “completed in amaxi-
mum of six appointments lasting approximately 1h each.” The treatment was completed
in 21 days. The CHX rinsing began with the SRP and continued for 42 days after the
end of this therapy
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: after toothbrushing
Outcomes Gingivitis (gingival bleeding 0/1, BOP 0/1); plaque (plaque accumulation 0/1); suppu-
ration (0/1); assessed at 42 and 63 days postSRP
Probing depth (mm); CAL (mm) assessed and microbiological monitoring also carried
out (not relevant to this review)
Funding Quote: “This study was supported by Guarulhos University, Guarulhos, SP-Brazil and
FAPESP”
Notes Sample size calculation: quote: “The sample size calculation determined that 14 subjects
per group would provide an 80% power to detect a true difference of 1.0 mm between
test and placebo using probing pocket depth reduction in pockets >/6mm as the primary
outcome variable. This calculation was based on a two-tailed comparison of α = 0.05”
Adverse effects: quote: “No severe adverse effects were reported by any of the subjects”
Non-smokers
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “During the enrollment visit, each
subject was given a code number, and a
computer-generated table was used to have
them randomly assigned to receive one of
the two proposed treatments”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) High risk Quote: “During the enrollment visit, each
subject was given a code number, and a
computer-generated table was used to have
them randomly assigned to receive one of
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the two proposed treatments. The coordi-
nator of the study assigned participants to
their groups”
Comment: it is likely that the study co-or-
dinator was aware of the upcoming assign-
ments when randomising the subjects
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study is described as single-blind. The
university pharmacy prepared the placebo
and CHX rinses and packaged them in
opaque plastic tubes. The study co-ordina-
tor marked the code number of each sub-
ject on a set of 9 tubes. The co-ordinator
gave the coded tubes to the 2 examiners
who at no time during the study had ac-
cess to information about the contents of
the tubes or the assignment of subjects to
groups. Quote: “All study personnel, in-
cluding the biostatistician and participants,
were blinded to treatment assignment for
the duration of the study”
Comment: blinding was unlikely to be
maintained if there was more staining and
other minor adverse effects in the CHX
group (it is stated that no serious adverse
effects were reported by any of the subjects)
. However, as these outcomes were not re-
ported, it is unclear whether blinding was
maintained
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study is described as single-blind. The
university pharmacy prepared the placebo
and CHX rinses and packaged them in
opaque plastic tubes. The study co-ordina-
tor marked the code number of each sub-
ject on a set of 9 tubes. The co-ordinator
gave the coded tubes to the 2 examiners
who at no time during the study had ac-
cess to information about the contents of
the tubes or the assignment of subjects to
groups. Quotes: “All study personnel, in-
cluding the biostatistician and participants,
were blinded to treatment assignment for
the duration of the study” and “One exam-
iner performed all clinical measurements..
. and treatment was performed by the sec-
ond examiner”
Comment: blinding was unlikely to be
maintained if there was more staining and
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other adverse effects in the CHX group (it
is stated that no serious adverse effects were
reported by any of the subjects). However,
as these outcomes were not reported, it is
unclear whether blinding was maintained
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition at 12 weeks: 1/30 (3.3%). 1 sub-
ject lost from the CHX group because they
had taken an antibiotic during the course
of the study
Selective reporting (reporting bias) High risk All outcomes are reported graphically with
bars representing a measure of variance in
the graphs. We obtained additional out-
come data from the first author. Tooth-
staining is considered to be an important
side effect of CHX mouthrinsing but this
is not reported
Other bias Low risk Quote: “The clinical monitoring was per-
formedby two trained and calibrated exam-
iners.. One examiner performed all clini-
cal measurements... and treatment was per-
formed by the second examiner”
The examiners were calibrated to pro-
vide reproducible measurements for prob-
ing depth and CAL. Inter- and intraex-
aminer variability is reported for probing
depth and CAL measurements
“The demographic and clinical baseline
characteristicswere similar between the two
groups (P > 0.05)”
Feres 2009
Methods Trial design: parallel (3 arms - 2 arms relevant to this review)
Location: Periodontal Clinic of Guarulhos University, Guarulhos, Sao Paulo, Brazil
Number of centres: 1
Study duration: recruitment period is not stated. Study duration was 6 months and 21
days. Duration of rinsing was 63 days
Participants Participants: quote: “population referred to the Periodontal Clinic of Guarulhos Univer-
sity”
Inclusion criteria: quote: “subjects with untreated previously periodontal disease... good
general health and were diagnosed with generalized chronic periodontitis based on the
current classification of the American Academy of Periodontology. The inclusion criteria
were as follows: >30 years of age, at least 15 teeth, minimum of six teeth with at least
one interproximal site with PD between 5 and 7 mm and CAL between 5 and 10 mm,
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at least 30% of the sites with PD and CAL >/5 mm and presence of bleeding on probing
(BOP)”
Exclusion criteria: quote: “The exclusion criteria were as follows: previous subgingival
periodontal therapy, smoking, pregnancy, nursing, systemic diseases that could affect
the progression of periodontal disease (e.g. diabetes and immunological disorders), long-
term administration of anti-inflammatory medication, need for antibiotic coverage for
routine dental therapy, antibiotic therapy in the previous 6 months and allergy to CHX”
Baseline gingivitis: (gingival bleeding) Gp A: mean 29.6 (+/- 13.8); Gp B: mean 34.9
(+/- 19.4); Gp C: mean 40.3 (+/- 22.5)
Age at baseline (years): range not stated. Gp A: mean 45.1 (+/- 9.6); Gp B: mean 39.6
(+/- 6.1); Gp C: mean 42.5 (+/- 7.3)
Gender: overall: male 24 (40%), female 36 (60%). Gp A: male 8 (40%), female 12
(60%); Gp B: male 7 (35%), female 13 (65%); Gp C: male 9 (45%), female 11 (55%)
Number randomised: 60 (Gp A: 20; Gp B: 20; Gp C: 20)
Number evaluated: 60 (Gp A: 20; Gp B: 20; Gp C: 20)
Interventions Comparison: (SRP + CHX) versus (SRP + placebo) versus (SRP, professional plaque
control and placebo)*
All participants received full-mouth SRP under local anaesthesia in 4-6 appointments
of 1 hour each. SRP was completed 21 days after baseline. Participants started rinsing at
the beginning of the study and continued rinsing for 42 days after the end of the SRP
Gp A (n = 20): SRP + CHX 0.12%, 15 mL, twice daily, 1 min, 63 days
Gp B (n = 20): SRP + placebo, 15 mL, twice daily, 1 min, 63 days
*Gp C (n = 20): SRP, professional plaque control and placebo, 15 mL, twice daily, 1
min, 63 days (data not included in the review). We excluded this arm from our risk of
bias and analysis
Prophylaxis at baseline: quote: “During the initial phase, all subjects received... full-
mouth supragingival scaling”
OHI: quote: “During the initial phase, all subjects received instruction on proper home-
care techniques”
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: after toothbrushing
Outcomes Outcomes measured at 2 and 6 months post-therapy (i.e. first follow-up examination
occurred approx 20 days after rinsing had ceased at approx 83 days after baseline)
Gingivitis: (gingival bleeding (0/1); BOP (0/1)); visible plaque (0/1) measured at 2 and
6 months post-therapy
Suppuration (0/1); PD (mm); CAL (mm); also microbiological monitoring; assessed at
2 and 6 months post-therapy (not relevant to this review)
Funding This study was supported in part by research grants from the state of Sao Paulo research
foundation and FOGARTY from the National Institutes of Health (NIH), USA
Notes Sample size calculation: quote: “The ideal sample size to assure adequate power for this
clinical trial was calculated considering differences of at least 1 mm between groups for
clinical attachment level (CAL) in initially deep periodontal sites [probing depth (PD)
>/ 7 mm]... Based on these calculations, it was defined that 16 subjects per group would
be necessary to provide an 80% power with an [alpha] of 0.05”
Adverse effects: quote: “No severe adverse effects were reported by any of the subjects.
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Two subjects from the CHX group reported adverse events during the study, such as
tooth staining and an unpleasant taste”
Non-smokers
Declarations/conflicts of interest: none stated
Notes: intention-to treat analysis. The last available recordings were carried forward to
represent all subsequent time points of evaluation. Data from professional plaque control
group are not included in the review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Each subject was given a code
number at the enrolment visit and the
study coordinators used a computer-gener-
ated table (in blocks of three) to randomly
allocate them to one of three therapeutic
groups”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quotes: “Each subject was given a code
number at the enrolment visit and the
study coordinators used a computer-gener-
ated table (in blocks of three) to randomly
allocate them to one of three therapeutic
groups.” The mouthrinses were prepared
and dispensed in opaque plastic tubes by
the Guarulhos university pharmacy. “The
study coordinators marked the code num-
ber of each subject on a set of 9 tubes ac-
cording to the therapy assigned”
Additional information provided by the
study authors: “Allocation concealment
was assured by placing the numbered bot-
tles in indistinguishable plastic bags with
the same numbering. The numbered bags
with the medication/placebo were given to
the therapists by a clinical assistant, follow-
ing the sequence of numbers from 1 to 60.
This assistant and the clinicians had no ac-
cess to the randomization list, assuring the
allocation concealment. The study coordi-
nators had access to the list but did not par-
ticipate on the clinical treatment/examina-
tion of the patients”
Comment: the details suggest that conceal-
ment of allocation sequence was adequate
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk CHX and placebo rinse was packaged in
opaque plastic tubes with the patients code
number written on the tubes. “The exam-
ining researchers had no access to informa-
tion about the contents of the tubes or as-
signment of subjects to the three therapies.
All study personnel, including the biostatis-
tician and participants were not aware of
the treatment assignments for the duration
of the study”
2 subjects from the CHX group reported
adverse events during the study, such as
tooth staining and an unpleasant taste
Comment: blinding of all participants is
not possible in this study because of differ-
ences between the interventions (subjects
in the professional plaque control group
attended the clinic twice a week and the
others did not) although the CHX and
placebo groups could be considered blind.
The presence of noticeable tooth staining
was noted by 2 of the participants. It is
not clear if other participants in the CHX
group noticed increased tooth staining
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quotes: “The examining researchers had
no access to information about the con-
tents of the tubes or assignment of subjects
to the three therapies. All study person-
nel, including the biostatistician and par-
ticipants were not aware of the treatment
assignments for the duration of the study”
and “One examiner carried out all clinical
measurements in a given subject and treat-
ment was performed by the second clini-
cian. Thus, the monitoring clinician was
masked to the treatment protocol”
Comment: the presence of noticeable tooth
staining was noted by 2 of the participants
and would also have been visible to the
outcome assessors. As tooth staining was
not measured in the course of the study,
it is not clear if other participants in the
CHX group had increased tooth staining
that would have been visible to the out-
come assessors
98Chlorhexidine mouthrinse as an adjunctive treatment for gingival health (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Feres 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis was carried out
using last available recordings for those lost
to follow-up. Therefore all subjects who en-
tered the study were included in the analy-
sis at all time points
Attrition (all study arms) 11/60 (18.3%)
. Dropouts by group: CHX 5/20 (25%)
, placebo 3/20 (15%). Reasons for loss to
follow-up:CHX: 2moved to another city, 1
got pregnant and 2 could not be contacted;
placebo: 3 could not be contacted
Comment: dropouts are high particularly
in the CHX group. Reasons for losses do
not appear to be related to the intervention
Selective reporting (reporting bias) High risk All outcomes stated in the methods sec-
tion are adequately reported in the results
section. However, tooth staining is consid-
ered to be an important side effect of CHX
mouthrinsing and apart from being self-re-
ported by 2 participants, this is not other-
wise reported
Other bias Unclear risk The 2 examining researchers were cali-
brated for the periodontal PD and CAL
measurements only
Quote: “No statistically significant differ-
ences were observed among groups for any
parameter at baseline”
Feres 2012
Methods Trial design: parallel (6 arms) (2 x 3 factorial design; 2 arms relevant to this review are
described here)
Location: Periodontal Clinic of Guarulhos University, Brazil
Number of centres: 1
Study duration: the recruitment period is not stated, however, the study duration was 1
year and the duration of rinsing was 2 months
Participants Participants: healthy subjects with untreated generalized chronic periodontitis
Inclusion criteria: at least 30 years old, at least 6 teeth, at least 1 site with PD and CAL
4 mm or more, BOP
Exclusion criteria: previous subgingival periodontal therapy, pregnant or breastfeeding,
smoking, systemic disease that could affect progression of periodontal disease, long-
term use of anti-inflammatory medication, need for antibiotic premedication for routine
dental therapy, use of antibiotic therapy in previous 6 months, allergy to metronidazole,
amoxicillin or CHX
Baseline gingivitis: (% of sites with BOP) overall mean for SRP group (1): 70.6 (SD 23.
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8); within group (1) CHX + SRP 69.2 ± 26.5, SRP 72.0 ± 21.4
Age at baseline (years): mean 45.8 (SD 8.54) from Table 1 (mean of data reported in
Table S1 is 43.3); CHX: 41.6±7.2, placebo: 45.2±10.1
Gender: overall: male 12 (30%), female 28 (70%); CHX: male: 7, female: 13; placebo:
male: 5, female: 15
Number randomised: 40 (Gp A: 20; Gp B: 20)
Number evaluated: 40 (Gp A: 20; Gp B: 20) at 3 months; ITT analysis (last observation
carried forward) used to account for dropouts at 6 and 12 months (not reported by
CHX/placebo)
Interventions Comparison: (1) SRP versus (2) SRP + metronidazole versus (3) root planing +
metronidazole + amoxicillin
Each arm was further randomised to receive CHX rinse or placebo rinse. Only the first
arm (1) was eligible for inclusion in this review
Gp A (n = 20): CHX 0.12% + SRP, 15 mL, twice daily, 1 min, 2 months
Gp B (n = 20): placebo + SRP as above
Prophylaxis at baseline: SRP (4 to 6 1-hour sessions under local anaesthesia over 14
days) and “all subjects received periodontal maintenance at the three post-treatment
monitoring visits”
OHI: “During the initial phase, all subjects received instruction on proper home-care
techniques and were given the same dentifrice (Colgate Total; Colgate Palmolive Co,
São Bernardo do Campo, SP, Brazil) to use during the study period”
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: “Subjects were instructed to rinse
in the morning, 30 min after breakfast and toothbrushing, and also at night 30 min after
toothbrushing”
Outcomes Gingivitis (BOP yes/no, gingival bleeding yes/no); plaque (% sites with accumulation);
periodontitis (probing depth, CAL); and suppuration assessed at 3, 6 and 12 months
Because participants received periodontal maintenance at 3, 6 and 12 months, the 3-
month data are considered to be the only data relevant to this review
Funding Quote: “This study was supported by Research Grant #07/55291-9 from Fundação de
Amparo à Pesquisa do Estado de São Paulo (FAPESP, Brazil)”
Notes Sample size calculation: accounting for 15% attrition, 39 participants were needed per
group (the initial 3 groups before further division into CHX/placebo) in order to detect
a difference of 4 sites with probing depth 5 mm or greater at 90% power and 5%
significance (unclear whether the study is powered to detect a difference between CHX/
placebo within each of the 3 arms)
Adverse effects: adverse effects reported appear to be related to the metronidazole and
amoxicillin, but there were no statistically significant differences between any of the 3
groups
Declarations/conflicts of interest: quote: “The authors declare that they have no conflict
of interests”
Data for the SRP+CHX and SRP groups within group (1) were obtained from the study
authors
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “each of the selected subjects was
given a code number during the enrolment
visit and the study coordinators (M.Fe. and
L.C.F.) used a computer-generated table to
allocate them to one of the three therapeu-
tic groups” and “A second randomization
was performed to allocate half of the sub-
jects in each group to rinse with…CHX or
placebo”
Comment: second randomisation not ade-
quately described
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quotes: “double-blind” and “Masking of
CHX rinsing may have been hampered by
tooth staining”
Comment: tooth staining is likely to have
been noticeable in the CHX group rinsing
for 2 months, therefore participants could
have worked out which group they were
in and this could have affected their oral
health behaviours and hence the outcome.
However, tooth staining is not reported
and there is not enough information upon
which to base a judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quotes: “double-blind” and “Masking of
CHX rinsing may have been hampered by
tooth staining”
Comment: tooth staining is likely to have
been noticeable in the CHX groups at 3
months follow-up and in this situation the
outcome assessor could have worked out
which individuals used CHX and not be
adequately blinded. However, tooth stain-
ing is not reported and there is not enough
information upon which to base a judge-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses. ITT analysis (last observa-
tion carried forward) used to account for
dropouts at 6 and 12 months (not reported
by CHX/placebo)
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Selective reporting (reporting bias) High risk Tooth staining is considered to be an im-
portant side effect of CHX mouthrinsing
but this is not reported. Only the pri-
mary outcome (PD)was reported byCHX/
placebo in the published article
Other bias Unclear risk Calibration carried out with high Kappa
scores for inter- and intraexaminer agree-
ment (> 92%), but this may have only
been for the primary outcomes of the study,
whichwere for periodontitis (PDandCAL)
Ferretti 1987
Methods Trial design: parallel (2 arms)
Location: assumed to be University of Kentucky Medical Center, USA
Number of centres: 1
Study duration: recruitment period not stated. Study duration is 90 days. Duration of
rinsing was 60 days
Participants Participants: quote: “patients undergoing assessment for bone marrow transplantation”
Inclusion criteria: quote: “patients undergoing assessment for bone marrow transplanta-
tion... patients with dentition”
Exclusion criteria: quote: “Two patients were not included in evaluation because, for
medical reasons, they did not undergo bone marrow transplantation. These excluded
patients were similar in all other aspects to the 33 patients who were evaluated”
Baseline gingivitis: not reported
Age at baseline (years): Gp A: mean 25.3 ±3.3; Gp B: mean 27.1±3.9. Gp A: range 5-
48; Gp B: range 5-51
Gender: not reported
Number randomised: 35 (Gp A: 18; Gp B: 17)
Number evaluated: assumed 33 (Gp A: 16; Gp B: 17) but this is unclear. See note under
’Attrition bias’
Interventions Comparison: CHX versus placebo control
Gp A (n = 16): CHX 0.12%, 15 mL, 3 times daily, 30 seconds, 60 days
Gp B (n = 17): placebo, 15 mL, 3 times daily, 30 seconds, 60 days
Prophylaxis at baseline: quote: “Necessary dental care, including dental cleaning... was
implemented before the initiation of chemoradiotherapy”
OHI: none, usual but with foam rubber toothbrush substitute and saline solution irri-
gations
Partially supervised rinsing. Quote: “Supervised by the nursing staff of the transplant
unit for the duration of the patients’ hospitalization (usually 35-45 days). After discharge,
patients continued this regimen for the remainder of the 60-day treatment period”
Timing of mouthrinsing in relation to toothbrushing: after toothbrushing (with a foam
rubber toothbrush)
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Outcomes Gingivitis (gingival inflammation: PMGI, de la Rosa 1976); plaque (TQH, Turesky
1970); extrinsic tooth stain (Meckel’s stain grading method, Lang 1977) assessed at 33,
60, and 90 days follow-up
Mucositis, oral streptococci and candida are also reported but are not relevant to this
review
Funding Quote: “This study was supported by funds from theUniversity of Kentucky, the Procter
& Gamble Co, and the Veterans Administration”
Notes Sample size calculation: not reported
Adverse effects: quote: “Extrinsic dental staining was similar throughout the study for
both the chlorhexidine and control groups. There was amodest, although not significant,
increase in dental staining noted in both groups during the treatment”
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Through prospective randomisa-
tion..”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “..in a double-blind fashion.” The
placebowas identical in composition to the
CHX only without the CHX. Rinsing was
supervised by the nursing staff. Blinding
of the nursing staff although likely is not
explicitly stated
Comment: there was a modest although
not significant increase in dental staining
noted in both groups during the treatment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotes: “..in a double-blind fashion” and
“All clinical indexes were scored by the
same examiner”
Comment: there was a modest although
not significant increase in dental staining
noted in both groups during the treatment.
The incidence of oral candida and mucosi-
tis is markedly lower in the CHX group
which may have affected blinding by po-
tentially alerting the examiner to the group
assignment of the subjects
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Incomplete outcome data (attrition bias)
All outcomes
High risk According to Table 2: patient characteris-
tics, 35 patients were randomised (18CHX
and 17 control) and 33 were evaluated (16
CHX and 17 control). 2 participants were
lost from the CHX group because they did
not undergo bone marrow transplantation
for medical reasons. We assume that the
remaining patients were evaluated for in-
clusion in the study rather than evaluated
at the end of the study. This is because
data presented within the bar charts for the
CHX group indicate substantial losses to
follow-up throughout the trial in the CHX
group (44% by day 33). Losses from the
control groups are not reported but include
2 deaths in the control group early on post-
transplant
Selective reporting (reporting bias) Low risk All outcomes are reported graphically with
bars representing a measure of variance (as-
sumed to be SD) in the graphs. We esti-
mated the mean scores and SDs for each
outcome so that we could include the data
in meta-analyses
Other bias Unclear risk Quote: “All clinical indexes were scored by
the same examiner”
Comment: there is no mention of training
for the clinical examiner
The groups were comparable with regard
to age, pretransplant disease status, type
of transplant, graft-versus-host disease pro-
phylaxis and graft-versus-host disease. The
baseline plaque and gingivitis scores appear
balanced between the groups. The control
group appears to have had less extrinsic
staining at baseline but the statistical sig-
nificance of the difference is not reported
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Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: dental practice in the UK
Number of centres: 1
Study duration: the recruitment period is not stated. Study duration and duration of
rinsing was 4 months
Participants Participants: quote: “patients coming to the surgery”
Inclusion criteria: quote: “patients had to have some degree of gingival inflammation.
A gingival score system was chosen to measure the degree of inflammation present, and
patients selected were required to have a total score of greater than 36 points”
Exclusion criteria: quote: “No patient under the age of 12 years was included”
Baseline gingivitis: not reported
Age at baseline (years): range not stated but minimum age was 12
Gender: not reported
Number randomised: 133 (Gp A: 45, Gp B: 50, Gp C: 38)
Number evaluated: 116 - breakdown not specified
Interventions Comparison: (CHX rinse + OH) versus (PVP rinse + OH)* versus OH
Gp A (n = 45): CHX (concentration not reported) + OH (toothbrushing plus floss and/
or wood points), volume not reported, once daily, 30 seconds, 4 months
*Gp B (n = 50): PVP + OH (toothbrushing plus floss and/or wood points), volume not
reported, once daily, 30 seconds, 4 months. We excluded this arm from our risk of bias
and analysis
Gp C (n = 38): OH (toothbrushing plus floss and/or wood points), 4 months
Prophylaxis at baseline: quote: “At the first visit thorough scaling and polishing...were
given”
OHI: quote: “At the first visit thorough... instruction in oral hygiene techniques were
given”
Non-supervised rinsing
Timing of toothbrushing in relation to mouthrinsing: not reported
Duration of treatment: 4 months
Outcomes Gingivitis (’a gingival inflammation index’). Total score was recorded and presented in
results; assessed at 1 week, 1 month, and 4 months follow-up
Funding Not reported but Napp Laboratories helped with the statistical analysis
Notes Sample size calculation: not reported
Adverse effects: quote: “Several patients having been on chlorhexidine-gluconate mouth-
wash previously preferred the PVP-I as it did not stain the teeth or fillings... There was
also marked differences in the individual tendency to develop extrinsic dental staining
after using chlorhexidine as a mouth rinse... Patients also reported a drop in the number
of aphthous ulcers whilst using PVP-I”
Declarations/conflicts of interest: none stated
There appears to be an error in Figure 1. Outcome data were estimated from the graph
at 3 months but as the outcome was not measured at 3 months we assumed that these
data related to the outcome at 4 months
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Once the patient had been se-
lected… he/she was then put into one of
three groups by completely random allo-
cation according to a random allocation
code”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) High risk Quote: “Once the patient had been se-
lected… he/she was then put into one of
three groups by completely random alloca-
tion according to a random allocation code.
” This was done by the dental nurse
Comment: the use of an open random al-
location schedule means that the practice
dental nurse could likely foresee assignment
and there is a possibility that randomisa-
tion could have been subverted
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participant blinding was not
possible for CHX rinse plus oral hygiene
versus oral hygiene alone
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “During the visit neither the dentist
nor the hygienist knew which group the
patient was in”
Comment: since this study was conducted
in a single practice, and randomisation was
done by the dental nurse, it is unlikely
that blinding was maintained. In addition,
tooth staining was noted to have occurred
in the CHX group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition at 3 months (all study arms): 17/
133 (12.78%). Losses not broken down by
group. Reasons for losses not reported
Selective reporting (reporting bias) High risk Outcome measured at 1 and 4 months and
reported in graphs
Gingivitis: quote: “a gingival inflammation
index” reported as ’total score’. No infor-
mation on the variance of the total score
is provided. The data show an unusual in-
crease in mean gingivitis score for CHX at
3 months which is not discussed
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Other bias Unclear risk There were 2 examiners: a dentist and hy-
gienist. There is no reference to calibration
Baseline demographic data are not re-
ported. Mean total gingivitis scores appear
similar in Figure 1
Flemmig 1990
Methods Trial design: parallel (4 arms - 2 arms relevant to this review)
Location: USA. Setting not reported
Number of centres: assumed to be 1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 6 months
Participants Participants: quote: “patients with naturally-occurring gingivitis”
Inclusion criteria: quote: “1.Minimumof 16 natural teeth including at least 4molars, not
including third molars. 2. Demonstrated Bleeding on Probing (BOP) using a standard
periodontal probe at screening examination and an electronic pressure sensitive probe*
(25p) at baseline examination at a minimum of 6 sites on a minimum of 4 teeth. These
sitesmust have been equal to or less than4mmpocket probing depth andwere considered
sites with moderate to severe gingivitis”
Exclusion criteria: quote: “1. Systemic disorders or medications which might influence
the appearance of the oral tissue or the nature of the plaque. 2. History of adverse
reactions which might affect the participation in this study. 3. Used systemic antibiotics
for a period of more than 7 days 30 days prior to the baseline examination, or 10 days
prior to either the 3 month or 6 month examinations. 4. Diabetics, pregnant or lactating
women, or patients on long-term anti-inflammatory medications”
Baseline gingivitis: (GI) Gp A: mean 0.52 (+/- 0.04); Gp B: mean 0.56 (+/- 0.05); Gp
C: mean 0.51 (+/- 0.04); Gp D: mean 0.54 (+/- 0.04)
Age at baseline (years): mean age 36.6 years. Range not stated
Gender: not reported
Number randomised: 222 (Gp A: 58, Gp B: 55, Gp C: 54, Gp D: 55)
Number evaluated: 175 (Gp A: 43, Gp B: 40, Gp C: 44, Gp D: 48)
Interventions Comparison: CHX rinse versus CHX irrigationa versus water irrigationb versus
toothbrushing
Gp A (n = 58): CHX (Peridex) 0.12%, 15 mL, twice daily, 30 seconds, 6 months
aGp B (n = 55): CHX irrigation 0.06%, 200 mL, once daily, time not reported, 6
months. We excluded this arm from our risk of bias and analysis
bGp C (n = 54): water irrigation, 500 mL, repeat not reported, time not reported, 6
months. We excluded this arm from our risk of bias and analysis
GpD (n = 55): toothbrushing, volumeN/A, frequencyN/A, time not reported, duration
N/A
Prophylaxis at baseline: quote: “Patients received a full mouth professional removal of
supra- and subgingival plaque and calculus and a prophylaxis after the baseline and 6-
month examinations”
OHI: quote: “During the entire course of the study subjects were encouraged to continue
to practice their usual oral hygiene and no additional oral hygiene instructions were
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given, except that all patients used the same dentifrice”
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Outcomes Gingivitis (gingival inflammation: GI, Löe 1967; gingival bleeding: BOP yes/no using
pressure sensitive probe 25 p); plaque (PI, Silness & Löe 1964); extrinsic tooth stain
(Staining Index, photo of facial surfaces of the 12 anterior maxillary and mandibular
teeth were graded for (1) overall stain, (2) stain of each anterior surface, (3) % coverage
against 2 sets of established photo standards); supragingival calculus (Volpe-Manhold
Calculus Index, Volpe 1965); PPD (using pressure sensitive probe 25 p) - not relevant
to this review; assessed at 3 and 6 months follow-up
Funding Quote: “This study was supported by the Teledyne Research Assistance Program”
Notes Sample size calculation: not reported
Adverse effects: quotes: “No predominant reasons for not completing the study was
found. The most frequent reasons were patient not available for examination, tooth
staining, and pregnancy. Adverse soft tissue reactions consisting of epithelial desquama-
tion of the ventral surface of the tongue resulted in the exclusion of one patient from the
study who irrigated with chlorhexidine” and “Both CHX irrigation and rinse resulted in
significant (P≤ 0.05) increase in the calculus index and stain compared to toothbrushing
and water irrigation”
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (from report): “After the baseline ex-
amination patients were assigned to one of
the following treatment groups after bal-
ancing according to sex and marginal gin-
gival bleeding”
Quote (from correspondence): “Treatment
was assigned randomly... the study protocol
is not available”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk Quote (from correspondence): “..alloca-
tion was concealed... the study protocol is
not available”
Comment: not enough information is pro-
vided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors report that this is a single-blind
study which must apply to the examiner,
since participants could not be blinded (ir-
rigation versus rinse versus toothbrushing
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alone)
Quote: “At 6 months calculus was in-
creased by 273.2% in the CHX rinse.
. group compared to the toothbrushing
group. In the CHX rinsing group stain at
the facial surfaces of anterior teeth was in-
creased by 74.2%... compared to tooth-
brushing”
Comment: the higher level of tooth stain-
ing in the CHX group meant that partici-
pants could have worked out which group
they were in and this could have affected
their oral health behaviours and hence the
outcome. The direction of this potential
bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The authors report that this is a single-
blind study which must apply to the exam-
iner, since participants could not be blinded
(irrigation versus rinse versus toothbrush-
ing alone). Examiner 1 assessed soft tissues
and the plaque index. The other examin-
ers each assessed 1 of the remaining pa-
rameters (GI, pocket probing depth and
BOP andCalculus Index). Each clinical pa-
rameter was assessed by the same examiner
throughout the study. Tooth discoloura-
tion and staining was assessed in a single-
blind manner. Quote: “At 6 months calcu-
lus was increased by 273.2% in the CHX
rinse.. group compared to the toothbrush-
ing group. In the CHX rinsing group stain
at the facial surfaces of anterior teeth was
increased by 74.2%... compared to tooth-
brushing”
Comment: the higher level of staining in
the CHX group meant that the outcome
assessor could not be adequately blinded
and this could have affected the outcome
assessment. The direction of this potential
bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition 22/113 (19.5%). Attrition by
group: CHX 15/58 (25.86%), toothbrush-
ing (normal oral hygiene) 7/55 (12.73%)
. Losses higher in CHX group. Reasons
for loss to follow-up (not broken down by
group): patient not available for examina-
tion, tooth staining and pregnancy. Insuf-
ficient information to determine if losses
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are due to the intervention but authors re-
port a significant increase in stain in the
rinse group compared to the toothbrushing
group at 6 months and staining was one of
the reasons for loss to follow-up
Selective reporting (reporting bias) Low risk All outcomes stated in the methods section
are adequately reported in the results sec-
tion. Bacteriological results are presented in
another paper
SD was estimated as sqrt(MSE) so that
these data could be included in meta-anal-
yses
Other bias Unclear risk There were 4 examiners, each measuring a
different outcome. No measure of intraex-
aminer reliability for each index is given
Comment: there is no mention of training
or calibration of the clinical examiners
Baseline demographic data by group are not
reported
Flotra 1972
Methods Trial design: parallel (4 arms). *Note: data are reported for the 3 treatment groups
combined. Therefore, there are 2 overall groups in the analysis: control and experimental
Location: examinations were conducted at the military garrison at Rygge, approximately
50 kilometres south of Oslo, Norway
Number of centres: 1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 17 weeks
Participants Participants: Norweigan Air Force soldiers
Inclusion criteria: not reported
Exclusion criteria: not reported
Baseline gingivitis: (GI): Gp A: mean 1.11; Gp B: 1.22
Age at baseline (years): mean age: 27; range: 19-39
Gender: not reported
Number randomised: 50 (Gp A: 40, Gp B: 10)
Number evaluated: 28 (Gp A: 22, Gp B: 6)
Interventions Comparison: 0.2% CHX gluconate versus 0.1% CHX gluconate versus 0.1% CHX
acetate versus benzene alcohol control
Gp A (n = 40): 0.2% CHX rinse, 0.1% CHX rinse, 0.1% CHX acetate rinse, 10 mL,
twice daily, 1 min, 17 weeks
Gp B (n = 10): control (benzene alcohol),10 mL, twice daily, 1 min, 17 weeks
Prophylaxis at baseline: none at baseline. Supra- and subgingival scaling was performed
during the study starting during week 9
OHI: none given. Quote: “The established oral hygiene routine was not otherwise
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changed”
Non-supervised mouthrinsing
No information provided on timing of rinsing in relation to toothbrushing or postrinse
instructions
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1963); plaque (PI Silness & Löe
1964); calculus (Retention Index, Bjorby & Löe 1966); and pocket depth (mm) - not
relevant for this review; assessed at 8, 11, and 17 weeks follow-up
Funding Not reported
Notes Sample size calculation: not reported
Adverse effects: quote: “The taste of the control solution, like the test solution, was some-
what unpleasant”
Side effects are reported in a separate publication. During the experimental period, 11
participants exhibited lesions in the oral mucosa (10 CHX and 1 control). 3 of the 10
participants developed more severe lesions (2 in the 0.2% CHX gluconate group and 1
in the 0.1% CHX acetate group). 1 individual (0.1% CHX gluconate) developed what
appeared to be a viral stomatitis and another (0.1% CHX acetate) a viral parotitis. 1
individual developed small ulcers under the upper lip - probably due to an aphthous
lesion. In the test groups at 4weeks (n =48), 12%of the tooth surfaceswithout fillings and
62% of the silicate fillings became discoloured while 36% of the test persons developed
discoloured tongues during the experimental period
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation is not mentioned in the
study report
Quote (from correspondence): “The allo-
cation of participants to the various groups
was performed in this way: First we decided
how many we wanted in each group, the
appropriate no of lots for each group were
made and drawn for each participant from
a jar”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Allocation concealment is not mentioned
in the study report
Quote (from correspondence): “The draw-
ing of lots was performed by Dr Waerhaug
and myself (Prof Gjermo), with particular
attention that the group allocation was not
revealed for Dr Flötra who performed the
examinations. This was done at the De-
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partment of Periodontology at the Univer-
sity of Oslo, whereas the actual examina-
tions were performed at a military garrison
at Rygge, approximately 50 km south of
Oslo. Dr Flötra brought the results to Oslo
before the seal for the allocation was bro-
ken and data analyzed”
Comment: we consider it unlikely that par-
ticipants or investigators enrolling partici-
pants could foresee assignments
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The experiment was a double-
blind study.” Additional information was
obtained from the second author of the pa-
per: “neither the examiners nor the partic-
ipants were aware of which group they be-
longed to.” The control mouthrinse con-
tained 0.5% benzene alcohol
Quotes: “The test mouth washes were dis-
tributed in coded plastic bottles..” and
“The taste of the control solution, like the
test solution was somewhat unpleasant”
In the test groups, 12% of the tooth sur-
faces and 62% of the silicate fillings became
discoloured while 36% of the test persons
developed discoloured tongues during the
experimental period
Comment: the higher level of tooth stain-
ing in the CHX group meant that partici-
pants could have worked out which group
they were in and this could have affected
their oral health behaviours and hence the
outcome. The direction of this potential
bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “The experiment was a double-
blind study.” Additional information was
obtained from the second author of the pa-
per: “neither the examiners nor the partic-
ipants were aware of which group they be-
longed to” and “One investigator recorded
the Plaque Index throughout the study and
another recorded the gingival index” and
“Dr Flötra brought the results to Oslo be-
fore the seal for the allocation was broken
and data analyzed”
In the test groups, 12% of the tooth sur-
faces and 62% of the silicate fillings became
discoloured while 36% of the test persons
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developed discoloured tongues during the
experimental period
Comment: despite the efforts taken to
maintain blinding, the higher level of stain-
ing in the CHX group meant that the
outcome assessor could not be adequately
blinded and this could have affected the
outcome assessment. The direction of this
potential bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
High risk From Table 1 and 2 n = 28 at 17 weeks.
22/50 (44%) lost to follow-up at 17 weeks.
By group: Gp A 18/40 (45%); Gp B 4/10
(40%). Reasons for losses given for 11/22:
2 excludedbecause of stomatitis andparoti-
tis, 9 for various reasons such as discharge
from service, transfers, etc
Comment: losses to follow-up although
proportionately balanced between the
groups were unacceptably high
Selective reporting (reporting bias) High risk The outcome data for the 3 CHX rinse
groups are not reported by individual rinse
group; combined data for the 3 CHX
groups are presented in the results. The re-
sults for the Retention Index are not re-
ported fully. Pocket probing depth is mea-
sured at baseline but not reported. Side ef-
fects including oral lesions, discolouration
of the teeth and tongue are reported in de-
tail in a separate publication although not
in a format that would allow their inclusion
in meta- analyses
Other bias Unclear risk 2 examiners, 1 for each index. Nomeasure-
ment of intraexaminer reliability
Baseline demographic data are not re-
ported. Mean GI and PI in the 2 groups
at baseline appear similar (not significantly
different for GI)
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Methods Trial design: parallel (4 arms)
Location: Unit of Dentistry and Oral Surgery, University Hospital of Pisa, Italy
Number of centres: 1
Study duration: the recruitment period is not stated. Study duration and duration of
rinsing was 5 weeks
Participants Participants: healthy adults
Inclusion criteria: at least 20 teeth, the 8 incisors free of restorations or prosthetic recon-
structions, general good health
Exclusion criteria: systemic illness (including cardiovascular, renal of liver diseases), smok-
ers, periodontal/dental treatment within the 35 days preceding the study, pregnant or
lactating females, undergoing orthodontic treatment, inability to sign consent form
Baseline gingivitis: (Löe & Silness GI) Gp A: mean 1.8 (95% CI 1.4 to 2.2); Gp B: mean
1.6 (95% CI 1.3 to 1.9); Gp C: mean 1.8 (95% CI 1.5 to 2.2); Gp D: mean 1.5 (95%
CI 1.3 to 1.8)
Age at baseline (years): Gp A: mean 29.7 (95% CI 23.4 to 35.9); Gp B: mean 39.5 (95%
CI 31.6 to 35.9); Gp C: mean 36 (95% CI 30.3 to 37.2); Gp D: mean 29.7 (95% CI
24 to 35.5)
Gender: overall: male 36 (51%), female 34 (49%). Gp A: male 6 (40%), female 9 (60%)
; Gp B: male 11 (52%), female 10 (48%); Gp C: male 10 (53%), female 9 (47%); Gp
D: male 9 (60%), female 6 (40%)
Number randomised: 70 (Gp A: 15; Gp B: 21; Gp C: 19; Gp D: 15)
Number evaluated: 70 (Gp A: 15; Gp B: 21; Gp C: 19; Gp D: 15)
Interventions Comparison: CHX rinse 1 versus CHX rinse 2 versus CHX rinse 3 versus control
rinse
Gp A (n = 15): CHX 0.2% (with alcohol), 10 mL, twice daily, 1 min, 5 weeks
Gp B (n = 21): CHX 0.2% (alcohol-free), 10 mL, twice daily, 1 min, 5 weeks
Gp C (n = 19): CHX 0.2% with antidiscolouration system (alcohol-free), 10 mL, twice
daily, 1 min, 5 weeks
Gp D (n = 15): H2O/NaCl control, 10 mL, twice daily, 1 min, 5 weeks
Prophylaxis at baseline: supragingival scaling and polishing
OHI: quote: “Oral hygiene instructions were provided… as follows: interdental brush-
ing… and/or dental floss when interdental embrasures did not allow interdental brush-
ing. Interdental cleaning was followed by electric toothbrushing… A sodium lauryl sul-
fate-free toothpaste was provided to each participant”
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: participants were instructed to refrain from tea, coffee and red
wine consumption for at least 1 hour after rinsing
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1963; gingival bleeding: full-mouth
bleeding score, Ainamo and Bay 1975); plaque (full-mouth plaque score, O’Leary 1972)
; tooth discolouration/staining (staining index, modification of Lobene 1968, Grunde-
mann 2000) using digital photographic measurements of the buccal surfaces of the 8
incisors, tooth colour was measured using spectrophotometric analysis; other adverse
effects; assessed at 1, 3 and 5 weeks follow-up
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Funding Quote: “Johnson & Johnson supported this study with a grant to purchase the Vita
EasyShade spectrophotometer and to perform the data analysis (Dr D’Aiuto). UCLH/
UCL received a proportion of funding from the Department of Health’s NIHR Biomed-
ical Research Centres funding scheme”
Notes Sample size calculation: sample size was geared towards comparing each treatment mean
with the control mean. The calculation was reported and achieved. Quote: “A sample
size of 12 individuals per group, with at least three subjects to compensate for dropouts,
with 3 treatment arms and one control group would provide any-pair power of 80%
(α = 0.05) (Kruskal-Wallis Test) for comparing each treatment mean with the control
mean”
Adverse effects: “At 35 days, staining was frequent, reported in well above 60% of all
cases rinsing with the three CHX formulations.” Tongue staining incidence: Gp A: 1 at
35 days; Gp B: 2 at 21 days; Gp C: 2 at 7 and 21 days. Taste alteration: Gp A: 2 at 7
days; Gp B: 2 at 7 days and 2 at 21 days; Gp C: 1 at 35 days. Gastric acidity: Gp B: 1
at 7 days. No serious side effects reported
Non-smokers
Declarations/conflicts of interest: quote: “Dr Graziani has received lecture fees from
Johnson & Johnson and from Curaden healthcare” (Johnson & Johnson and Curaden
were the manufacturers of 2 of the 3 CHX rinses)
Participants in the study were described as having “mild periodontal involvement and
periodontal inflammation limited to approximately one-fifth of the entire dentition”
We combined groups A, B and C for the main analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “a computer-generated random se-
quence was used to assign participants to
one of the four treatment groups”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quote: “random sequence conducted by
a research fellow not directly involved in
the experiments was used to assign partic-
ipants... Allocation to the treatment was
concealed as a code number identifying the
allocated group. It was sealed in an opaque
envelope which was opened at the baseline
visit after completion of clinical measure-
ments, photographs, supragingival scaling
and polishing”
Comment: numerous steps were taken to
ensure that the random sequence was ap-
plied exactly as it was generated without
any manipulation
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “double-blind” and
“the mouthrinse bottles were dispensed to
the participants according to the allocated
group by a research fellow not directly in-
volved in the research. The control rinse
was saline”
Quote: “At 35 days, staining was frequent,
reported in well above 60% of all cases rins-
ing with the three CHX formulations”
Comment: the higher level of tooth stain-
ing in the CHX groups meant that partici-
pants could have worked out which group
they were in (or that they were in 1 of the
active mouthrinse groups) and this could
have affected their oral health behaviours
and hence the outcome. The direction of
this potential bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotes: “double-blind” and “Clinical ex-
aminations were performed… by an exam-
iner unaware of the group allocation”
Comment: the higher level of staining in
the CHX groups meant that the outcome
assessor could not be adequately blinded
and this could have affected the outcome
assessment. The direction of this potential
bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses (ITT analysis)
Attrition at 35 days was 17/70 (24.3%).
By group: Gp A 4/15 (26.7%); Gp B 3/21
(14.3%); Gp C 4/19 (21.1%); Gp D 6/15
(40%)
Selective reporting (reporting bias) High risk Percentage reduction in full-mouth bleed-
ing score was not reported forGpA.Due to
incomplete reporting of this outcome, data
on full-mouth bleeding score could not be
included in a meta-analysis
Other bias High risk Full-mouth bleeding score measurement
was carried out by a “blinded, calibrated
and experienced examiner.” Apart from
that statement, training and calibration of
the 1 outcome assessor are not mentioned.
The 4 groups do not appear to be balanced
with respect to mean age, % periodontitis
diagnosed, mean number of pockets and%
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of pockets ≥5 mm. The 95% confidence
intervals indicate some statistically signifi-
cant differences between the groups but the
P values for the differences are not reported
Grossman 1986
Methods Trial design: parallel (2 arms)
Location: USA. Quote: “Dental office conditions”
Number of centres: assumed to be 1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 6 months
Participants Participants: adults
Inclusion criteria: quote: “To be accepted into the study, subjects had to have at least 16
natural teeth, including 4 molars”
Exclusion criteria: quote: “Subjects were not enrolled if they had existing soft-tissue
damage due to ill-fitting appliances, evidence of overt periodontal disease or gross dental
neglect, an unfavorable medical history, or a history of routine antibiotic use”
Baseline gingivitis: (GI) examiner A (GpA:mean 0.5530,GpB:mean 0.5388); examiner
B (Gp A: mean 0.7472, Gp B: mean 0.7470)
Age at baseline (years): Gp A: 33.02; Gp B: 32.25. Range Gp A: 18-58; Gp B: 18-60
Gender: Gp A: male 72 (33%), female 147 (67%); Gp B: male 71 (34%), female 140
(66%)
Number randomised: 430 (Gp A: 219, Gp B: 211)
Number evaluated: 380 (Gp A: 187, Gp B: 193)
Interventions Comparison: CHX versus placebo
Gp A (n = 187): CHX 0.12%,15 mL, twice daily, 30 seconds, 6 months
Gp B (n = 193): placebo, 15 mL, twice daily, 30 seconds, 6 months
Prophylaxis at baseline: quote: “All subjects received a thorough prophylaxis after the
baseline examination for plaque, gingivitis, and oral soft tissue health”
OHI: quote: “A sodium fluoride dentifrice (Crest) and soft toothbrushes were given to
each subject to be used according to their own individual habits”
Non-supervised mouthrinsing
No information is provided on timing of rinsing in relation to toothbrushing or postrinse
instructions
Duration of treatment: 6 months
Outcomes Gingivitis (gingival inflammation (GI, Löe 1967); gingival bleeding (GI sites with scores
2 or 3 indicating bleeding)); plaque (TQH,Turesky 1970); oral soft tissue effects; calculus
(index not reported); and tooth stain (index not reported) and tongue stain assessed at
3 and 6 months follow-up
Funding Quote: “The support of this study by the Procter & Gamble Company, Cincinnati,
Ohio, is gratefully acknowledged”
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Notes Sample size calculation: not reported
Adverse effects: quotes: “As expectedwith the use of any oral antimicrobial, some extrinsic
tooth staining was observed in the chlorhexidine group” and “Supragingival calculus
was higher in the group using chlorhexidine” and “The systematic evaluation of the
oral structures did not yield any indication of chlorhexidine-related changes in the oral
mucosa”
Declarations/conflicts of interest: none stated
Gingivitis data were extracted for examiner A only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “subjects were stratified by sex, age
and gingivitis severity. Within strata they
were assigned to one of two treatment
groups by random permutations of 2”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk Comment: no information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “.. double-blind clinical trial” and
“Neither the subject nor the dental exam-
iners knewwhich treatment the subject was
assigned to at any time during the study.
” The control mouthrinse was identical
to the CHX mouthrinse but without the
CHX gluconate
Quote: “more extrinsic tooth staining was
observed in the chlorhexidine group”
Comment: the higher level of tooth stain-
ing in the active group meant that partici-
pants could have worked out which group
they were in and this could have affected
their oral health behaviours and hence the
outcome. The direction of this potential
bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotes: “.. double-blind clinical trial” and
“Neither the subject nor the dental ex-
aminers knew which treatment the sub-
ject was assigned to at any time during the
study” and “gingivitis was measured inde-
pendently by two examiners” and “Prior to
the 6-month examination, a subset of sub-
jects was fitted with custom-made tooth
covers fabricated from opaque plastic. This
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procedure was included to eliminate bias
due to chlorhexidine related tooth stain.
The subjects’ tongues were also coated with
a paste mixture of food colors to eliminate
the chance of bias which could result from
stained tongues during the gingivitis exam-
inations” and “The GI and bleeding scores
recorded by each examiner were consistent
regardless of whether subjects were graded
with or without tooth covers”
Comment: the presence of tooth staining
in the CHX group did not appear to have
an effect on the measurement of gingivi-
tis. The effect of the tooth staining in the
CHX group on plaque is less clear and the
measurement of plaque could have been
affected if the examiners noticed the in-
creased tooth staining in the active group. It
is also unclear how the tooth staining may
have influenced recording of outcomes at 3
months when no tooth covers were used
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition at 6months was 50/430 (11.6%).
Attrition by group: CHX 32/219 (14.6%)
; control: 18/211 (9%). Reasons: quote:
“Most of the drop outs were people who
had moved or could not meet examination
schedules”
Comment: assuming the missing partici-
pants in 1 group had a higher mean (e.
g. gingivitis score) than those in the other
group, as the attrition rate increased, so
would the mean difference between groups
Selective reporting (reporting bias) High risk Outcome data for gingivitis, occurrence,
severity and bleeding are reported sepa-
rately for examiner A and B. We extracted
gingivitis data for examiner A only. Infor-
mation on the variance of the mean scores
for gingivitis and plaque were not reported.
We used the SDs for each clinical param-
eter at baseline so that we could include
the data in meta-analyses. Outcome data
for tooth and tongue staining and calcu-
lus (measured at 3 and 6 months) are men-
tioned in the methods and discussion but
are not reported in the results
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Other bias Unclear risk The demographics of the study population
were balanced at baseline
Gingivitis was measured independently by
2 examiners. There is no mention of train-
ing or calibration for either examiner
Grossman 1989
Methods Trial design: parallel (4 arms - 2 arms relevant to this review)
Location: assumed to beNorthfield,New Jersey, USA.Quote: “Dental office conditions”
Number of centres: 1
Study duration: recruitment period is not stated. Study duration and duration of rinsing
was 6 months
Participants Participants: quote: “adult males and females from the Northfield, New Jersey area”
Inclusion criteria: quote: “To be accepted into the study, subjects had to sign an informed
consent, have at least 16 natural teeth (including four molars), and have at least one
gingival site that bled on probing”
Exclusion criteria: quote: “Subjects were not enrolled if they had evidence of overt
periodontal disease or gross dental neglect, an unfavorable medical history, or a history
of routine antibiotic use”
Baseline gingivitis: (GI) Gp A: mean 0.5332, Gp B: mean 0.5227, Gp C: mean 0.5457,
Gp D: mean 0.4994
Age at baseline (years): Gp A: mean 36.8, Gp B: mean 37.1, Gp C: mean 35.9, Gp D:
mean 36.5. Range not reported
Gender: overall: male 166 (33%), female 336 (67%). Gp A: male 35 (31%), female 78
(69%); Gp B: male 46 (36%), female 83 (64%); Gp C: male 42 (33%), female 85 (67%)
; Gp D: male 43 (32%), female 90 (68%)
Number randomised: 502 (Gp A: 113, Gp B: 129, Gp C: 127, Gp D: 133). *Note:
unclear if this is the number initially randomised
Number evaluated: 481
Note: n by group taken from Table 1 showing initial balance for subjects completing the
study
Interventions Comparison: CHX versus phenolic essential oilsa versus Sanguinarineb versus
placebo
Gp A (n = 113): CHX 0.12%, 15 mL, twice daily, 30 seconds, 6 months
aGp B (n = 129): phenolic essential oils, 20 mL, twice daily, 30 seconds, 6 months. We
excluded this arm from our risk of bias and analysis
bGp C (n = 127): Sanguinarine, 15 mL, twice daily, 15 seconds (2 consecutive rinses
of 15 seconds twice a day), 6 months. We excluded this arm from our risk of bias and
analysis
Gp D (n = 133): placebo, 15 mL, twice daily, 30 seconds, 6 months
Prophylaxis at baseline: quote: “Following baseline examinations... all subjects received
a thorough prophylaxis”
OHI: none given. Quote: “A sodium fluoride dentifrice (Crest, Proctor and Gamble)
and soft toothbrushes were given to all subjects to be used according to individual habits”
Non-supervised rinsing
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Timing of mouthrinsing in relation to toothbrushing: not reported
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1967; gingival bleeding: GI grades
2 or 3); plaque (PI, TQH, Turesky 1970); extrinsic tooth stain (photographs of the facial
surfaces of the 12 anterior teeth in the maxilla and mandible were graded for dental stain
intensity (0-4 scale none-very dark) and coverage (0-6 scale none-heavy)); oral soft tissue
health assessed at 3 and 6 months follow-up
Funding Quote: “The support of this study by the Procter & Gamble Company, Cincinnati,
Ohio is gratefully acknowledged”
Notes Sample size calculation: not reported
Adverse effects: quote: “As would be expected, the extended use of chlorhexidine resulted
in more extrinsic dental stain than in other groups. In contrast to previously published
reports using different methods of evaluation, use of the phenolic rinse produced a
significant increase in dental stain aswell. After 3 and6months, those subjects using either
chlorhexidine or the rinse containing phenolic compounds experienced a significant
increase in stain when compared to those on placebo or the sanguinarine rinse”
Declarations/conflicts of interest: none reported, however some of the authors worked
for the Procter & Gamble Company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Subjects were stratified by age and GI score
at baseline. Quote: “Within strata, sub-
jects were randomly assigned to one of four
treatments”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors state that the study is double-
blind. Quotes: “Neither the subjects nor
the examiners knew which treatments were
assigned at any time during the study” and
“All products were supplied to the sub-
jects in identical amber pint bottles.” The
placebo rinsewas Peridexwithout theCHX
Comment: there was a significantly higher
level of staining in the CHX group com-
pared to the placebo group and this meant
that participants could have worked out
which group they were in, and this could
have affected their oral health behaviours,
and hence the outcome. The direction of
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this potential bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk At the 6-month examination each subject
was graded twice, first without a custom-
made plastic tooth cover in place and then
with the tooth cover in place. Quote: “In
addition the dorsum of the tongue was
stained brown with food color to imitate
the antimicrobial tongue stain.” Analysis of
gingivitis scores recorded with and without
masking devices revealed that the reduc-
tions for each treatment group were com-
parable
Comment: the presence of tooth staining
in the CHX group did not appear to have
an effect on the measurement of gingivitis
(our primary outcome). The effect of the
tooth staining in theCHXgroup on plaque
is less clear and the measurement of plaque
could have been affected if the examiners
noticed the increased tooth staining in the
active group. It is also unclear how the tooth
staining may have influenced recording of
outcomes at 3 months when no tooth cov-
ers were used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Total number randomised is not specified,
only number completing. Baseline data on
completers is provided inTable 1, but num-
ber does not tally with number of com-
pleters reported in the abstract. No details
are provided on number of losses to follow-
up
Selective reporting (reporting bias) High risk The covariance adjusted mean scores for
gingivitis, bleeding and plaque are pre-
sented with the covariance analysis mean
squared error term for the 3 and 6-month
exams. SD was calculated as the sqrt of the
covariance analysis mean squared error so
that these data could be included in meta-
analysis. Data onmean extrinsic tooth stain
accumulation is reported without any in-
formation on variance of the mean scores
Other bias Unclear risk No information is provided on intra- and
interexaminer reproducibility
Quote: “All groups were well-balanced at
the beginning of the study with respect to
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age, gender, initial plaque, stain, gingivitis
or bleeding grades”
Hase 1995
Methods Trial design: parallel, (3 arms - 2 are relevant to this review)
Location: not explicitly stated and authors from Sweden and Finland (setting not re-
ported)
Number of centres: 1
Study duration: recruitment period is not stated. Study duration and duration of rinsing
was 4 weeks
Participants Participants: adult males with gingivitis
Inclusion criteria: males aged 18 to 60 years; at least 25% of all gingival sites (6 sites per
tooth) having a minimum Löe & Silness GI score of 2; minimum 10 teeth per jaw; no
pocket probing depth greater than 5 mm
Exclusion criteria: people with buccal or extensive interproximal restorations reaching
beyond the axial angle of the teeth assigned for the gingival fluid flow measurement;
peoplewith crowns or bridgework; previous hypersensitivity or reactions to drugs; alcohol
or drug addiction; severe liver or renal disease; psychiatric disorders; severe disability
with multiple drug therapy; current antibiotics or antiphlogistics (including sprays with
corticosteroids) or anticholinergic antiparkinson or antidepressant treatments
Baseline gingivitis: (% sites BOP) Gp A: mean 16 (SE unclear); Gp B: mean 14 (SE
unclear); Gp C: mean 19 (SE unclear)
Age at baseline (years): Gp A: mean 41 (SE 2); Gp B: mean 41 (SE 2); Gp C: mean 39
(SE 2). Age range 18-60
Gender: males only
Number randomised: 62 (Gp A: 21; Gp B: 20; Gp C: 21)
Number evaluated: 57 (Gp A: 21; Gp B: 18; Gp C: 18)
Interventions Comparison: CHXdigluconate rinse versus delmopinol hydrochloride rinse* versus
placebo rinse
Gp A (n = 21): CHX (0.2%), 10 mL, 1 min, twice daily (morning and evening)
*Gp B (n = 20): delmopinol hydrochloride (0.2%), same routine. We excluded this arm
from our risk of bias and analysis
Gp C (n = 21): same routine using placebo (flavoured in order to imitate the sensation
of rinsing with the active solutions)
Prophylaxis at baseline: supra- and subgingival scaling
OHI: participants were instructed to brush their teeth without toothpaste
Non-supervised rinsing
Timing of rinsing in relation to toothbrushing: after brushing without toothpaste
Postrinsing instructions: not reported
Duration of treatment: 4 weeks
Outcomes Quote: “The split-mouth technique was used in the study in order to avoid interference
between various assessments.” Plaque measurements were made on the left halves of the
jaws and gingivitis measurements on the right
Gingivitis (gingival BOP, no reference), measured at 2 and 4 weeks; plaque (PI, Silness
& Löe 1964; plaque wet weight, Scheinin &Makinen 1971 - not relevant to this review)
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measured at 4 weeks
Subjective opinion of participants regarding taste, staining (teeth or tongue or both)
, clean mouth, vesicles or ulcerations or both, burning sensation, transient anaesthetic
sensation, all measured at 4 weeks on a 1 to 100 mm VAS
Gingival fluid flow (Löe & Holm Pedersen 1965) measured at 2 and 4 weeks
Safety (physical examinations including blood tests and ECG), measured before starting
treatment and within 3 weeks after the termination of the study - not relevant to this
review
Funding Not reported
Notes Sample size calculation: not reported. Quote: “.. the number of patients in this study
turned out to be too small to yield conclusive results on the effect of either delmopinol
or chlorhexidine on pre-established gingivitis”
Adverse effects: results from the safety assessment were focussed on delmopinol rather
thanCHX.Otherswere reported on aVAS scale. TreatmentwithCHXresulted according
to patients in more staining of teeth and tongue than the other 2 mouthrinses. An
anaesthetic sensation transient anaesthesia at the tip of the tongue in the oral mucosa was
experienced more clearly by the patients in the delmopinol group than by those using
placebo or CHX
Results from the VAS (estimated from Figure 3):
-Taste: CHX 58 (SE 8), placebo 23 (SE 5), delmopinol 60 (SE 8)
-Staining of teeth/tongue: CHX 38 (SE 7), placebo 9 (SE 1), delmopinol 10 (SE 5)
-Clean mouth: CHX 29 (SE 9), placebo 33 (SE 7), delmopinol 30 (SE 8)
-Vesicles and/or ulcerations: CHX 9 (SE 1), placebo 8 (SE 1), delmopinol 7 (SE 0.5)
-Burning sensation: CHX 18 (SE 5), placebo 8 (SE 0.5), delmopinol 17 (SE 6)
-Transient anaesthetic sensation: CHX 21 (SE 9), placebo 10 (SE 4), delmopinol 38 (SE
9)
Declarations/conflicts of interest: none explicitly stated but first and last authors were
employees of Biosurface AB, Malmo, Sweden
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were allocated to treat-
ment groups according to a computer-gen-
erated randomisation list, where treatment
was balanced within blocks of 6 patients”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Unclear risk Quote: “Packaging and labelling were car-
ried out at an independent Clinical Service
Department”
Comment: it is not clear whether the as-
signment of subjects to groups was carried
out at the independentClinical ServiceDe-
partment
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “double-blind” and “The various
test solutions were dispensed in identi-
cal 200 ml amber glass bottles” and “The
placebo was flavoured in order to imitate
the sensation of rinsing with the active so-
lutions”
Comment: the higher incidence of staining
in theCHX group (plus worse taste, greater
transient anaesthetic sensation, and greater
burning sensation in the active groups)
meant that participants could have worked
outwhich group theywere in and this could
have affected their oral health behaviours
and hence the outcomes. The direction of
this potential bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study is reported to be “double-blind”.
There was 1 clinical examiner.Quote: “The
split-mouth technique was used in the
study in order to avoid interference be-
tween various assessments”
Comment: the authors do not report pre-
cisely who was blinded, but even if this in-
cludes the outcomes assessor he higher inci-
dence of staining in the CHX group meant
that they could not be adequately blinded
and this could have affected the outcome
assessment. The direction of this potential
bias is not clear
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up at 4 weeks: 3/42 (7%)
. By group: placebo 3/21 (14.29%). There
were no losses from the CHX group. Rea-
sons for losses by group: placebo, 1 did not
meet the eligibility criteria and 2 took an-
tibiotics during the trial
Comment: although reasons for attrition
do not appear to be related to the particu-
lar interventions, the differential loss intro-
duces the possibility that the results may be
distorted
Selective reporting (reporting bias) Low risk Information on means and SEs are pre-
sented graphically. From correspondence
with the author/research team, additional
information was obtained on means and
SEs which enabled calculation of SDs from
SEs and inclusion of these data in themeta-
analyses
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Other bias Unclear risk No information is provided on intra- and
interexaminer reproducibility
Mean age was balanced across groups at
baseline. No statistically significant demo-
graphic differences between the groups
were recorded. Baseline BOP and mean
plaque scores appear balanced but the sta-
tistical significance of the differences is not
reported
Hase 1998
Methods Trial design: parallel (3 arms - 2 arms relevant to this review)
Location: military regiment, Halmstad, Sweden
Number of centres: 1
Study duration: recruitment period is not stated but the duration of rinsing was 6months
Participants Participants: military conscripts and military staff (adult males) with gingivitis
Inclusion criteria: males aged at least 18 years; at least 25% bleeding sites of all gingival
sites (6 sites per tooth) on BOP using a Florida-probe with a pressure of 0.25 N to the
bottom of the pocket; minimum 16 healthy teeth without crowns, bridge-work, or ill-
fitting dental restorations
Exclusion criteria: 4 or more teeth with cavities or pocket probing depth 5 mm or more;
previous hypersensitive reactions to drugs; alcohol or drug addiction; severe liver or
renal disease; psychiatric disorders; severe disability with multiple drug therapy; receiving
antibiotics within 6 weeks of the prestudy visit; antiphlogistics (including sprays with
corticosteroids) or anticholinergic drugs such as antiparkinson drugs or antidepressants
Baseline gingivitis: (% sites BOP) Gp A: mean 42.7 (SE 2.7); Gp B: mean 47.3 (SE 2.
6); Gp C: mean 43.9 (SE 2.7) (unpublished data)
Age at baseline (years): Gp A: mean 24 (SD 10); Gp B: mean 26 (SD 7); Gp C: mean
23 (SD 7)
Gender: males only
Number randomised: 140 (Table 2 page 748) (Gp A: 47; Gp B: 48; Gp C: 45)
Number evaluated (per protocol analysis): 100 (Gp A: 30; Gp B: 37; Gp C: 33)
Interventions Comparison: CHXdigluconate rinse versus delmopinol hydrochloride rinse* versus
placebo rinse
Gp A (n = 47): CHX (0.2% Hibitane Dental), 10 mL, 1 min, twice daily
*Gp B (n = 48): delmopinol hydrochloride (0.2%), same routine. We excluded this arm
from our risk of bias and analysis
Gp C (n = 45): same routine using placebo (same as Gp B but without delmopinol and
sodium hydroxide)
Prophylaxis at baseline: supra- and subgingival scaling
OHI: participants were instructed not to change their normal mechanical tooth cleaning
methods during the study
Partly supervised rinsing (mostly supervised but occasionally unsupervised due tomilitary
training)
Timing of rinsing in relation to toothbrushing: after toothbrushing
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Postrinsing instructions: not reported
Outcomes Gingivitis (gingival BOP using a Florida-probe with a pressure of 0.25 N to the bottom
of the pocket (Gibbs 1988, Löe 1967)), measured at 3 and 6 months
Plaque (PI, TQH, Turesky 1970) measured at 3 and 6 months
Calculus (Volpe-Manhold Calculus Index, Volpe 1967), measured at 3 and 6 months
Extrinsic tooth staining (Staining Index of Shaw & Murray 1977), measured at 3 and 6
months
Adverse events (transient anaesthetic sensation, taste modification, staining (teeth or
tongue or both)) were recorded
Microbiological monitoring of plaque and salivary microflora was performed during the
treatment period and also 3 months after the end of treatment for 65 patients - results
(excluding BOPwhich is presented here) presented separately - not relevant to this review
Funding Not reported
Notes Sample size calculation: based on BOP. The standard deviation was estimated to 14
and a difference of 10% units between placebo and delmopinol was considered worth
detecting. Based on a power of 95% at significance level of 5%, 50 participants per group
were required. Therefore this was not achieved
Adverse effects: transient anaesthetic sensation in the oral mucosa especially at the tip
of the tongue in delmopinol and CHX groups reached the same level of reporting at 6
months. Taste modification was commonly reported in both the delmopinol and CHX
groups. Staining of teeth or tongue was common in the CHX group
Adverse effects at 6 months (Table 4) (% participants experiencing the adverse effect):
local anaesthesia/hypoasthesia/parasthesia CHX 18%, placebo 0%, delmopinol
22%; taste loss/taste perversion: CHX 16%, placebo 0%, delmopinol 24%; discoloura-
tion teeth/discolouration tongue: CHX 13%, placebo 7%, delmopinol 8%
Declarations/conflicts of interest: nothing explicitly stated but first author was employee
of Biosurface AB, Malmo, Sweden
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were allocated to treat-
ment groups according to a computer-gen-
erated randomisation list, where treatment
was balanced within blocks of 6 patients”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Unclear risk Quote: “Packaging and labelling were car-
ried out at an independent Clinical Service
Department”
Comment: it is not clear whether the as-
signment of subjects to groups was carried
out at the independentClinical ServiceDe-
partment
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study is reported to be “double-blind”
and “The various test solutions were dis-
pensed in identical 200 ml amber glass bot-
tles.” The placebo was the same composi-
tion as the delmopinol rinse but without
the delmopinol and sodium hydroxide. It
is unclear who supervised the rinsing and if
they were blinded to allocation of the rinse
Comment: the higher level of staining of
the teeth and tongue in the CHX group
(plus greater taste modification and tran-
sient anaesthetic sensation in the active
groups) meant that participants could have
worked out which group they were in and
this could have affected their oral health
behaviours and hence the outcomes. The
direction of this potential bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study is reported to be “double-blind”.
Assessments were made by 5 trained dental
hygienists who followed the same subjects
throughout the treatment period
Comment: the authors do not report pre-
cisely who was blinded, but even if this in-
cludes the outcomes assessors the higher
level of staining of the teeth and tongue in
the CHX group meant that they could not
be adequately blinded and this could have
affected the outcome assessment. The di-
rection of this potential bias is not clear
Incomplete outcome data (attrition bias)
All outcomes
High risk At 6 months 29 participants are excluded
from the analysis in the study arms of inter-
est to this review but only 16 are reported
as withdrawn from the study with reasons
for withdrawal. Data presented here for loss
to follow-up are based on the total lost to
follow-up (n = 29)
Attrition at 6 months 29/92 (31.5%). By
group: CHX 17/47 (36.2%), placebo 12/
45 (26.7%). Reasons for loss to follow-
up: CHX: adverse events/lack of coopera-
tion, release frommilitary service; placebo:
adverse events/lack of cooperation, release
from military service, moved away
Comment: very high attrition which may
be related to type of mouthrinse and could
feasibly introduce bias in the results
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Selective reporting (reporting bias) Low risk Information on means and SEs are pre-
sented graphically. From correspondence
with the author, additional information
was obtained on means and SEs which en-
abled calculation of SDs from SEs and in-
clusion of these data in the meta-analyses
Other bias Unclear risk Assessments were made by 5 trained den-
tal hygienists who followed the same sub-
jects throughout the treatment period. A
calibration session for all assessments was
performed before the start of treatment but
the results of the calibration (Inter- and in-
traexaminer reliability) are not reported
Mean age was balanced across groups at
baseline. No statistically significant demo-
graphic differences between the groups
were recorded. Baseline BOP and mean
plaque scores appear balanced but the sta-
tistical significance of the differences is not
reported
Hoffmann 2001
Methods Trial design: parallel (5 arms - 4 arms relevant to this review)
Location: subjects were recruited from the University of Technology, Dresden. The
setting was the University Periodontal Clinic
Number of centres: 1
Study duration: the period of recruitment is not stated. Study duration and duration of
rinsing was 6 months after a run in period of 2 weeks
Participants Participants: medical students
Inclusion criteria: quote: “exhibiting good oral hygiene... Inclusion criteria were at least
20 teeth, ginigival index (GI) <1.5, and no periodontitis”
Exclusion criteria: quote: “Exclusion criteria were allergic reactions to any of the compo-
nents of any mouth rinse, antibiotic/antiphlogistic medication in the previous 8 weeks,
dental-treatment needs (e.g. due to acute carious lesions), pregnancy or any kind of sys-
temic diseases”
Baseline gingivitis: not reported but had to be <1.5 for inclusion in the study
Age at baseline (years): mean age is not reported. Age range 18-36 years
Gender: males 28/81 (34.6%), females 53/81 (65.4%)
Number randomised: 81 (CHX 0.10% 16, CHX 0.06% 17, CHX 0.06%/F 17, ASF
16, control 15)
Number evaluated: 73 (CHX 0.10% 14, CHX 0.06% 16, CHX 0.06%/F 17, ASF 15,
control 11)
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Interventions Comparison: CHX 0.10% versus CHX 0.06% versus CHX 0.06%/F versus ASF*
versus control
- CHX 0.10% (Chlorhexamed) (n = 16): 15 mL, twice daily, 30 seconds, 6 months
- CHX 0.06% (Corsodyl Zahnfleisch Fluid) (n = 17): 10 mL, twice daily, 30 seconds, 6
months
- CHX 0.06%/F (Odol med3 Depot) (n = 17): 10 mL, twice daily, 30 seconds, 6months
- *ASF (Meridol) (n = 16): 10 mL, once daily, 30 seconds, 6 months. We excluded this
arm from our risk of bias and analysis
- Control (water) (n = 15): 10 mL, twice daily, 30 seconds, 6 months
Prophylaxis at baseline: professional oral hygiene was performed 2 weeks before baseline
and at baseline teeth were polished again
OHI: quote: “At the time of selection (day -14) all participants received oral-hygiene
instructions.” However, they were then advised to follow their habitual tooth cleaning
procedure using the new toothbrush provided and their usual toothpaste for 2 weeks. At
each follow-up no attempt was made to influence participants’ other cleaning habits
Assumed to be non-supervised
Timing of mouthrinsing in relation to toothbrushing: after brushing
Outcomes Gingivitis (gingival inflammation: GI, Löe & Silness 1967); plaque (PI, Silness & Löe
1964); tooth staining (Discolouration Index (Lang & Räber 1981) assessed at day -14,
at baseline and at 1, 2, 3, and 6 months
Funding Not reported
Notes Sample size calculation: not reported
Adverse effects: Quotes: “One subject in the control group, however, had to be taken
out because of leukoplakia..., no dropout occurred due to side effects of any of the
mouthwash preparations” and in relation to tooth staining “Except the 0.06% CHX,
all test solutions showed significantly higher DI scores when compared to the control.
.. However from a clinical point of view, regarding the DI, no important differences
between the active groups were seen” and “the 0.1% resulted in stronger staining than
the ASF and the 0.06% CHX..”
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “According to their clinical param-
eters... and their sex, the 85 panellists were
distributed at random and stratified to the
5 test groups”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors report this to be a “blind clin-
ical study”
Quote: “The different test solutions were
presented in similar bottles. However each
participant got his/her specific information
regarding the use of mouthwashes from an
independent person not involved in the ex-
aminations”
The control rinse was tap water which the
authors recognise as an issue (page 93).
Quote: “After investigation it was revealed
that some of the participants of the con-
trol group did not understand the scientific
sense of rinsing with tap water”
The 0.1% CHX group rinsed with 15 mL
and the other groups rinsed with 10 mL
In relation to tooth staining, quotes: “Ex-
cept the 0.06% CHX, all test solutions
showed significantly higher DI scores when
compared to the control.. However from a
clinical point of view, regarding the DI, no
important differences between the active
groups were seen” and “the 0.1% resulted
in stronger staining than the ASF and the
0.06% CHX..”
Comment: the control group cannot be
considered blind. The higher level of stain-
ing in the active groups (ASF and CHX)
meant that participants could have worked
out that they were in 1 of the active
mouthrinse groups and this could have
affected their oral health behaviours and
hence the outcome. The direction of this
potential bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The authors report this to be a “blind clin-
ical study”
Quote: “One investigator assessed PII and
GI, while another estimated DI during the
study”
In relation to tooth staining, quotes: “Ex-
cept the 0.06% CHX, all test solutions
showed significantly higher DI scores when
compared to the control... However from
a clinical point of view, regarding the DI,
no important differences between the ac-
tive groups were seen” and “the 0.1% re-
sulted in stronger staining than the ASF
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and the 0.06% CHX..”
Comment: the higher level of staining in
the active groups meant that the outcome
assessor could not be adequately blinded
and this could have affected the outcome
assessment. Even though a separate exam-
iner was used to record PI and GI and the
DI the examiners recording the PI and GI
would still be aware of the increased tooth
staining.The directionof this potential bias
is not clear
Incomplete outcome data (attrition bias)
All outcomes
High risk 85 individuals were randomised to groups
but only 81 were “included in the study”.
The total number originally allocated to
each group (from the 85) is not reported
therefore 85 is used as the denominator for
the calculation of overall attrition and 81
is used as the denominator for calculating
the attrition in each group
Attrition at 6 months 8/85 (9.4%). Attri-
tion by group: CHX 0.1% 2/16 (12.5%)
, CHX 0.06% 1/17 (5.9%), CHX 0.06%/
F 0%, ASF 1/16 (6.3%), control 4/15 (26.
7%). Reasons for loss to follow-up: quote:
“One subject in the control group.. had to
be taken out because of leukoplakia; two
others did not show up at the last examina-
tion. Another two losses were in the 0.1%
CHXgroup, but these cases were not due to
any adverse effects. Furthermore, two losses
occurred because of antibiotic medication
during this long experimental time”
Comment: there were differential losses be-
tween the groups with a notably higher loss
in the control group. This is conjunction
with the loss of 4 participants before the
study started indicate an increased risk of
bias
Selective reporting (reporting bias) High risk Results for all outcomes were reported in
text at 3 and 6months and at all time points
in box plot diagrams. Median values only
were reported and no information on the
variance of the scores was provided
Other bias Unclear risk There is no mention of training and cali-
bration of the 2 examiners
Thereweremore females thanmales in each
group at baseline ranging from 66% in the
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control group to 70% in both 0.06%CHX
groups. It is reported that there were no
differences between the groups at baseline
for the 3 clinical parameters
No other baseline data are reported by
group
Jayaprakash 2007
Methods Trial design: parallel 3 arms
Location: Sri Laksmi Narasimha High School, Bangalore, India
Number of centres: 1
Study duration: the recruitment period is not reported. Study duration and duration of
rinsing was 6 months
Participants Participants: school children (from Sri Laksmi Narasimha High School) in Bangalore
city
Inclusion criteria: quote: “Inclusion criteria involved written informed consent from
parents, good general health of children, a minimum of 12 gradable teeth, agreement to
delay any elective dental treatment, including oral prophylaxis during the course of the
study, and the agreement to comply with the study visits and procedures”
Exclusion criteria: quote: “Exclusion criteria involved antibiotic therapy, history of early-
onset periodontitis, acute necrotizing ulcerative gingivitis, gross oral pathology, treat-
ment for cancer or seizure disorders and conditions that interfered with the examination
procedures”
Baseline gingivitis: (GI, Löe & Silness 1963) CHX 0.0536, CHX/NaF 0.0562, placebo
0.0609. SD not reported
Age at baseline (years): mean age not reported. Age range 13-16 years
Gender: not reported
Number randomised: 150 (numbers allocated to each group not reported, assumed 50
in each group at baseline)
Number evaluated: not reported
Interventions Comparison: CHX rinse versus CHX/NaF rinse versus placebo rinse
Gp A (n = assumed to be 50) CHX 0.05%: 10 mL, once daily, 6 months
Gp B (n = assumed to be 50) CHX/NaF 0.05%: 10 mL, once daily, 6 months
Gp C (n = assumed to be 50) placebo: 10 mL, once daily, 6 months
Rinse duration not reported
Prophylaxis at baseline: quote: “...no oral prophylaxis ... were given”
OHI: quote: “no ...oral hygiene instructions were given”
Supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not stated, however rinsing was
done in school so likely at a different time to toothbrushing
Postrinsing instructions: instructed not to eat or drink anything for an hour after using
the mouthrinse
Outcomes Gingivitis (gingival inflammation: GI, Löe & Silness 1963) and plaque (PI, Silness &
Löe 1964), assessed after 1, 3, and 6 months
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Funding Not reported
Notes Sample size calculation: not reported
Adverse effects: not reported
Declarations/conflicts of interest: not reported
Gingivitis data for Gp A and Gp B were combined for the main analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The studentswere randomly num-
bered 1-150 and the mouthwash samples
were numbered randomly 1-150 by the
mouthrinse manufacturer.... the students
whowere assigned with particular numbers
were provided with the mouthwash with
the same number”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Low risk Quote: “The studentswere randomly num-
bered 1-150 and the mouthwash samples
were numbered randomly 1-150 by the
mouthrinse manufacturer.... the students
whowere assigned with particular numbers
were provided with the mouthwash with
the same number”
Comment: coding of mouthrinse samples
done by manufacturer. We consider it un-
likely that participants or investigators en-
rolling participants could foresee assign-
ments
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study is reported to be “double-blind”.
The investigator supervised themouthrins-
ing performed by the students daily. No in-
formation is provided on the composition
of the placebo. Tooth staining is not men-
tioned
Comment: tooth staining is likely to have
been noticeable in both CHX groups com-
pared toplaceboduring this 6-month study
and in this situationparticipants could have
worked out which group they were in and
this could have affected their oral health be-
haviours and hence the outcome. However,
tooth staining is not reported and there
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is not enough information upon which to
base a judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study is reported to be “double-blind”.
The investigator supervised themouthrins-
ing performed by the students daily. Tooth
staining is not mentioned
Comment: tooth staining is likely to have
been noticeable in both CHX groups com-
pared toplaceboduring this 6-month study
and in this situation the outcome assessor
could have worked out which individuals
were in the placebo group and not be ad-
equately blinded. However, tooth staining
is not reported and there is not enough in-
formation upon which to base a judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number in each group at the start and
end of the study is not reported
Selective reporting (reporting bias) High risk Mean scores for gingivitis and plaque are
reported without any measure of variance
of the mean scores. We estimated the SD
for gingivitis (measured using theGI) as the
median of the SDs in the placebo/control
groups from similar studies that also used
the GI at 6 months so that we could in-
clude the gingivitis data in the meta-analy-
ses. Furthermore, adverse effects including
tooth staining are considered to be impor-
tant outcomes but are not reported
Other bias Unclear risk Outcomes were assessed by 1 individual.
Details of training and intraexaminer reli-
ability are not reported
Baseline demographic data for the partici-
pants are not reported
Jenkins 1993
Methods Trial design: parallel, 2 arms
Location: dental clinic, University of Wales College of Medicine, Cardiff, Wales, UK
Number of centres: 1
Study duration: recruitment periodnot stated. Study duration and the duration of rinsing
was 6 weeks
Participants Participants: adults with gingivitis (employees of the University of Wales College of
Medicine and South Glamorgan Area Health Authority)
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Inclusion criteria: between 18 and 60 years old; minimum 16 natural teeth; minimum
Löe & Silness GI score of 0.5
Exclusion criteria: wearing dental prosthesis or appliance; advanced restorative dental
work; medical or pharmacotherapy history affecting the study
Baseline gingivitis: (Löe & Silness GI) Gp A: mean 0.89 (SD 0.24); Gp B mean 0.88
(SD 0.21) - means read from graph (Figure 3)
Age at baseline (years): 18 to 60 (not reported by group)
Gender: not reported
Number randomised: 102 (Gp A: 51; Gp B: 51)
Number evaluated: 99 (Gp A: 49; Gp B: 50)
Interventions Comparison: (CHX gluconate + sodium fluoride (NaF) rinse) versus (placebo rinse
(without CHX or fluoride))
Gp A (n = 51): CHX (0.12%) plus NaF (100 ppm F), 15 mL, 1 min, twice daily
(morning and evening)
Gp B (n = 51): same routine using placebo
Prophylaxis at baseline: none but could request and receive at any time a polishing of
the anterior teeth if they perceived a cosmetic problem
OHI: none, but all participants received same toothbrush and fluoride toothpaste but
the use of any oral hygiene products other than those supplied was not permitted
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1963 “modified to standardize the
probing force, to elicit bleeding, using a constant pressure probe set at 25 g”); plaque
(PI, TQH, Turesky 1970); stain area (modification of Shaw&Murray stain index 1977,
stain severity graded according to colour (0 to 5 scale)), all measured at 6 weeks Problems
associatedwith the use of rinses, particularly due to stainingwere elicited by questionnaire
Funding Quote: “The authors are grateful to Smith Kline Beecham for supporting this study...”
Notes Sample size calculation: not reported
Adverse effects: quotes: “Mucosal erosions were clinically apparent in two subjects using
the active rinse and a further 2 subjects in this group reported mucosal soreness” and
“soreness tingling and taste disturbance were more commonly reported for the active
rinse and the difference between the groups reached statistical significance for taste
disturbance (P < 0.05). Significantly more subjects (49%) using the active rinse were
noted to have staining than using the control rinse (4%) (P < 0.001). Also 82% of the
active group reported staining compared with 14% in the control group (P < 0.001). 2/
3 of those reporting staining on active treatment classed it as quite bad or unacceptable,
compared to none on the control rinse (P < 0.001). In response to the question of liking
the taste of the mouthrinse coded as yes = 1, equivocal = 1.5 and no = 2 there was a clear
preference for the control rinse (P < 0.001)”
Declarations/conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “..volunteers randomly allocated to
the active or control rinse”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Low risk Quote: “..volunteers were dispensed the al-
located rinse through the Dental Hospital
Pharmacy where a sealed code-breaker was
kept”
Comment: we consider it unlikely that par-
ticipants and investigators enrolling partic-
ipants could foresee assignment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study is reported to be “double-blind”
The control rinse was identical to the
test rinse “except that it contained neither
chlorhexidine or fluoride”
Quote: “Significantly more subjects (49%)
using the active rinse were noted to have
staining than using the control rinse (4%)
(P < 0.001)”
Comment: the higher level of staining in
the CHX group meant that participants
could have worked out which group they
were in and this could have affected their
oral health behaviours and hence the out-
come. The direction of this potential bias
is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study is reported to be “double-blind”.
Quote: “Significantly more subjects (49%)
using the active rinse were noted to have
staining than using the control rinse (4%)
(P < 0.001)”
Comment: the authors do not report pre-
cisely who was blinded, but even if this in-
cludes the outcomes assessors the higher
incidence of staining in the active group
meant that they could not be adequately
blinded and this could have affected the
outcome assessment. The direction of this
potential bias is not clear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition after 6 weeks was 3/102 (2.9%)
. Attrition by group: 2/51 (3.9%) CHX
0.12%, 1/51 (2.0%) control. Reasons for
losses not broken down by group: quote:
“..three subjects withdrew, 1 for reasons of
taste of the active rinse and 2 for reasons
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unrelated to treatment”
Comment: losses are very low and not con-
sidered sufficient to have any effect on the
results
Selective reporting (reporting bias) Low risk Mean gingival and plaque data, stain area
and intensity are reported graphically with
SD (as a number on the graph). Mean
scores were estimated from graphs. Stain
area only was used in the meta-analysis
Other bias Unclear risk No information is provided on number of
examiners, examiner training or intra- or
interexaminer reproducibility so it is un-
clear whether or not there was a risk of dif-
ferential diagnostic activity. Baseline par-
ticipant characteristics (age, gender, etc)
are not reported. There was no significant
difference between the CHX and control
groups for plaque, gingivitis, proportion of
smokers and tooth staining at baseline
Jose 2015
Methods Trial design: parallel group (3 arms)
Location: Manchester and Wirral, UK, Clinical Research Facility
Number of centres: 2
Study duration: the recruitment period is not stated. Study duration and duration of
rinsing was 6 weeks
Participants Participants: healthy adults recruited from the sites’ databases and via advertisements
Inclusion criteria: at the screening visit, subjects were asked to brush as they normally
would for 1 timed minute and to expectorate into a white cup. Evidence of blood in the
expectorant or bleeding while brushing were the initial inclusion criteria. Additional in-
clusion/exclusion criteria used were:≥16 permanent, gradable teeth, including 4 molars
(protocol amendment 3: changed from 20 gradable teeth); and ≥20 or more bleeding
sites at the baseline examination
Exclusion criteria: womenwhowere pregnant, lactating or those of child bearingpotential
not practising a reliable method of contraception were excluded from the study. Subjects
who were taking antibiotics within 2 weeks before the screening visit or throughout the
study were excluded, as were those on concomitant medication that, in the opinion of
the investigator, might interfere with the outcome of the study. Other than having mild
to moderate gingivitis, subjects were to be in good oral health with no active caries, no
heavy calculus deposits and no more than 5 periodontal pockets measuring ≥5 mm in
depth (protocol amendment 3: changed from more than 3 pockets >/- 5 mm in depth)
Baseline gingivitis: (GI, Löe & Silness) Gp A: mean 1.24 (SE 0.009); Gp B: mean 1.24
(SE 0.009); Gp C: mean 1.24 (SE 0.01)
Age (years): Gp A: mean 37.8; Gp B: mean 36.2; Gp C: 36.5. Range 18-63 years. Gp
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A: range 18-62; Gp B: range 18-63; Gp C: range: 18-56
Gender: overall: male 85 (26%), female 239 (74%). Gp A: male 23 (21%), female 85
(79%); Gp B: male 30 (28%), female 79 (73%); Gp C: male 32 (30%), female 75 (70%)
Number randomised: 324 (Gp A: 108; Gp B: 109; Gp C: 107)
Number evaluated (ITT): 319 (Gp A: 105; Gp B: 109; Gp C: 105)
Interventions Comparison: (CHX rinse with alcohol + standard fluoride toothpaste) versus (CHX
rinse alcohol-free + standard fluoride toothpaste) versus (brushing alone with stan-
dard fluoride toothpaste)
Gp A (n = 108): CHX with alcohol 0.2%, 10 mL, twice daily, 1 min, 6 weeks
Gp B (n = 109): CHX alcohol-free 0.2%, 10 mL, twice daily, 1 min, 6 weeks
Gp C (n = 107): brushing alone (standard toothbrush and toothpaste)
All 3 groups brushed twice daily with full brush head of toothpaste for 1 timed minute
Prophylaxis at baseline: quote: “A complete dental prophylaxis, which included flossing
to ensure removal of all plaque, was performed by an appropriately trained professional
at the baseline visit or on a separate visit within 7 days of baseline”
OHI: the first use of the product/toothbrushing (1 timed minute) was supervised but
it is not clear whether the participants received instructions on brushing technique. We
assumed not
Rinsing was unsupervised (apart from the first use of the rinse)
Timing of mouthrinsing in relation to toothbrushing: quote: “subjects .... brushed their
teeth with a full brush head of toothpaste for one timed minute, rinsed their mouth with
water then waited for five timed minutes. After five minutes, they swished with 10 ml of
their assigned mouthwash (mouthwash groups only) for a timed one minute followed
by expectorating”
Duration of rinsing: 6 weeks
Outcomes Gingivitis (gingival inflammation: GI, Löe & Silness 1963; gingival bleeding: Gingival
Severity Index); plaque (Soparkar’s modification of the TQH, Turesky 1970, Lobene
1982); oral soft tissue examination and CHX pharmacokinetic variables (from saliva
samples) - not relevant to this review at 6 weeks follow-up
Funding The study and writing support for the manuscript were funded by GSK Consumer
Healthcare
Notes The study protocol was registered at Clinicaltrials.gov (NCT01751178) and at www.
gsk-clinicalstudyregister.com/study/RH01561#ps
Sample size calculation: not reported
Adverse effects: quote: “A total of 338 TEAEs (treatment emergent adverse events) were
recorded among174 (53.7%) of subjects (Table 4a). A large number ofTRAEs (treatment
related adverse events) were recorded in the two chlorhexidine groups where 27.8% of
subjects in the 0.2% CHX-alcohol group and 24.8% in the 0.2% CHX-alcohol-free
group reported at least one TRAE compared to only 3.7% in the brushing alone group.
Themost commonly reportedTRAEswere coated tongue, glossodynia, oral paraesthesia,
ageusia, dry mouth, oral hypoaesthesia and dysgeusia (Table 4b). There was one serious
adverse event, not related to study product and one severe event (oral paresthesia) in the
0.2% CHX-alcohol group which did resolve. The subject withdrew from the study due
to the event. A second subject withdrew from the study due to a non-TRAE”
Smoking status: overall smoker 43 (13%), non-smoker 281 (87%). Gp A: smoker 14
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(13%), non-smoker 94 (87%); Gp B: smoker 15 (14%), non-smoker 94 (86%); Gp C:
smoker 14 (13%), non-smoker 93 (87%)
Declarations/conflicts of interest: none stated, however the authors of the study are either
employees of GSK Consumer Healthcare or employees of Intertek Clinical Research
Services, Wirral and Manchester, UK which has received funding from GSK Consumer
Healthcare
Groups A and B were combined in the main analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were then stratified, ac-
cording to the study site (Manchester or
Wirral, UK), baseline number of bleeding
sites and smoking status, and randomised
into one of three treatment groups”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study is described as “examiner-
blinded”. All participants could not be
blinded due to the design of the study
which included a ’brushing alone’ group
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study is described as “examiner-
blinded”. Adverse events are described but
tooth staining was not measured or men-
tioned
Comment: tooth staining is likely to have
been noticeable in the CHX groups after
4 weeks, and in this situation the outcome
assessor could have worked out which in-
dividuals used CHX and not be adequately
blinded. However, tooth staining is not re-
ported and there is not enough information
upon which to base a judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition (ITT rather than PP): 5/324 (1.
5%). Gp A: 3/108 (2.8%), Gp B: no losses,
Gp C: 2/107 (1.9%). Reasons for loss to
follow-up: Gp A: 2 subjects with adverse
events and 1 withdrew consent; Gp C: 2
subjects withdrew consent
Comment: we do not believe the losses de-
scribed could pose a risk of bias
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Selective reporting (reporting bias) High risk All outcome stated in the methods section
are described fully in the results. Tooth
staining is considered to be an important
side effect of CHXmouthrinsing but is not
reported
Other bias Low risk Quote: “All assessments of GI were per-
formed by a single, experienced examiner.
” Repeat assessment of PI were performed
and showed excellent agreement (kappa
value for PI 0.891 (95% CI 0.884 to -0.
889)
Baseline demographics and % bleeding
sites at baseline appear balanced (Table 1)
. Mean Gingival Severity Index, GI and PI
appear similar at baseline
Joyston-Bechal 1993
Methods Trial design: parallel, 2 arms
Location: Department of Oral Medicine and Periodontology, The London Hospital
Medical College, UK
Number of centres: 1
Study duration: recruitment period is not stated. Study duration and duration of rinsing
was 8 weeks
Participants Participants: adults with gingivitis
Inclusion criteria: over 18 years old; minimum 20 natural teeth; minimum Community
Periodontal Index of Treatment Needs (CPITN) score of greater than 1 in at least 2
sextants but less than 4 in any sextant. This method of selection ensured that all subjects
showed signs of gingivitis but no pockets greater than 5.5 mm in depth were present
Exclusion criteria: medical history affecting the study; pregnancy or lactation; open
carious lesions; partial dentures; orthodontic banding; current periodontal treatment;
mentally or physically handicapped with impaired dexterity
Baseline gingivitis: not reported
Age at baseline (years): not reported. Mean age of completers at baseline (years): Gp A:
mean 30.5 (SE 2.5); Gp B: mean 32.8 (SE 2.9)
Gender (completers): overall: male 38.46%; female 61.54%. Gp A: male 6 (31.6%),
female 13 (68.4%); Gp B: male 9 (45.0%), female 11 (55.0%)
Number randomised: 47 (not reported by group)
Number evaluated: 39 (Gp A: 19; Gp B: 20)
(The text of the paper indicates that there were 20 individuals in the test group and 19 in
the control group but Table 1 reports 19 individuals in the test group and 20 in control
group. We have extracted the data presented in Table 1)
Interventions Comparison: (CHX + sodium fluoride (NaF) rinse) versus (placebo rinse (similar
colour and flavour but without CHX or fluoride))
Gp A (n = 19 analysed): CHX (0.05%) + 0.05% NaF (500 ± 25 ppm NaF), 10 mL, 30
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seconds, twice daily
Gp B (n = 20 analysed): same routine using placebo
Note: all subjects received the control mouthrinse for a run in period of 10 days to allow
familiarisation with the requirements of the study
Prophylaxis at baseline: all teethwere scaled andpolished on the first visit after assessments
OHI: subjects were asked to follow their routine dental hygiene practices, no oral hy-
giene instructions were given. All participants received the same toothbrush and fluoride
toothpaste
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: after brushing with toothpaste
and rinsing with water
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival bleeding - Cowell 1975 with the following modification: the pe-
riodontal probe was inserted into the periodontal pockets to a depth of only 1-2 mm
and not to the base of the pocket); plaque (PI, Silness & Löe 1964); degree of staining
(Lobene Stain Index 1968), all measured at 8 weeks
Funding Quote: “We are most grateful to Johnson and Johnson Limited for financial support for
this study”
Notes Sample size calculation: not reported
Adverse effects: not reported apart from tooth staining. The active rinse group had more
staining than the control group at baseline before the scale and polish and more staining
than the control at the end of the study
Smokers: by group: Gp A: 5/19 (26% of completers); Gp B: 7/20 (35% of completers)
(differences between the groups are not statistically significant)
Declarations/conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised into test and control
groups”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk Quote: “The bottles were randomly num-
bered so that neither examiners or subjects
were aware of the distribution of test or
placebo solutions”
Comment: not enough information is pro-
vided. It is not clear how the allocation se-
quence was concealed before participants
were randomised to groups
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors describe the study as “double-
blind”
Quotes: “The bottles were randomly num-
bered so that neither examiners or subjects
were aware of the distribution of the test or
placebo solutions” and “The placebo solu-
tion was of similar colour and flavour but
with no active components” and “Test and
placebo solutionswere supplied... in identi-
cal bottles..” Baseline assessments of stain-
ing were completed before the scale and
polish and there was a statistically signifi-
cant difference between the groups at base-
line with the test group having a higher
mean staining score at baseline and at the
end of the study. The authors state that
“subjects and examiners were unaware of
any staining” but it is not clear how this
information was obtained
Comment: the active rinse group hadmore
staining than the control group at baseline
before the scale and polish and more stain-
ing than the control group at the end of
the study. The higher incidence of staining
in the active group meant that participants
could have worked out which group they
were in and this could have affected their
oral health behaviours and hence the out-
come. The direction of this potential bias
is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotes: “..double-blind study..” and “The
bottles were randomly numbered so that
neither examiners or subjects were aware of
the distribution of the test or placebo solu-
tions” and “Test and placebo solutions were
supplied... in identical bottles..” Baseline
assessments of staining were completed be-
fore the scale and polish and there was a sta-
tistically significant difference between the
groups at baseline with the test group hav-
ing a higher mean staining score at baseline
and at the end of the study. The authors
state that “subjects and examiners were un-
aware of any staining” but it is not clear
how this information was obtained
Comment: the authors do not report pre-
cisely who was blinded, but even if this in-
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cludes the outcomes assessors the higher
level of staining in the active group meant
that the outcome assessors could not be ad-
equately blinded and this could have af-
fected the outcome assessment. The direc-
tion of this potential bias is not clear
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition after 8 weeks was 8/47 (17.0%)
. Losses not broken down by group and
reasons for losses not reported
Comment: assuming the missing partici-
pants in 1 group had a higher mean (e.
g. gingivitis score) than those in the other
group, as the attrition rate increased, so
would themeandifference between groups.
Also, although attrition was not reported
by group, it could be associated with the
outcomes
Selective reporting (reporting bias) High risk Mean scores are reported graphically with a
measure of variance (assumed to be SD) as
a bar on the graphs. Mean scores and SDs
were estimated from graphs so that these
data could be included in meta-analyses.
Apart from tooth staining, adverse effects
are not mentioned
Other bias Low risk Outcome assessment at the initial visit and
the final visit were by different examiners
but their interexaminer reproducibility is
reported and is adequate. There was a sta-
tistically significant difference between the
groups at baseline with the test group hav-
ing a higher mean staining score at baseline
and at the end of the study. No other ap-
parent sources of bias were identified
Lang 1998
Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: Berne, Switzerland. University Department of Periodontology and Fixed
Prosthodontics
Number of centres: 1
Study duration: the recruitment period is not stated but the duration of rinsing is 6
months
Participants Participants: males and females from a telecommunication company in Berne, Switzer-
land
Inclusion criteria: quote: “Inclusion criteria were: 18 years old and above, with≥25% of
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all gingival sites (six sites around each tooth) with bleeding upon probing (BOP) using
the Florida probe with a standardized force of 0.25N... at least 16 sound natural teeth
without crowns, bridgework or ill-fitting dental restorations”
Exclusion criteria: quote: “Exclusion criteria were: more than four pockets ≥5 mm -
third molars and the distal sites of the second molars not included, caries with cavities,
known previous hypersensitivity reactions to drugs, alcohol or drug addiction, severe
liver or renal disease, psychiatric disorders, severe disability with multiple drug therapy,
pregnancy or planned pregnancy and breast feeding. Neither should patients have been
on treatment with antibiotics within the last 6 weeks prior to the pre-study visit, nor
should they have treatment with anti-inflammatory or anti-cholinergic drugs”
Baseline gingivitis: not reported
Age at baseline (years): mean ages (SD): delmopinol 39 (8) years; CHX 40 (12) years;
placebo 43 (11) years. Range not stated
Gender: males: 85.8%, females: 14.2%
Number randomised: 162 (CHX 50, delmopinol 53, placebo 53) (Note: discrepancy
between the total number entering the study and the number included in per protocol
analysis in each group at baseline)
Number evaluated: 133 (CHX 41, delmopinol 47, placebo 45)
Interventions Comparison: CHX rinse versus delmopinol rinse* versus placebo rinse
- CHX 0.2% (Hibitane) (n = 50): 10 mL, twice daily, 60 seconds, 6 months
- *Delmopinol (Decapinol) (n = 53): 10 mL, twice daily, 60 seconds, 6 months. We
excluded this arm from our risk of bias and analysis
- Placebo (n = 53): 10 mL, twice daily, 60 seconds, 6 months
Prophylaxis at baseline: quote: “After baseline, but before starting to rinse, the patients
underwent professional cleaning of the teeth including supra- and subgingival scaling”
OHI: none. Quote: “..patients were instructed to brush their teeth as usual... No oral
hygiene instructions were given before or during the study”
Partially supervised rinsing (supervised on weekdays, unsupervised at weekends)
Timing of mouthrinsing in relation to toothbrushing: if rinsing took place in connection
with toothbrushing the rinsing should always be performed after themechanical cleaning
of the teeth
Outcomes Gingivitis (gingival inflammation: GI, Löe 1963; BOP, bleeding yes/no Florida probe
to bottom pocket, Löe 1967, Gibbs 1988); plaque (PI, Silness & Löe 1964); calculus
(Calculus Surface Index / Calculus Surface Severity Index (CSI/CSSI), Ennever 1961,
Conroy 1968); stain (DI, Lang & Räber 1981) assessed at baseline, 3 months and 6
months
Oral soft tissue examined and adverse effects reported during the study
Funding Not reported
Notes Sample size calculation: quote: “The sample size calculation was based on BOP. The
standard deviation was estimated to 14 and a difference of 10 percentage units between
placebo and delmopinol was considered worth detecting. The calculation which was
based on a power of 95% and a significance level of P = 0.05, resulted in a required
number of 50 subjects in each treatment group”
Adverse effects: quote: “No serious adverse events were reported in this study... one of the
most frequent adverse events when rinsing with delmopinol was a transient anaesthetic
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sensation in various parts of the oral mucosa. This event was reported as ’anaesthesia
local’ or ’paraesthesia’... Taste affection (’taste loss’, ’taste perversion’) was reported by
35% and 20% of the patients in the delmopinol group after 3 and 6months, respectively.
..The patients in the chlorhexidine group.. reported this event to the same extent, namely
35% after 3 months and 14% after 6 months.. Staining of the teeth and tongue was
reported more often in the chlorhexidine group than the delmopinol group both at the
3-month (69% and 20% of patients in each respective group) and 6-month examination
(88% and 16% in each respective group)... The most common adverse events causing
withdrawal from treatment by the 10 patients rinsing with chlorhexidine were, staining
of teeth, especially black staining (four patients), altered or bad taste (four patients),
burning tongue (three patients) and black or brown staining of the tongue (three patients)
. The patient rinsing with delmopinol who was withdrawn from treatment due to adverse
events reported anaesthesia of mucous membrane, burning tongue, dry mouth and taste
alteration. The withdrawal patient in the placebo group due to adverse events reported
bad taste, stomach problems, and tendency to vomit”
Declarations/conflicts of interest: none declared, however, 2 of the authors are associated
with Biosurface Pharma AB
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were allocated to treat-
ment groups, according to a computer-gen-
erated randomization list, where treatment
was balanced within blocks of six patients”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Unclear risk Quote: “Packaging and labelling were car-
ried out at an independent Clinical Service
Department in Uppsala, Sweden. The var-
ious test solutions were dispensed in iden-
tical 200 ml amber glass bottles”
Comment: it is not clear whether the as-
signment of subjects to groups was carried
out at the independentClinical ServiceDe-
partment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors report the study to be “double-
blind”
Quote: “The various test solutionswere dis-
pensed in identical 200 ml amber glass bot-
tles.” The placebo consisted “of the vehicle
of active delmopinol solution except del-
mopinol and sodium hydroxide”
Quote: “..rinsing with chlorhexidine re-
sulted in statistically significantly more
staining than both placebo and del-
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mopinol”
Comment: while every effort was made to
ensure blinding of participants and per-
sonnel, the higher level of staining of the
tongue and teeth in the CHX group rela-
tive to the placebo groupmeant that partic-
ipants could have worked out which group
they were in and this could have affected
their oral health behaviours and hence the
outcomes. The direction of this potential
bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The authors report the study to be “double-
blind”
Quotes: “The various test solutions were
dispensed in identical 200ml amber glass
bottles” and “Assessments were performed
by trained examiners....E ach examiner
scored one type of parameter for all patients
throughout the whole study” and “Rins-
ing with chlorhexidine resulted in statisti-
cally significantly more staining than both
placebo and delmopinol” and “The deci-
sions to exclude patients/visits were taken
before breaking the blind”
Comment: while every effort was made to
ensure blinding of outcome assessment, the
higher level of staining of the tongue and
teeth in the CHX group relative to the
placebo group meant that outcome asses-
sors could not be adequately blinded and
this could have affected the outcome assess-
ment. The direction of this potential bias
is not clear
Incomplete outcome data (attrition bias)
All outcomes
High risk Different data are reported for the num-
ber of patients excluded from the per pro-
tocol analysis (Table 2) and the number
of patients withdrawn from treatment and
reasons for withdrawal (Table 3). After 6
months (Table 2) 17/103 (16.5%) ran-
domised participants were not included in
the final analysis. Atrition by group (Table
2): CHX 9/50 (18%), placebo 8/53 (15.
1%). Total number of patients withdrawn
from treatment and reasons forwithdrawals
by group: CHX (n = 13, 24%) adverse
events (n = 10) and refusal to cooperate (n
= 3); placebo (n = 2, 4%), adverse events (n
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= 1), refusal to cooperate (n = 1)
Comment: there are a high proportion of
losses between the groups whichever source
of information (Table 2/Table 3) is used
and reasons for losses are unbalanced be-
tween the groups with a high proportion of
the withdrawals in the CHX group due to
adverse effects
Selective reporting (reporting bias) Low risk All outcomes stated in the methods section
are adequately reported in the results sec-
tion
Information on means and SEs are pre-
sented graphically. From correspondence
with the author, additional information
was obtained on means and SEs which en-
abled calculation of SDs from SEs and in-
clusion of these data in the meta-analyses
Other bias Unclear risk Although this is an experienced research
team and the examiners were trained there
is no mention of calibration or reliability of
outcome measurements
Mean age appears similar across groups.
86% of participants were male but the
breakdown for gender across groups is not
reported
16 and 10 patients in theCHXand placebo
groups were using medication at the time
of the premedical screening (P < 0.001)
Assessments of GI were performed directly
after BOP. Quote: “thus the possible trau-
matising effect on the gingival crevice may
have affected the results of the GI”
Lopez-Jornet 2012
Methods Trial design: parallel (2 arms)
Location: pensioners home in Murcia, Spain
Number of centres:1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 30 days (with a 7-day whitening period before rinsing commenced)
Participants Participants: volunteers from a pensioners home in Murcia, Spain of either sex over 65
years of age
Inclusion criteria: subjects of either sex over 65 years of age, with removable dentures
who upon clinical examination did not present manifestations of oral candidiasis in any
of its forms (pseudomembranous, erythematous, hyperplastic or angular cheilitis). None
of the subjects had used adhesives for
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their dentures, and all of them were in good general health
Exclusion criteria: smokers, patients with hypersensitivity or allergy to the study medica-
tion, individuals with oral mucosal disease and antibiotic treatment in the month prior
to inclusion in the study
Baseline gingivitis: (GI Löe & Silness 1963) Gp A: CHX 1.51 ± 0.98, Gp B: placebo 1.
33 ± 0.69
Age at baseline (years): mean 75 years (range 65-94)
Gender: total: 30 males (42.86%), 40 females (57.14%); CHX: 12 males (34.29%) and
23 females (65.71%); placebo: 18 males (51.43%) and 17 females (48.57)
Number randomised: 70 (Gp A: 35; Gp B: 35)
Number evaluated: 70 (Gp A: 35; Gp B: 35)
Interventions Comparison: CHX rinse versus placebo control rinse
Gp A: CHX 0.2%, 10 mL, 30 seconds, twice daily for 30 days
Gp B: placebo, same formulation without CHX 10 mL, 30 seconds, twice daily for 30
days
Prophylaxis at baseline: none
OHI: both groups were supplied with a whitening rinse and toothbrush with 0.05%
fluoridated toothpaste, and an instruction sheet and were advised to use for 7 days prior
to recording of Silness & Löe PI and GI. They also received instructions for accurate
oral hygiene
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: quote: “the subjects avoided rinsing with water, eating and
drinking for 30 min following use of the mouthwash. They also received instructions for
accurate oral hygiene, and were required to avoid all products other than those included
in the study”
Outcomes Gingivitis (ginginal inflammation: GI Löe & Silness 1963) and plaque (Silness & Löe
1964) measured after 30 days of rinsing
Microbiological evaluation ofCandida albicans (colony forming units) measured at base-
line and after 30 days of rinsing - not relevant to this review
Adverse effects: teeth/dentures/tongue staining, mucosal desquamation, alteration in
taste sensation after 15 and 30 days of rinsing
Funding Not reported
Notes Sample size calculation: not reported
Adverse effects: quote: “In reference to the presence of adverse effects, examination of the
oral cavity in both groups revealed statistically significant differences after 15 days and
at the end of the study (30 days) in terms of staining of the teeth/dentures and tongue.
No patient showed mucosal desquamation or alterations in taste sensation”
Number and % of participants with observed adverse effects at 30 days (Table 4): tongue
staining: CHX: 11, 31.43%; placebo 8, 22.86. Denture/dental staining: CHX 2, 5.71%;
placebo: 3, 8.57%
Non-smokers
Declarations/conflicts of interest: not reported
The GI data appear to be transposed (Table 2 page 295). These were entered in the
opposite order in RevMan for analysis
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “randomized” and “the random-
ization list in the form of envelopes was
generated using specifically designed soft-
ware”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk Quotes: “randomized” and “the random-
ization list in the form of envelopes was
generated using specifically designed soft-
ware” and “both products were supplied in
identical opaque bottles”
Comment: mentioning the use of en-
velopes does not provide enough infor-
mation to make a judgement. It is not
clear how the allocation sequence was con-
cealed before participants were randomised
to groups
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quotes: “double-blind” and “both prod-
ucts were supplied in identical opaque bot-
tles” and “..both groups revealed statisti-
cally significant differences after 15 days
and at the end of the study (30 days) in
terms of staining of the teeth/dentures and
tongue.” The placebo was the same formu-
lation as the test rinse without the CHX
Comment: there does not appear to be sig-
nificantly more staining in the CHX group
compared to the placebo group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotes: “double-blind” and “All examina-
tions were carried out by a single experi-
enced examiner..” and “..both groups re-
vealed statistically significant differences af-
ter 15 days and at the end of the study (30
days) in terms of staining of the teeth/den-
tures and tongue”
Commet: there does not appear to be sig-
nificantly more staining in the CHX group
compared to the placebo group
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up
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Selective reporting (reporting bias) Low risk All outcomes stated in the methods section
are reported in the results section
Other bias Unclear risk The groups were comparable at baseline in
relation to age, gender, gingivitis, plaque
and colony forming units of Candida albi-
cans
Denture/dental staining was not reported
at baseline only at 15 and 30 days
Quote: “All examinations were carried out
by a single experienced examiner..”
Comment: intraexaminer reliability is not
reported
Lucas 1999
Methods Trial design: parallel (4 arms - 2 arms are relevant to this review)
Location: Faculty of Dentistry, National University of Nordeste, Corrientes, Argentina
Number of centres: 1
Study duration: the duration of recruitment is not stated. 2 studies are reported; the
first was a 21-day study with participants abstaining from all oral hygiene practices, the
second involved the use of CHX or placebo rinse as an adjunct to oral hygiene for 180
days. The second study is relevant to this review and is described here
Participants Participants: dental students
Inclusion criteria: quote: “All had at least sixteen natural teeth including four molars”
Exclusion criteria: quote: “Patients affected with systemic diseases or on regular medica-
tion were excluded”
Baseline gingivitis: mean CHX: 0, mean placebo: 0
Age at baseline (years): mean: 20.9 years. Range not reported
Gender: male: 40%, female: 60%
Number randomised: 20 (Gp A: 10; Gp B: 10)
Number evaluated: not explicitly stated but appears to be 20 (Gp A: 10; Gp B: 10)
Interventions Comparison: CHX mouthrinse versus placebo mouthrinse
Gp A (n = 10): CHX mouthrinse (0.12%), 10 mL, twice daily, 180 days
Gp B (n = 10): placebo mouthrinse, 10 mL, twice daily, 180 days
The rinse duration was not reported
Prophylaxis at baseline: quote: “Clinically normal gingiva was obtained by scaling, pol-
ishing and twice daily tooth brushing”
OHI: quote: “Each subject participating in this study received regular instruction and
reinforcement in personal plaque control procedures throughout the entire pre-experi-
mental phase”
Assumed to be non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: participants were advised to rinse
30 min after toothbrushing
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Outcomes Gingivitis (gingival inflammation: GI, Löe & Silness 1967, severity (mean GI score of
entire mouth) and occurrence (proportion of surfaces with GI ≥ 1), gingival bleeding:
GI, Löe & Silness 1967 (proportion of surfaces with GI 2 or 3 )); plaque (PI, Greene &
Vermillion 1964); effect on oral tissues assessed at days 0, 90 and 180 days
Funding Not reported
Notes Sample size calculation: not reported
Adverse effects: quotes: “The clinical and tactile evaluation of the oral tissues throughout
the experimental period did not reveal any type of irreversible pathology associated with
the use of chlorhexidine” and “some extrinsic staining was observed in the chlorhexidine
group”
Non-smokers
Declarations/conflicts of interest: none stated. CHX and placebo were kindly supplied
by the Microsules Bernabo Laboratories, Buenos Aires, Argentina
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “The subjects were divided at ran-
dom into four groups..”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Neither the experimental subjects
nor the examiner responsible for the clinical
examinations had previous knowledge of
what group was rinsing with chlorhexidine
or placebo. (Chlorhexidine and placebo
rinses were kindly supplied... with a code
number which was revealed after all data
collection was completed and tabulated.)”
The composition of the placebo is not re-
ported. Although tooth staining and cal-
culus were not measured the authors note
that “...some extrinsic tooth staining was
observed in the chlorhexidine group” and
that “Supraginigival calculi were more nu-
merous in the group using chlorhexidine..
”
Comment: the higher level of tooth stain-
ing and calculus in the CHX group meant
that participants could have worked out
which group they were in and this could
have affected their oral health behaviours
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and hence the outcome. The direction of
this potential bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Neither the experimental subjects
nor the examiner responsible for the clinical
examinations had previous knowledge of
what group was rinsing with chlorhexidine
or placebo. (Chlorhexidine and placebo
rinses were kindly supplied... with a code
number which was revealed after all data
collection was completed and tabulated)”
Although tooth staining and calculus were
notmeasured the authors note that “...some
extrinsic tooth staining was observed in the
chlorhexidine group” and that “Supragini-
gival calculi were more numerous in the
group using chlorhexidine..”
Comment: the higher level of staining in
the CHX group meant that the outcome
assessor could not be adequately blinded
and this could have affected the outcome
assessment. The direction of this potential
bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk The number of participants at 180 days
is not explicitly stated and the results are
presented by number of surfaces not num-
ber of participants. However it would seem
that all the participants were included in
the data at 180 days
Selective reporting (reporting bias) High risk Reported numbers represent number of
surfaces of teeth evaluated rather than the
number of individuals. No measures of
variance were reported for either outcome.
We estimated the SD for gingivitis (mea-
sured using the GI) as the median of the
SDs in the placebo/control groups from
similar studies that also used the GI at
6 months so that we could include the
gingivitis data in the meta-analyses. Tooth
staining is considered to be an important
outcome but this is not adequately reported
Other bias Unclear risk Training of the single examiner and intraex-
aminer reliability are not mentioned. The
baseline demographics of the groups are not
reported. There is no way to determine if
the groups were similar at the start of the
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study
Navarro 1998
Methods Trial design: parallel, (3 arms - 2 arms relevant to this review)
Location: periodontal clinic, State University of Ponta Grossa, Brazil
Number of centres: 1
Study duration: recruitment period is not stated but the study duration and duration of
rinsing was 42 days
Participants Participants: males aged between 14 and 35 years
Inclusion criteria:minimum16permanent teeth (including 4molars, but excluding teeth
with excessive decay, crowns, bridges, fixed orthodontic appliances, and third molars)
Exclusion criteria: active periodontal disease; deposits of calculus; use of antibiotics, anti-
inflammatory, and antibacterial or other drugs that could influence the study
Baseline gingivitis (completers): (GI, Löe & Silness 1963) Gp A: mean 0.043 (SE 0.021)
; Gp B: mean 0.065 (SE 0.026); Gp C: mean 0.040 (SE 0.022)
Age at baseline (years): range 14 to 35 (not reported by group)
Gender: males only
Number randomised: not reported
Number evaluated: 31 (Gp A: 9; Gp B: 11; Gp C: 11)
Interventions Comparison: CHX digluconate rinse versus Plantago major rinse* versus placebo
rinse
Gp A (n = 9 analysed): CHX (0.12%), 10 mL, once daily before bedtime
*Gp B (n = 11 analysed): same routine using Plantago major. We excluded this arm from
our risk of bias and analysis
Gp B (n = 11 analysed): same routine using placebo
Prophylaxis at baseline: participants had a thorough prophylaxis to remove plaque
OHI: yes. Quote: “Patients were subjected to a regular program of plaque control not
supervised and instructed to swish 10 mls of solution daily before bedtime”
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival inflammation: GI, Löe & Silness 1963); plaque (PI, TQH, Turesky
1970); tooth staining (Lobene Stain Index 1968); adverse events (soft tissues), measured
at 3 and 6 weeks follow-up
Funding Not reported
Notes Sample size calculation: not reported
Adverse effects: 1 person reported epithelial desquamation in the CHX group
Declarations/conflicts of interest: unclear from translation
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomized into
treatment group, positive control or
placebo”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Patients were randomised into
treatment group, positive control or
placebo following a double-blind scheme.”
A placebo solution containing distilled wa-
ter, essence, colorant and methylparaben 0.
1% was used. The CHX group showed an
increase in tooth pigmentation at 6months
Comment: the higher incidence of staining
in the CHX group meant that participants
could have worked out which group they
were in and this could have affected their
oral health behaviours and hence the out-
come. The direction of this potential bias
is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Patients were randomised into
treatment group, positive control or
placebo following a double-blind scheme.”
No further information is given
Comment: the authors do not report pre-
cisely who was blinded, but even if this in-
cludes the outcomes assessors the higher
level of staining in the active group meant
that they may not have been adequately
blinded and this could have affected the
outcome assessment. The direction of this
potential bias is not clear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The number of patients at baseline is not
reported. Results are presented for the 31
subjects who completed the study. The au-
thors report that 1 person in the CHX
group left the study between 0 and 21 days
due to epithelial desquamation and that
others withdrew from the study citing per-
sonal reasons
Comment: not enough information is pro-
vided
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Selective reporting (reporting bias) Low risk All outcomes stated in the methods section
are adequately reported in the results sec-
tion. We calculated SDs from the SEs re-
ported so that the data could be included
in meta-analyses
Other bias Unclear risk No information is provided on intra- and
interexaminer reproducibility. At baseline
the groups had similar mean gingivitis,
plaque and staining scores
Overholser 1990
Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: assumed to be at the Baltimore College of Dental Surgery, Dental School,
University of Maryland at Baltimore, USA
Number of centres: 1
Study duration: the recruitment period is not stated. Study duration and duration of
rinsing was 6 months
Participants Participants: healthy adults
Inclusion criteria: quote: “...with pre-existing plaque and gingivitis but without clinical
evidence of periodontitis... minimum of 20 sound natural teeth, and plaque and gingival
indexmeans≥1.95 as determinedby theTureskymodificationof theQuigley-Hein index
(Turesky et al 1970) and the modified gingival index (Lobene et al 1986), respectively”
Exclusion criteria: quote: “Grossly carious, fully crowned, orthodontically banded, abut-
ment and third molar teeth were not included. Subjects with gross oral pathology or on
antibiotic, antibacterial or anti-inflammatory therapy were excluded from the study”
Baseline gingivitis: (modified GI) Gp A: mean 2.28 (SE 0.03); Gp B: mean 2.23 (SE 0.
02); Gp C: mean 2.22 (SE 0.02)
Age of completers (years): Gp A: mean 29.24; Gp B: mean 29.17; Gp C: mean 28.62.
Range 21-62 years. Gp A: range 23-62; Gp B: range 21-47; Gp C: range 22-42
Gender (completers): overall: male 44 (36%), female 80 (65%). Gp A: male 22 (54%)
, female 19 (46%); Gp B: male 10 (24%), female 31 (76%); Gp C: male 12 (29%),
female 30 (71%)
Number randomised: 128 (not reported by group)
Number evaluated: 124 (Gp A: 41; Gp B: 41; Gp C: 42)
Interventions Comparison: CHX rinse versus Listerine rinse* versus control
Gp A (n completers = 41): CHX (Peridex) 0.12%,15 mL, twice daily, 30 seconds, 6
months
*Gp B (n completers = 41): Listerine, 20 mL, twice daily, 30 seconds, 6 months. We
excluded this arm from our risk of bias and analysis
Gp C (n completers = 42): control (flavoured coloured 5% hydroalcohol solution), 20
mL, twice daily, 30 seconds, 6 months
Prophylaxis at baseline: quote: “Following the baseline examination, patients were given
a complete prophylaxis to remove all plaque, calculus and extrinsic stain”
OHI: none given. Subjects followed their usual oral hygiene and dietary habits, but were
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instructed to refrain from using other mouthrinses
Rinsings were supervised twice daily on weekdays
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: quote: “Subjects were instructed not to rinse, eat or drink for
30 mins following use of the test rinses”
Outcomes Gingivitis (gingival inflammation: modified GI, no reference; gingival bleeding: Inter-
dental Bleeding Index, Caton & Polson 1985); plaque (TQH, Turesky 1970 ); extrinsic
tooth stain (Lobene Stain Index, Lobene 1968); supragingival calculus (Volpe 1965,
Manhold 1965, Volpe 1967); assessed at 3 and 6months follow-up. Plaque was collected
for microbiological study (reported separately)
Funding Quote: “This study was supported by a grant from the Warner-Lambert Company”
Notes Sample size calculation: not reported
Adverse effects: no abnormal soft tissue findings were noted in any group. Quote: “The
PX group, showed significant increases (P<0.001) in stain at 3 and 6 months, compared
to its baseline”
Smokers: by group: Gp A: 5/41 (12%); Gp B: 2/41 (5%); Gp C: 6/42 (14%)
Declarations/conflicts of interest: none stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Subjects were assigned to groups
according to a computer-generated ran-
dom code”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Product was dispensed in coded amber bot-
tles. Product code was not disclosed to the
examiners or recorded on case report forms
Comment: we consider it unlikely that par-
ticipants and investigators enrolling partic-
ipants could foresee assignment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors state that the study is dou-
ble-blind. The products were dispensed in
coded amber bottles. The placebo control
was a flavoured, coloured 5% hydroalcohol
solution. Personnel dispensing rinses did
not participate in any other aspect of the
study. Quote: “Significantly greater (P<0.
01) extrinsic stain was observed in the PX
group when compared to LA and the con-
trol at both 3 and 6 months..”
Comment: the higher level of tooth stain-
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ing in the CHX group compared to the
other 2 groups meant that participants
could have worked out which group they
were in and this could have affected their
oral health behaviours and hence the out-
come. The direction of this potential bias
is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The authors state that the study is dou-
ble-blind. The products were dispensed
in coded amber bottles. Quotes: “Product
code was not disclosed to the examiners or
recorded on case report forms” and “Sub-
jects refrained from all oral hygiene and use
of experimental products on examination
days until after the examination were com-
pleted in order to eliminate possible bias
due to product odor” Separate forms were
used to record the outcome data at each
examination interval and the examiner did
not have access to case report forms during
the study. To assure maximum objectivity
and reproducibility, 1 examiner was used
for gingivitis, bleeding and plaque indices
and another for the stain and calculus in-
dices. Quote: “Significantly greater (P<0.
01) extrinsic stain was observed in the PX
group when compared to LA and the con-
trol at both 3 and 6 months..”
Comment: despite the considerable efforts
made to ensure blinding of outcome assess-
ment, the higher level of staining in the
CHX group meant that the outcome as-
sessor could not be adequately blinded and
this could have affected the outcome assess-
ment. The direction of this potential bias
is not clear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition at 6months 4/128 (3.1%). Losses
not broken down by group. 3 subjects were
lost because they were unable to comply
with the supervised rinsing schedule. 1 sub-
ject in the Peridex group dropped out when
stain began to form
Comment: attrition is very low over the 6
months of the study
Selective reporting (reporting bias) Low risk All outcomes stated in the methods section
were addressed in the results with the ex-
ception of microbiological plaque analysis
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which is reported in a separate paper. We
calculated SDs from the SEs reported so
that the data could be included in meta-
analyses
Other bias Low risk Efforts were made to standardise examiners
in a series of sessions inwhich the examiners
reviewed the clinical criteria in each index
prior to the initiation of the study. There
is no indication of inter- or intraexaminer
reliability. To assure maximum objectivity
and reproducibility, 1 examiner was used
for gingivitis, bleeding and plaque indices
and another for the stain and calculus in-
dices
Comment: the standardisation sessions and
use of 1 examiner to record each in-
dex would reduce inter- and intraexaminer
variability
Quote: “The treatment groups were well-
balanced with respect to age and smoking
status.” The authors report a statistically
significant imbalance in the distribution of
sexes within groups. The treatment-by-sex
interaction was investigated and was not
significant. The groups appear balanced for
gingival index, plaque scores, bleeding in-
dex, supragingival calculus and tooth stain-
ing at baseline (although no P values for the
differences are reported)
Pereira 2011
Methods Trial design: parallel (3 arms - 2 are relevant to this review)
Location: Department of Periodontics, Dental School, University of Fortaleza, Brazil
Number of centres: 1 centre
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 90 days
Participants Participants: adult subjects from the University of Fortaleza
Inclusion criteria: quote: “Bleeding index > 20%, presence of at least 20 natural teeth
and absence of supragingival calculus and other plaque retentive factors, such as carious
cavity and restoration excess”
Exclusion criteria: quote: “Participants with medical disorders and under antimicrobial
therapy, as well as smokers, pregnant women and individuals presenting a probing depth
> 3 mm were excluded from the trial”
Baseline gingivitis: bleeding index, Gp A (0.27 ± 0.02); Gp B (0.22 ± 0.04); Gp C (0.
23 ± 0.07)
Age at baseline (years): mean age not reported. Age range 27 to 42 years (not reported
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by group)
Gender: male: 15 (50%), female: 15 (50%) (not reported by group)
Number randomised: 30 (Gp A: 10; Gp B: 10 and Gp C: 10)
Number evaluated: 30 (Gp A: 10; Gp B: 10 and Gp C: 10)
Interventions Comparison: CHX rinse versus Ocimum gratissimum rinse* versus placebo control
rinse
Gp A (n = 10): CHX (0.12%) 10 mL, 1 min, 3 times daily
*Gp B (n = 10): Ocimum gratissimum (Og) 10 mL, 1 min, 3 times daily. We excluded
this arm from our risk of bias and analysis
Gp C (n = 10): triethanolamine (qsp), alcohol, water (qsp), nipagin (0.2%), glycerine
(2.5%), aspartame (qsp); 10 mL, 1 min, 3 times daily
Prophylaxis at baseline: quote: “After the initial examination all teeth of each subject
were polished with a pumice and flossed to eliminate plaque remnants”
OHI: quote: “A personal ’kit’ containing a new toothbrush, a commercial dentifrice
with no anti-inflammatory properties and tests or control mouth rinses was given to all
participants. They were instructed to brush their teeth for 1 minute, three times a day,
using their habitual technique”
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: quote: “After each brushing the
participants rinsed with one of the formulations”
Postrinsing instructions: not reported
Duration of rinsing: 90 days
Outcomes Gingivitis (bleeding index (BOP), Ainamo & Bay 1975); plaque (TQH, Turesky 1970)
; hard and soft oral tissues for the presence of any adverse reaction. All at 90 days
Funding Quote: “Source of support - Nil”
Notes Sample size calculation: not reported
Adverse effects: quote: “The tests mouth rinses had a good acceptance and did not show
formations of abscess, ulceration or allergic reactions. However, three volunteers from
CLX (CHX) group reported pigmentation and temporary taste disturbance”
Non-smokers
Declarations/conflicts of interest: quote: “Conflict of interest: none declared”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The participants were assigned to groups
by random permutations of 3
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “double-blind” and “The bottles
were previously coded to warrant that nei-
ther the examiner nor the participants
knew their content, which was revealed by
the pharmacist only after the study was
completed” and “.. three volunteers from
CLX (CHX) group reported pigmentation
and temporary taste disturbance”
The control mouthrinse had the same for-
mulation as the test rinses but without
CHX or Og
Comment: the higher incidence of pigmen-
tation and temporary taste disturbance in
the CHX group meant that participants
could have worked out which group they
were in (or that they were in 1 of the active
mouthrinse groups) and this could have af-
fected their oral health behaviours
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotes: “double-blind” and “The bottles
were previously coded to warrant that nei-
ther the examiner nor the participants
knew their content, which was revealed
by the pharmacist only after the study
was completed” and “.. three volunteers
from CLX (CHX) group (30%) reported
pigmentation and temporary taste distur-
bance”
Comment: the higher incidence of pigmen-
tation in the CHX group meant that the
outcome assessor could have worked out
that these 3 participants were in the CHX
group and could not be adequately blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “All participants completed the
trial”
Selective reporting (reporting bias) High risk All outcomes stated in the methods section
are adequately reported in the results sec-
tion. Tooth staining is considered to be an
important outcome but is not adequately
reported
Other bias Unclear risk Quote: “At the beginning, there was no sta-
tistically significant difference between the
control and tests groups with respect to PLI
and BI (P>0.05) means”
No information is provided on the balance
of demographic factors (age, gender etc) be-
161Chlorhexidine mouthrinse as an adjunctive treatment for gingival health (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pereira 2011 (Continued)
tween groups
Quote: “A single, previously calibrated ex-
aminer scored the BI and the plaque Index
(PLI).” No information on intra- and inte-
examiner reliability (from the previous cal-
ibration) are reported
Rahmani 2006
Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: assumed university dental school, Iran
Number of centres: 1
Study duration: quote: “This study was conducted in 2003 for 10 months.” Duration
of rinsing and end point for outcome assessment was 6 weeks
Participants Participants: those attending for treatment in the periodontal clinic of the University of
Mashhad, Dental school, Iran
Inclusion criteria: non-pregnant, no risk factors for increased susceptibility to bacterial
endocarditis, no currentmedications or antibiotics within past 2months, moderate adult
periodontitis, at least 1 site with 4 mm or more pocket depth among their 6 lower
anterior teeth and without a history of professional periodontal treatment within the
past 6 months
Exclusion criteria: not reported
Baseline gingivitis: (GI Löe & Silness 1963) Gp A: mean 1.97 (SD 0.19); Gp B: mean
1.78 (SD 0.39); Group C mean 1.85 (SD 0.14)
Age at baseline (years): mean age and age range are not reported
Gender: not reported
Number randomised: 30 (Gp A: 10; Gp B: 10; Gp C: 10)
Number evaluated: not reported
Interventions Comparison: (ultrasonic SRP with 0.2% CHX delivered through the tip of ultra-
sonically activated scaler)* versus (CHX 0.2%+ ultrasonic SRPwith distilled water)
versus (ultrasonic SRP using distilled water alone)
*Gp A (n = 10): ultrasonic SRP with 0.2% CHX delivered through the tip of ultrason-
ically activated scale after baseline examination and 1 week later (data from this group
were not extracted). We excluded this arm from our risk of bias and analysis
Gp B (n = 10): CHX (0.2%) + ultrasonic SRP with distilled water after baseline exami-
nation and 1 week later: CHX twice daily, 6 weeks
Gp C (n = 10): ultrasonic SRP using distilled water alone after baseline examination and
1 week later
Prophylaxis at baseline: quote: “Following the baseline measurements, the entire denti-
tion was ultrasonically scaled and irrigated according to the treatment protocol for each
group. After one week the same procedure was repeated for all groups until all supra-
and subgingival calculus was removed according to both visual and tactile inspection”
OHI: quote: “At the first visit all patients were instructed tooth brushing using the
Bass technique and interdental cleaning aids were given and given similar toothbrushes
and toothpastes.” OHI was reinforced 1 week after the baseline measurements and
throughout the study
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Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival inflammation: GI Löe & Silness 1963, gingival bleeding: Gingival
Bleeding Index, Ainamo & Bay 1975); plaque (PI Silness & Löe 1964) measured at 6
weeks
Probing pocket depth (6 sites on each tooth using a William’s periodontal probe)
CAL (6 sites on each tooth using aWilliam’s periodontal probe) also measured at 6 weeks
- not relevant to this review
Funding Quote: “Research Vice-Chancellor of Mashhad University of Medical Sciences who
supported the study by a grant”
Notes Sample size calculation: not mentioned
Adverse effects: not reported
Declarations/conflicts of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomly divided into three treat-
ment groups”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants were not blinded.
The different interventions meant that par-
ticipants would know which group they
were in and this could have affected their
oral health behaviours and hence the out-
come. The direction of this potential bias
is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment not men-
tioned but, even if there was outcome asses-
sor blinding, it is likely that there would be
more staining in theCHX group thus com-
promising any blinding. However, tooth
staining is not mentioned in the report so
it remains unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up are not reported.Num-
ber of participants analysed at 6 weeks is
not reported
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Selective reporting (reporting bias) High risk Adverse effects are not mentioned. Tooth
staining is considered to be an important
side effect of CHX mouthrinsing but this
is not reported
Other bias Unclear risk Number of examiners and training of ex-
aminers not mentioned
Quote: “There were no significant differ-
ences in the clinical parameters between
test and control groups at the baseline ex-
amination”
Sanz 1989
Methods Trial design: parallel, 2 arms
Location: private practice limited to periodontics, Los Angeles, USA
Number of centres: 1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 6 weeks
Participants Participants: patients with periodontitis who required osseous periodontal surgery
Inclusion criteria: diagnosis of AAPClass III periodontitis; requiring periodontal osseous
surgery; able to perform adequate mechanical plaque control
Exclusion criteria: patients receiving osseous grafts, pregnancy; diabetes or other
metabolic diseases; receiving systemic antibiotics within 3 months of the start of the
study; receiving anti-inflammatory or other systemic drugs capable of altering clinical
response
Baseline gingivitis: not reported
Age at baseline (years): not reported
Gender: not stated
Number randomised: 40 (Gp A: 19; Gp B: 21)
Number evaluated: 38 (Gp A: 17; Gp B: 21)
Interventions Comparison: CHX gluconate rinse versus placebo rinse used postperiodontal
surgery
Gp A (n = 19): CHX (0.12%), 15 mL, 30 seconds, twice daily
Gp B (n = 21): same routine using placebo
Prophylaxis at baseline: full-mouth SRP followed by osseous periodontal surgery in 1
quadrant (periodontal dressing then placed over entire surgical area). All participants
received prescription for Tylenol II as pain relief
OHI: prior to surgery patients received instructions in oral hygiene
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: after usual oral hygiene practices
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival inflammation: modified Löe & Silness GI 1963 using a pressure
sensitive probe standardised at 30 g inserted to the bottom of the sulcus - reported as
GI severity (overall mean scores) and GI bleeding (scores 2 and 3), measured at 4 and
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6 weeks (not measured at 1 and 2 weeks due to early healing of wound masking the
inflammatory status of the gingiva))
Plaque (Silness & Löe PI 1964 - reported as plaque accumulation and visible plaque),
measured at 1, 2, 4 and 6 weeks
Extrinsic stain (stain/no stain scored from oral photographs of mandibular facial anterior
teeth), measured at 6 weeks
Participants’ subjective assessment (questionnaire on whether or not they liked the as-
signed rinse including taste and compliance), unclear when measured (reported at 1 and
2 weeks)
Periodontal status (pocket probing depth and CAL), measured at 4 and 6 weeks - not
relevant to this review
Postsurgical soft tissue health (epithelialisation - poor/moderate/good), measured at 1,
2, 4 and 6 weeks - not relevant to this review
Pain (participants’ own perception on 0 to 10 scale and by medication consumption
pain on soft palpation with periodontal probe - none/mild/severe), measured at 1, 2, 4
and 6 weeks - not relevant to this review
Funding Quote: “This study was supported in part by a grant from the Procter & Gamble Com-
pany, Cincinnati, OH”
Notes Sample size calculation: not reported
Adverse effects: no case of desquamation was seen with the use of 0.12% CHX rinse
in this study. 24% of participants (n = 5) in the CHX group disliked the taste of the
mouthrinse mainly because of a ’burning sensation’ and ’a too strong taste’. Quote: “In
the CHX group, 47.1% of the patients who did not have stain at the time of surgery
developed light extrinsic dental stain” compared to 4.7% of patients in the placebo group
Declarations/conflicts of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “they were randomly assigned to
receive either chlorhexidine or placebo
mouthrinse via a computer-generated ran-
dom list”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The authors describe the study as double-
blind. The control mouthrinse was identi-
cal to the testmouthrinse but without CHx
gluconate. Quote: “ ...at 6 weeks, 47.1%
(8/17) of the patients in the CHX group
and 4.7% (1/21) in the placebo group
showed light stain” (on the lower anterior
teeth)
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Comment: the higher level of tooth stain-
ing in the CHX group meant that partici-
pants could have worked out which group
they were in and this could have affected
their oral health behaviours and hence the
outcome. The direction of this potential
bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The authors describe the study as double-
blind. Clinical examinations were carried
out. Quotes: “..by an independent clini-
cal examiner (not the periodontist) at pre-
surgery, 1, 2, 4, and 6 weeks post-surgi-
cally” and “.. at 6 weeks, 47.1% (8/17) of
the patients in the CHX group and 4.7%
(1/21) in the placebo group showed light
stain” (on the lower anterior teeth)
Comment: the higher level of staining in
the CHX group meant that the outcome
assessor could not be adequately blinded
and this could have affected the outcome
assessment. The direction of this potential
bias is not clear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition at 6 weeks overall 2/40 (5%). At-
trition by group: CHX 2/19 (11%), all par-
ticipants in the control group contributed
data for the main outcomes of gingivitis,
plaque and staining
2 subjects were lost from the CHX group
due to concomitant systemic antibiotic use.
In the placebo group, 1 subject did not have
a PD and PAL measurements taken and
was excluded from analysis of these mea-
surements
Comment: attrition is low (although all
losses were from the CHX group) and do
not appear to be related to the intervention
Selective reporting (reporting bias) High risk Nomeasures of variance were reported.We
estimated the SD for gingivitis (measured
using the GI) as the median of the SDs
in the placebo/control groups from similar
studies that also used the GI at 4-6 weeks
so that we could include the gingivitis data
in the meta-analyses
Other bias High risk Training and calibration of the 1 (indepen-
dent) clinical examiner is not mentioned.
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Baseline demographics of the subjects are
not described. With the exception of visi-
ble plaque and stain, the baseline balance
of the outcomes is not reported
Staining was poorly reported but appears
that 94.2% of CHX group had staining at
baseline compared to 33.3% in placebo
Sanz 1994
Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: unclear
Number of centres: 1
Study duration: recruitment period not stated but the duration of the intervention was
6 months
Participants Participants: adults with a history of established gingivitis
Inclusion criteria: aged 18 to 65 years; minimum 16 natural teeth (including 4 anterior
teeth in each jaw); GI Löe & Silness 1967 score greater than 0.7
Exclusion criteria: evidence of periodontitis (probing pockets greater than 4 mm); med-
ical history that would interfere with participation; evidence of gross oral neglect
Baseline gingivitis: (GI Löe & Silness 1967) Gp A: mean 1.57; Gp B: mean 1.53
Age at baseline (years): Gp A: mean 33.5 (range 18 to 60); Gp B: mean 33.6 (range 18
to 65)
Gender: Gp A: male 29 (41%), female 42 (59%); Gp B: male 29 (43%), female 39
(57%)
Number randomised: 139 (Gp A: 71; Gp B: 68) (208 including ineligible arm)
Number evaluated: 130 (Gp A: 66; Gp B: 64) (191 including ineligible arm)
Interventions Comparison: (CHX digluconate rinse + gum care dentifrice) versus (placebo rinse
+ gum care dentifrice) versus (placebo rinse + CHX digluconate and zinc lactate
dentifrice)*
*We excluded this arm from our risk of bias and analysis
Gp A (n = 71): CHX (0.12%) rinse + gum care dentifrice containing allantoin, urea,
azulene, medical soap, calcium carbonate, and sodium monofluorophosphate 1100 ppm
(Blend-a-med Parodontoseschutz), quantities and time not specified, twice daily
Gp B (n = 68): as above but the rinse was a placebo
Prophylaxis at baseline: quote: “After this examination all subjects received a dental
prophylaxis in order to remove completely existing plaque and calculus”
OHI: new toothbrushes were available to all participants but no OHI was provided
Non-supervised rinsing
Timing of rinsing in relation to toothbrushing: immediately after toothbrushing
Postrinsing instructions: none
Duration of treatment: 6 months
Outcomes Gingivitis: gingival inflammation (using a modification of GI Löe & Silness 1967. An
electronic periodontal pressure sensitive probe standardised at 25 g was used and mean
scores were reported); gingival bleeding (GI = 2 was recorded when bleeding appeared
on probing, measured at 3 and 6 months)
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Plaque (PI Silness & Löe 1964), measured at 3 and 6 months
Calculus (Volpe-Manhold Calculus Index (Volpe 1965)), measured at 3 and 6 months
Tooth staining (facial surfaces of the 12 anterior teeth. Comparisons made against a
photographic standard; overall stain measured on a 0 to 6 scale; each tooth measured on
a 0 to 4 scale for stain intensity; each tooth measured on a 0 to 6 scale for stain coverage)
, measured at 3 and 6 months
Oral soft tissue health attributable to product use, measured at 3 and 6 months
Funding Rinse and dentifrice supplied by Procter & Gamble
Notes Sample size calculation: not reported
Adverse effects: quote: “No adverse effects on oral soft tissues were seen and no deviations
from clinically normal were recorded which would indicate possible side effects which
are related to any of the products used in this study.” There was a statistically significant
increase in calculus for the positive control group compared with the control group.
Quote: “Statistically significant more overall staining, more intense staining and stain
coverage per tooth were detected for the positive control group and the experimental
group compared with the control group”
Declarations/conflicts of interest: nothing explicitly stated but 2 of the 5 authors were
employees of Procter & Gamble (manufacturers of the products being tested)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were then stratified by
plaque Index (PII) and gingival index (GI)
and gender and they were randomly as-
signed to one of the three treatment groups”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study is described as double-blind.The
control mouthrinse was Peridex without
the CHX gluconate. Quotes: “All products
were supplied in identical tubes and bot-
tles, respectively” and “Statistically signif-
icant more overall staining, more intense
staining and stain coverage per tooth were
detected for the positive control group and
the experimental group compared with the
control group”
Comment: the higher level of staining in
the CHX group than the placebo group
meant that participants could have worked
outwhich group theywere in and this could
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have affected their oral health behaviours
and hence the outcome. The direction of
this potential bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study is described as double-blind.
Quotes: “The oral examinations were car-
ried out by 2 examiners each carrying
out the same examinations throughout the
study” and “Statistically significant more
overall staining, more intense staining and
stain coverage per tooth were detected for
the positive control group and the exper-
imental group compared with the control
group”
Comment: the authors do not report pre-
cisely who was blinded, but even if this in-
cludes the outcomes assessors the higher
level of staining in the CHX group meant
that the outcome assessor could not be ad-
equately blinded and this could have af-
fected the outcome assessment. The direc-
tion of this potential bias is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition at 6 months overall 17/208 (8.
2%). Attrition by group: CHX + gum care
dentifrice 5/71 (7%); placebo + gum care
dentifrice 4/68 (6%); placebo + experimen-
tal dentifrice 8/69 (11.6%)
Reason for losses: quote: “Reasons not as-
sociated with product use”
Comments: losses are low and although ex-
act reasons for losses are not described and
not brokendownby group they are thought
unlikely to have affected the outcome
Selective reporting (reporting bias) High risk Themain outcome data presented in tables
were broken down into subgroups with low
and high initial gingivitis. The overall out-
come data were presented only in graphs.
No measures of variance were reported.
We estimated the mean scores for gingivitis
from the graphs. We estimated the SD for
gingivitis (measured using the GI) as the
median of the SDs in the placebo/control
groups from similar studies that also used
theGI at 6months so that we could include
the gingivitis data in the meta-analyses
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Other bias Unclear risk Training and calibration of the 2 examiners
is not mentioned. Quote: “All treatment
groups were well balanced at the beginning
of the study with regard to age, gender, ini-
tial plaque and initial gingivitis index scores
as summarized in table 1”
Segreto 1986
Methods Trial design: parallel, 3 arms
Location: University of Texas Health Science Centre, San Antonio, Texas, USA
Number of centres: 1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 3 months
Participants Participants: adult volunteers from the University of Texas Health Science Centre at San
Antonio Texas and towns people from San Antonio
Inclusion criteria: minimum 16 natural teeth (including 4 molars)
Exclusion criteria: existing soft tissue damage caused by ill-fitting appliances; advanced
periodontal disease; dental neglect needing prompt professional attention; unfavourable
medical history; regular use of antibiotics; pregnancy
Baseline gingivitis (fromTable 8): (GI Löe 1967) Gp A: mean 0.6745 (SD not reported)
; Gp B: mean 0.6468 (SD not reported); Gp C: mean 0.6750 (SD not reported)
Age at baseline (years) (from Table 7): Gp A: 31.29 (range 18 to 61); Gp B: mean 32.
33 (range 18 to 60); Gp C: mean 30.74 (range 18 to 60)
Gender: overall: male 234 (39%), female 363 (61%). Gp A: male 80 (40%), female 122
(60%); Gp B: male 81 (41%), female 118 (59%); Gp C: male 73 (37%), female 123
(63%)
Number randomised: 597 (Gp A: 202; Gp B: 199; Gp C: 196)
Number evaluated: 454 (Gp A: 144; Gp B: 157; Gp C: 153)
Interventions Comparison: 0.2% CHX gluconate rinse versus 0.12% CHX gluconate rinse versus
placebo rinse
Gp A (n = 202): CHX (0.2%), 15 mL, 30 seconds, twice daily
Gp B (n = 199): CHX (0.12%), 15 mL, 30 seconds, twice daily
Gp C (n = 196): same routine using placebo
Prophylaxis at baseline: after the baseline examination all subjects received a thorough
prophylaxis
OHI: participants followed usual habits but were given fluoride toothpaste and soft
toothbrush
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: none reported
Outcomes Gingivitis: gingival inflammation measured using GI (Löe 1967) and Papillary Marginal
Gingivitis Index (PMGI) (de la Rosa & Sturzenberger 197, visual inspection only - no
probing); severity (mean extent of disease) and occurrence (meaning mean % gingival
sites with GI or PMGI score ≥ 1). Gingival bleeding measured using GI (Löe 1967)
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mean % of gingival sites with a GI score ≥ 2)
Plaque (plaque disclosed using standard red dye and quantity on facial and lingual
surfaces assessed using TQH PI (Turesky 1970))
Oral soft tissue effects (visual-tactile examination of the oral mucosa), measured at 6
weeks and 3 months
All measured at 6 weeks and 3 months
Funding Quote: “The support of this study by the Procter & Gamble Company, Cincinnati,
Ohio, is gratefully acknowledged”
Notes Sample size calculation: not reported
Adverse effects: quote: “With the exception of some subjective comments, there were no
differences in the systematic examination of oral soft tissues which would indicate that
adverse effects were produced by either chlorhexidine mouthrinse in comparison to the
placebo mouthrinse.” 12% of subjects in the 0.2% group dropped out because they did
not like the mouthrinse, compared to 4% of the 0.12% group and 1% of the placebo
subjects
The results are reported separately for examiner A and examiner B. Data for examiner
A only were extracted and used in the analysis
Declarations/conflicts of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “..they were stratified by age, sex,
and gingivitis severity. Within strata they
were assigned to one of three treatment
groups by random permutations of 3”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study is described as double-blind.
Quotes: “Neither the subject nor the den-
tal examiners knew to which treatment the
subject was assigned at any time during
the study” and “.. the mouthrinses were
supplied in pint bottles with child-resis-
tant closures.”The placebomouthrinsewas
identical in composition to the 2 active
mouthrinses but without the CHX
Comment: tooth staining is likely to have
been noticeable in the CHX groups after 3
months, therefore participants could have
worked out which group they were in and
this could have affected their oral health be-
haviours and hence the outcome. However,
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tooth staining is not reported and there
is not enough information upon which to
base a judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study is described as double-blind.
Quote: “Neither the subject nor the den-
tal examiners knew to which treatment the
subject was assigned at any time during the
study”
Comment: tooth staining is likely to have
been noticeable in the CHX groups after 3
months, and in this situation the outcome
assessor could have worked out which in-
dividuals used CHX and not be adequately
blinded. However, tooth staining is not re-
ported and there is not enough information
upon which to base a judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition at 3 months overall 143/597
(24%) and by group: CHX (0.2%) 58/202
(29%), CHX (0.12%) 42/199 (21%), con-
trol 43/196 (22%)
Reasons for losses: most were people who
had moved or could not meet examina-
tion schedules, 12% of subjects in the 0.
2% group dropped out because they did
not like the mouthrinse, compared to 4%
of the 0.12% group and 1% of the placebo
subjects
Selective reporting (reporting bias) High risk Nomeasures of variance are reported so the
data could not be included in meta-analy-
ses. Furthermore, tooth staining is consid-
ered to be an important side effect of CHX
mouthrinsing but this is not reported
Other bias Unclear risk Training and calibration of the 2 examiners
is not mentioned. We used data for exam-
iner A only. Intraexaminer reliability is not
reported for this examiner
Baseline demographic and clinical data for
the 3 groups appear balanced
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Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: Virginia, USA (type of setting not reported assumed to be a university dental
school)
Number of centres: not reported
Study duration: recruitment period is not reported. Study duration and duration of
rinsing was 3 months
Participants Participants: healthy adults with gingivitis
Inclusion criteria: minimum age of 18 years; Löe & Silness 1967 GI score of 2 or 3;
general good health
Exclusion criteria: advanced periodontal disease (AAP IV or greater); use of antibiotics
in the 90 days before the start of the study; need for antibiotics premedication; anterior
facial restorations; use of a daily antigingivitis rinse in the 3 months before the start of
the study; pregnancy; smoker; poor general health
Baseline gingivitis: not reported. Quote: “Randomization produced similar equivalent
baseline groups that exhibited overall GI scores of 2 or 3”
Age at baseline (years): mean 25 (SD 7.67) (not reported by group but “Randomization
produced similar equivalent baseline groups”)
Gender: male n = 35 (57%), female n = 28 (43%) (not reported by group but “Ran-
domization produced similar equivalent baseline groups”)
Number randomised: 63 (not reported by group)
Number evaluated: 60 (not reported by group)*
*Text states: “final sample size of 60 (30 in each group)” - which does not make sense as
there were 3 groups. Assumed final sample size 20 in each group (21 at baseline)
Interventions Comparison: CHX rinse versus herbal rinse* versus placebo rinse
Gp A (n = not reported, assumed 21): CHX (0.12%), half an ounce (15 mL), length of
time not specified, twice daily (morning and evening)
*Gp B (n = not reported, assumed 21): same as above with herbal rinse (filtered spring
water, vegetable glycerin, echinacea, goldenseal, calendula, aloe, bloodroot, grapefruit
seed extract, citric acid, spearmint oil, peppermint oil and cinnamon). This arm is not
included in our risk of bias or analysis
Gp C (n = not reported, assumed 21): same as above with placebo rinse
Prophylaxis at baseline: none. Quote: “no prophylaxis was conducted prior to study
initiation”
OHI: all groups given same soft toothbrush and whitening fluoride toothpaste, and
instructed to follow their usual oral hygiene routine (but not to use any other oral rinse
during the study)
Partially supervised rinsing: as described in methods it appears to be non-supervised rins-
ing but the authors state that “A research assistant was responsible for product allocation
and supervising rinsing procedures”
Timing ofmouthrinsing in relation to toothbrushing: after usualmechanical oral hygiene
routine
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival inflammation: GI Löe 1967 and BOP), measured at 1, 2 and 3
months
Plaque (PI Silness & Löe 1964), measured at 1, 2 and 3 months
Oral soft tissue health, measured at baseline, 1, 2 and 3 months
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Funding Not reported
Notes Sample size calculation: not reported
Adverse effects: not reported
Non-smokers
Declarations/conflicts of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “participants were randomized to
one of three product groups”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk Quotes: “participants were randomized to
one of three product groups” and “Indi-
viduals were identified by code numbers
throughout the study” and “A research as-
sistant was responsible for product alloca-
tion and supervising rinsing procedures”
Comment: not enough information is pro-
vided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quotes: “product identifiers were removed
from all containers” and “The examiner
and participants were blinded to product
allocation” and “A research assistant was re-
sponsible for product allocation and super-
vising rinsing procedures.” It is not clear if
the research assistant was blinded to alloca-
tion of mouthrinses
Comment: the participants rinsed for 3
months. No information is provided about
the ingredients in the placebo rinse. Tooth
staining, although likely in theCHXgroup,
is not mentioned in the report. The re-
search assistant who was responsible for
product allocation appears to have also
supervised the mouthrinsing which may
have compromised personnel blinding (al-
though the methods imply that the rinsing
was unsupervised so whether the rinsing
was supervised/unsupervised is not clear)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quotes: “The examiner and participants
were blinded to product allocation.” Indi-
viduals were identified by code numbers
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throughout the study. Participants were
given fluoride whitening toothpaste “to de-
crease the possible side effects of staining
and lessen examiner bias”
Comment: tooth staining is likely to have
been noticeable in the CHX groups after 3
months, and in this situation the outcome
assessor could have worked out which in-
dividuals used CHX and not be adequately
blinded. However, tooth staining is not re-
ported and there is not enough information
upon which to base a judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition at 3 months overall 2/42 (4.8%),
1 participant from each group. Reasons for
loss to follow-up: personal reasons
Comment: attrition is low and there are no
differential group losses
Selective reporting (reporting bias) High risk The GI was recorded but the mean GI was
not reported. Instead the change in propor-
tion of GI scores of 2 or 3 compared to
placebo was reported. No data are reported
for probing pocket depth. Quote: “statisti-
cal analysis showed no statistically signifi-
cant change in PPD in any of the groups.
” Tooth staining is considered to be an im-
portant side effect of CHX mouthrinsing
but this is not reported
Other bias Unclear risk Quote: “A single calibrated dental hygienist
was used to collect all data”
Comment: no information provided on in-
traexaminer reproducibility
Quotes: “Randomization produced similar
equivalent baseline groups” and “Random-
ization produced similar equivalent base-
line groups that exhibited overall GI scores
of 2 or 3”
Insufficient information is provided upon
which to judge the baseline balance of de-
mographic factors
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Stookey 2005
Methods Trial design: parallel (4 arms - 2 arms are relevant to this review)
Location: USA, setting ”clinical site“
Number of centres: 1
Study duration: the recruitment period is not reported but the duration of rinsing was
6 months
Participants Participants: healthy adults
Inclusion criteria: at least 18 years of age with minimum 16 gradable natural teeth with 4
molars and in good general health. Subjects also had to have a minimum baseline whole
mouth average GI score 0.50, at least 10 bleeding sites and a maximum baseline plaque
score of 3
Exclusion criteria: quote: ”Patients were unable to continue in the study for the following
reasons: participation in any other dental study; use of other oral care products; evidence
of rampant caries, obvious periodontal disease, chronic neglect requiring urgent treat-
ment, history of any medical diseases that may interfere with the study (e.g. bleeding
tendencies, infectious diseases) wearing removable or fixed orthodontic devices; use of
antibiotics or immunosuppressives within 1week prior to baseline, 3- or 6-month exams;
use of antiinflammatory drugs or analgesics within 48 hours of baseline, 3- or 6-month
exam; known hypersensitivity to chlorhexidine or tartrazine; oral prophylaxis outside of
study; use of oral chlorhexidine products or participation in an oral rinse study within
3 months prior to baseline examination; pregnancy/nursing; noncompliance by missing
more than five consecutive supervised rinses and/or more than 15% of all supervised
rinses
Baseline gingivitis: (Löe & Silness GI) Gp A: mean 0.794 (SE 0.025); Gp B: mean 0.
792 (SE 0.018); Gp C mean 0.800 (SE 0.018); Gp D mean 0.814 (SE 0.020)
Age at baseline (years): Gp A: mean 32.9; Gp B: mean 33.7; Gp C: mean 33.8; Gp D
mean 34.3. Gp A: range 18-53; Gp B: range 18-59; Gp C: range 18-57; Gp D range
18-66
Gender: number in each group not reported. Male: Gp A: 60%; Gp B: 63%; Gp C:
59%; Gp D: 62%. Female: Gp A: 40%; Gp B: 37%; Gp C: 41%; Gp D: 38%
Number randomised: 366 (Gp A: 49; Gp B: 97; Gp C: 103; Gp D: 102)
Number evaluated (6 months): 298 (Gp A: 40; Gp B: 82; Gp C: 90, Gp D: 86)
Interventions Comparison: CHX rinse versus cetylpyridinium chloride rinse (CPC 0.075%)a
versus cetylpyridinium chloride rinse (CPC 0.1%)b versus placebo
Gp A (n = 49): CHX (Peridex) 0.12%: 15 mL, twice daily, 30 seconds, 6 months
aGp B (n = 97): CPC 0.075%: 15 mL, twice daily, 30 seconds, 6 months. This arm was
excluded from our risk of bias and analysis
bGp C (n = 103): CPC 0.10%: 15 mL, twice daily, 30 seconds, 6 months. This arm was
excluded from our risk of bias and analysis
Gp D (n = 102): placebo (of CPC): 15 mL, twice daily, 30 seconds, 6 months
Prophylaxis at baseline: quote: “approximately 1 week following the baseline examina-
tion, qualifying subjects received a thorough dental prophylaxis”
OHI: supervised toothbrushing but unclear if there was OHI
Quote: “From Monday to Friday, subjects came to the clinical site each morning for
supervised brushing and rinsing.. Subjects were instructed to follow the same instructions
in the evening and on the weekends”
Timimg of mouthrinsing in relation to toothbrushing: quote: “Subjects were instructed
to brush with a 0.243% sodium fluoride toothpaste (Crest Cavity Protection) using a
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disposable Anchor toothbrush, rinse with water, then rinse with 15 ml of product for 30
seconds”
Outcomes Gingivitis (GI Löe & Silness 1963 to measure gingival inflammation and bleeding (GI
scores 2 or 3)); plaque (TQH PI, Turesky 1970); oral soft tissue examinations; assessed
at 3 and 6 months follow-up
Funding The test formulations (CPC) were provided by the Procter & Gamble Company
Notes Sample size calculation: not reported
Adverse effects: quote: “There were no serious adverse events reported during the study
that were deemed related to the test products. OST examinations showed that subjects
rinsing with the chlorhexidine treatment had significantly more ”tongue lesion“ com-
ments at month 3 than those rinsing with either the CPC rinse or the placebo rinse.
There were no significant differences between either of the CPC rinse groups and the
placebo group in the number of subjects that had OST comments at 3 or 6 months”
Declarations/conflicts of interest: nothing explicit stated, however 2 of the co-authors
(Dr Witt and Dr Gibb) were employees of the Procter & Gamble Company at the time
the study was published
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “Subjects were randomly assigned
to... four treatments, balancing for gender
and baseline mean GI score..” and “The
randomizationwas performed such that the
sample size per group ratio was 2:2:2:1
with 1 representing the chlorhexidine rinse
group”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quotes: “double-
blind” and “all mouthrinses were packed in
identical amber bottles.” The control rinse
was a placebo of CPC rinse
Quote: “From Monday to Friday, subjects
came to the clinical site each morning for
supervised brushing and rinsing.. Subjects
were instructed to follow the same instruc-
tions in the evening and on the weekends”
Comment: it is not clear if the personnel su-
pervised the rinsing were blinded to prod-
uct allocation. Tooth staining is likely to
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have been noticeable in the CHX group af-
ter 6 months, therefore participants could
have worked out which group they were
in and this could have affected their oral
health behaviours and hence the outcome.
However, tooth staining is not reported
and there is not enough information upon
which to base a judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “double-blind”
Comment: tooth staining is likely to have
been noticeable in the CHX group after 6
months, and in this situation the outcome
assessor could have worked out which in-
dividuals used CHX and not be adequately
blinded. However, tooth staining is not re-
ported and there is not enough information
upon which to base a judgement
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition at 6 months all arms: 68/366 (18.
6%). Attrition by group: CHX 9/49 (18%)
, control 16/102 (15.7%). Reasons for at-
trition: (not broken down by group) pro-
tocol violation (NSAIDS) (n = 15); medi-
cation use outside study protocol (n = 41
at 3 months, 17 at 6 months); not avail-
able (n = 10 at 3 months, 17 at 6 months)
; non-compliance (n = 5 at 3 months and
5 at 6 months); adverse event (n = 5 at 3
months and 8 at 6 months); non-study re-
lated medical reasons (n = 2 at 3 months
and 6 at 6 months)
Comment: attrition was high and some
losses were possibly related to the interven-
tion
Selective reporting (reporting bias) High risk We calculated SDs from the SEs reported
so that the data could be included in
meta-analyses. Tooth staining is considered
to be an important side effect of CHX
mouthrinsing but this is not reported
Other bias Unclear risk Number of examiners not mentioned.
Training and calibration of examiners not
mentioned
Subjects balanced at baseline with regard to
gender, age, gingival health and plaque
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Methods Trial design: parallel (3 arms - 2 arms are relevant to this review)
Location: New Jersey, USA (type of setting not reported)
Number of centres: not reported
Study duration: recruitment period is not reported. Study duration and duration of
rinsing was 5 weeks
Participants Participants: adults with gingival bleeding
Inclusion criteria: adults with gingival bleeding; non-contributory medical history; not
taking antibiotics; minimum of 20 teeth; minimum total gingival bleeding score of 10
(bleeding points recorded on 4 areas of 6 teeth (0 = no bleeding; 1 = bleeding) so that
maximum score would be 24)
Exclusion criteria: not reported
Baseline gingivitis: (gingival bleeding score on 0 to 24 scale as described above) Gp A:
mean 14.46 (SD 3.13); Gp B: mean 13.57 (SD 3.84); Gp C: mean 13.77 (SD 1.64)
Age at baseline (years): mean 46 (range 21 to 71) (not reported by group but “no statistical
differences between the ages of the groups (P = 0.23 for one way and over)”)
Gender: (reported for completers only) males 23 (57.5%), females 17 (42.5%) (not
reported by group but “sex was sufficiently randomized (P = 0.92 by chi square test)”)
Number randomised: 42 (not reported by group)
Number evaluated: 40 (Gp A: 13; Gp B: 14; Gp C: 13)
Interventions Comparison: CHX gluconate rinse versus baking soda/hydrogen peroxide tooth-
paste* versus control (usual care)
Gp A (n = 13 analysed): CHX (0.12%), 15 mL, 30 seconds, twice daily
*Gp B (n = 14 analysed): baking soda/hydrogen peroxide toothpaste used instead of
usual toothpaste. We excluded this arm from our risk of bias and analysis
Gp C (n = 13 analysed): usual toothpaste
Prophylaxis at baseline: not reported, assume none
OHI: all groups given OHI, same toothbrush and dental floss, and instructed to brush
and floss 3 times per day
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: twice per day after brushing and
flossing
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival bleeding on probing on a 0 to 24 scale - a score of 12 would mean
that 50% of sites bled), measured at 5 weeks
Signs of pathology of oral tissues
Funding Not clear. The authors acknowledged the support of the University of Medicine &
Dentistry of New Jersey on the project
Notes Sample size calculation: not reported
Adverse effects: quote: “There was no evidence of pathology of the oral tissues of any
subject”
Declarations/conflicts of interest: not stated
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomly assigned
to each group”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants is not stated and
not possible with the interventions being
tested and this could have affected partici-
pants’ oral health behaviours and hence the
outcome. The direction of this potential
bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “the same examiner scored all sub-
jects and did not know the group each sub-
ject was assigned to at any time”
Comment: blinding attempted but, as
there is no information on tooth staining,
it is not clear whether or not it would be
possible for the outcome assessor to remain
blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition at 5 weeks 2/42 (4.8%). Losses
not broken down by group. Reason for
losses: did not return at 5 weeks
Comment: it is not clear which groups the
participants were lost from, however losses
are low and are considered unlikely to have
affected the outcome
Selective reporting (reporting bias) High risk Tooth staining is considered to be an im-
portant side effect of CHX mouthrinsing
but this is not reported
Other bias Unclear risk 1 examiner scored all subjects which elim-
inates interexaminer variability as a source
of bias. However, there is no mention of
training or intraexaminer reproducibility
The groups are balanced at baseline for
bleeding points, age and sex
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Turkoglu 2009
Methods Trial design: parallel, 2 arms
Location: Department of Periodontology, Ege University, Izmir, Turkey
Number of centres: 1
Study duration: quote: “subjects were recruited…over a period of 1 year between 2006
and 2007.” Study duration and duration of rinsing was 4 weeks
Participants Participants: adults with gingivitis attending the Department of Periodontology, Ege
University
Inclusion criteria: 18 to 45 years old; gingivitis associated with dental plaque; no sign of
destructive periodontal disease; clinical attachment loss less than 3 mm; minimum 20
teeth (teeth that were grossly carious fully crowned or extensively restored, orthodontic
banded, abutments, or third molars were not included in the tooth count)
Exclusion criteria: use of tobacco products; current or historic serious systemic disease
affecting immune response (e.g. diabetes, immune disorders, hepatitis, HIV); use of
antibiotics, anti-inflammatory, or immunosuppressive drugs within 3months of the start
of the study; periodontal therapy within 3 months of the start of the study; pregnancy
or lactation; use of oral contraceptives
Baseline gingivitis: (Papillary Bleeding Index) Gp A: mean 1.47 (SD 0.5); Gp B: mean
1.44 (SD 0.7)
Age at baseline (years): Gp A: mean 27.56 (SD 8.3) (range 18 to 45); Gp B: mean 25.
44 (SD 5.6) (range 19 to 35)
Gender: Gp A: males 13 (52%), females 12 (48%); Gp B: males 12 (48%), females 13
(52%)
Number randomised: 87 (Gp A: 45; Gp B: 42)
Number evaluated: 50 (Gp A: 25; Gp B: 25)
Interventions Comparison: CHX digluconate rinse versus placebo rinse
Gp A (n = 45): CHX (concentration not reported), 10 mL, 1 min, twice daily (morning
and before bedtime)
Gp B (n = 42): same procedure as above using placebo rinse
Prophylaxis at baseline: not reported. Assumed none
OHI: all participants given the same fluoride toothpaste and toothbrush, and given
toothbrush instruction (Modified Bass technique), instructed to brush twice daily
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: 30 min after toothbrushing
Postrinsing instructions: no rinsing with water or eating or drinking for 30 min after
using their allocated rinse
Outcomes Gingivitis (gingival bleeding: Papillary Bleeding Index, Saxer 1975)
Plaque (PI, Quigley & Hein 1962)
Calculus (scale not specified; references Oral Health of United States Adults. Epidemi-
ology and oral disease prevention program. Bethesda, MD: National Institute of Dental
Research; 1987; 159-67. NIH publication no 87-2868); probing depth* and gingival
crevicular fluid cytokine levels*, all measured at 4 weeks using a Williams periodontal
probe
Adverse effects, recorded weekly throughout the study
*Not relevant to this review
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Funding Quote: “This work was supported by an unrestricted grant from Procter & Gamble. We
would like to thankDrogsanCompany for supplying theCHXand placebomouthrinses”
Notes Sample size calculation: based on detecting a 0.5 difference in plaque index and papillary
bleeding index at 5% significance and 80% power, required 15 participants per group,
which was achieved
Adverse effects: of the 25 who rinsed with CHX; 5 subjects experienced taste distur-
bances and 14 showed discolouration of teeth and/or tongue and 3 subjects had mucosal
ulcerations
Non-smokers
Declarations/conflicts of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly assigned
to CHX or placebo groups by taking into
account the gender, age and the extent of
the gingivitis”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Low risk Quote: “patientswere randomly assigned to
CHX or placebo groups by taking into ac-
count the gender, age and the extent of the
gingivitis by an independent periodontist
who kept the allocation information confi-
dent until the data collection and biochem-
ical analysis were completed”
Comment: we consider it unlikely that par-
ticipants and investigators could foresee as-
signment of the intervention
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Double-blind. Quotes: “The subjects ..
were unaware of the type of mouthrinse
provided to the patient” and “The
placebo mouthrinse was composed of
CHX mouthrinse ingredients except that
it lacked the active ingredients (Chlorhexi-
dine digluconate). Both CHX and placebo
bottles were similar in appearance”
Comment: many of the participants in the
CHX group experienced taste disturbances
and/or discolouration of the teeth and/or
tongue. Subjects in this group could have
worked out which group they were in and
this could have affected their oral health be-
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haviours and hence the outcome. The di-
rection of this potential bias is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Double-blind.Quote: “The same examiner
recorded all clinical measurements over the
course of the study that was unaware of the
type of mouthrinse provided to the patient.
” In addition an independent periodon-
tist performed the randomisation of par-
ticipants to groups and kept the allocation
information confidential until the analyses
were completed
Comment: more than half of the subjects
in the CHX showed discolouration of the
teeth and/or tongue. It is unlikely that the
clinical examiner could remain unaware of
the group allocation of these subjects and
this could have affected the outcome assess-
ment. The direction of this potential bias
is not clear
Incomplete outcome data (attrition bias)
All outcomes
High risk Losses to follow-up at 4 weeks 37/87 (42.
5%). By group: CHX 20/45 (44.4%),
placebo 17/42 (40.5%). Reasons for loss to
follow-up: CHX: 3 discontinued the inter-
vention and 17 were lost follow-up due to
antibiotic usage,mucosal ulcerations, irreg-
ular mouthrinse usage. Placebo: 3 discon-
tinued the intervention and 14 were lost
follow-up due to antibiotic usage, mucosal
ulcerations, irregular mouthrinse usage
Comment: the numbers lost in each group
for each reason are not fully broken down.
Losses are very high especially considering
the short study duration. With such a high
rate of attrition, if the missing participants
in 1 grouphad ahighermean (e.g. gingivitis
score) than those in the other group, as the
attrition rate increased, so would the MD
between groups
Selective reporting (reporting bias) Low risk All outcomes stated in the methods section
are adequately reported in the results sec-
tion. Adverse effects were only reported for
the CHX group (presumably there were no
adverse effects in the control group)
Other bias Low risk Quotes: “All measurements were per-
formed by a single-blinded and calibrated
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examiner.. the intra-examiner reliability
was high as was revealed by intraclass cor-
relation coefficient 0.87 for PD measure-
ments and 0.85 for plaque measurements”
and “There were no differences between
CHX and placebo groups in the distribu-
tion of the extent of gingivitis, gender and
age. The groups were balanced at baseline
for PD, PBI, PI and CI values (P>0.05)”
Van Strydonck 2008
Methods Study design: parallel (3 arms 2 arms are relevant to this review)
Location: the Netherlands. Department of Periodontology, Academic Centre for Den-
tistry (ACTA)
Number of centres:1
Study duration: Recruitment period is not reported. Study duration and duration of
rinsing was 6 weeks
Participants Participants: non-dental students at the University of Amsterdam
Inclusion criteria: quotes: “Good general health, no medical or dental history or med-
ication which might interfere with the outcome or the progress of the study” and “a
minimum of 18 scorable natural teeth excluding third molars or crowned teeth with
porcelain or gold restorations. To be enrolled in the study, the subjects were required
to have a minimum of 40% bleeding sites as determined by the Bleeding on Marginal
Probing Index (BOMP)”
Exclusion criteria: quote: “Subjects were excluded if they had any physical limitations or
restrictions which might preclude normal toothbrushing skills. They were also excluded
if they had used an oral CHX product or had taken a systemic antibiotic or antiin-
flammatory drug for 3 consecutive days within the previous 3 months. Subjects with
removable prostheses or orthodontic appliances were not allowed to participate”
Baseline gingivitis: Bleeding on Marginal Probing Index (Van der Weijden 1994) Gp A:
1.21 (SD 0.24), Grp B: 1.22 (SD 0.25), Gp C: 1.26 (SD 0.26)
Age at baseline: mean Gp A: 21, Gp B: 22, Gp C: 23. Age range 18-65 years
Gender: Gp A: male 21% female 79%, Gp B: male 26% female 74%, Gp C: male 37%
female 63%
Number randomised: 150 (Gp A 50, Gp B 50, Gp C 50)
Number evaluated: 140 (Gp A 47, Gp B 47, Gp C 46)
Interventions Comparison: (CHX mouthrinse and template control brush) versus (template con-
trol brush) versus (template test brush (with slow-releasing delivery of 124mgCHX
digluconate))*
Gp A (n = 50): template control brush and CHX rinse 0.2% CHX digluconate: 10 mL,
twice daily, 60 seconds and brush twice daily for 1 min without dentifrice
Gp B (n = 50): template control brush: brush twice daily for 1 min without dentifrice
*GP C (n = 50): test brush (with slow-releasing delivery of 124 mg CHX digluconate)
: brush twice daily for 1 min without dentifrice. We excluded this arm from our risk of
bias and analysis
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Prophylaxis at baseline: quote: “At baseline subjects received a supragingival prophylaxis
to render them plaque and stain free”
OHI: quote “..instructed to brush twice daily without a dentifrice for 1 min (in the
morning and in the evening)”
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: rinsed twice daily after tooth-
brushing without a dentifrice
Postrinsing instructions: quote: “subjects were asked to refrain from rinsing eating or
drinking for 30 mins after using their assigned product”
Outcomes Gingivitis (gingival bleeding: Bleeding on Marginal Probing Index (Saxton & Van der
Ouderaa, Van der Weijden 1994); plaque (Silness & Löe 1964, Danser 2003); stain
(Gründermann Modified Stain Index (Gründermann 2000) all measured at 3 and 6
weeks
Funding Quote: “This study was supported by a grant from Oral-B Laboratories, Belmont, CA,
USA.” GSK provided the Corsodyl mouthrinse
Notes No dentifrice was used when toothbrushing
Sample size calculation: very detailed description provided. Quote: “.... a sample size of
45 subjects per treatment group was needed to ensure an 80% (power = 1-β) or greater
chance of detecting differences of ≥0.11 whole-mouth BOMP units”
Adverse effects: apart from tooth staining, quotes: “no adverse events were reported” and
“No differences were detected in the proportion of oral tissue abnormalities among the
groups, with the exception of the tongue. Changes noted were the presence of stain or
discoloration on the tongue. Treament Ctb+R (Gp A) yielded a statistically significantly
(P=0.0001) greater proportion of abnormal observations than treatments Ttb (Gp C,
excluded from this review) and Ctb (Gp B)”
Declarations/conflicts if interest: quote: “The authors declare that they have no conflict
of interests”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisationwas performed us-
ing a computer-generated list of random-
numbers”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Unclear risk The study co-ordinator was responsible for
allocation concealment
Comment: not enough information is pro-
vided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants is not possible due
to the interventions being tested: template
toothbrush versus template toothbrush and
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CHX mouthrinse and this could have af-
fected participants’ oral health behaviours
and hence the outcome. The direction of
this potential bias is unclear
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Study products were coded and
distributed to the subjects in a location
away from the examiners to ensure and
maintain blinding.... the examiners were
blind to treatment randomization and
records of earlier examinations were not
available at the time of re-examinations...
One examiner assessed all plaque scores and
performed all stain evaluations... Another
examiner assessed all the bleeding scores us-
ing BOMP and all safety evaluations”
Quote: “The mean stain scores for treat-
ment Ctb+R (CHX) were statistically
greater (P=0.0001) than for treatments Ttb
(CHX template toothbrush) and Ctb (con-
trol toothbrush)”
Comment: despite the efforts made to en-
sure blinding of outcome assessment, the
higher level of tooth staining in the CHX
rinse group meant that examining clini-
cians could not be adequately blinded and
this could have affected the outcome assess-
ment. The direction of this potential bias
is unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition: all arms: 10/150 (6.7%). By
group: CHX rinse 3/50 (6.0%), template
control brush 3/50 (6%). Reasons for losses
not broken down by group. Subjects lost
after randomisation and before baseline ex-
amination: 4 were disqualified, 4 refused to
participate and 2 were excluded for other
reasons
Comment: all losses were after randomisa-
tion before the start of the trial. They were
balanced across groups
Selective reporting (reporting bias) Low risk All outcomes stated in themethods sections
were reported in the results section
Other bias Low risk Quote: “Both examiners were well-trained
and had been involved in previous studies.
” Calibration is not mentioned
There was no statistically significant differ-
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ence in mean age, or whole mouth plaque
and gingival bleeding levels
Weitz 1992
Methods Trial design: parallel, 2 arms
Locaton: geriatric facility, USA
Number of centres: 1
Study duration: recruitment period not stated. Study duration and duration of rinsing
was 60 days
Participants Participants: residents in a geriatric facility
Inclusion criteria: residents in the geriatric facility receiving “emergency only” care.
Quote: “.. at least 60 years old and in good health”
Exclusion criteria: quote: “Patients presenting with a history of antibiotic therapy within
the last 3 months were not accepted into the study sample”
Baseline gingivitis: GI (Löe & Silness 1963) Gp A: 1.88, Gp B: 1.80. SD not reported
Age at baseline: at least 60 years old at recruitment, mean 83 years. Not reported by
group
Gender: overall: male 12 (33.33%), females 24 (66.66%). Not reported by group
Number randomised: 36 (number in each group is not reported). 12 with removable
dentures, 12 with overdentures and 12 with no prosthesis
Number evaluated: 36 (number in each group is not reported)
Interventions Comparison: CHX rinse versus placebo rinse
Gp A: CHX (0.12%) (n = not reported): 15 mL, twice daily, 30 seconds
Gp B: placebo (n = not reported): 15 mL, twice daily, 30 seconds
Prophylaxis at baseline: none, prophylaxis performed after final measurements at 60 days
OHI: none. Quote: “.. instructed to continue their normal oral hygiene routine”
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival inflammation: GI (Löe & Silness 1963), measured at 60 days
Plaque (PI Silness & Löe 1964), measured at 60 days
Funding Not reported
Notes Sample size calculation: not reported
Adverse effects: not reported
Declarations/conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote: “patients were randomly divided
into two groups”
Comment: no description of the method
of random sequence generation
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study is not described as a single-blind
study but the control group rinsed with a
quote “matched placebo”. Information on
tooth staining is not reported
Comment: not enough information is pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessor is not men-
tioned and is unlikely. Information on
tooth staining is not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no losses to follow-up
Selective reporting (reporting bias) High risk No measure of variance was reported. We
were unable to estimate the SD and there-
fore could not include these data in meta-
analyses. Furthermore, tooth staining is
considered to be an important side effect
of CHX mouthrinsing but this is not re-
ported. Adverse effects are not reported
Other bias Unclear risk No information is provided on number of
examiners and examiner training and cali-
bration
Quote: “At baseline, the active and control
groups were not statistically different (in-
dependent t-test, P<0.05) with respect to
age, gingival index or plaque index”
Zimmer 2006
Methods Trial design: parallel (4 arms - 2 arms relevant to this review)
Location:Department ofOperative andPreventiveDentistry andEndodontics,Heinrich
Heine University of Düsseldorf, Germany
Number of centres: 1
Study duration: recruitment period is not stated. Study duration and duration of rinsing
was 8 weeks
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Participants Participants: adult blood donors who visited the blood bank of the University Hospital,
Düsseldorf, Germany in July and August 2004
Inclusion criteria: minimum Papillary Bleeding Index and Modified Proximal Plaque
Index scores per tooth of 0.5 and 1.5 respectively
Exclusion criteria: wearing fixed orthodontic appliances; severe periodontitis (defined
as CAL 5 mm or greater in a minimum of 3 teeth); long-term use of drugs with anti-
inflammatory effects within 1month prior and/or during the study; removable dentures;
less than 20 natural teeth; regular use of dental floss or antimicrobial mouthrinses during
past 3 months; furcation involvement; pathological tooth mobility
Baseline gingivitis: (Papillary Bleeding Index) Gp A: mean 1.23 (SD 0.44); Gp B: mean
1.25 (SD 0.45); Gp C: mean 1.19 (SD 0.44); Gp D: mean 1.27 (SD 0.45)
Age at baseline (years): mean 31.7 (range 20 to 64.4) (not reported by group but authors
state that there were no statistically significant differences between groups)
Gender: 78 (50%) males, 78 (50%) females (not reported by group)
Number randomised: 156 (Gp A: 39; Gp B: 39; Gp C: 39; Gp D: 39)
Number evaluated: 156 (Gp A: 39; Gp B: 39; Gp C: 39; Gp D: 39)
Interventions Comparison: (CHX + sodium fluoride (NaF) rinse and toothbrushing) versus
(cetylpyridinium chloride (CPC) + sodium fluoride (NaF) rinse and toothbrush-
ing)a versus (flossing and toothbrushing)b versus toothbrushing
Gp A (n = 39): CHX (0.06%) + 0.025% NaF, amount not specified, 30 seconds, once
daily (after toothbrushing at bedtime)
*Gp B (n = 39): CPC (0.1%) + 0.025% NaF, amount not specified, 30 seconds, once
daily (after toothbrushing at bedtime). We excluded this arm from our risk of bias and
analysis
*Gp C (n = 39): flossing once daily (after toothbrushing at bedtime). We excluded this
arm from our risk of bias and analysis
Gp D (n = 39): usual toothbrushing routine
Prophylaxis at baseline: quote: “The screening examination was followed by calculus
removal in the lower front teeth”
OHI: quote: “Participants received brief instructions for the procedure they had to
perform in addition to using the toothbrush, dental floss and oral rinsing. The dental
floss instruction was demonstrated with a plastic tooth model did not exceed 2 minutes.
The subjects were advised to brush their teeth in the usual manner. No instructions
concerning brushing technique and brushing time were given.” All participants received
same toothbrush and fluoride toothpaste
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: after brushing with toothpaste
Postrinsing instructions: not reported
Outcomes Gingivitis (gingival bleeding: Papillary Bleeding Index, Saxer & Muhlemann 1975);
plaque (Modified Proximal Plaque Index, Lange 1977 and Zimmer 2005 and Quigley
and Hein Index, Quigley and Hein 1962); adverse effects (“discomfort in taste, dis-
comfort in sensibility, gingival damage, gingival bleeding, staining of teeth and tongue,
mouth burning during application, and white plaque on tongue immediately after use”)
, all measured at 4 and 8 weeks
Funding Quote: “This study was supported by GlaxoSmithKline”
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Notes Sample size calculation: not reported
Adverse effects: reported with no double counting - if any participant experienced more
than 1 adverse effect, only the most ’relevant’ one was reported
- At 4 weeks: no side effects: Gp A: 21/39, Gp B: 15/39, Gp C: 36/39, Gp D: 37/39.
Discomfort in taste: Gp A: 5/39, GP B: 7/39, Gp C: 0, Gp D: 1/39. Discomfort in
sensibility: Gp A: 2/39, Gp B: 2/39, Gp C: 0, Gp D: 0. Gingival damage: Gp A: 0, Gp
B: 0, Gp C: 3/39, Gp D: 0. Stain on teeth/tongue: Gp A: 4/39, Gp B: 9/39, Gp C: 0,
Gp D: 0. Mouth burning during application: Gp A: 7/39, Gp B: 5/39, Gp C: 0, Gp
D: 0. Bleeding of the gingiva: Gp A: 0, Gp B: 0, Gp C: 0, Gp D: 1. White plaque on
tongue immediately after use: Gp A: 0, Gp B: 1/39, Gp C: 0, Gp D: 0
- At 8 weeks: no side effects: Gp A: 19/39, Gp B: 10/39, Gp C: 38/39, Gp D: 39/
39. Discomfort in taste: Gp A: 6/39, GP B: 4/39, Gp C: 0, Gp D: 0. Discomfort in
sensibility: Gp A: 2/39, Gp B: 1/39, Gp C: 0, Gp D: 0. Gingival damage: Gp A: 0, Gp
B: 0, Gp C: 1/39, Gp D: 0. Stain on teeth/tongue: Gp A: 6/39, Gp B: 19/39, Gp C:
0, Gp D: 0. Mouth burning during application: Gp A: 6/39, Gp B: 4/39, Gp C: 0, Gp
D: 0. Bleeding of the gingiva: Gp A: 0, Gp B: 0, Gp C: 0, Gp D: 0. White plaque on
tongue immediately after use: Gp A: 0, Gp B: 1/39, Gp C: 0, Gp D: 0
Smokers: 33 (21.15%) overall. By group: Gp A: 10%; Gp B: 31%; Gp C: 28%; Gp D:
15%
Declarations/conflicts of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “.. the 156 participants were ran-
domly assigned to four groups with 39 sub-
jects in each group.. In a box containing
156 envelopes in four strata (three strata
with 40 and one with 36), each participant
had to draw one envelope containing the
number of the attributed product”
Comment: drawing of lots is an adequate
method of random sequence generation
Allocation concealment (selection bias) Low risk Quote: “.. the 156 participants were ran-
domly assigned to four groups with 39 sub-
jects in each group.. In a box containing
156 envelopes in four strata (three strata
with 40 and one with 36), each participant
had to draw one envelope containing the
number of the attributed product”
Quote: “The assignment of subjects to
groups was performed by a person not in-
volved in the examination”
Comment: allocation of subjects to groups
was concealed up to the point that partici-
pants drew an envelope and were allocated
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to a group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: participants were not blinded.
The different interventions meant that par-
ticipants would know which group they
were in and this could have affected their
oral health behaviours and hence the out-
come. The direction of this potential bias
is not clear
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotes: “The study was conducted by a
blinded operator..” and “Because clinically
visible side effects…might have influenced
examiner blinding, an additional statistical
analysis was performed for subjects with-
out visible side effects. Again, compared
to all subjects, only small discrepancies of
this subgroup and no changes in statistical
significance were found. This finding indi-
cates that clinically visible side effects did
not affect examiner accuracy”
Comment: aAlthough a risk of bias of out-
come assessment due to staining of teeth/
tongue in both active mouthrinse groups
was likely, it did not appear to influence the
results
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants were included
in the analyses
Selective reporting (reporting bias) High risk Adverse effects were reported with no dou-
ble counting - if any participant experi-
enced more than 1 adverse effect, only the
’most relevant’ one was reported. No in-
formation is provided on how the ’most
relevant’ side effect was chosen to be re-
ported and information about participants
who experiencedmore than 1 adverse effect
is not reported
Other bias Low risk Quote: “Before starting the study the in-
traexaminer reliability was tested by re-
peated measurements of MPPI, QHI, and
PBI and analysed by Cohen’s test. the re-
sults were as follows: MPPI=0.86, QHI=0.
82 and PBI=0.88.” No other apparent bias
identified
Quote: “All examinations were conducted
by one single examiner (GK)”
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Smokers: CHX NaF (4) 10.26%, control
(6) 15.38%. The authors state that this
difference failed to reach statistical signifi-
cance (P = 0.076)
Zimmer 2015
Methods Trial design: parallel (4 arms - 3 arms are relevant to this review)
Location: Dental School of the Witten/Herdecke University, Witten, Germany
Number of centres: 1
Study duration: quote: “Subjects were recruited between April 20th, 2010 and June16th,
2010.” Study duration and duration of rinsing was 8 weeks
Participants Participants: healthy adults
Inclusion criteria: quotes: “subjects aged 18-65 years and having a mean PBI per tooth
≥0.5 were enrolled in the study” and “... Informed consent was obtained by each subject.
Each subject had a minimum of 20 permanent natural teeth. Third molars, orthodonti-
cally banded, fully crowned or extensively restored or abutment teeth were not included
in the tooth count”
Exclusion criteria: quote: “Subjects were excluded from the study if theywere pregnant or
breast-feeding, had diabetes type I or II, or severe periodontal disease, or wore removable
dentures. Severe periodontal disease was defined as the presence of clinical attachment
loss ofmore than5mmaccording to the periodontal disease classificationof theAmerican
Academy of Periodontology.... However, a subject was excluded only if this applied for a
minimum of three teeth. Subjects were also excluded if any of the following conditions
was present: use of antibiotics within 2 weeks prior the first examination or use of any
systemic medication which would have an effect on gingival conditions within 30 days
prior to the screening visit, or recent history (within the last year) of alcohol or other
substance abuse. Dental professionals, dental students and employees of the sponsor or
members of their immediate families were also excluded from the study”
Baseline gingivitis: (Papillary Bleeding Index) Gp A: mean 1.06 (SD 0.4); Gp B: mean
0.99 (SD 0.37); Gp C: mean 0.94 (SD 0.31); Gp D: mean 1.02 (SD 0.39)
Age (years): overall: mean 33.9. Gp A: mean 33.8; Gp B: mean 34.0; Gp C: mean 33.
9; Gp D: mean 33.8. Range 18-65 years
Gender: nt reported
Number randomised: 160 (Gp A: 40; Gp B: 40; Gp C: 40; Gp D: 40)
Number evaluated: 155 (Gp A: 39; Gp B: 39; Gp C: 40; Gp D: 37)
Interventions Comparison: (twice daily toothbrushing and 0.06% CHX digluconate + 0.025%
F as sodium fluoride mouthrinse) versus (twice daily toothbrushing and an ex-
perimental alcohol-free mouthrinse with 0.06% CHX digluconate + 0.025% F as
sodium fluoride) versus (twice daily toothbrushing alone) versus (twice daily tooth-
brushing and an experimental alcohol-free mouthrinse with 0.06% CHX diglu-
conate + 0.03% cetylpyridinium chloride (CPC) + 0.025% F as sodium fluoride)*
Gp A (n = 40): twice daily toothbrushing and rinsing twice a day for 30 seconds with
10 mL of an alcohol-containing mouthrinse with 0.06% CHX digluconate + 0.025%
fluoride as sodium fluoride for 8 weeks
Gp B (n = 40): twice daily toothbrushing and rinsing twice a day for 30 seconds with
10 mL of an experimental alcohol-free mouthrinse with 0.06% CHX digluconate + 0.
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025% fluoride as sodium fluoride for 8 weeks
Gp C (n = 40): twice daily toothbrushing alone
*GpD (n = 40): twice daily toothbrushing and rinsing twice a day for 30 seconds with 10
mL of an experimental alcohol-free mouthrinse with 0.06% CHX digluconate + 0.03%
cetylpyridinium chloride (CPC) + 0.025% fluoride as sodium fluoride. We excluded this
arm from our risk of bias and analysis
Prophylaxis at baseline: not reported
OHI: quotes: “All participants received a short instruction on how to conduct the at-
tributed oral hygiene measurements. The subjects were advised to brush their teeth in
the morning and in the evening postprandial in the usual manner. No instructions con-
cerning brushing technique and brushing duration were given. After using the brush,
the subjects rinsed their mouth with tap water” and “During the study period, the use
of other than the attributed oral hygiene tools strictly was prohibited... Interproximal
cleaning devices had been permitted if they were part of the usual oral hygiene routine
of the included subjects”
Timing of toothbrushing in relation tomouthrinsing: quote: “The subjects of the rinsing
groups waited for 30 min. Thereafter, they rinsed for 30 s with 10 ml of the assigned
rinse. Afterwards, the subjects refrained from drinking, eating and rinsing for at least
30 min. To control the waiting and the rinsing time, each subject was provided with a
digital stop watch”
Outcomes Gingivitis (gingival bleeding: Papillary Bleeding Index, Saxer 1975); plaque (TQH,
Turesky 1970; Modified Proximal Plaque Index, Zimmer 2005) assessed at 4 and 8weeks
follow-up. All adverse events occurring during the study period were recorded using a
questionnaire and by clinical examination. Occurrence of discomfort in taste, discomfort
in sensibility, gingival damage, gingival bleeding, staining of teeth and tongue, mouth
burning and white plaque on tongue immediately after use was registered at baseline and
after 4 and 8 weeks. Oral soft tissue examination was performed at each visit
Funding Quote: “This study was funded by GlaxoSmithKline Consumer Healthcare (Bühl, Ger-
many). GlaxoSmithKline was involved in the design and conduct of the study and pro-
vided logistical support during the trial. Data management and statistical analysis were
performed by an independent institute at the Heinrich-Heine-University Düsseldorf.
The manuscript was prepared by Prof. Zimmer, Dr. Naumova and Dr. Jordan. Glaxo-
SmithKline was permitted to review the manuscript and suggest changes, but the final
decision on content was exclusively retained by the authors”
Notes Sample size calculation: quote: “... was calculated on the basis of the following assump-
tions: power 0.8; alpha error: 0.05; delta-QHI between groups after 8 weeks: 0.3 (SD 0.
5); one tailed analysis (Axum 7.0)”
Adverse effects: tooth staining at 8 weeks: Gp A: 18/39, Gp B: 21/39 and Gp C: 8/40.
Tongue staining at 8 weeks: Gp A: 18/39, Gp B: 22/39 and Gp C: 14/40
Gastrointestinal adverse events were found in all groups (Gp 1 (A): 1 case, Gp 2 (B)
: 2 cases, Gp 3 (no data extracted): 7 cases, Gp 4 (C): 1 case); in 5 cases (1 in Gp 2
(B) and 4 in Gp 3 (no data extracted)), gastrointestinal infection was given as reason;
in 4 cases, diarrhoea; and in 1 case, ’stomach burning’ and meteorism, respectively. No
serious adverse events were observed in the study
Smokers by group: Gp A: 10/40 (25%); Gp B: 9/40 (23%); Gp C: 10/40 (25%) (dif-
ferences between the groups were not statistically significant)
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The trial was registered at the Clinical Trials Register of the National Institutes of Health
(NCT01811615, www.clinicaltrials.gov)
Declarations/conflicts of interest: none stated
Tooth staining data for groups A and B (at 4 weeks) were combined in the main analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Using the stratification by sex
and PBI (PBI/tooth≥0.5 and<1.0 or PBI/
tooth≥1.0), the 160 eligible participants
were allocated by block randomization to
one of four groups with 40 subjects each.
Block randomization was performed by a
statistician not involved in the study”
Comment: adequatemethod of random se-
quence generation
Allocation concealment (selection bias) Low risk Quotes: “Subjects within each group were
randomly assigned to one of the follow-
ing groups” and “Block randomization was
performed by a statistician not involved in
the study”
Comment: we consider it unlikely that par-
ticipants and investigators enrolling partic-
ipants could foresee assignment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotes: “All personal instructions and de-
livering of the study products were per-
formed by a study nurse not involved (A.
P.) in the study examinations. The subjects
were forbidden to tell the examiner their
regimen during the study visits” and “With
respect to tooth staining, chi square-test re-
vealed significant more occurrences in the
three rinsing groups when compared to the
negative control (P<0.001)”
Comment: due to the design of the study
the participants in toothbrushing only
group could not be blinded. The higher
incidence of staining in the CHX groups
means that blinding may not be possible in
a comparison against the control
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study was designed to be examined
blind. Quotes: “All assessments of an in-
dividual subject in the course of the study
have been conducted by the same investi-
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gator (P.K.) who had experience from pre-
vious clinical studies” and “with respect to
tooth staining, chi square-test revealed sig-
nificantly more occurrences in the rinsing
groupswhen compared to the negative con-
trol (P<0.001)”
Comment: the higher incidence of staining
in the CHX groups means that blinding
maynot be possible in a comparison against
the control
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition 2/120 (1.7%). By group: Gp A:
1/40 (0.03%); Gp B: 1/40 (0.03%); Gp
C: no losses. Reasons for losses: Gp A: in-
formed consent withdrawn; Gp B: proto-
col violation
Comment: attrition is minimal and un-
likely to affect the outcome
Selective reporting (reporting bias) Low risk All outcomes stated in themethods sections
were reported in the results section
Other bias Unclear risk Nomentionof intraexaminer reproducibil-
ity
Groups were balanced at baseline for age
and smoking status, gingivitis and plaque
Tooth staining at baseline is not reported
ASF = amine fluoride and stannous fluoride; BOP = bleeding on probing; CAL = clinical attachment level; CHX = chlorhexidine;
CI = Calculus Index; CI = confidence interval; CSSI = Calculus Surface Severity Index; DI = Discolouration Index; F = fluoride;
Gp = group; GI = Gingival Index; ITT = intention-to-treat analysis; MSE = mean squared error; OH = oral hygiene; OHI = oral
hygiene instruction; PAL = probing attachment level; PBS = Papillary Bleeding Score; PD = pocket depth; PI = Plaque Index; PMGI
= Papillary Marginal Gingival Index; PPD = probing pocket depth; ppm = parts per million; PVP = polyvinyl pyrrolidone; SD =
standard deviation; SE = standard error; SES = socioeconomic status; SRP = scaling and root planing; TQH = Turesky modification
of the Quigley and Hein Index; VAS = visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bay 1975 It is unclear from the published report whether the study is a randomised trial. Attempts to contact the first
author for clarification were unsuccessful
Biswas 2014 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
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Bouwsma 1992 The test group used a triangular wooden interdental cleaner once daily after toothbrushing which the CHX
group did not use. The mechanical OH procedures were not the same in both groups
Brown 2002 The study compares CHX plus mechanical OH and 2-monthly professional prophylaxis versus mechanical
OH and 6-monthly check up and professional prophylaxis (standard care). The mechanical OH procedures
were not the same in both groups
Caton 1993 The CHX group received OH instructions but the control group did not. The mechanical OH procedures
were potentially not the same in both groups
Cortelli 2015 The CHX arms used CHX gel (tongue brushing for 1 min after rinsing) in addition to CHX rinse. We were
unable to separate the effect of the CHX rinse from the effect of the other active agent
CTRI 2014 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
Ernst 1998 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
Eshwar 2016 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
Fischman 1975 This study compared CHX, zinc and placebomouthrinses but each rinse group was further split into those who
received a professional prophylaxis prior to the start of the study and those that did not. The study outcomes
were not reported in a format that could be used in the review and data were not available from the authors of
the study
Goutham 2013 It is unclear from the published report whether the study is a randomised trial. Attempts to contact the first
author for clarification were unsuccessful
Gupta 2014 Concern about inclusion of duplicated outcome data from another study by the same authors
Gupta 2015 Concern about inclusion of duplicated outcome data from another study by the same authors
Gupta 2015a Concern about inclusion of duplicated outcome data from other studies in other published trials from these
researchers
Haffajee 2009 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
Karim 2014 Concern about inclusion of duplicated outcome data from another study by the same authors
Lang 1982 It is unclear from the published report whether the study is a randomised trial. Attempts to contact the first
author for clarification were unsuccessful
Leyes Borrajo 2002 It is unclear from the published report whether the study is a randomised trial. Additional information obtained
from the contact author indicate quasi-randomisation (participants were assigned to groups according to the
order that they came to the university)
Luoma 1978 CHX, F and placebo groups also used a toothpaste at evenings and weekend with the same composition as
their respective rinse solution. Therefore the CHX rinse group also used a CHX-containing toothpaste. We
were unable to separate the effect of the CHX rinse from the effect of the other active agent
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Madden 2008 The CHX group received a more intensive intervention including 2-monthly OH instruction compared to the
control group who received 6-monthly OH alone. The mechanical OH procedures were (potentially) not the
same in both groups
McKenzie 1992 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
Nadkerny 2015 Duration of rinsing was 15 days
NCT01750801 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
NCT02546804 Comparison is with another active rinse and hot salt mouthwash and there is no placebo/control or mechanical
OH only group
Ousehal 2011 It is unclear from the published report whether the study is a randomised trial. Attempts to contact the first
author for clarification were unsuccessful
Paknejad 2006 It is unclear from the published report whether the study is a randomised trial. Attempts to contact the first
author for clarification were unsuccessful
Persson 1991 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
Persson 1998 The CHX group received a more intensive intervention including cognitive behavioural education (2 hours)
compared to the control group who received standard care
Priya 2015 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
Quirynen 2005 The study involves 1-stage full-mouth disinfection involving use of CHX gel at baseline in addition to the
mouthrinses. We were unable to separate the effect of the CHX rinse from the effect of the other active agent
Quirynen 2006 The study involves 1-stage full-mouth disinfection involving use of CHX gel at baseline and 1 week in addition
to the mouthrinses. We were unable to separate the effect of the CHX rinse from the effect of the other active
agent
Radafshar 2017 Comparison is with another active rinse and there is no placebo/control or mechanical OH only group
Saltini 1988 This is an abstract. It was not possible to contact the first author, therefore co-authors were contacted but they
did not have access to the data
Segreto 1993 We were unable to obtain a copy of this unpublished study despite following up several lines of enquiry
Subhash 1985 The brushing method differs between the groups. The mechanical OH procedures are not considered to be
the same in both groups
Todkar 2012 It is unclear from the published report whether the study is a randomised trial. Attempts to contact the first
author for clarification were unsuccessful
Vechis-Bon 1989 It is unclear from the published report whether the study is a randomised trial. Attempts to contact the first
author for clarification were unsuccessful
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Yates 2002 Experimental gingivitis study, the CHX mouthrinse is used in the absence of any mechanical tooth cleaning
CHX = chlorhexidine; OH = oral hygiene; F = fluoride.
Characteristics of studies awaiting assessment [ordered by study ID]
CTRI/2011/05/001774
Methods Study design: parallel group 3 arms
Location: Apollo Hospital, Dental and Facial Surgical Centre, RV Dental College, Santosh Hospital, Bangalore,
Karnataka, India
Number of centres: appears to be 4
Study duration: 7/8 months. Duration of rinsing appears to be 6 months
Participants Participants: minimum 12 years old with mild to moderate gingivitis
Inclusion criteria: with a reasonable standard of oral hygiene with no severe gingivitis (score of not 2 on the GI).
Subjects with mild to moderate gingivitis, with probing depths of not more than 3 mm
Age 12-99 eligible for inclusion
Total sample size 120; 96 evaluable subjects required. Not clear how many subjects actually participated in trial
Interventions Chlorhexidine 0.12% (Orocleanse) with alcohol versus chlorhexidine 0.12% (Oroclear) without alcohol versus
placebo in conjunction with regular self-performed oral hygiene measures
Rinsing with 15 mL twice daily for 30 seconds for 6 months
Outcomes Gingival inflammation: GI, also stain indices
Brief summary of results mentions PI, PBI and CI not specified in methods
Notes Study completed. Brief summary of results reported but no outcome data are reported. We contacted the author for
further information but did not receive a reply
NCT01898000
Methods Study design: parallel, (3 arms - 2 arms relevant to this review)
Location: Government Dental College and Research Institute, Bangalore, India
Number of centres: not clear
Study duration: duration of rinsing 60 days
Participants Participants: subjects with chronic generalised gingivitis reporting to outpatient Department of Periodontics, Gov-
ernment Dental College and Research Institute, Bangalore from January 2013 to April 2013
Quote: “..instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain
from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No
oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved
oral hygiene practices on the results”
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NCT01898000 (Continued)
Interventions Group I: placebo mouthwash. Group II: Triphala (TRP) mouthwash. Group III: chlorhexidine mouthwash. Subjects
were instructed to use 15 mL of mouthwash twice daily
Outcomes PI, GI and OHI-S, and microbiological colony counts were recorded on baseline and 7, 30 and 60 days respectively
Notes Study completed. Brief summary of results reported but no outcome data are reported. We contacted the author for
further information but did not receive a reply
NCT02065414
Methods Study design: parallel, (3 arms - 2 arms are relevant to this review)
Location: not clear “Clinical Centre”
Number of centres: 1
Study duration: 4 weeks
Participants Participants: aged 18 years and older with gingivitis, but without moderate/advanced periodontitis
Interventions Chlorhexidine rinse (Corsodyl) 0.12% versus experimental mouthrinse (Listerine Advance Gum Defense) versus
placebo
Chlorhexidine: rinse with 10 mL for 60 seconds twice daily for 4 weeks (5 min after brushing and rinsing mouth
with water)
Experimental rinse: rinse with 20 mL for 30 seconds twice daily for 4 weeks (immediately after brushing and rinsing
mouth with water)
Placebo: rinse with 20 mL for 30 seconds twice daily for 4 weeks (immediately after brushing and rinsing mouth
with water)
Outcomes Gingivitis: gingival inflammation, Modified Gingival Index at 4 weeks; gingival bleeding, Gingival Bleeding Index
at 1 and 4 weeks. Plaque: Turesky Modification of the Quigley and Hein Plaque Index at 4 weeks. Extrinsic tooth
stain: Macpherson Modification of the Lobene Stain Index at 4 weeks
Notes Study completed. Contacted investigator for further details but did not receive a reply
Radvar 2016
Methods Trial design: parallel, (3 arms - 2 arms relevant to this review) (study number 2 only, study number 1 does not meet
the inclusion criteria for the review)
Location: Periodontology Department, Mashad Dental School, Iran
Number of centres: assume 1 centre
Study duration: recruitment period not stated. Duration of rinsing was 4 weeks and the outcome was assessed 6
weeks after scaling and root planing
Participants Participants: outpatients with chronic periodontitis referred to the Periodontology Department, Mashad Dental
School, Iran
Inclusion criteria: chronic periodontitis with pocketing and attachment loss in all quadrants (over 45 years old)
Exclusion criteria: “Patients on antibiotic therapy or anti-inflammatory drugs, those with any history of systemic
disease, or allergy to components of the mouthwash, those who had undergone any form of non-surgical or surgical
periodontal therapy in the last 6 months, pregnant and lactating mothers and smokers were excluded”
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Radvar 2016 (Continued)
Baseline gingivitis: BOP, Group A (66.8 ± 14.85); Group B (71.08 ± 10.23); Group C (57.18 ± 19.47)
Age at baseline (years): not reported. Over 45 years old
Gender: not reported
Number randomised: 30 (number randomised to each group not reported, assumed 10 in each group at baseline)
Number evaluated: not reported
Interventions Chlorhexidine rinse versus herbal rinse* versus control rinse
Group A (assume n = 10 ): CHX (concentration not reported) 10 mL, 1 min, twice daily
*Group B (assume n = 10): herbal mouthwash (S alba, M sylvestris and A officinalis) 10 mL, 1 min, twice daily. (We
excluded this arm from our risk of bias and analysis)
Group C (assume n = 10): control (normal saline) 10 mL, 1 min, twice daily
Prophylaxis at baseline: quote: “Scaling and root planing was accomplished in two visits for all patients and local
anaesthesia was used when required”
OHI: not reported
Non-supervised rinsing
Timing of mouthrinsing in relation to toothbrushing: not reported
Postrinsing instructions: quote: “Subsequent rinsing with water was not allowed”
Duration of rinsing: 4 weeks
Outcomes Gingivitis: BOP (no reference), PD, CAL were measured using a periodontal probe at baseline and then 6 weeks
after scaling and root planing
Notes Sample size calculation: not reported
Adverse effects: quote: “No adverse reaction was seen in the herbal mouthwash group, however, in the CHX group
there were some adverse reactions such as dental and tongue staining”
Declarations/conflicts of interest: none reported
It is not clear exactly when the outcome was assessed. Outcome assessment appears to have been completed 2 weeks
after rinsing ceased
We are awaiting clarification from the authors about various aspects of this study
BOP = bleeding on probing; CAL = clinical attachment level; CHX = chlorhexidine; CI = Calculus Index; GI = Gingival Index; OHI =
oral hygiene instruction; OHI-S = Oral Hygiene Index-Simplified; PBI = Papillary Bleeding Index; PD = pocket depth; PI = Plaque
Index.
Characteristics of ongoing studies [ordered by study ID]
NCT02709785
Trial name or title SmartMouth Advanced Clinical Formula clinical research design protocol
Methods Trial design: parallel, (3 arms - 2 arms relevant to this review)
Location: Saint Louis University Center for Advanced Dental Education, Saint Louis, Missouri, USA and
Southern Illinois University School of Dental Medicine, Alton, Illinois, USA
Number of centres: 2
Study duration: March 2016 to June 2017. Study duration 10 weeks. Duration of rinsing 6 weeks
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NCT02709785 (Continued)
Participants Participants: adults with gingivitis or chronic periodontitis
Inclusion criteria: subjects between the ages of 18 to 80, with a diagnosis of gingivitis or chronic periodontitis,
mean GI ≥ 0.4 and PI ≥ 1.0, subjects that are in good medical health at time of the study, at least 20
permanent natural teeth
Exclusion criteria: use of local or systemic antibiotics during the course of the study, subjects that are pregnant
or nursing mothers, undergoing orthodontic therapy, subjects wearing removable prostheses, subjects taking
medication which is altering the gingiva or causing inflammation, gingival overgrowth, history of sensitivity
or suspected allergies following the use of oral hygiene products, subjects taking anti-inflammatory or an-
ticoagulant medications that would alter the gingiva and promote bleeding, subjects that require antibiotic
prophylaxis prior to dental treatment, subjects that have acute dental problems requiring immediate treatment
Baseline gingivitis: GI ≥ 0.4 (Löe & Silness 1963)
Age at baseline: 18-80 years are eligible
Prophylaxis: all subjects will be given a complete dental prophylaxis to remove plaque, calculus, and stain
OHI: written and verbal OHI will be given that include a regular regimen of brushing twice daily and flossing
daily. All subjects will be assigned a commercially available ADA-accepted toothbrush and dental floss
Number to be randomised: 85 (each group will have at least 25 subjects)
Interventions 0.12% chlorhexidine rinse versus SmartMouth Advanced Clinical Formula (ACF) rinse versus placebo rinse
Outcomes Gingivitis: gingival inflammation: GI Löe & Silness 1963; gingival bleeding (GI scores 2 and 3); Turesky
modification of the Quigley and Hein Plaque Index, Turesky 1970. Extrinsic tooth staining: modification of
the LobeneTooth Stain Index, Lobene 1968. Supragingival calculus on the lingual surfaces of the 6mandibular
anterior teeth will be scored using the Volpe-Manhold Calculus Index, Volpe 1965. Safety assessments and
assessment of the oral soft tissues will be conducted at each visit by visual examination of the oral cavity.
Evaluation of taste perception, malodour via questionnaire
Starting date March 2016
Contact information Contact:DavidDMiley, Saint LouisUniversityCenter forAdvancedDental Education, Saint Louis,Missouri,
USA
Notes Sponsor: Saint Louis University
Collaborator: Triumph Pharmaceuticals
NCT02709785
ADA = American Dental Association; GI = Gingival Index; PI = Plaque Index; OHI = oral hygiene instruction.
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D A T A A N D A N A L Y S E S
Comparison 1. CHX versus placebo/control mouthrinse or no mouthrinse
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Gingival Index (0-3) 4-6 weeks 10 805 Mean Difference (IV, Random, 95% CI) -0.21 [-0.31, -0.11]
1.1 CHX versus no rinse 2 339 Mean Difference (IV, Random, 95% CI) -0.13 [-0.31, 0.05]
1.2 CHX versus
placebo/control rinse
8 466 Mean Difference (IV, Random, 95% CI) -0.23 [-0.34, -0.13]
2 Gingival Index (0-3) 6 months 13 2616 Mean Difference (IV, Random, 95% CI) -0.20 [-0.30, -0.11]
2.1 CHX versus no rinse 2 142 Mean Difference (IV, Random, 95% CI) -0.12 [-0.18, -0.05]
2.2 CHX versus
placebo/control rinse
11 2474 Mean Difference (IV, Random, 95% CI) -0.22 [-0.33, -0.11]
3 Gingival bleeding 4-6 weeks 8 649 Std. Mean Difference (IV, Random, 95% CI) -0.56 [-0.79, -0.33]
3.1 CHX versus no rinse 4 459 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-0.89, -0.50]
3.2 CHX versus
placebo/control rinse
4 190 Std. Mean Difference (IV, Random, 95% CI) -0.36 [-0.77, 0.06]
4 Gingival bleeding 6 months 8 1132 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-1.02, -0.42]
4.1 CHX versus no rinse 2 142 Std. Mean Difference (IV, Random, 95% CI) -0.49 [-0.83, -0.16]
4.2 CHX versus
placebo/control rinse
6 990 Std. Mean Difference (IV, Random, 95% CI) -0.79 [-1.16, -0.41]
5 Plaque 4-6 weeks 12 950 Std. Mean Difference (IV, Random, 95% CI) -1.45 [-1.90, 1.00]
5.1 CHX versus no rinse 3 433 Std. Mean Difference (IV, Random, 95% CI) -1.43 [-2.39, -0.47]
5.2 CHX versus
placebo/control rinse
9 517 Std. Mean Difference (IV, Random, 95% CI) -1.48 [-2.07, -0.89]
6 Plaque 4-6 weeks PI (0-3) 4 223 Mean Difference (IV, Random, 95% CI) -0.58 [-0.78, -0.39]
6.1 CHX versus no rinse 2 114 Mean Difference (IV, Random, 95% CI) -0.59 [-0.94, -0.24]
6.2 CHX versus
placebo/control rinse
2 109 Mean Difference (IV, Random, 95% CI) -0.50 [-0.97, -0.04]
7 Plaque 4-6 weeks TQH (0-5) 5 546 Mean Difference (IV, Random, 95% CI) -0.78 [-0.85, -0.70]
7.1 CHX versus no rinse 1 319 Mean Difference (IV, Random, 95% CI) -0.83 [1.00, -0.66]
7.2 CHX versus
placebo/control rinse
4 227 Mean Difference (IV, Random, 95% CI) -0.76 [-0.85, -0.68]
8 Plaque 6 months 11 2075 Std. Mean Difference (IV, Random, 95% CI) -1.43 [-1.76, -1.10]
8.1 CHX versus no rinse 2 142 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-1.35, -0.01]
8.2 CHX versus
placebo/control rinse
9 1933 Std. Mean Difference (IV, Random, 95% CI) -1.59 [-1.89, -1.29]
9 Plaque 6 months PI (0-3) 5 1108 Mean Difference (IV, Random, 95% CI) -0.62 [-1.12, -0.12]
9.1 CHX versus no rinse 2 142 Mean Difference (IV, Random, 95% CI) -0.30 [-0.42, -0.18]
9.2 CHX versus
placebo/control rinse
3 966 Mean Difference (IV, Random, 95% CI) -0.86 [-1.46, -0.25]
10 Plaque 6 months TQH (0-5) 6 967 Mean Difference (IV, Random, 95% CI) -0.73 [-0.88, -0.57]
10.1 CHX versus
placebo/control rinse
6 967 Mean Difference (IV, Random, 95% CI) -0.73 [-0.88, -0.57]
11 Calculus 4-6 weeks 2 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 CHX versus
placebo/control rinse
2 102 Mean Difference (IV, Random, 95% CI) 0.02 [-0.09, 0.14]
12 Calculus 7-12 weeks 6 425 Std. Mean Difference (IV, Random, 95% CI) 0.32 [-0.04, 0.69]
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12.1 CHX versus no rinse 1 95 Std. Mean Difference (IV, Random, 95% CI) 1.02 [0.59, 1.45]
12.2 CHX versus
placebo/control rinse
5 330 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.08, 0.36]
13 Calculus 6 months 4 323 Std. Mean Difference (IV, Random, 95% CI) 0.80 [0.33, 1.26]
13.1 CHX versus no rinse 1 91 Std. Mean Difference (IV, Random, 95% CI) 1.39 [0.93, 1.85]
13.2 CHX versus
placebo/control rinse
3 232 Std. Mean Difference (IV, Random, 95% CI) 0.60 [0.24, 0.96]
14 Tooth staining 4-6 weeks
dichotomous
2 156 Risk Ratio (M-H, Random, 95% CI) 5.41 [2.03, 14.47]
14.1 CHX versus no rinse 1 118 Risk Ratio (M-H, Random, 95% CI) 4.44 [1.43, 13.80]
14.2 CHX versus
placebo/control rinse
1 38 Risk Ratio (M-H, Random, 95% CI) 9.88 [1.37, 71.44]
15 Tooth staining 7-12 weeks
dichotomous
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 CHX versus no rinse 1 118 Risk Ratio (M-H, Random, 95% CI) 2.5 [1.29, 4.83]
16 Tooth staining 4-6 weeks 8 415 Std. Mean Difference (IV, Random, 95% CI) 1.07 [0.80, 1.34]
16.1 CHX versus no rinse 1 94 Std. Mean Difference (IV, Random, 95% CI) 1.54 [1.08, 2.00]
16.2 CHX versus
placebo/control rinse
7 321 Std. Mean Difference (IV, Random, 95% CI) 0.97 [0.73, 1.22]
17 Tooth staining 7-12 weeks 11 581 Std. Mean Difference (IV, Random, 95% CI) 1.19 [0.98, 1.40]
17.1 CHX versus no rinse 1 95 Std. Mean Difference (IV, Random, 95% CI) 1.32 [0.88, 1.77]
17.2 CHX versus
placebo/control rinse
10 486 Std. Mean Difference (IV, Random, 95% CI) 1.17 [0.93, 1.41]
18 Tooth staining 6 months 4 323 Std. Mean Difference (IV, Random, 95% CI) 1.54 [1.22, 1.86]
18.1 CHX versus no rinse 1 91 Std. Mean Difference (IV, Random, 95% CI) 1.18 [0.73, 1.62]
18.2 CHX versus
placebo/control rinse
3 232 Std. Mean Difference (IV, Random, 95% CI) 1.69 [1.38, 1.99]
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Analysis 1.1. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 1
Gingival Index (0-3) 4-6 weeks.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 1 Gingival Index (0-3) 4-6 weeks
Study or subgroup CHX Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Jose 2015 214 1.1149 (0.1137) 105 1.19 (0.1435) 20.3 % -0.08 [ -0.11, -0.04 ]
Rahmani 2006 10 1.12 (0.31) 10 1.4 (0.31) 8.1 % -0.28 [ -0.55, -0.01 ]
Subtotal (95% CI) 224 115 28.3 % -0.13 [ -0.31, 0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.16, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 1.44 (P = 0.15)
2 CHX versus placebo/control rinse
Axelsson 1987 42 0.6271 (0.297) 22 1 (0.3) 13.7 % -0.37 [ -0.53, -0.22 ]
Bhat 2014 22 0.42 (0.43) 22 1.02 (0.79) 5.2 % -0.60 [ -0.98, -0.22 ]
Ernst 2005 33 0.45 (0.45) 28 0.56 (0.49) 9.4 % -0.11 [ -0.35, 0.13 ]
Graziani 2015 55 0.6818 (0.6659) 15 0.8 (0.7223) 4.6 % -0.12 [ -0.52, 0.29 ]
Jenkins 1993 49 0.54 (0.27) 50 0.72 (0.26) 16.8 % -0.18 [ -0.28, -0.08 ]
Lopez-Jornet 2012 35 0.75 (0.83) 35 1.15 (0.85) 4.8 % -0.40 [ -0.79, -0.01 ]
Navarro 1998 9 0.048 (0.099) 11 0.17 (0.2885) 12.1 % -0.13 [ -0.31, 0.06 ]
Sanz 1989 17 1.1164 (0.6) 21 1.24 (0.6) 5.0 % -0.13 [ -0.51, 0.26 ]
Subtotal (95% CI) 262 204 71.7 % -0.23 [ -0.34, -0.13 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 11.37, df = 7 (P = 0.12); I2 =38%
Test for overall effect: Z = 4.44 (P < 0.00001)
Total (95% CI) 486 319 100.0 % -0.21 [ -0.31, -0.11 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 27.51, df = 9 (P = 0.001); I2 =67%
Test for overall effect: Z = 4.11 (P = 0.000039)
Test for subgroup differences: Chi2 = 0.94, df = 1 (P = 0.33), I2 =0.0%
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Analysis 1.2. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 2
Gingival Index (0-3) 6 months.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 2 Gingival Index (0-3) 6 months
Study or subgroup CHX Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Chaves 1994 24 0.95 (0.3) 27 1.05 (0.4) 6.4 % -0.10 [ -0.29, 0.09 ]
Flemmig 1990 43 0.39 (0.1732051) 48 0.51 (0.1732051) 8.3 % -0.12 [ -0.19, -0.05 ]
Subtotal (95% CI) 67 75 14.7 % -0.12 [ -0.18, -0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.45 (P = 0.00057)
2 CHX versus placebo/control rinse
Bajaj 2011 440 0.54 (0.22) 412 1.18 (0.55) 8.4 % -0.64 [ -0.70, -0.58 ]
Banting 1989 190 0.23 (0.2) 193 0.36 (0.2) 8.5 % -0.13 [ -0.17, -0.09 ]
Charles 2004 36 0.99 (0.2) 37 1.21 (0.2) 8.0 % -0.22 [ -0.31, -0.13 ]
Flotra 1972 22 0.6 (0.34) 6 1.06 (0.43) 3.7 % -0.46 [ -0.83, -0.09 ]
Grossman 1986 187 0.3371 (0.3) 193 0.53 (0.3) 8.4 % -0.19 [ -0.25, -0.13 ]
Grossman 1989 113 0.2514 (0.1652271) 133 0.37 (0.1652271) 8.5 % -0.11 [ -0.16, -0.07 ]
Jayaprakash 2007 100 0.0616 (0.2) 50 0.1 (0.2) 8.3 % -0.04 [ -0.11, 0.03 ]
Lang 1998 41 0.85 (0.2) 45 0.97 (0.2) 8.1 % -0.12 [ -0.20, -0.04 ]
Lucas 1999 10 0.15 (0.2) 10 0.35 (0.2) 6.7 % -0.20 [ -0.38, -0.02 ]
Sanz 1994 66 1.03 (0.2) 64 1.25 (0.2) 8.3 % -0.22 [ -0.29, -0.15 ]
Stookey 2005 40 0.459 (0.1518) 86 0.68 (0.1484) 8.4 % -0.22 [ -0.28, -0.17 ]
Subtotal (95% CI) 1245 1229 85.3 % -0.22 [ -0.33, -0.11 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 286.28, df = 10 (P<0.00001); I2 =97%
Test for overall effect: Z = 4.05 (P = 0.000052)
Total (95% CI) 1312 1304 100.0 % -0.20 [ -0.30, -0.11 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 292.10, df = 12 (P<0.00001); I2 =96%
Test for overall effect: Z = 4.21 (P = 0.000026)
Test for subgroup differences: Chi2 = 2.58, df = 1 (P = 0.11), I2 =61%
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Analysis 1.3. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 3
Gingival bleeding 4-6 weeks.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 3 Gingival bleeding 4-6 weeks
Study or subgroup CHX Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Jose 2015 214 0.1474 (0.0812) 105 0.21 (0.124) 27.6 % -0.66 [ -0.90, -0.42 ]
Rahmani 2006 10 0.28 (0.18) 10 0.5 (0.25) 5.1 % -0.97 [ -1.91, -0.03 ]
Taller 1993 13 0.4 (0.15625) 13 0.52 (0.0941666) 6.5 % -0.92 [ -1.73, -0.10 ]
Van Strydonck 2008 47 0.74 (0.31) 47 0.95 (0.31) 17.0 % -0.67 [ -1.09, -0.26 ]
Subtotal (95% CI) 284 175 56.2 % -0.69 [ -0.89, -0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 6.91 (P < 0.00001)
2 CHX versus placebo/control rinse
Anauate-Netto 2014 20 4.4 (5.2) 20 3.8 (2.9) 10.0 % 0.14 [ -0.48, 0.76 ]
Ernst 2005 33 0.38 (0.24) 28 0.48 (0.34) 13.3 % -0.34 [ -0.85, 0.17 ]
Hase 1995 21 0.0525 (0.046) 18 0.14 (0.122) 8.8 % -1.00 [ -1.67, -0.33 ]
Turkoglu 2009 25 0.8 (0.5) 25 0.96 (0.6) 11.7 % -0.29 [ -0.84, 0.27 ]
Subtotal (95% CI) 99 91 43.8 % -0.36 [ -0.77, 0.06 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 6.06, df = 3 (P = 0.11); I2 =51%
Test for overall effect: Z = 1.68 (P = 0.093)
Total (95% CI) 383 266 100.0 % -0.56 [ -0.79, -0.33 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 10.57, df = 7 (P = 0.16); I2 =34%
Test for overall effect: Z = 4.84 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.06, df = 1 (P = 0.15), I2 =51%
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Analysis 1.4. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 4
Gingival bleeding 6 months.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 4 Gingival bleeding 6 months
Study or subgroup CHX Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Chaves 1994 24 0.21 (0.147) 27 0.3 (0.156) 10.4 % -0.58 [ -1.15, -0.02 ]
Flemmig 1990 43 0.264 (0.1048809) 48 0.31 (0.1048809) 12.4 % -0.44 [ -0.86, -0.03 ]
Subtotal (95% CI) 67 75 22.8 % -0.49 [ -0.83, -0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
2 CHX versus placebo/control rinse
Grossman 1986 187 0.065 (0.1) 193 0.11 (0.1) 15.2 % -0.48 [ -0.68, -0.28 ]
Grossman 1989 113 0.0493 (0.0547723) 133 0.08 (0.0547723) 14.6 % -0.57 [ -0.83, -0.31 ]
Hase 1998 30 0.271 (0.197) 33 0.38 (0.19) 11.2 % -0.55 [ -1.05, -0.04 ]
Lang 1998 45 0.1108 (0.097) 47 0.34 (0.147) 11.4 % -1.85 [ -2.34, -1.36 ]
Overholser 1990 41 0.25 (0.2881) 42 0.33 (0.3694) 12.2 % -0.24 [ -0.67, 0.19 ]
Stookey 2005 40 0.088 (0.0613) 86 0.16 (0.061) 12.6 % -1.16 [ -1.56, -0.75 ]
Subtotal (95% CI) 456 534 77.2 % -0.79 [ -1.16, -0.41 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 35.66, df = 5 (P<0.00001); I2 =86%
Test for overall effect: Z = 4.08 (P = 0.000046)
Total (95% CI) 523 609 100.0 % -0.72 [ -1.02, -0.42 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 36.57, df = 7 (P<0.00001); I2 =81%
Test for overall effect: Z = 4.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.28, df = 1 (P = 0.26), I2 =22%
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Analysis 1.5. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 5 Plaque
4-6 weeks.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 5 Plaque 4-6 weeks
Study or subgroup CHX Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Jose 2015 214 2.4694 (0.8577) 105 3.3 (0.6353) 9.9 % -1.05 [ -1.29, -0.80 ]
Rahmani 2006 10 0.52 (0.48) 10 0.88 (0.39) 7.2 % -0.79 [ -1.71, 0.13 ]
Van Strydonck 2008 47 0.26 (0.29) 47 0.99 (0.32) 8.9 % -2.37 [ -2.90, -1.84 ]
Subtotal (95% CI) 271 162 26.0 % -1.43 [ -2.39, -0.47 ]
Heterogeneity: Tau2 = 0.63; Chi2 = 20.60, df = 2 (P = 0.00003); I2 =90%
Test for overall effect: Z = 2.91 (P = 0.0036)
2 CHX versus placebo/control rinse
Axelsson 1987 42 0.4143 (0.4594) 22 1.2 (0.469) 8.7 % -1.68 [ -2.27, -1.08 ]
Bhat 2014 22 0.68 (0.14) 22 1.46 (0.19) 6.1 % -4.59 [ -5.76, -3.42 ]
Ernst 2005 33 0.385 (0.232) 28 0.54 (0.204) 9.0 % -0.68 [ -1.20, -0.16 ]
Graziani 2015 55 0.1314 (0.0842) 15 0.21 (0.0636) 8.7 % -1.02 [ -1.61, -0.42 ]
Hase 1995 21 0.04 (0.0458) 18 0.75 (0.4) 7.4 % -2.55 [ -3.41, -1.68 ]
Jenkins 1993 49 1.15 (0.76) 50 1.8 (0.51) 9.4 % -1.00 [ -1.42, -0.58 ]
Lopez-Jornet 2012 35 0.83 (0.84) 35 1.06 (0.85) 9.2 % -0.27 [ -0.74, 0.20 ]
Navarro 1998 9 1.706 (0.783) 11 2.29 (0.4212) 7.1 % -0.92 [ -1.86, 0.02 ]
Turkoglu 2009 25 1.69 (0.6) 25 2.56 (0.5) 8.5 % -1.55 [ -2.19, -0.91 ]
Subtotal (95% CI) 291 226 74.0 % -1.48 [ -2.07, -0.89 ]
Heterogeneity: Tau2 = 0.69; Chi2 = 65.44, df = 8 (P<0.00001); I2 =88%
Test for overall effect: Z = 4.90 (P < 0.00001)
Total (95% CI) 562 388 100.0 % -1.45 [ -1.90, -1.00 ]
Heterogeneity: Tau2 = 0.52; Chi2 = 86.66, df = 11 (P<0.00001); I2 =87%
Test for overall effect: Z = 6.31 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 1.6. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 6 Plaque
4-6 weeks PI (0-3).
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 6 Plaque 4-6 weeks PI (0-3)
Study or subgroup CHX Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Rahmani 2006 10 0.52 (0.48) 10 0.88 (0.39) 16.4 % -0.36 [ -0.74, 0.02 ]
Van Strydonck 2008 47 0.26 (0.29) 47 0.99 (0.32) 36.8 % -0.73 [ -0.85, -0.61 ]
Subtotal (95% CI) 57 57 53.2 % -0.59 [ -0.94, -0.24 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 3.24, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 3.30 (P = 0.00096)
2 CHX versus placebo/control rinse
Hase 1995 21 0.04 (0.0458) 18 0.75 (0.4) 31.1 % -0.71 [ -0.90, -0.52 ]
Lopez-Jornet 2012 35 0.83 (0.84) 35 1.06 (0.85) 15.7 % -0.23 [ -0.63, 0.17 ]
Subtotal (95% CI) 56 53 46.8 % -0.50 [ -0.97, -0.04 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 4.63, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 2.12 (P = 0.034)
Total (95% CI) 113 110 100.0 % -0.58 [ -0.78, -0.39 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.34, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
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Analysis 1.7. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 7 Plaque
4-6 weeks TQH (0-5).
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 7 Plaque 4-6 weeks TQH (0-5)
Study or subgroup CHX Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Jose 2015 214 2.4694 (0.8577) 105 3.3 (0.6353) 20.5 % -0.83 [ -1.00, -0.66 ]
Subtotal (95% CI) 214 105 20.5 % -0.83 [ -1.00, -0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.73 (P < 0.00001)
2 CHX versus placebo/control rinse
Axelsson 1987 42 0.4143 (0.4594) 22 1.2 (0.469) 9.9 % -0.79 [ -1.03, -0.55 ]
Bhat 2014 22 0.68 (0.14) 22 1.46 (0.19) 59.0 % -0.78 [ -0.88, -0.68 ]
Jenkins 1993 49 1.15 (0.76) 50 1.8 (0.51) 8.8 % -0.65 [ -0.91, -0.39 ]
Navarro 1998 9 1.706 (0.783) 11 2.29 (0.4212) 1.8 % -0.59 [ -1.15, -0.02 ]
Subtotal (95% CI) 122 105 79.5 % -0.76 [ -0.85, -0.68 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.28, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 17.58 (P < 0.00001)
Total (95% CI) 336 210 100.0 % -0.78 [ -0.85, -0.70 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.79, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 20.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.51, df = 1 (P = 0.47), I2 =0.0%
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Analysis 1.8. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 8 Plaque
6 months.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 8 Plaque 6 months
Study or subgroup CHX Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Chaves 1994 24 0.8 (0.3) 27 1 (0.8) 8.6 % -0.32 [ -0.87, 0.23 ]
Flemmig 1990 43 0.43 (0.3162278) 48 0.75 (0.3162278) 9.5 % -1.00 [ -1.44, -0.57 ]
Subtotal (95% CI) 67 75 18.1 % -0.68 [ -1.35, -0.01 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 3.62, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 2.00 (P = 0.046)
2 CHX versus placebo/control rinse
Bajaj 2011 440 0.72 (0.26) 412 2.01 (0.84) 11.0 % -2.10 [ -2.27, -1.93 ]
Charles 2004 36 1.71 (0.5) 37 2.18 (0.4) 9.1 % -1.03 [ -1.52, -0.54 ]
Flotra 1972 22 0.15 (0.17) 6 0.94 (0.4) 4.1 % -3.30 [ -4.59, -2.00 ]
Grossman 1986 188 0.61 (0.5) 189 1.56 (0.5) 10.7 % -1.90 [ -2.14, -1.65 ]
Grossman 1989 113 0.76 (0.5086256) 133 1.49 (0.5086256) 10.5 % -1.43 [ -1.71, -1.15 ]
Hase 1998 30 0.96 (0.6573) 33 1.66 (0.6319) 8.8 % -1.07 [ -1.60, -0.54 ]
Lang 1998 41 0.31 (0.2561) 45 0.79 (0.4) 9.2 % -1.40 [ -1.88, -0.93 ]
Overholser 1990 41 0.815 (0.5) 42 1.64 (0.512) 9.0 % -1.61 [ -2.11, -1.11 ]
Stookey 2005 40 1.35 (0.468) 85 1.97 (0.461) 9.6 % -1.33 [ -1.74, -0.92 ]
Subtotal (95% CI) 951 982 81.9 % -1.59 [ -1.89, -1.29 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 49.48, df = 8 (P<0.00001); I2 =84%
Test for overall effect: Z = 10.24 (P < 0.00001)
Total (95% CI) 1018 1057 100.0 % -1.43 [ -1.76, -1.10 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 84.73, df = 10 (P<0.00001); I2 =88%
Test for overall effect: Z = 8.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.85, df = 1 (P = 0.02), I2 =83%
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Analysis 1.9. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 9 Plaque
6 months PI (0-3).
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 9 Plaque 6 months PI (0-3)
Study or subgroup CHX Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Flemmig 1990 43 0.43 (0.3162278) 48 0.75 (0.3162278) 20.5 % -0.32 [ -0.45, -0.19 ]
Chaves 1994 24 0.8 (0.3) 27 1 (0.8) 19.1 % -0.20 [ -0.52, 0.12 ]
Subtotal (95% CI) 67 75 39.7 % -0.30 [ -0.42, -0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 4.92 (P < 0.00001)
2 CHX versus placebo/control rinse
Bajaj 2011 440 0.72 (0.26) 412 2.01 (0.84) 20.7 % -1.29 [ -1.37, -1.21 ]
Flotra 1972 22 0.15 (0.17) 6 0.94 (0.4) 19.1 % -0.79 [ -1.12, -0.46 ]
Lang 1998 41 0.31 (0.2561) 45 0.79 (0.4) 20.5 % -0.48 [ -0.62, -0.34 ]
Subtotal (95% CI) 503 463 60.3 % -0.86 [ -1.46, -0.25 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 96.20, df = 2 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.76 (P = 0.0057)
Total (95% CI) 570 538 100.0 % -0.62 [ -1.12, -0.12 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 209.21, df = 4 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 3.06, df = 1 (P = 0.08), I2 =67%
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Analysis 1.10. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 10
Plaque 6 months TQH (0-5).
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 10 Plaque 6 months TQH (0-5)
Study or subgroup CHX Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus placebo/control rinse
Grossman 1986 188 0.61 (0.5) 189 1.56 (0.5) 20.6 % -0.95 [ -1.05, -0.85 ]
Overholser 1990 41 0.815 (0.5) 42 1.64 (0.512) 15.4 % -0.82 [ -1.04, -0.61 ]
Grossman 1989 113 0.76 (0.5086256) 133 1.49 (0.5086256) 19.5 % -0.73 [ -0.86, -0.60 ]
Hase 1998 30 0.96 (0.6573) 33 1.66 (0.6319) 11.3 % -0.70 [ -1.02, -0.38 ]
Stookey 2005 40 1.35 (0.468) 85 1.97 (0.461) 17.4 % -0.62 [ -0.80, -0.44 ]
Charles 2004 36 1.71 (0.5) 37 2.18 (0.4) 15.9 % -0.47 [ -0.68, -0.26 ]
Total (95% CI) 448 519 100.0 % -0.73 [ -0.88, -0.57 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 23.59, df = 5 (P = 0.00026); I2 =79%
Test for overall effect: Z = 9.39 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 11
Calculus 4-6 weeks.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 11 Calculus 4-6 weeks
Study or subgroup CHX Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus placebo/control rinse
Emling 1992 26 0.46 (0.287) 26 0.45 (0.4904) 28.6 % 0.01 [ -0.21, 0.23 ]
Turkoglu 2009 25 0.3385 (0.198) 25 0.31 (0.292) 71.4 % 0.03 [ -0.11, 0.17 ]
Subtotal (95% CI) 51 51 100.0 % 0.02 [ -0.09, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 12
Calculus 7-12 weeks.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 12 Calculus 7-12 weeks
Study or subgroup CHX Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Flemmig 1990 44 7.98 (4.8703183) 51 2.95 (4.8703183) 18.0 % 1.02 [ 0.59, 1.45 ]
Subtotal (95% CI) 44 51 18.0 % 1.02 [ 0.59, 1.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.67 (P < 0.00001)
2 CHX versus placebo/control rinse
Corbet 1997 13 2.67 (0.4687) 23 2.39 (0.9) 13.0 % 0.35 [ -0.33, 1.04 ]
Emling 1992 26 0.51 (0.2657) 26 0.4 (0.5142) 15.6 % 0.28 [ -0.27, 0.82 ]
Hase 1998 35 0.19 (0.2899) 34 0.14 (0.2449) 17.1 % 0.18 [ -0.29, 0.66 ]
Lang 1998 41 0.75 (0.4) 49 0.86 (0.56) 18.3 % -0.22 [ -0.64, 0.20 ]
Overholser 1990 41 0.15 (0.2241) 42 0.09 (0.1426) 17.9 % 0.32 [ -0.12, 0.75 ]
Subtotal (95% CI) 156 174 82.0 % 0.14 [ -0.08, 0.36 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.18, df = 4 (P = 0.38); I2 =4%
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 200 225 100.0 % 0.32 [ -0.04, 0.69 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 17.16, df = 5 (P = 0.004); I2 =71%
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Chi2 = 12.80, df = 1 (P = 0.00), I2 =92%
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Analysis 1.13. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 13
Calculus 6 months.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 13 Calculus 6 months
Study or subgroup CHX OH alone
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Flemmig 1990 43 12.65 (6.6257075) 48 3.39 (6.6257075) 25.0 % 1.39 [ 0.93, 1.85 ]
Subtotal (95% CI) 43 48 25.0 % 1.39 [ 0.93, 1.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.90 (P < 0.00001)
2 CHX versus placebo/control rinse
Hase 1998 30 0.27 (0.3122) 33 0.14 (0.2413) 23.9 % 0.46 [ -0.04, 0.96 ]
Lang 1998 41 0.97 (0.4482) 45 0.78 (0.5367) 25.9 % 0.38 [ -0.05, 0.81 ]
Overholser 1990 41 0.36 (0.3714) 42 0.09 (0.1361) 25.1 % 0.96 [ 0.51, 1.42 ]
Subtotal (95% CI) 112 120 75.0 % 0.60 [ 0.24, 0.96 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 3.72, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 3.25 (P = 0.0012)
Total (95% CI) 155 168 100.0 % 0.80 [ 0.33, 1.26 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 12.17, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 3.37 (P = 0.00074)
Test for subgroup differences: Chi2 = 6.90, df = 1 (P = 0.01), I2 =86%
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Analysis 1.14. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 14
Tooth staining 4-6 weeks dichotomous.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 14 Tooth staining 4-6 weeks dichotomous
Study or subgroup CHX Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CHX versus no rinse
Zimmer 2015 26/78 3/40 75.3 % 4.44 [ 1.43, 13.80 ]
Subtotal (95% CI) 78 40 75.3 % 4.44 [ 1.43, 13.80 ]
Total events: 26 (CHX), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.0098)
2 CHX versus placebo/control rinse
Sanz 1989 8/17 1/21 24.7 % 9.88 [ 1.37, 71.44 ]
Subtotal (95% CI) 17 21 24.7 % 9.88 [ 1.37, 71.44 ]
Total events: 8 (CHX), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Total (95% CI) 95 61 100.0 % 5.41 [ 2.03, 14.47 ]
Total events: 34 (CHX), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00076)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
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Analysis 1.15. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 15
Tooth staining 7-12 weeks dichotomous.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 15 Tooth staining 7-12 weeks dichotomous
Study or subgroup CHX Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CHX versus no rinse
Zimmer 2015 39/78 8/40 100.0 % 2.50 [ 1.29, 4.83 ]
Subtotal (95% CI) 78 40 100.0 % 2.50 [ 1.29, 4.83 ]
Total events: 39 (CHX), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 16
Tooth staining 4-6 weeks.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 16 Tooth staining 4-6 weeks
Study or subgroup CHX Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Van Strydonck 2008 47 1.02 (0.48) 47 0.42 (0.26) 17.6 % 1.54 [ 1.08, 2.00 ]
Subtotal (95% CI) 47 47 17.6 % 1.54 [ 1.08, 2.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.53 (P < 0.00001)
2 CHX versus placebo/control rinse
Brecx 1993 10 1.1 (0.4) 12 0.7 (0.3) 7.1 % 1.10 [ 0.19, 2.02 ]
Brightman 1991 16 0.9 (0.6) 18 0.5 (0.4) 10.6 % 0.78 [ 0.07, 1.48 ]
Emling 1992 26 0.8575 (0.6096) 26 0.51 (0.4616) 14.3 % 0.64 [ 0.08, 1.20 ]
Ernst 2005 33 0.69 (0.39) 28 0.25 (0.29) 14.5 % 1.25 [ 0.70, 1.80 ]
Ferretti 1987 16 4.2 (2.9) 17 0.9 (0.7) 8.9 % 1.55 [ 0.76, 2.34 ]
Jenkins 1993 49 0.052 (0.05) 50 0.01 (0.02) 19.4 % 1.02 [ 0.60, 1.44 ]
Navarro 1998 9 0.138 (0.414) 11 0.02 (0.0763) 7.4 % 0.39 [ -0.50, 1.28 ]
Subtotal (95% CI) 159 162 82.4 % 0.97 [ 0.73, 1.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.41, df = 6 (P = 0.38); I2 =6%
Test for overall effect: Z = 7.80 (P < 0.00001)
Total (95% CI) 206 209 100.0 % 1.07 [ 0.80, 1.34 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 10.98, df = 7 (P = 0.14); I2 =36%
Test for overall effect: Z = 7.70 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.50, df = 1 (P = 0.03), I2 =78%
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Analysis 1.17. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 17
Tooth staining 7-12 weeks.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 17 Tooth staining 7-12 weeks
Study or subgroup CHX Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Flemmig 1990 44 4.94 (1.4696938) 51 2.98 (1.4696938) 14.1 % 1.32 [ 0.88, 1.77 ]
Subtotal (95% CI) 44 51 14.1 % 1.32 [ 0.88, 1.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.80 (P < 0.00001)
2 CHX versus placebo/control rinse
Anderson 1997 13 1.465 (0.6550572) 15 0.57 (0.5150728) 5.2 % 1.50 [ 0.64, 2.35 ]
Brecx 1993 10 1.36 (0.5) 12 0.58 (1) 4.9 % 0.92 [ 0.03, 1.81 ]
Brightman 1991 16 1.4 (0.7) 18 0.5 (0.4) 6.1 % 1.57 [ 0.79, 2.35 ]
Corbet 1997 13 0.47 (0.3245) 23 0.31 (0.1) 7.2 % 0.75 [ 0.04, 1.45 ]
Emling 1992 26 0.92 (0.5739) 26 0.44 (0.4449) 10.0 % 0.92 [ 0.34, 1.49 ]
Ferretti 1987 16 10.7 (4.4) 17 7.3 (4.2) 7.1 % 0.77 [ 0.06, 1.48 ]
Hase 1998 35 0.0813 (0.0616) 34 0.02 (0.0337) 11.5 % 1.28 [ 0.76, 1.80 ]
Joyston-Bechal 1993 20 0.5 (0.55) 19 0.21 (0.39) 8.4 % 0.59 [ -0.05, 1.24 ]
Lang 1998 41 1.16 (0.6) 49 0.39 (0.35) 12.9 % 1.59 [ 1.11, 2.07 ]
Overholser 1990 41 0.71 (0.5955) 42 0.08 (0.1) 12.6 % 1.47 [ 0.98, 1.96 ]
Subtotal (95% CI) 231 255 85.9 % 1.17 [ 0.93, 1.41 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 12.84, df = 9 (P = 0.17); I2 =30%
Test for overall effect: Z = 9.55 (P < 0.00001)
Total (95% CI) 275 306 100.0 % 1.19 [ 0.98, 1.40 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 13.13, df = 10 (P = 0.22); I2 =24%
Test for overall effect: Z = 11.13 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.36, df = 1 (P = 0.55), I2 =0.0%
-2 -1 0 1 2
Favours CHX Favours control
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Analysis 1.18. Comparison 1 CHX versus placebo/control mouthrinse or no mouthrinse, Outcome 18
Tooth staining 6 months.
Review: Chlorhexidine mouthrinse as an adjunctive treatment for gingival health
Comparison: 1 CHX versus placebo/control mouthrinse or no mouthrinse
Outcome: 18 Tooth staining 6 months
Study or subgroup CHX Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CHX versus no rinse
Flemmig 1990 43 5.26 (1.8867962) 48 3.02 (1.8867962) 28.9 % 1.18 [ 0.73, 1.62 ]
Subtotal (95% CI) 43 48 28.9 % 1.18 [ 0.73, 1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.16 (P < 0.00001)
2 CHX versus placebo/control rinse
Hase 1998 30 0.1001 (0.0732) 33 0.01 (0.0219) 21.0 % 1.63 [ 1.05, 2.20 ]
Lang 1998 41 1.22 (0.5) 45 0.43 (0.3) 24.3 % 1.92 [ 1.41, 2.44 ]
Overholser 1990 41 1.45 (1.2742) 42 0.07 (0.1426) 25.8 % 1.52 [ 1.03, 2.01 ]
Subtotal (95% CI) 112 120 71.1 % 1.69 [ 1.38, 1.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.29, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 10.94 (P < 0.00001)
Total (95% CI) 155 168 100.0 % 1.54 [ 1.22, 1.86 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 4.72, df = 3 (P = 0.19); I2 =36%
Test for overall effect: Z = 9.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 3.43, df = 1 (P = 0.06), I2 =71%
-4 -2 0 2 4
Favours CHX Favours control
A D D I T I O N A L T A B L E S
Table 1. Random-effects metaregression analyses of Gingival Index (GI) at 4 to 6 weeks
Characteristic Number of studies Slope estimate 95% CI Slope interpretation P value
Adults versus chil-
dren
10 - no studies with
just children
Gingivitis alone ver-
sus gingivitis with
perio
8 0.12 -0.14 to 0.38 Increase in GI effect es-
timate for gingivitis and
perio
0.30
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Table 1. Random-effects metaregression analyses of Gingival Index (GI) at 4 to 6 weeks (Continued)
Prophylaxis or not 9 0.05 -0.22 to 0.32 Increase in GI effect esti-
mate for prophylaxis
0.66
Baseline gingivitis <
1 versus > 1
9 0.02 -0.25 to 0.30 Increase in GI effect esti-
mate for higher baseline
score
0.84
CI = confidence interval.
Table 2. Random-effects metaregression analyses of Gingival Index (GI) at 6 months
Characteristic Number of studies Slope estimate 95% CI Slope interpretation P value
Adults versus chil-
dren
13 -0.17 -0.42 to 0.09 Increase in GI effect es-
timate for adults
0.185
Gingivitis alone ver-
sus gingivitis with
perio
9 0.15 -0.14 to 0.44 Increase in GI effect es-
timate for gingivitis and
perio
0.25
Prophylaxis or not 11 -0.13 -0.25 to -0.004 Increase inGI effect esti-
mate for no prophylaxis
0.045
Baseline gingivitis
< 1 versus > 1
9 -0.05 -0.39 to 0.30 Decrease in GI effect es-
timate for higher base-
line score
0.75
CI = confidence interval.
Table 3. Chlorhexidine concentration: all trials
Outcome
(index)
Time Chlorhexidine
concentration
Studies (partici-
pants)
MD/SMD 95%
CI
Effect P value Subgroup P
value
Gin-
gival inflamma-
tion (Gingival
Index)
4 to 6 weeks 0.2 6 (552) MD -0.27 (-0.46
to -0.09)
0.003 favours
CHX
0.41
0.1 and 0.12 5 (253) MD -0.19 (-0.27
to -0.10)
< 0.0001 favours
CHX
Gin-
gival inflamma-
tion (Gingival
Index)
6 months 0.2 1 (86) MD -0.12 (-0.20
to -0.04)
0.005 Too few studies
in subgroup
0.1 and 0.12 10 (2352) MD -0.22 (-0.33
to -0.11)
< 0.00001
favours CHX
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Table 3. Chlorhexidine concentration: all trials (Continued)
0.05 1 (150) MD -0.04 (-0.11
to 0.03)
0.28
Gingival bleed-
ing
4 to 6 weeks 0.2 4 (472) SMD -0.71 (-0.
90 to -0.51)
< 0.00001
favours CHX
0.18
0.1 and 0.12 3 (127) SMD -0.32 (-0.
85 to 0.21)
0.23
Gingival bleed-
ing
6 months 0.2 2 (155) SMD -1.20 (-2.
48 to 0.08)
0.07 0.34
0.12 6 (977) SMD -0.57 (-0.
79 to -0.36)
< 0.00001
favours CHX
Plaque 4 to 6 weeks 0.2 8 (685) SMD -1.75 (-2.
45 to -1.04)
< 0.00001
favours CHX
0.04
0.1 and 0.12 4 (215) SMD -0.95 (-1.
23 to -0.66)
< 0.00001
favours CHX
Plaque 6 months 0.2 2 (149) SMD -1.26 (-1.
61 to -0.90)
< 0.00001
favours Chx
0.65
0.1 and 0.12 8 (1898) SMD -1.38 (-1.
75 to -1.00)
< 0.00001
favours CHX
Calculus 4 to 6 weeks 0.12 1 (52) MD 0.01 (-0.21
to 0.23)
0.93
Calculus 7 to 12 weeks 0.2 2 (159) SMD -0.03 (-0.
43 to 0.36)
0.86 0.05
0.12 4 (266) SMD 0.52 (0.13
to 0.91)
0.10
Calculus 6 months 0.2 2 (149) SMD 0.41 (0.09
to 0.74)
0.01 0.005
0.12 2 (174) SMD 1.17 (0.76
to 1.59)
< 0.00001
favours control
Tooth staining 4 to 6 weeks 0.2 2 (116) SMD 1.45 (1.04
to 1.87)
< 0.00001
favours control
0.05
0.1 and 0.12 6 (299) SMD 0.96 (0.68
to 1.24)
< 0.00001
favours control
Tooth staining 7 to 12 weeks 0.2 3 (181) SMD 1.38 (1.05
to 1.71)
< 0.00001
favours control
0.10
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Table 3. Chlorhexidine concentration: all trials (Continued)
0.12 7 (361) SMD 1.2 (0.96
to 1.45)
< 0.00001
favours control
0.05 1 (39) SMD0.59 (-0.05
to 1.24)
0.07
Tooth staining 6 months 0.2 2 (149) SMD 1.79 (1.41
to 2.17)
< 0.00001
favours control
0.08
0.12 2 (174) SMD 1.33 (1.00
to 1.66)
< 0.00001
favours control
CHX = chlorhexidine; CI = confidence interval; MD = mean difference; SMD = standardised mean difference.
Studies where the concentration of the chlorhexidine mouthrinse was not reported (Turkoglu 2009) and where data relate to a
combination of different chlorhexidine concentrations (Flotra 1972) were excluded from this analysis. Therefore, in certain analyses,
the number of studies and participants presented in the table are different from the data presented in the main analysis.
Table 4. Chlorhexidine rinse frequency of use: all trials
Outcome
(index)
Time Chlorhexidine
frequency
Studies (partici-
pants)
MD/SMD 95%
CI
Effect P value Subgroup P value
Gin-
gival inflamma-
tion (Gingival
Index)
4 to 6 weeks Twice per day 9 (785) MD -0.22 (-0.33
to -0.11)
< 0.0001 Too few studies in
subgroup
Once per day 1 (20) MD -0.13 (-0.31
to 0.06)
0.18
Gin-
gival inflamma-
tion (Gingival
Index)
6 months Twice per day 11 (1614) MD -0.17 (-0.20
to -0.13)
< 0.0001 0.56
Once per day 2 (1002) MD -0.34 (-0.93
to 0.25)
0.26
Gingival bleed-
ing
4 to 6 weeks Twice per day 8 (649) SMD -0.56 (-0.
79 to -0.33)
< 0.0001 -
Gingival bleed-
ing
6 months Twice per day 8 (1132) SMD -0.72 (-1.
02 to -0.42)
< 0.0001 -
Plaque 4 to 6 weeks Twice per day 11 (930) SMD -1.49 (-1.
97 to -1.02)
< 0.0001 Too few studies in
subgroup
Once per day 1 (20) SMD -0.92 (-1.
86 to 0.02)
0.05
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Table 4. Chlorhexidine rinse frequency of use: all trials (Continued)
Plaque 6 months Twice per day 10 (1223) SMD -1.34 (-1.
66 to -1.03)
< 0.0001 Too few studies in
subgroup
Once a day 1 (852) SMD -2.10 (-2.
27 to -1.93)
< 0.0001
Calculus 4 to 6 weeks Twice per day 1 (50) MD 0.03 (-0.11
to 0.17)
0.70 -
Calculus 7 to 12 weeks Twice per day 5 (373) SMD0.33 (-0.11
to 0.77)
0.14 -
Calculus 6 months Twice per day 4 (323) SMD 0.80 (0.33
to 1.26)
0.0007 -
Tooth staining 4 to 6 weeks 3 times per day 1 (33) SMD 1.55 (0.76
to 2.34)
< 0.0001 Too few studies in
subgroup
Twice per day 5 (310) SMD 1.18 (0.93
to 1.44)
< 0.0001
Once per day 1(20) SMD 0.39 (-0.5
to 1.28)
0.39
Tooth staining 7 to 12 weeks 3 times per day 1 (33) SMD 0.77 (0.06
to 1.48)
0.03 Too few studies in
subgroup
Twice per day 9 (496) SMD 1.26 (1.04
to 1.49)
< 0.0001
Tooth staining 6 months Twice per day 4 (323) SMD 1.54 (1.22
to 1.86)
< 0.0001 -
CI = confidence interval; MD = mean difference; SMD = standardised mean difference.
Table 5. Results for gingivitis and plaque at 7 to 12 weeks, > 6 months and long term (after cessation of mouthrinsing)
Outcome
(index)
Time Chlorhexidine
conc (%)
Studies (partici-
pants)
MD/SMD 95%
CI
Effect P value Heterogeneity
Results for studies with no rinse control arms
Gingival bleed-
ing
7 to 12 weeks < 0.1 2 (196) MD -0.07 (-0.16
to 0.02)
0.13 favours
CHX
P = 0.19, I2 =
40%
Plaque 7 to 12 weeks < 0.1 2 (196) SMD -0.77 (-1.
07 to -0.47)
< 0.00001
favours CHX
P = 0.61, I2 = 0%
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Table 5. Results for gingivitis and plaque at 7 to 12 weeks, > 6 months and long term (after cessation of mouthrinsing)
(Continued)
Results for studies with placebo/control rinse arms
Gin-
gival inflamma-
tion (Gingival
Index)
7 to 12 weeks 0.2 and 0.12 4 (144) MD -0.47 (-0.76
to -0.18)
0.001 favours
CHX
P < 0.0001, I2 =
86%
Gin-
gival inflamma-
tion (Gingival
Index)
> 6 months 0.1 and 0.12 2 (1124) MD -0.50 (-1.11
to 0.11)
0.11 favours
CHX
P < 0.0001, I2 =
99%
Gingival bleed-
ing
7 to 12 weeks 0.12 and < 0.1 5 (182) SMD -1.29 (-1.
85 to -0.72)
< 0.00001
favours CHX
P = 0.02, I2 =
64%
Gingival bleed-
ing
Long term 0.12 3 (99) MD -0.12 (-0.2
to -0.04)
0.003 favours
CHX
P = 0.33, I2 =
11%
Plaque 7 to 12 weeks 0.2, 0.12 and < 0.
1
10 (423) SMD -1.74 (-2.
51 to -0.98)
< 0.00001
favours CHX
P < 0.00001, I2 =
91%
Plaque > 6 months 0.1 1 (852) MD -1.55 (-1.79
to -1.31)
< 0.00001
favours CHX
N/A
Plaque Long term 0.12 4 (132) SMD -1.10 (-1.
18 to -0.40)
< 0.002 favours
CHX
P = 0.02, I2 =
71%
CHX=chlorhexidine;CI = confidence interval; conc = concentration;MD=meandifference;N/A=not applicable; SMD= standardised
mean difference.
There were no subgroup differences between the different chlorhexidine concentrations, therefore the overall effect for all concentrations
combined is reported.
Table 6. Studies with a gingival inflammation outcome not included in meta-analyses
Time Study ID Comparison Index CHX mean
(SD)
Control
mean (SD)
Total n Notes
4 to 6 weeks Anauate-
Netto 2014
CHX 0.12%
vs placebo
PBS 0.9 (0.6) 0.7 (0.4) 40 Did not report GI.
Quote: “..no statisti-
cally significant dif-
ferences
were detected among
groups”
7 to 12 weeks Anderson
1997
CHX 0.12%
vs placebo
GI 0.345 0.895 28 Reported mean GI
by surface + SD. No
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Table 6. Studies with a gingival inflammation outcome not included in meta-analyses (Continued)
overall SD. We cal-
culated overall mean.
Quote: “The means
of the …gingival in-
dices did not show
any significant dif-
fer-
ences (P<0.05) 1 or
2 months after base-
line. However there
were significant dif-
ferences (P<0.05) in
the changes recorded
at 30 and 60 days at
all sites in…..the ex-
perimental group”
de la Rosa
1888b
CHX 0.12%
vs placebo
PMGI
severity (mean
score of all
sites graded)
0.1413 0.2902 92 Did not report GI or
a SD. Quote: “..the
effect
of the chlorhexidine
rinse on the occur-
rence and severity of
gingivitis amounted
to a 51% reduction
of the disease com-
pared to the placebo
rinse…differences
were statistically sig-
nificant”
de la Rosa
1988a
CHX 0.12%
vs placebo
PMGI
severity (mean
score of all
sites graded)
0.2892 0.4526 99 Did not report GI
or a SD. Quote: “..
the gingivitis reduc-
tions were 34% and
36% for occurrence
and severity respec-
tively…differences
were statistically sig-
nificant”
Eaton 1997 CHX 0.12%
vs placebo
mGI 0.42 (0.383) 0.55 (0.382) 98 Did not report GI.
Quote: “..the pooled
mean mGI score im-
proved by 25% from
0.56 at baseline to
0.42 at 12 weeks
in the ChD (CHX)
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Table 6. Studies with a gingival inflammation outcome not included in meta-analyses (Continued)
group but showed no
change (0.54 to 0.
55) in the placebo
group”
Ferretti 1987 CHX 0.12%
vs placebo
PMGI 0.8 1.94 33 Did not report GI
and SD depicted in
graph but not re-
ported. Quote: “Sig-
nificant reductions
in …gingivitis scores
were seen on days
33 (P<0.0001) and
60… (P<0.001) for
those patients using
chlorhexidine rinse”
Segreto 1986 0.
2% vs 0.12%
vs placebo
GI 0.4112/0.
3640
0.5039 454 Did not report a
SD. Quote: “Gin-
givitis severity by the
GI method was…
significantly lower at
3 months for both
chlorhexidine
groups compared to
the placebo group.
Differences ranged
from 28-46% and
averaged 37% for the
0.12% group. Dif-
ferences ranged from
18-40% for the 0.
20% group and aver-
aged 29%”
Weitz 1992 CHX 0.12%
vs placebo
GI 1.69 1.86 36 Did not report a SD.
Quote: “…the active
(CHX) groups had
significantly lower…
gingivitis scores than
the respective con-
trol groups. Over-
all, the active group
had a 10.27% reduc-
tion in the gingival
index…compared to
insignificant changes
in the control
groups”
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Table 6. Studies with a gingival inflammation outcome not included in meta-analyses (Continued)
6 months Fine 1985 CHX+OH vs
OH
Not clear.
Quote: “a gin-
gival inflam-
mation Index”
NR NR 83 Outcomes reported
in graphs which are
difficult to decipher.
Quote: “Whilst there
was a general im-
provement in all…
groups of patients,
no one group was
statistically signifi-
cantly different from
the other…”
Hoffmann
2001
CHX
0.1%,CHX0.
06%, CHX 0.
06%+F vs
control
GI Median 0.15/
0.29/0.34
Median 0.45 58 No
SD. At 3 months “..
only the 0.1% CHX
was different from
the control”. At 6
months “…the 0.1%
CHX showed signif-
icant differences…in
the GI…when com-
pared to the 0.06%
CHX/F” (P = 0.043)
Overholser
1990
CHX 0.12%
vs control
mGI 0.81 (SE 0.
065)
1.166 (SE 0.
063)
83 Did not report a SD.
Quote: “PX (CHX)
inhibited gin-
givitis development
by 26.8% (P<0.001)
at 3 months and by
30.5% (P<0.001) at
6 months, compared
to the control”
CHX = chlorhexidine; F = fluoride; NR = not reported; OH = oral hygiene; SD = standard deviation; SE = standard error.
Total n is the number of participants analysed in the study arms relevant to the review.
PBS (Papillary Bleeding Score, Loesche 1979) is measured on a 0-5 increasing scale.
GI (Gingival Index, Löe 1967; Löe and Silness 1963) is measured on a 0-3 increasing scale.
PMGI (Papillary Marginal Gingivitis Index, de la Rosa and Sturzenberger 1976) is measured on a 0-3 increasing scale.
mGI (modified Gingival Index, Lobene 1986) is measured on a 0-4 increasing scale.
Table 7. Studies with a gingival bleeding outcome not included in meta-analyses
Time Study ID Comparison Index CHX mean
(SD)
Control
mean (SD)
Total n Notes
229Chlorhexidine mouthrinse as an adjunctive treatment for gingival health (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 7. Studies with a gingival bleeding outcome not included in meta-analyses (Continued)
4 to 6 weeks Axelsson 1987 CHX 0.2% vs
CHX 0.1% vs
placebo
Mean % of
gingival units
with GI score
2 or 3
12%/11% 25% 64 Did not report a
SD. Quote: “In
all…study groups,
the % of gingi-
val units scoredGI
2+3 was reduced
between baseline..
and end of trial”
Graziani 2015 CHX
0.2%+Alc vs
CHX0.2%no
Alc vs
CHX+ADS vs
control rinse
FMBS /BOP Not clear 13.47% 70 Partial reporting
of outcome data.
Quote: “Statis-
tically significant
decreases in mean
full-mouth scores
of gingival inflam-
mation were
noted for all ex-
perimental study
groups at day 35
compared to base-
line. Between-
group changes in
FMBS…were
statistically signif-
icant only when
CHX2 (mean dif-
ference of 43.4 ±
22.4, P = 0.05)
andCHX3 (mean
difference of 46.1
± 23.1, P = 0.05)
were compared to
the CTRL group”
(note: CHX
2 = CHX no Alc,
CHX 3 = CHX +
ADS)
Sanz 1989 CHX 0.12%
vs placebo
Mean % sites
GI score 2 and
3
18.78% 31.31% 38 Did not report a
SD. Quote: “Be-
ginning at 4 weeks
of rinsing, gingi-
val bleeding was
significantly lower
in the CHX group
compared to the
placebo group by
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Table 7. Studies with a gingival bleeding outcome not included in meta-analyses (Continued)
an average of 41.
6% (P < 0.05). At
6 weeks that re-
duction was 40%,
(P < 0.05)”
7 to 12 weeks Corbet 1997 CHX 0.12%
vs placebo
Mean % sites
GI score 2 and
3
27%(anterior)
42%
(posterior)
52%(anterior)
75%
(posterior)
36 Did not report a
SD. Quote: “The
difference
between the mean
percentage of GB
of the test and
control groups at 3
months
was highly signifi-
cant (P < 0.001)”
Segreto 1986 CHX 0.2% vs
CHX 0.12%
vs placebo
Mean % sites
GI score 2 and
3
Examiner A:
3.4%/2%
Examiner B:
7.2%/6.2%
Examiner A:
3.81%
Examiner B:
14.9%
454 Did not report a
SD.
O.2%
Quote: “Bleeding
was 31% lower
(range 11-52%)
compared to the
placebo group” (P
> 0.05)
0.12% Quote: “.
.gingival bleeding
was sig-
nificantly lower by
an average of 53%
for both exam-
iners (range 48-
59%)” (P ≤ 0.05)
6 months Banting 1989 CHX 0.12%
vs placebo
Mean % sites
GI score 2 and
3
2.41% 4.12% 383 Did not re-
port a SD.Regard-
ing outcomes at 6
months to 2 years:
Quote: “Subjects
in the treatment
group…displayed
between 42% and
51% fewer
sites with moder-
ate to severe gin-
givitis (GI scores
of 2 or 3) com-
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Table 7. Studies with a gingival bleeding outcome not included in meta-analyses (Continued)
pared with sub-
jects in the con-
trol group” (P < 0.
0001)
Charles 2004 CHX 0.12%
vs control
Mean % sites
GI score 2 and
3
11.01% 20.65% 1156 sites % of bleeding sites
in each group is
presented. There
is a unit of anal-
ysis error (num-
ber of sites rather
than number of
subjects)
. Quote: “There
was a considerable
reduction in per-
cent bleeding sites
in the chlorhexi-
dine…groups at 6
months compared
with both control
and baseline”
Lucas 1999 CHX 0.12%
vs placebo
Mean % sites
GI score 2 and
3
1% 4.2% 20 Did not report a
SD. Quote: “Al-
though the per-
centage of bleed-
ing surfaces in the
chlorhex-
idine group was
less than in the
placebo group on
days 90 (33%)
and 180 (76%)
, the differences
were not signifi-
cant” (P = 0.07)
Sanz 1994 CHX 0.12%
vs placebo
% sites GI
score 2 and 3
Graph Graph 130 % bleeding sites
reported incom-
pletely in text and
also in a graph.
Did not report a
SD
Quote: “At 6
months…the pos-
itive
control group had
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Table 7. Studies with a gingival bleeding outcome not included in meta-analyses (Continued)
significantly fewer
bleeding sites than
the control group
(.. 23%...)”
Gingi-
val bleeding >
6 months
Banting 1989 CHX 0.12%
vs placebo
Mean % sites
GI score 2 and
3
4.41% 8.88% 272 Did not re-
port a SD.Regard-
ing outcomes at 6
months to 2 years:
Quote: “Subjects
in the treatment
group…displayed
between 42% and
51% fewer
sites with moder-
ate to severe gin-
givitis (GI scores
of 2 or 3) com-
pared with sub-
jects in the con-
trol group” (P < 0.
0001)
ADS = antidiscolouration system; Alc = alcohol; BOP = bleeding on probing; CHX = chlorhexidine; FMBS = Full-Mouth Bleeding
Score; GI = Gingival Index; SD = standard deviation.
Total n is the number of participants analysed in the study arms relevant to the review.
Table 8. Studies with a plaque outcome not included in meta-analyses
Time Study ID Comparison Index CHX mean
(SD)
Control mean
(SD)
Total n Notes
4 to 6 weeks Sanz 1989 CHX 0.12%
vs placebo
PI 0.452 0.9907 38 Did not report a SD
7 to 12 weeks Anderson
1997
CHX 0.12%
vs placebo
PI 0.3175* 0.8425* 28 Mean GI by surface +
SD reported. We calcu-
lated the overall mean.
No overall SD
de la Rosa
1888b
CHX 0.12%
vs placebo
TQH NR NR 92 Quote: “The reductions
in dental plaque were
not statistically signifi-
cant..”
de la Rosa
1988a
CHX 0.12%
vs placebo
TQH NR NR 99 Quote: “The reductions
in dental plaque were
not statistically signifi-
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Table 8. Studies with a plaque outcome not included in meta-analyses (Continued)
cant..”
Segreto 1986 0.
2% vs 0.12%
vs placebo
TQH 1.14/1.01 1.58 451 Did not report a SD
Weitz 1992 CHX 0.12%
vs placebo
PI 1.84 2.21 36 Did not report a SD
6 months Banting 1989 CHX 0.12%
vs placebo
TQH Graph Graph 383 Data presented in a
graph. Did not report
a SD. Quote: “Subjects
in the treatment group
had significantly lower
mean plaque scores than
those in the control
group at sixmonths, and
at one and two years.
The difference between
the groups ranged from
35% to 46%”
Hoffmann
2001
CHX
0.1%/CHX 0.
06%/CHX 0.
06%+F vs
control rinse
PI Median 0.13/0.
25/0.27
Median 0.72 58 Median only. Did not
report a SD
Jayaprakash
2007
CHX 0.
05%/ CHX 0.
05%+F vs
placebo
PI 0.0813/0.0459 0.1189 100 Did not report a SD
Lucas 1999 CHX 0.12%
vs placebo
OHI-S 0.33 0.59 20 Did not report a SD
Sanz 1994 CHX 0.12%
vs placebo
PI Graph Graph 130 Data presented in a
graph. Did not report
a SD. Quote: “…reduc-
tions in Plaque Index...
were statistically signifi-
cant for the positive con-
trol group…compared
with the reduction ob-
tained with the control
group.. These reduc-
tions were 41% (pos-
itive control)…after 3
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Table 8. Studies with a plaque outcome not included in meta-analyses (Continued)
months and 35%..after
6 months..”
Plaque > 6
months
Banting 1989 CHX 0.12%
vs placebo
TQH Graph Graph 272 Data presented in a
graph. Did not report
a SD. Quote: “Subjects
in the treatment group
had significantly lower
mean plaque scores than
those in the control
group at sixmonths, and
at one and two years.
The difference between
the groups ranged from
35% to 46%”
CHX = chlorhexidine; F = Fluoride; NR = not reported; SD = standard deviation.
Total n is the number of participants analysed in the study arms relevant to the review.
PI (Plaque Index, Silness and Löe 1964) is measured on a 0-3 increasing scale.
TQH (Turesky modification of the Quigley and Hein Index, Turesky 1970) is measured on a 0-5 increasing scale.
OHI-S (Simplified Oral Hygiene Index, Greene and Vermillion 1964) is measured on a 0-3 increasing scale.
Table 9. Studies with a calculus outcome not included in meta-analyses
Time Study ID Comparison Index CHX mean
(SD)
Controlmean
(SD)
Total n Notes
4 to 6 weeks Anderson
1997
CHX 0.12%
vs placebo
RI 0.1075 0.0475 29 Mean RI by surface +
SD reported. We cal-
culated overall mean.
No overall SD
7 to 12 weeks Anderson
1997
CHX 0.12%
vs placebo
RI 0.0875 0.0525 28 Mean RI by surface +
SD reported. We cal-
culated overall mean.
No overall SD
Charles 2004 CHX 0.12%
vs control
VM 0.37 (SD NR) 0.11 (SD NR) 74 Did not report a SD
Sanz 1994 CHX 0.12%
vs placebo
VM Graph Graph 130 Data presented in
graph. Did not re-
port a SD. Quote:
“All groups devel-
oped calculus after
the initial cleaning
at baseline. This in-
crease was only statis-
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Table 9. Studies with a calculus outcome not included in meta-analyses (Continued)
tically significant for
the positive control
group
compared with the
control group at 6
months”
Calculus 6
months
Banting 1989 CHX 0.12%
vs placebo
VM NR NR 383 Results reported at
24 months only. See
results at > 6 months
below
Charles 2004 CHX 0.12%
vs control
VM 0.45 (SD NR) 0.21 (SD NR) 73 Did not report a SD
Grossman
1986
CHX 0.12%
vs placebo
Not specified NR NR 380 Quote: “Supragingi-
val
calculus was higher
in the group using
chlorhexidine but
this increase in cal-
culus did not dimin-
ish the therapeutic ef-
fects of chlorhexidine
since subjects with
significant increases
in calculus also had
significant decreases
in gingivitis”
Sanz 1994 CHX 0.12%
vs placebo
VM Graph Graph 130 Data presented in a
graph. Did not re-
port a SD. Quote:
“All groups devel-
oped calculus after
the initial cleaning
at baseline. This in-
crease was only statis-
tically significant for
the positive control
group
compared with the
control group at 6
months”
Calculus > 6
months
Banting 1989 CHX 0.12%
vs placebo
VM NR NR 272 At 24 months sub-
jects in the treatment
group had higher
mean supragingival
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Table 9. Studies with a calculus outcome not included in meta-analyses (Continued)
calculus scores, but at
the same time more
subjects were free of
subgingival calculus
CHX = chlorhexidine; NR = not reported; SD = standard deviation.
Total n is the number of participants analysed in the study arms relevant to the review.
RI (Retention Index, Björby and Löe 1966) is measured on a 0-3 increasing scale.
VM (Volpe-Manhold Calculus Index, Manhold 1965; Volpe 1965) measures calculus present on the lingual surface of the lower 6
anterior teeth. Calculus is measured in 3 planes using a standard periodontal probe.The greatest value allowed for any 1 plane is 3 units,
therefore the maximum score per tooth is 9 units or 54 units per subject. The mean per subject score is obtained by dividing the total
calculus score by the number of lower anterior teeth. A mean calculus score for the group is then calculated.
Table 10. Studies with a staining outcome not included in meta-analyses
Time Study ID Comparison Index CHX mean
(SD/SE) or n
(%)
Control
mean (SD)
Total n Notes
4 to 6 weeks Axelsson 1987 CHX 0.2%/0.
1% vs control
DI (Lobene) 0.1171 (0.
297)
0 64 Not included
in meta-anal-
ysis as con-
trol mean is 0.
We combined
data from the
0.
2% and 0.1%
CHX groups
Bhat 2014 CHX 0.2% vs
control
Re-
ported num-
ber and pro-
portion of par-
ticipants with
mild or
moderate ’dis-
colouration’ in
text
20 (91%) 0 44 Not
clear whether
discolouration
relates to teeth
or oral tissues
or both
Flotra 1972 &
1971 (4-
month study
that reports
this outcome
at 4 weeks)
CHX 0.2%/0.
1%/0.1% (ac-
etate) vs con-
trol
No index
Reported nar-
ratively
12% of tooth
surfaces with-
out fillings
62% of silicate
fillings
NR 48 (at 4weeks) Quote:
“..12% of the
tooth surfaces
with-
out fillings be-
came dis-
colored within
the
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Table 10. Studies with a staining outcome not included in meta-analyses (Continued)
first 4 weeks
of the experi-
ment…this
happened
more
frequently on
the interprox-
imal surfaces
than on the
labial surfaces
(ra-
tio2:1). Sixty-
two per cent of
the silicate fill-
ings in these
areas were dis-
colored..”
Graziani 2015 CHX 0.2% vs
control
SI 0.2228 (0.18) 0 70 Not included
in meta-anal-
ysis as con-
trol mean is 0.
We combined
data from the
3CHXgroups
Hase 1995 CHX 0.2% vs
placebo
Subjec-
tive of partic-
ipants regard-
ing staining of
teeth
and/or tongue
using VAS
38 (SE 7) 9 (SE 1) 39 Teeth and/or
tongue stain-
ing reported
together. Data
estimated
from a graph
López-Jornet
2012
CHX 0.2% vs
placebo
Registra-
tion of side ef-
fects including
denture/den-
tal staining (n
and %)
2 (5.71%) 3 (8.57%) 70 Den-
ture and den-
tal staining re-
ported
together
Turkoglu
2009
CHX (conc
not reported)
vs placebo
No index
Reported nar-
ratively
14 (56%) Assumed 0 50 Quote: “Of
the 25 subjects
who rinsed
their mouth
with CHX
mouthrinse..
14 showed
discolouration
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Table 10. Studies with a staining outcome not included in meta-analyses (Continued)
of teeth and/
or tongue”
Zimmer 2006 CHX 0.
06%+F+OH
vs OH
Staining
of teeth and
tongue regis-
tered
at final exami-
nation (n)
4 0 78 Stain on teeth/
tongue
reported
together.
If more than 1
side effect was
present, only
the most rele-
vant was listed
i.e. side effects
were reported
with no dou-
ble counting
7 to 12 weeks Charles 2004 CHX 0.12%
vs control
DI (Lobene) 1.61 (SD NR) 0.01 (SD NR) 74 Did not report
a SD
Grossman
1989
CHX 0.12%
vs placebo
Not specified
Quote: “Pho-
tographs of fa-
cial surfaces of
the 12 anterior
teeth (maxil-
lary
and mandibu-
lar, cus-
pid to cuspid)
were graded
for stain inten-
sity and cover-
age”
4.66 (SD NR) 2.59 (SD NR) 246 Did not report
a SD
Sanz 1994 CHX 0.12%
vs placebo
Not specified NR NR 130 Data
presented in a
graph at
6 months only
See 6-month
results below
Zimmer 2006 CHX 0.
06% +F+OH
vs OH
Staining
of teeth and
tongue regis-
tered
at final exami-
nation (n)
6 0 78 Stain on teeth/
tongue
reported
together.
If more than 1
side effect was
present, only
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Table 10. Studies with a staining outcome not included in meta-analyses (Continued)
the most rele-
vant was listed
i.e. side effects
were reported
with no dou-
ble counting
6 months Charles 2004 CHX 0.12%
vs control
DI (Lobene) 2.08 (SD NR) 0.01 (SD NR) 73 Did not report
a SD
Grossman
1986
CHX 0.12%
vs placebo
Not specified NR NR 380 Outcome data
not reported.
Quote: “Some
extrinsic tooth
staining was
observed in
the chlorhexi-
dine group”
Grossman
1989
CHX 0.12%
vs placebo
Not specified
Quote: “Pho-
tographs of fa-
cial surfaces of
the 12 anterior
teeth (maxil-
lary
and mandibu-
lar, cus-
pid to cuspid)
were graded
for stain inten-
sity and cover-
age”
5.15 (SD NR) 2.75 (SD NR) 246 Did not report
a SD
Hoffmann
2001
CHX 0.
1%/ 0.06%/0.
06%+F vs
control
DI (Lang and
Räber)
1.13/1.02/1.
06 (SD NR)
0.38 (SD NR) 58 Median only.
Did not report
a SD
Sanz 1994 CHX 0.12%
vs placebo
Not specified
Quote: “Pho-
tographs of fa-
cial surfaces of
the 12 anterior
teeth (maxil-
lary
and mandibu-
lar, cus-
pid to cuspid)
Graph Graph 130 Data
presented in
graph Did not
report a SD
Quote: “Sta-
tistically
significant
more overall
staining,
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Table 10. Studies with a staining outcome not included in meta-analyses (Continued)
were graded
for stain inten-
sity and cover-
age”
more intense
staining and
stain coverage
per tooth
were detected
for the posi-
tive control
group…compared
with the con-
trol group”
CHX = chlorhexidine; conc = concentration; F = fluoride; NR = not reported; OH = oral hygiene; SD = standard deviation; SE =
standard error; VAS = visual analogue scale.
Total n is the number of participants analysed in the study arms relevant to the review.
DI (Discolouration Index, Lobene 1968): gingival and body regions of the tooth are scored for intensity (0-3 increasing scale) and
severity (0-3 increasing scale).
DI (Discolouration Index, Lang and Räber 1981) is measured on a 0-3 increasing scale.
SI (Staining Index): the buccal surfaces of the 8 central incisors were divided into 3 areas: incisal, approximal and gingival according
to Lobene 1968 and Grundemann 2000 and a SI was used to record the dichotomous presence or absence of staining in each area and
to calculate the percentage of the total area showing staining.
A P P E N D I C E S
Appendix 1. Cochrane Oral Health’s Trials Register search strategy
From July 2014, searches of Cochrane Oral Health’s Trials Register were conducted using the Cochrane Register of Studies using the
search strategy below:
1 ((plaque or gingivitis or gingiva* or periodont* or “gum disease*”):ti,ab) AND (INREGISTER)
2 ((mouthwash* or mouthrinse* or wash* or rins*):ti,ab) AND (INREGISTER)
3 ((chlorhexidine* or MK-412a or “MK 412a” or MK412a or CHX or Corsodyl or Peridex or Hibident or Prexidine or Parodex
or Chlorexil or Peridont or Eludril or Perioxidin or Chlorohex or Savacol or Periogard or Chlorhexamed or Nolvasan or Sebidin or
Tubulicid or hibitane):ti,ab) AND (INREGISTER)
4 (#1 and #2 and #3) AND (INREGISTER)
Previous searches of Cochrane Oral Health’s Trials Register were undertaken in April 2010 and February 2012 using the Procite software
and the search strategy below:
((plaque or gingivitis or gingiva* or periodont* or “gum disease*”) AND (mouthwash* or mouthrinse* or wash* or rins*) AND
(chlorhexidine* or MK-412a or “MK 412a” or MK412a or CHX or Corsodyl or Peridex or Hibident or Prexidine or Parodex or
Chlorexil or Peridont or Eludril or Perioxidin or Chlorohex or Savacol or Periogard or Chlorhexamed or Nolvasan or Sebidin or
Tubulicid or hibitane))
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Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
#1 MeSH descriptor Dental Plaque, this term only
#2 ((dental or oral or tooth or teeth) and plaque)
#3 MeSH descriptor Gingivitis explode all trees
#4 gingivitis
#5 ((gingiva* near/3 inflamm*) or (gingiva* near/3 bleed*) or (gingiva* near/3 pocket*) or (gingiva* near/3 attachment*))
#6 MeSH descriptor Periodontitis explode all trees
#7 periodont*
#8 ((haemorrhag* near/5 gum*) or (hemorrhag* near/5 gum*) or (hemorrag* near/5 gum*) or (haemorrhag* near/5 gingiva*) or
(hemorrhag* near/5 gingiva*) or (hemorrag* near/5 gingiva*))
#9 ((bleed* near/5 gum*) or (bleed* near/5 gingiva*))
#10 ((inflamm* near/5 gum*) or (inflamm* near/5 gingiva*))
#11 ((gum next disease) or (disease* near/5 gum*) or (disease near/5 gingiva*))
#12 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)
#13 MeSH descriptor Mouthwashes explode all trees
#14 (mouthrins* or “mouth rins*” or mouth-rins* or rinse* or rinsing* or mouthwash* or “mouth wash*” or mouth-wash*)
#15 ((oral near/3 wash*) or (dental near/3 wash*) or (mouth* near/3 wash*) or (oral near/3 rins*) or (dental near/3 rins*) or (mouth*
near/3 rins*))
#16 (#13 OR #14 OR #15)
#17 MeSH descriptor Chlorhexidine, this term only
#18 chlorhexidine
#19 (MK-412a or “MK 412a” or MK412a)
#20 (CHX):ti,ab,kw
#21 (Corsodyl or Peridex or Hibident or Prexidine or Parodex or Chlorexil or Peridont or Eludril or Perioxidin or Chlorohex or Savacol
or Periogard or Chlorhexamed or Nolvasan or Sebidin or Tubulicid or hibitane)
#22 (#17 OR #18 OR #19 OR #20 OR #21)
#23 (#12 AND #16 AND #22)
Appendix 3. MEDLINE Ovid search strategy
1. Dental plaque/
2. ((dental or oral or tooth or teeth) and plaque).mp.
3. exp Gingivitis/
4. gingivitis.mp.
5. ((gingiva$ adj3 inflamm$) or (gingiva$ adj3 bleed$) or (gingiva$ adj3 pocket$) or (gingiva$ adj3 attachment$)).mp.
6. exp Periodontitis/
7. periodont$.mp.
8. ((haemorrhag$ adj5 gum$) or (hemorrhag$ adj5 gum$) or (hemorrag$ adj5 gum$) or (haemorrhag$ adj5 gingiva$) or
(hemorrhag$ adj5 gingiva$) or (hemorrag$ adj5 gingiva$)).mp.
9. ((bleed$ adj5 gum$) or (bleed$ adj5 gingiva$)).mp.
10. ((inflamm$ adj5 gum$) or (inflamm$ adj5 gingiva$)).mp.
11. ((gum adj disease) or (disease$ adj5 gum$) or (disease adj5 gingiva$)).mp.
12. or/1-11
13. exp Mouthwashes/
14. (mouthrins$ or “mouth rins$” or mouth-rins$ or rinse$ or rinsing$ or mouthwash$ or “mouth wash$” or mouth-wash$).mp.
15. ((oral or dental or mouth) adj3 (wash$ or rins$)).mp.
16. or/13-15
17. Chlorhexidine/
18. chlorhexidine.mp.
19. (MK-412a or “MK 412a” or MK412a).mp.
20. CHX.ti,ab.
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21. (Corsodyl or Peridex or Hibident or Prexidine or Parodex or Chlorexil or Peridont or Eludril or Perioxidin or Chlorohex or
Savacol or Periogard or Chlorhexamed or Nolvasan or Sebidin or Tubulicid or hibitane).mp.
22. or/17-21
23. 12 and 16 and 22
This subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials (RCTs) in
MEDLINE: sensitivity-maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of theCochrane
Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011) (Lefebvre 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
Appendix 4. Embase Ovid search strategy
1. Dental plaque/
2. ((dental or oral or tooth or teeth) and plaque).mp.
3. exp Gingivitis/
4. gingivitis.mp.
5. ((gingiva$ adj3 inflamm$) or (gingiva$ adj3 bleed$) or (gingiva$ adj3 pocket$) or (gingiva$ adj3 attachment$)).mp.
6. exp Periodontitis/
7. periodont$.mp.
8. ((haemorrhag$ adj5 gum$) or (hemorrhag$ adj5 gum$) or (hemorrag$ adj5 gum$) or (haemorrhag$ adj5 gingiva$) or
(hemorrhag$ adj5 gingiva$) or (hemorrag$ adj5 gingiva$)).mp.
9. ((bleed$ adj5 gum$) or (bleed$ adj5 gingiva$)).mp.
10. ((inflamm$ adj5 gum$) or (inflamm$ adj5 gingiva$)).mp.
11. ((gum adj disease) or (disease$ adj5 gum$) or (disease adj5 gingiva$)).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identifier]
12. or/1-11
13. exp Mouthwashes/
14. (mouthrins$ or “mouth rins$” or mouth-rins$ or rinse$ or rinsing$ or mouthwash$ or “mouth wash$” or mouth-wash$).mp.
15. ((oral or dental or mouth) adj3 (wash$ or rins$)).mp.
16. or/13-15
17. Chlorhexidine/
18. chlorhexidine.mp.
19. (MK-412a or “MK 412a” or MK412a).mp.
20. CHX.ti,ab.
21. (Corsodyl or Peridex or Hibident or Prexidine or Parodex or Chlorexil or Peridont or Eludril or Perioxidin or Chlorohex or
Savacol or Periogard or Chlorhexamed or Nolvasan or Sebidin or Tubulicid or hibitane).mp.
22. or/17-21
23. 12 and 16 and 22
The above subject search was linked to adapted version of the Cochrane Embase Project filter for identifying RCTs in Embase Ovid
(see http://www.cochranelibrary.com/help/central-creation-details.html for information):
1. Randomized controlled trial/
2. Controlled clinical study/
3. Random$.ti,ab.
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4. randomization/
5. intermethod comparison/
6. placebo.ti,ab.
7. (compare or compared or comparison).ti.
8. ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab.
9. (open adj label).ti,ab.
10. ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab.
11. double blind procedure/
12. parallel group$1.ti,ab.
13. (crossover or cross over).ti,ab.
14. ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or partici-
pant$1)).ti,ab.
15. (assigned or allocated).ti,ab.
16. (controlled adj7 (study or design or trial)).ti,ab.
17. (volunteer or volunteers).ti,ab.
18. trial.ti.
19. or/1-18
20. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
21. 19 not 20
Appendix 5. CINAHL EBSCO search strategy
S1 MH “Dental Plaque+”
S2 ((dental or oral or tooth or teeth) and plaque)
S3 MH “Gingivitis+”
S4 gingivitis
S5 (gingiva* N3 inflamm*) or (gingiva* N3 bleed*) or (gingiva* N3 pocket*) or (gingiva* N3 attachment*)
S6 MH “Periodontitis+”
S7 periodont*
S8 (haemorrhag* N5 gum*) or (hemorrhag* N5 gum*) or (hemorrag* N5 gum*) or (haemorrhag* N5 gingiva*) or (hemorrhag* N5
gingiva*) or (hemorrag* N5 gingiva*)
S9 (bleed* N5 gum*) or (bleed* N5 gingiva*)
S10 (inflamm* N5 gum*) or (inflamm* N5 gingiva*)
S11 “gum disease” or (disease* N5 gum*) or (disease* N5 gingiva*)
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S13 MH “Mouthwashes+”
S14 mouthrins* or “mouth rins*” or mouth-rins* or rinse* or rinsing* or mouthwash* or “mouth wash*” or mouth-wash*
S15 (oral N3 wash*) or (dental N3 wash*) or (mouth* N3 wash*) or (oral N3 rins*) or (dental N3 rins*) or(mouth* N3 rins*)
S16 S13 or S14 or S15
S17 MH “Chlorhexidine+”
S18 chlorhexidine
S19 MK-412a or “MK 412a” or MK412a
S20 TI CHX or AB CHX
S21 (Corsodyl or Peridex or Hibident or Prexidine or Parodex or Chlorexil or Peridont or Eludril or Perioxidin or Chlorohex or Savacol
or Periogard or Chlorhexamed or Nolvasan or Sebidin or Tubulicid or hibitane)
S22 S17 or S18 or S19 or S20 or S21
S23 S12 and S16 and S22
The above subject search was linked to Cochrane Oral Health’s filter for identifying RCTs in CINAHL:
S1 MH Random Assignment or MH Single-blind Studies or MHDouble-blind Studies or MH Triple-blind Studies or MH Crossover
design or MH Factorial Design
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S2 TI (“multicentre study” or “multicenter study” or “multi-centre study” or “multi-center study”) or AB (“multicentre study” or
“multicenter study” or “multi-centre study” or “multi-center study”) or SU (“multicentre study” or “multicenter study” or “multi-
centre study” or “multi-center study”)
S3 TI random* or AB random*
S4 AB “latin square” or TI “latin square”
S5 TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over)
S6 MH Placebos
S7 AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)
S8 TI blind* or AB mask* or AB blind* or TI mask*
S9 S7 and S8
S10 TI Placebo* or AB Placebo* or SU Placebo*
S11 MH Clinical Trials
S12 TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial)
S13 S1 or S2 or S3 or S4 or S5 or S6 or S9 or S10 or S11 or S12
Appendix 6. US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) search
strategy
chlorhexidine AND mouthrinse AND gingivitis
chlorhexidine AND mouthwash AND gingivitis
Appendix 7. World Health Organization International Clinical Trials Registry Platform search
strategy
chlorhexidine AND mouthrinse AND gingivitis
chlorhexidine AND mouthwash AND gingivitis
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In Spring 2016, in conjunction with the editorial board of Cochrane Oral Health, the decision was made to address the comparison
of chlorhexidine mouthrinse with placebo, control or mechanical oral hygiene alone in this review and to report the comparison of
chlorhexidine mouthrinse with other active mouthrinses in a subsequent review. This decision will enable us to comprehensively report
all of the results for the objectives set out in the published protocol (James 2010) across two reviews.
A number of additional changes were made in relation to the criteria for including studies in the review after the protocol was published
but early in the review process.
• Types of studies
◦ It was decided to exclude cross-over trials due to concerns that chlorhexidine could exert an effect beyond the washout
period.
◦ When we wrote the protocol, we did not anticipate encountering split-mouth studies meeting the inclusion criteria because
it is not possible to conduct a split-mouth study when using mouthrinse as the intervention. However, we encountered split-mouth
studies comparing different scaling and root planing regimens and different periodontal surgical techniques that incorporated a
chlorhexidine and placebo/control comparison. Such study designs were considered inappropriate to answer the question posed by
this review and were excluded.
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• Types of participants
◦ Individuals no longer need to have undergone periodontal treatment and be in the maintenance phase to be included. This
change was made to allow us to include studies where chlorhexidine was used as an adjunct to surgical and non-surgical periodontal
therapy. Individuals of any age, gender or race with periodontal disease (gingivitis or periodontitis) provided they are capable of
performing mechanical oral hygiene procedures are included.
• Risk of bias
◦ Assessment of blinding for participants, personnel and outcome assessors was changed to allow for low and unclear risk of
bias in these domains in certain situations.
The following were not explicitly addressed in the protocol and required clarification.
• Types of intervention
◦ We clarified that the mechanical oral hygiene procedures must be the same in both the chlorhexidine mouthrinse and the
comparison arms so that the chlorhexidine mouthrinse is the only difference between the arms to ensure that the groups are truly
comparable.
◦ Studies where the chlorhexidine mouthrinse also contained fluoride were included.
◦ Studies where gum care or antigingivitis dentifrices (that do not contain chlorhexidine) are used for mechanical oral
hygiene in both test and comparator arms were included.
◦ Studies where chlorhexidine mouthrinse formed part of a combined intervention with other agents (such as other
chlorhexidine vehicles, dentifrice containing chlorhexidine, or other antigingivitis agents (e.g. cetylpyridinium chloride (CPC)) that
the comparator arm/s did not receive were excluded because the effect of the chlorhexidine could not be separated from the effect of
the other active agents.
• Types of outcome
◦ A hierarchy to guide data extraction of gingivitis and plaque data was developed to facilitate data extraction and analysis.
The main analysis however, was based on the main prespecified gingivitis index: the Gingival Index of Löe and Silness (Löe 1967; Löe
and Silness 1963).
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Medical Subject Headings (MeSH)
Chemotherapy, Adjuvant; Chlorhexidine [adverse effects; ∗therapeutic use]; Dental Plaque [complications; ∗drug therapy]; Dental
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Publication Bias; Randomized Controlled Trials as Topic; Time Factors; Tooth Discoloration [chemically induced]
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